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ABSTRACT 
 
IDENTIFICATION OF GENES INDUCED BY BRCA1 IN  
BREAST CANCER CELLS 
 
ARZU ATALAY 
Ph.D. in Molecular Biology and Genetics 
Supervisor:  Assist. Prof. Işık G.Yuluğ 
December 2002, 235 Pages 
 
Inherited mutations of the BRCA1 gene predispose to cancer of the breast, ovaries 
and other organs. The BRCA1 protein product is implicated in the maintenance of 
chromosomal integrity as BRCA1-deficient cells display gross chromosomal 
rearrangements. Chromosomal instability in BRCA1-deficient cells is related to 
inappropriate DNA double-strand break repair. The role of the BRCA1 gene in the 
maintenance of chromosomal integrity is linked to a number of biological properties 
of its protein product including transcriptional regulation. The aim of this study is to 
identify genes that are regulated by BRCA1. Initial attempts to overexpress BRCA1 
in breast cancer cells with the tightly-regulated ecdysone inducible system did not 
result in the desired levels of BRCA1 protein and ectopic BRCA1 expression was 
therefore performed by using the constitutive expression vector. In this study, we have 
identified genes whose expression levels are upregulated as a result of BRCA1 
overexpression in MCF7 breast carcinoma cells by using the suppression subtractive 
hybridisation (SSH) method. Differential screening, sequencing and homology search 
studies showed that BRCA1 overexpression in breast cancer cells leads to 
transcriptional upregulation of distinct classes of genes encoding proteins involved in 
cellular processes such as DNA repair, chromosome assembly and segregation, signal 
transduction, RNA surveillance, ubiquitin-mediated proteolysis, amino acid transport, 
RNA metabolism and glucose metabolism. This study is the first to report BRCA1-
induced genes in breast carcinoma cells with the SSH technique. The identified genes 
in this study may provide new insights into the tumour suppressor functions of 
BRCA1. 
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ÖZET 
 
MEME KANSERİ HÜCRELERİNDE BRCA1 TARAFINDAN İNDÜKLENEN 
GENLERİN TANIMLANMASI 
 
ARZU ATALAY 
Doktora Tezi,  Moleküler Biyoloji ve Genetik Bölümü 
Tez Yöneticisi: Yar. Doç. Dr. Işık G.Yuluğ 
Aralık 2002, 235 sayfa 
 
 
 
BRCA1 geninin kalıtsal mutasyonları meme, rahim ve diğer organlarda kansere 
yatkınlığa yol açar. BRCA1-eksik hücrelerde yeni kromozomal düzenlenmeler 
görüldüğünden BRCA1 protein ürününün kromozomal bütünlüğün devam 
ettirilmesinde görevli olduğu düşünülmektedir. BRCA1-eksik hücrelerdeki 
kromozomal dengesizlik DNA çift-ipliğinin yanlış tamiriyle ilişkilidir.  BRCA1 
geninin kromozomal bütünlüğün sağlanmasındaki rolü protein ürününün 
transkripsiyonel düzenleme dahil bir kaç biyolojik özelliğine bağlıdır. Bu çalışmanın 
amacı BRCA1 tarafından düzenlenen genlerin tanımlanmasıdır. BRCA1'i meme 
kanseri hücrelerinde sıkı-düzenlenen "ecdysone" ile indüklenebilen bir sistemle fazla 
ifade etmek için yapılan ilk çalışmalar,  istenen düzeyde BRCA1 proteini vermemiştir 
ve bu nedenle ektopik BRCA1 ifadesi konstitütif ekspresyon vektörü kullanılarak 
yapılmıştır. Bu  çalışmada MCF7 meme kanseri hücrelerinde BRCA1’in fazla ifade 
edilmesi sonucu ifade düzeyleri artan genler "Suppression Subtractive Hybridisation" 
(SSH) metodu kullanılarak tanımlanmıştır. Ayrımsal tarama, dizileme ve homoloji 
araştırma çalışmaları meme kanseri hücrelerinde BRCA1’in fazla ifade edilmesinin 
DNA tamiri, kromozom yapımı ve ayrılması, sinyal iletimi, RNA tarama, ubikitin 
aracılıklı proteoliz, amino asit taşınımı, RNA metabolizması ve glukoz metabolizması 
gibi hücresel olaylarda yer alan proteinleri kodlayan farklı gen gruplarının 
ifadelerinde artışa yol açtığını göstermiştir. Bu çalışma meme karsinom hücrelerinde 
SSH tekniği kullanılarak BRCA1 tarafından indüklenen genleri gösteren ilk 
çalışmadır. Bu çalışmada tanımlanan genler BRCA1'in tümör baskılayıcı görevlerine 
yeni bir bakış açısı sağlayabilir. 
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CHAPTER 1. INTRODUCTION 
 
 
 
Breast cancer, which is the most common female malignancy, is a major cause 
of death in middle-aged women and its incidence is increasing (Parkin and Coleman, 
1990). Breast cancer affects almost one million women worldwide at any given time. 
One in eight American women will develop breast cancer at some point in their 
lifetimes, and of these women approximately 30% will develop the metastatic form 
which is ultimately fatal (Bowcock, 1999).  
 
The breast epithelium undergoes distinct developmental programs during 
puberty and pregnancy. During puberty, in particular, rapid proliferation of breast 
tissue occurs. Lobules of the breast are clonal (Kordon and Smith, 1998) and the 
progeny of this proliferative burst are retained within the breast lobule. In this way, 
breast epithelial cells have the potential to retain “memory” of genetic alterations that 
occurred earlier in breast development. In contrast, some other epithelia that are 
characterized by rapid proliferation, such as the intestinal epithelium, shed cells 
continuously.  
 
 
1.1 Risk factors for breast and ovarian cancer  
 
It is well understood that one of the most important risk factors for developing 
breast cancer is a family history of the disease. However, many other nongenetic risk 
factors contribute to disease etiology. Besides sex and country of birth, increasing age 
is an important risk factor. Other suggested risk factors are influences of hormones. 
Early age at menarche, late menopause, and late first full-term pregnancy, all confer 
increased risk for breast cancer. Even the prenatal environment might be of 
importance. It has been shown repeatedly that estrogen exposure is directly associated 
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with risk for developing breast cancer. High body-mass index after menopause, high 
alcohol consumption and some dietary factors increase the risk (Martin and Weber, 
2000). Exposure to ionising radiation is a well-known risk factor for different kinds of 
malignancies; young women who received mantle radiation for Hodgkin’s lymphoma 
have a markedly increased risk for developing breast cancer (Wolden et al., 1998). All 
these mentioned nongenetic factors increase the risk by about 1.5- to three-fold. 
 
Multiple epidemiological studies have reported that a family history of breast 
cancer is a reproducible predictor of breast cancer risk (Lynch et al., 1981; Ottman et 
al., 1986). The risk conferred by having relatives with breast cancer varies with 
closeness of kinship, numbers of affected relatives and the age of onset. A more than 
two-fold increase in risk for women with one first-degree relative with early onset 
breast cancer has been reported in many studies (Arver et al., 2000). Having more 
than one close relative with breast cancer, or cases of bilateral disease among 
relatives, seem to confer even higher risks. 
 
Families with three or more close relatives with breast cancer are, in the 
literature, classified as ‘breast cancer families’. One of the earliest descriptions of a 
breast cancer family was written in 1866 by the French surgeon P. Broca in the 
publication ‘Traite des tumeurs’. Numerous pedigrees from families with apparent 
inherited breast cancer susceptibility have been reported (Lindblom et al., 1993; 
Lynch et al., 1978) and it was noticed early on that ovarian cancer was frequent in 
many of these families (Go et al., 1983). Other features found in breast cancer 
families are early age of onset and bilateral disease (Lynch, 1990; Lynch et al., 1978). 
In ovarian cancers, about 10% of cases have a hereditary basis. A family history of 
ovarian cancer is the strongest risk factor for developing the disease. Germline 
mutations in BRCA genes appear to account for most hereditary ovarian cancers. 
DNA repair gene mutations (in HNPCC families) account for a much smaller fraction 
of cases (Lynch et al., 1998). 
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1.2 Genes implicated in breast cancer 
 
BRCA1, BRCA2, p53, STK11/LKB1, PTEN, MSH2/MLH1, ATM are the genes 
implicated in formation of hereditary breast cancer. Besides, CYP1A1, GSTs, NAT2 
and androgen receptor are some of the low penetrance breast cancer susceptibility 
genes.  
 
BRCA1 and BRCA2: Familial breast and ovarian cancer predisposition syndromes 
have long been recognized. Their genetic bases have become clear with the cloning of 
two major disease susceptibility genes BRCA1 and BRCA2 (Hall et al., 1990; Miki et 
al., 1994; Wooster et al., 1995; Wooster et al., 1994).  Each has characteristics of a 
tumour suppressor gene; inheritance within affected families follows an autosomal-
dominant pattern of inheritance and loss of heterozygosity (LOH) at the relevant gene 
locus is seen in familial tumours with retention of the disease-predisposing allele 
(Collins, 1995; Gudmundsson et al., 1995; Neuhausen and Marshall, 1994).  The 
spectrum of disease-associated mutations includes frequent truncating mutations and 
less frequent missense mutations. Although LOH is frequently at the BRCA1 or 
BRCA2 locus in sporadic breast cancer, the retained allele is almost wild-type (Futreal 
et al., 1994; Lancaster et al., 1996).  Thus, in contrast to the casual role of BRCA1 
gene mutation in the hereditary syndrome, BRCA1 gene mutation in sporadic breast 
and ovarian cancer seldom conforms to Knudson’s model for tumour suppressor 
genes (Knudson, 1971). Cancer risk in BRCA gene mutation carriers may be increased 
modestly in other organs, but, highly penetrant, early-onset, site specific cancer is 
restricted to the breast and ovary.  
 
p53: p53 germline mutations are thought to be a rare cause of breast cancer, except in 
the setting of Li-Fraumeni syndrome. The first documentation of Li-Fraumeni 
syndrome was in 1969, in which four families with children with soft tissue sarcomas 
were found to have an excess of sarcomas in other relatives. In addition these families 
exhibited an excess of early onset breast cancer and other cancers such as childhood 
leukemia, adrenocortical carcinoma and brain cancer (Li and Fraumeni, 1969). In 
1990, the presence of germline p53 mutations in approximately half of the families 
with classic Li-Fraumeni syndrome was reported (Malkin et al., 1990). In women 
 4 
with germline p53 mutations who survive childhood cancers, it is estimated that 50% 
will have developed breast cancer by the age of 50 (Easton et al., 1993b).   
 
STK11/LKB1: Peutz-Jeghers syndrome is caused by germline mutations in 
STK11/LKB1, a serine-threonine kinase located on chromosome 19q13.3 (Jenne et al., 
1998). Peutz-Jeghers syndrome is characterized by hamartomatous polyps in the small 
bowel and pigmented macules of the buccal mucosa, lips, fingers and toes. In spite of 
the early-onset breast cancer that can be seen in patients with Peutz-Jeghers 
syndrome, mutations in STK11/LKB1 do not appear to play an important role in 
sporadic breast cancers, based on the very low prevalence of mutations in the 
population. 
 
PTEN: Cowden syndrome is a rare autosomal dominant predisposition to both benign 
and malignant neoplasms. Breast cancer develops in 20-30% of carrier women. Other 
tumours seen among patients with Cowden syndrome include adenomas and follicular 
cell carcinomas of the thyroid gland, polyps and adenocarcinomas of the 
gastrointestinal tract and ovarian cysts and carcinoma (Hanssen and Fryns, 1995). 
Cowden syndrome is caused by germline mutations in the PTEN gene 
(MMAC1/TEP1). PTEN, a tumour suppressor gene on 10q23.3, is a dual-specifity 
phosphatase (Steck et al., 1997). PTEN does not play a role in familial breast cancer, 
apart from its role in Cowden syndrome. 
 
MSH2/MLH1: Muir-Torre syndrome is defined by the presence of sebaceous gland 
tumours and visceral malignancy. It is inherited in an autosomal dominant fashion 
with high penetrance because of mutations in the same genes associated with 
hereditary nonpolyposis colorectal cancer (HNPCC) (Schwartz and Torre, 1995). The 
most common malignancy in this syndrome is colorectal cancer, seen in 50% of 
patients, but breast cancer occurs in approximately 25% of women carriers. As in 
HNPCC, microsatelite instability is observed in the tumours of patients with Muir-
Torre syndrome. Mutational analysis has shown that the mutations are predominantly 
in MSH2. 
 
ATM: Ataxia-telangiectasia (AT) is a complex, autosomal recessive disorder 
characterized by cerebellar ataxia, telangiectasia, immunodeficiency, radiation 
 5 
sensitivity and cancer predisposition caused by homozygous mutations in the ATM 
gene. Epidomiologic studies have shown that AT carriers might have an increased 
risk for breast cancer, and this observation was consistent with the recent finding that 
ATM phosphorylates BRCA1 protein upon DNA damage (Li et al., 2000). 
 
 
Low penetrance breast cancer susceptibility alleles: Low-penetrance 
susceptibility alleles, sometimes called “modifier genes”, are defined as polymorphic 
genes with specific alleles that are associated with an altered risk for disease 
susceptibility. Further studies are needed to clarify the role of all the following genes 
in breast cancer as rewieved by Martin and Weber (2000):  
 
The P450 gene CYP1A1 encodes aryl hydrocarbon hydroxylase, which is the primary 
catalyst in the conversion of estradiol to hydroxylated estrogen. A reduced estrogen 
level is protective for developing breast cancer, whereas increased estrogen exposure 
can increase the risk for developing breast cancer. Alterations in the activity of aryl 
hydrocarbon hydroxylase could therefore plausibly lead to a change in the levels of 
estrogen and could ultimately affect breast cancer risk. 
  
The glutathione S-transferases (GSTs) constitute a family of genes that encode for 
enzymes that catalyze the conjunction of reactive chemical intermediates to soluble 
glutathione conjugates to facilitate clearance. Inability to metabolise carcinogens may 
increase breast cancer risk.  
 
N-acetyltransferase (NAT2) is an important component of the carcinogen 
metabolism pathway and polymorphisms in the NAT2 gene are associated with an 
altered rate of metabolism of carcinogens.  
 
The effect of CAG microsatelite found in exon 1 of androgen receptor gene has been 
investigated for its role in breast cancer penetrance. BRCA1 mutation carriers who 
carry at least one androgen receptor allele with more than 29 CAG repeats were 
diagnosed with breast cancer statistically significantly earlier than women with 
shorter CAG repeats in their androgen receptor genes, suggesting that pathways 
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involving androgen signalling may affect the penetrance of BRCA1-associated breast 
cancer (Rebbeck et al., 1999). 
 
 
1.3 Mechanisms of BRCA-mediated breast and ovarian cancer formation 
 
Relationship between mutation events and formation of breast or ovarian 
carcinomas are summarized in Figure 1. Estrogen mediated proliferation of breast and 
ovarian epithelial cells and the distinctive genomic context (high percentage of 
repetitive sequences) of the BRCA genes are critical components of this pathway. 
During puberty estrogen stimulates breast epithelial cells to proliferate. Among 
somatic mutations that appear in these rapidly dividing cells, alterations of BRCA 
genes are likely to be relatively frequent because of the density of repeats in these 
genes. Inactivation of the second allele in such a cell would generally result in cell 
death. Tumorigenesis would require inactivation of both alleles in a cell capable of 
escaping cell cycle checkpoints. Unlike inherited disease, inactivation of genes critical 
to cell cycle checkpoints could occur prior to inactivation of the second allele. 
Therefore, BRCA1-mediated sporadic tumorigenesis would be less likely. Also, 
because more mutational events are required, tumours occur later in a woman’s life.  
 
Various genetic mechanisms may be responsible for somatic inactivation of 
both alleles by generation of large deletions of BRCA1 and BRCA2 in both inherited 
and somatic tumours. Deletion of a chromatin loop containing all or a large portion of 
BRCA genes may be mediated by homologous recombination between repeat 
sequences. Repeat mediated loss of chromatin formed at different points in the cell 
cycle will yield deletion of different sizes. If this process occurs in both copies of the 
BRCA1 region, deletions including the BRCA gene will overlap but not be identical. If 
genomic deletions overlap, they may incorrectly appear to define one region of LOH. 
This hypothesis may explain the large deletions observed in BRCA1 tumours (Welcsh 
and King, 2001). 
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Figure 1: Relationship between mutation events and formation of breast or 
ovarian cancers. (Welcsh and King, 2001).  
Estrogen levels in women are cyclic from menarche until menopause when peak 
estrogen levels decrease. In response to estrogen at puberty and pregnancy, breast 
epithelial cells proliferate. Among women with a germline mutation in BRCA1 or 
BRCA2, somatic inactivation of the remaining allele will result in repair-deficient 
cells. These cells will be unable to repair damaged DNA in the following cell cycle 
and will ultimately die due to activation of critical cell cycle checkpoints. The rare 
repair-deficient cell (shown in red) that escapes death by checkpoint may acquire 
mutations at other sites including critical checkpoint genes, ultimately resulting in 
tumour formation. In inherited BRCA tumorigenesis, somatic inactivation of the 
second BRCA allele likely occurs early in a young woman’s life, leading to early 
onset of breast cancer. In women without a BRCA germline mutation (sporadic BRCA 
tumorigenesis), somatic alteration of one allele of BRCA1 or BRCA2 in breast 
epithelial cells is likely to occur during estrogen-mediated proliferation, due to the 
density of repetitive elements in these genes. Inactivation of a second BRCA allele in 
a cell would generally result in cell death. 
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Alternatively it has been proposed that inactivation of a BRCA allele could 
result in an overall decrease in BRCA function (haplo-insufficiency). Presence of only 
one BRCA allele is clearly sufficient for normal growth and development, because 
persons heterozygous for BRCA mutations have normal phenotypes apart from their 
cancer predisposition. However under conditions of cellular stress in breast and 
ovarian epithelium, caused by estrogen-stimulated proliferation, it is possible that 
even a modest decrease in BRCA function in cells with one somatically inactivated 
allele could increase the risk for additional cancer promoting mutations.  
 
Third, transcriptional silencing may inactivate BRCA alleles, by loss of 
proteins that positively regulate their expression or by an increase in negative 
regulatory proteins. Table 1 summarizes the known BRCA1 regulatory proteins, and 
the nucleotide sites at which they function if the regulation is direct: 
 
BRCA1 regulatory protein Binding domain on BRCA1 (L78833) Reference 
Brn-3b    -400 to –1 (2944-3344)             (Budhram-Mahadeo et al., 1999) 
GA binding protein α/β  -204 to –159 (3140-3185)             (Atlas et al., 2000) 
RB-E2F    -23 to 15  (3321-3339)             (Wang et al., 2000a) 
p53    indirect               (Arizti et al., 2000) 
TGFβ (requires RB)    ?               (Satterwhite et al., 2000) 
Id4    indirect               (Beger et al., 2001) 
     
Table 1: BRCA1 regulatory proteins 
 
Among the BRCA1 regulatory proteins, Id4 (inhibitor of DNA binding 4) 
inversely regulates BRCA1 expression (Beger et al., 2001). Overexpression of Id4 
(and concomitant reduction of BRCA1 expression) is associated with anchorage-
independent growth, a critical characteristic of tumour cells. The relationship between 
Id4 and BRCA1 may be important for breast cancer because estrogen reduces Id4 
expression, hence increasing expression of BRCA1. Conversely, breast epithelial cells 
that are no longer responsive to estrogen may overexpress Id4, with consequent 
reduction of BRCA1 expression. If this occurs in a cell that has lost one BRCA1 allele 
through somatic inactivation, these cells would then be BRCA1 deficient. 
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Transcriptional silencing of one BRCA1 allele could be accomplished through 
methylation of CpG islands, which are often found in the regulatory region of many 
genes. The 5’ regulatory region of the BRCA1 gene contains a TATA-less promoter 
with high cytosine-guanine content, making BRCA1 an excellent candidate for CpG 
methylation. In 5-10% of sporadic breast tumours, BRCA1 transcription is silenced by 
the methylation of CpG residues, which leads to absence of protein expression 
(Esteller et al., 2000).  In a recent report, the BRCA1 promoter was methylated in 15% 
of sporadic ovarian tumours (Baldwin et al., 2000). 
 
BRCA1 might be inactivated post-transcriptionally by failure of 
phosphorylation or other posttranslational modifications. Phosphorylation of BRCA1 
is required for normal functioning of BRCA1. The roles of ATM, ATR and Chk2 in 
phosphorylating BRCA1 in response to DNA damage are likely to be most critical to 
carcinogenesis. 
 
 
1.4 BRCA1 
 
Hereditary breast cancer families account for only 5-10% of all breast cancer 
cases. Mutations in BRCA1 are responsible for nearly all of the hereditary breast and 
ovarian cancer families and up to 40-50% of families with hereditary breast cancer 
only (Easton et al., 1993a). BRCA2 is strongly linked to hereditary breast cancer in 
both males and females (Wooster et al., 1995; Wooster et al., 1994). Together 
BRCA1 and BRCA2 account for the majority, although not all, of hereditary breast 
cancer cases. 
 
 
1.4.1 Mutational spectrum of BRCA1  
 
Since the isolation of BRCA1, more than 700 sequence variations have been 
identified. Initially eight disease-associated mutations were described within the gene 
(Futreal et al., 1994; Miki et al., 1994), followed shortly by an increasing number of 
mutations (Castilla et al., 1994; Friedman et al., 1994; Simard et al., 1994). Most are 
frameshift mutations, but several missense mutations are known to alter protein 
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function. Mutational spectrum of BRCA genes is summarized in Table 2. Most known 
mutations are listed in the Breast cancer Information Core (BIC) and are available on 
the Internet (http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic). Several 
founder mutations have been identified in BRCA1. 
 
Gene     BRCA1         BRCA2 
Mutation type 
Frameshifts    70%   68% 
Nonsense mutations   20%   12% 
Splice site    5%   7% 
Missense    5%   13%         
  
Table 2: Mutation types in BRCA1 and BRCA2 (Bowcock, 1999) 
 
 
 
1.4.2 BRCA1 gene and protein structure 
 
BRCA1 gene is localized on chromosome 17q21 and spans 100 kb genomic 
sequence. BRCA1 is a large gene with a total mRNA of 5711 base pairs, divided into 
24 exons, of which 22 are coding. Exon 1 is not coding and exon 4 is an Alu repetitive 
motif. The coding region begins in exon 2. Exon 11 constitutes more than 60% of the 
coding region, while most of the other exons are relatively small (Miki et al., 1994). 
The gene encodes a nuclear phosphoprotein of 220 kDa (Chen et al., 1996a) and 
smaller splice variants have been described (Wang et al., 1997). Full-length BRCA1 
protein is localized in the nuclear foci of epithelial cells (Wilson et al., 1999) while a 
splice variant, BRCA1 delta 11b, might be cytoplasmic (Thakur et al., 1997). 
 
Functional domains have been identified in BRCA1 (Figure 2). The most 
phylogenetically conserved region is the C3HC4 zinc binding RING-finger domain at 
the amino terminus of the protein (Chen et al., 1996a; Saurin et al., 1996). Several 
other human proteins with zinc finger motifs have suggested this domain to be a 
region of protein-protein interactions and such motifs are found in a number of 
regulatory proteins. In addition, BRCA1 has two nuclear localization signals in exon 
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11 (Chen et al., 1995; Miki et al., 1994). The “BRCT” (BRCA1 Carboxyl-terminal) 
domain is an evolutionary region in BRCA1 (Callebaut and Mornon, 1997; Koonin et 
al., 1996).  This region resembles the transactivation domain of a number of 
transcription factors (Abel et al., 1995) and contains two BRCT domains, which are 
situated in tandem at amino acids 1646-1736 and 1760-1855. BRCT motifs have been 
described in a number of proteins such as 53BP1, RAD9, RAD4, Crb2 and RAP1, 
that have function in cell cycle control and DNA damage repair pathways (Callebaut 
and Mornon, 1997; Koonin et al., 1996), consistent with recent data suggesting an 
important role for BRCA1 in cellular responses to DNA damage.  
 
 
 
 
 
 
Figure 2: Features of the human BRCA Proteins (Venkitaraman, 2002) BRCA1 
contains an N-terminal RING domain, nuclear localization signals (NLSs), and two 
C-terminal BRCT domains of ~110 residues (also found in several proteins with 
functions in DNA repair or cell cycle control). BRCA2 contains eight repeats of the 
~40 residue BRC motifs. Six of the eight motifs in human BRCA2 can bind directly 
to RAD51 when expressed in vitro. 
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1.4.3 Cellular expression of BRCA1 
 
In normal cells BRCA1 is a nuclear protein. BRCA1 protein expression is 
reduced or absent in most sporadic, advanced (grade III) ductal breast carcinomas 
(Wilson et al., 1999). Nuclear localization signals have been identified on BRCA1 
(Thakur et al., 1997), which interact with importin-α, a subunit of the nuclear 
transport signal receptor. 
 
BRCA1 mRNA and protein are prefentially expressed during the late G1-early 
S phase of the cell cycle (Gudas et al., 1996). In mitotic cells, BRCA1, BRCA2 and 
RAD51 interact and co-localize in a punctate pattern in the nucleus during the S phase 
of the cell cycle, whereas in meiotic cells all three proteins associate with unsynapsed 
axial elements along developing synaptonemal complexes (Chen et al., 1998b; Scully 
et al., 1997b). BRCA1 function is regulated by phosphorylation; it is 
hyperphosphorylated during the late G1 and S phases by an endogenous kinase 
activity from S1497 and T967 residues, minimally composed of the CDK2-cyclin 
complex that controls the G1-S transition, with dephosphorylation occurring at the M 
phase (Ruffner et al., 1999). A function of BRCA1 at the G1-S transition might be to 
arrest cell cycle progression by binding hyperphosphorylated retinoblastoma protein 
(Aprelikova et al., 1999). 
 
BRCA1 might also regulate the G2-M checkpoint by controlling the assembly 
of mitotic spindles and the appropriate segregation of chromosomes to daughter cells. 
Mouse embryonic fibroblasts carrying a targeted deletion of Brca1 exon 11 had an 
intact G1-S checkpoint but were unable to arrest at the G2-M checkpoint (Xu et al., 
1999). In a significant fraction of cells centrosomes were amplified, resulting in 
abnormal chromosomal segregation and aneuploidy. Proteins that regulated the G2-M 
checkpoint, including p53 and pRB, localize to centrosomes. BRCA1 also localizes to 
centrosomes during mitosis and interacts with γ tubulin, a component of the 
centrosome (Hsu and White, 1998). Mutant BRCA1 might induce genetic instability 
by disrupting centrosome duplication. 
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BRCA1 and BRCA2 are expressed ubiquitously with the highest levels in the 
thymus and testis (Hakem et al., 1996; Miki et al., 1994). In developing mouse 
embryos, both genes are highly expressed in rapidly dividing, differentiating tissues 
and most notably during mammary epithelial proliferation and differentiation (Rajan 
et al., 1997; Rajan et al., 1996). In the mammary gland the expression of both 
messages is developmentally regulated and is induced during puberty and pregnancy 
and reduced during lactation.  
 
 
1.4.4 BRCA1-deficient cells and animal models  
 
To understand how the loss of BRCA1 leads to breast cancer formation, mouse 
genetic models for Brca1 mutation have been established. This work has revealed that 
Brca1 homozygous deletions are lethal at early embryonic day E6.5 (Hakem et al., 
1996; Liu et al., 1996; Ludwig et al., 1997).  Gowen et al generated a distinct 
mutation in Brca1 and observed that embryos survived until E13.5 and exhibited 
defects in neural development, including anencephaly and spina bifida (Gowen et al., 
1996). Another group generated a mouse model with targeted deletion of Brca1 exon 
11 and the resulting embryo died at E12-E18.5 (Xu et al., 1999). Collectively these 
findings imply a role for the BRCA1 gene product in growth and/or differentiation 
during mouse embryogenesis.  
 
Both BRCA1 and BRCA2-deficient cells are characterized by cumulative 
chromosomal abnormalities including chromosomal breaks, aberrant mitotic 
exchanges and aneuploidy (Lee et al., 1999; Xu et al., 1999). BRCA1 and BRCA2 
deficient mice harbor inactivating mutations in p53 and mitotic checkpoint genes (Lee 
et al., 1999; Xu et al., 1999). Mutational inactivation of p53, which governs the G1/S 
cell cycle checkpoint, may thus circumvent the growth arrest that is normally induced 
upon DNA damage and also inhibit p53-mediated apoptosis, thereby permitting the 
survival of cells with severe chromosomal damage. Consistently, the embryonic 
lethality associated with brca1-null mutations can be partially rescued by targeted 
deletion of p53 or p21 (Hakem et al., 1997). On the other hand, inactivation of mitotic 
checkpoint genes could bypass mitotic arrest and permit aberrant chromosomes to 
segregate into progeny cells.  
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BRCA1-deficient HCC1937 cells, BRCA1-null embryonic stem (ES) cells and 
Brca1-exon 11 deletion MEF (fibroblast) cells are all characterized by radiation 
hypersensitivity. Increased sensitivity to the radiomimetic agent methyl methane-
sulfonate (MMS) and ionising radiation (IR), but not to ultraviolet (UV) radiation, has 
also been observed in BRCA1-deficient cells (Gowen et al., 1998; Scully et al., 1999; 
Xu et al., 1999; Zhong et al., 1999). Reintroduction of a wild type BRCA1 allele, but 
not clinically validated BRCA1 missense mutant alleles, can complement the MMS 
and IR sensitivity of BRCA1-deficient cells, suggesting that cellular response to DNA 
damage is compromised in breast cancer patients carrying BRCA1 mutations (Scully 
et al., 1999; Zhong et al., 1999)  
 
 
1.4.5 BRCA1 and p53   
 
One of the key checkpoint genes for BRCA1-mediated tumorigenesis is p53, 
which is the most commonly mutated gene in many common human cancers.  There 
are interesting parallels between p53 and BRCA1. BRCA1, like p53, is a cell cycle 
regulated nuclear phosphoprotein and has also been implicated in DNA damage 
response and repair pathways. In addition BRCA1 interacts with some of the major 
proteins involved in DSB repair and HR and participates in TCR. Both p53 and 
BRCA1 are post-translationally altered by phosphorylation in response to DNA 
damage. p53 regulates BRCA1 expression in response to stress conditions (Arizti et 
al., 2000). BRCA1 associates with the C-terminus of wild-type p53 (Ouchi et al., 
1998) and stimulates transcription from p53-responsive promoters; whereas tumour 
associated mutants of BRCA1 are deficient in this coactivating activity 
(Somasundaram et al., 1999; Zhang et al., 1998).  p53 coimmunoprecipitates with 
BRCA1. Interaction domains of p53 on BRCA1 were identified both at the N-
terminus, overlapping the Rad50 binding domain, and in the second BRCT motif at 
the C-terminus. While BRCA1 is a potent enhancer of p53-mediated transcription, 
BRCA1 mediated stabilization of wild type p53 protein occurs through transcriptional 
activation of the p14 ARF gene and effects on the phosphorylation of p53 through the 
presence of BRCA1. Indeed, cells with deletions of exon 11 of BRCA1 are defective 
in the rapid stabilization of p53 following DNA damage (Xu et al., 2001). It is likely 
that BRCA1 participates in p53 stabilization in vivo. Like p14ARF, p53 has been 
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shown to repress the transcription of BRCA1, acting in a negative feedback loop of its 
own stabilization (Arizti et al., 2000; MacLachlan et al., 2000). 
 
Evidence from conditional knockout mice suggests that loss of BRCA1 in 
mammary epithelial cells leads to incomplete proliferation, apoptosis and tumours at a 
low frequency (Xu et al., 1999). In these mice additional heterozygous mutations in 
p53 leads to many more mammary tumours, most of which have lost the remaining 
p53 allele. Tumours in patients with germline BRCA1 or BRCA2 mutations are 
frequently associated with somatic mutations of p53. In the proposed model, mutant 
p53 would inactivate a cell cycle checkpoint and lead to uncontrolled growth and 
invasive growth. Cells that have successfully escaped death by checkpoint will 
probably accumulate multiple mutations. Amplification of MYB oncogene and 
reduction of anti-apoptotic gene Bcl-2 are characteristics of most breast tumours from 
BRCA1 mutation carriers (Freneaux et al., 2000; Kauraniemi et al., 2000). 
 
A recent report indicated that BRCA1 selectively coactivates the p53 
transcription factor towards the genes that direct DNA repair and cell cycle arrest but 
not towards those that direct apoptosis (MacLachlan et al., 2002). Because BRCA1 
overexpression stabilizes wild-type p53 but does not lead to apoptosis in most cell 
lines, the selectivity of BRCA1 for p53 dependent target gene activation has been 
analyzed using arrays containing known targets. It has been found that BRCA1-
stabilized p53 regulates transcription of DNA repair and growth arrest genes, while 
p53 stabilized by DNA damaging agents induces genes involved in apoptosis. 
 
 
1.5 Functions of BRCA1  
 
Cancer susceptibility gene mutations fall into two general classes (Kinzler and 
Vogelstein, 1997). Genes whose mutation or altered expression relieves normal 
controls on cell division, death or lifespan, promoting the outgrowth of cancer cells, 
have been termed “gatekeepers”. Those whose disruption causes genome instability, 
increasing the frequency of alterations in gatekeeper genes, work instead as 
“caretakers”. BRCA genes are essential for preserving chromosome structure, 
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suggesting that, in their role as tumour suppressors, they behave as caretakers, 
suppressing genome instability (Figure 3). 
 
BRCA1 may function as a scaffold in the assembly of a multi-protein 
complex, which is important in maintenance of genomic integrity by functioning in 
gene transcription, chromatin remodelling, checkpoint activation, DNA damage repair 
and transcription-coupled DNA-damage repair. Some of the functions in which the 
BRCA1 protein has been implicated are summarized in Figure 4. Figure 5 shows the 
putative roles of BRCA1 based on reported interactions. BRCA1 interacting proteins 
are summarized in Table 3.  BRCA1 performs its tumour suppressor function in many 
ways: 
 
 
 
Figure 3: Repair genes as caretakers of the genome. (Khanna and Jackson, 2001) 
When cells lack one of the repair proteins, they fail to repair the DSBs correctly. This 
leads to genetic instability, gross chromosomal rearrangements and accumulation of 
mutations. These events then trigger cell-cycle checkpoints resulting in permanent 
growth arrest or death of affected cells. If the checkpoints are inactivated by 
mutations, this leads to tumorigenesis. 
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Figure 4: Multiple cellular functions of BRCA1 
 
 
 
 
Figure 5: Putative roles of BRCA1 (Venkitaraman, 2002) 
BRCA1 works as a signal processor (1) during DNA damage responses in complex 
with proteins that bind to aberrant DNA structures (sensors), and the kinases that 
signal their presence. Phosphorylation of BRCA1 may be essential for local functions 
[control of DSB resection (2), altering DNA topology (3)] near a DNA lesion, as well 
as for distant functions such as transcriptional control of checkpoint genes (4) (e.g., 
GADD45) or targets of estrogen receptor signalling, or transcription-coupled DNA 
repair (5) BRCA1 works with BARD1 (6) works as an ubiquitin ligase
BRCA1         BRCA1-P 
DNA damage 
      Transcriptional regulation 
DNA repair by homologous recombination 
Checkpoint activation and apoptosis 
Transcription-coupled DNA repair 
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Table 3: BRCA1 interacting proteins (Modified from Welcsh and King, 2002) 
 
BRCA1 interacting protein or complex Function of interacting protein Interacting domain on BRCA1 (aa) Reference 
RAD51 DSB repair exon 11 (758-1064) Scully et al., 1997 
RAD50 DSB repair exon 11 (341-748) Zhong et al., 1999 
BRCA2 DSB repair BRCT domain (1314-1863) Scully et al., 1997 
BASC (ATM, BLM, MSH2, MSH6, MLH1, RCF) Mismatch repair BRCA1 part of complex Wang et al., 2000 
ATP-MSH2 Mismatch repair ? Wang et al., 2000 
H2AX Signals DNA damage ? Paull et al.,2000 
p53 transcription factor, tumor suppressor Exon 11 and BRCT domain (244-500 and 1760-1863) Zhang et al., 1998;Ouchi et al., 1998; Chai et al., 1999 
pRB cell cycle regulator, tumor suppressor exon 11 and BRCT domain (304-394 and 1536-1863) Aprelikova et al., 1999 
c-Myc transcription factor, oncogene N-terminus and exon 11 (175-303 and 433-511 Wang et al., 1998 
ZBRK1 transcription factor, represses GADD45 exon 11 (341-748) Zheng et al., 2000 
ATF transcription factor RING (1-101) Houvras et al., 2000 
STAT1 signal transducer, transcriptional activation exon 11 (502-802) Ouchi et al.,2000 
E2F transcription factor, cell cycle regulator N-terminus (1-76) Wang et al., 1997 
RNA Pol II Holoenzyme (hRPB10a;hRPB2) transcription BRCT domain (1650-1800) Scully et al., 1997; Schlegel et al.,2000 
RNA helicase A component of RNA PolII holoenzyme BRCT domain (1650-1800) Anderson et al., 1998 
BACH1 DNA helicase BRCT domain (1650-1800) Cantor et al., 2001 
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Estrogen receptor ligand responsive transcription factor N-terminus (1-300) Fan et al., 1999;2001  
Androgen receptor ligand responsive transcription factor exon 11 and BRCT domain (758-1064 and 1314-1863) Yeh et al., 2000 
CtIP binds CtBP; transcriptional co-repressor BRCT domain (1651-1863) Li et al., 1999; Yu et al.,1998; Wong et al.,1998 
p300/CBP transcriptional co-activator RING and BRCT domain (1-303 and 1314-1863) Pao et al.,1998 
SWI/SNF chromatin remodelling complex exon 11 (260-553) Bochar et al., 2000 
HDAC l and 2 Histone deacetylation, chromatin remodelling BRCT domain (1563-1863) Yarden and Brody, 1999 
Centrosome (p53, pRB, Nm23) chromosome segregation BRCA1 part of complex Hsu and White, 1998 
BRAP2 cytoplasmic retention NLS (303-701) Li et al.,1998 
Vasolin containing protein (VCP) ATPase exon 11 (303-625) Zhang et al.,2000 
BARD1 Ubiquitination? Polyadenylation via CstF-50? RING (1-101) Wu et al.,1996 
BAP1 Deubiquitinating enzyme RING (1-101) Jensen et al., 1998 
Importin a nuclear transport NLS (303-701) Chen et al., 1996 
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1.5.1 BRCA1 in damage signalling  
 
An important step in the cellular response to DNA damage is to transduce 
damaged signals to downstream effectors involved in the arrest of cell cycle and 
repair of damaged DNA (figure 6). In mammalian cells, several kinases such as, 
ATM, ATR, DNA-PK, Chk1 and Chk2 are activated in response to DNA damage. 
BRCA1 becomes hyperphosphorylated in response to treatment of cells with a variety 
of DNA damaging agents including UV, hydroxyurea, mitomycin C, MMS, IR, H2O2 
and adriamycin (Chen et al., 1996a; Li et al., 1999; Scully et al., 1997b). In vitro and 
in vivo phosphorylation sites in BRCA1 have been identified. The data from these 
studies have suggested that phosphorylation of BRCA1 by these kinases is necessary 
for BRCA1-mediated DNA damage response and multiple kinase activities are 
responsible for the DNA damage-induced hyperphosphorylation of BRCA1. Table 4 
shows the in vivo phosphorylation sites on BRCA1. In addition to ATM, ATR and 
Chk2, DNA-PK have been shown to phosphorylate BRCA1 in vitro (Lim et al., 2000) 
 
 
BRCA1 kinases  In vivo phosphorylation sites      Reference 
ATM   S1189, S1457, S1524, S1542  (Li et al., 2000) 
ATR   S1423     (Tibbetts et al., 2000) 
Chk2   S988     (Lee et al., 2000) 
 
Table 4: BRCA1 modifying proteins 
 
 
 Besides its roles in maintenance of genomic integrity, chromatin remodelling, 
and transcriptional regulation, BRCA1 has also been implicated in cell 
cycle/checkpoint control. BRCA1 regulates the G2/M checkpoint by activating Chk1 
kinase upon DNA damage. BRCA1 regulates the expression of both Wee1 kinase, an 
inhibitor Cdc2/Cyclin B kinase and 14-3-3 family of proteins that sequesters 
phosphorylated Cdc25C and Cdc2/cyclin B kinase in the cytoplasm, leading to a 
conclusion that BRCA1 regulates key effectors that control the G2/M checkpoint and 
is therefore involved in regulating the onset of mitosis (Yarden et al., 2002).  
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Figure 6: Signaling of DSBs. (Khanna and Jackson, 2001) 
a, The general organization of the DNA-damage response pathway. The presence of 
DSBs is recognized by a sensor, which transmits the signal to a series of downstream 
effector molecules through a transduction cascade to activate signaling mechanisms 
for cell-cycle arrest and induction of repair, or cell death if the damage is irreparable. 
b, A central role for ATM in the cellular response to DSBs. ATM is activated in 
response to DSBs. Activated ATM signals the presence of DNA damage by 
phosphorylating targets involved in cell-cycle arrest, DNA repair and stress response. 
p21 inhibits the activity of cdk2/cyclinE and 14-3-3  inhibits the activity of 
cdc2/cyclin B and effecting cell-cycle arrest. c-Abl activates stress-activated protein 
kinase (SAPK) for transcriptional regulation of stress-response genes. 
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Phosphorylation of BRCA1 is apparently important for a proper DNA damage 
response. However, it remains unclear how phosphorylation modulates activities of 
BRCA1. Since BRCA1 forms a complex with RAD50/MRE11/NBS1 and colocalizes 
to DNA damage sites following ionizing radiation, it has been speculated that BRCA1 
is involved in double strand break repair (Cortez et al., 1999; Lee et al., 2000). 
Alternatively, phosphorylation of BRCA1 may influence the transcriptional regulation 
activities of BRCA1 leading to cell cycle checkpoint.  ATM phosphorylates CtIP in 
vivo and in vitro following IR treatment (Li et al., 2000). This ATM dependent 
phosphorylation is required for dissociation of the CtIP/CtBP corepressor complex 
from BRCA1 and subsequently leads to relieving BRCA1 mediated repression of 
GADD45 transcription and p21 expression (Li et al., 2000). These studies suggest that 
CtIP mediates one of the functional links between ATM and BRCA1 in DNA damage 
signaling pathways. 
 
 
1.5.2 BRCA1 in chromatin remodelling  
 
BRCA1 plays an important role in the cellular response to double strand 
breaks. Within minutes of DNA damage, the histone H2A family member H2AX 
becomes extensively phosphorylated and forms foci at break sites. BRCA1 is 
recruited to these foci several hours before other factors such as RAD50 and RAD51, 
suggesting that BRCA1 and H2AX initiate repair by modifying local chromatin 
structure, thereby allowing DNA repair proteins access to damaged sites (Paull et al., 
2000). In support of this role for BRCA1 in response to DNA damage, it has been 
shown that BRCT domains of BRCA1 bind double strand breaks (Yamane et al., 
2000). 
 
BRCA1 interacts with the SWI/SNF chromatin remodelling complex (Bochar 
et al., 2000),  with regulators of histone acetylation/deacetylation (Pao et al., 2000; 
Yarden and Brody, 1999), with a novel helicase BACH1 (Cantor et al., 2001) and 
RecQ homolog encoded by the Bloom’s syndrome gene, BLM helicase (Wang et al., 
2000b). How these interactions may assist DSB repair is currently speculative. 
Chromatin changes mediated by histone modification may make DNA more 
accessible by the helicases and repair machinery.  
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1.5.3 BRCA1 in DNA repair 
 
BRCA1 appears to participate in the cellular DNA damage response at 
multiple stages. In normal cells, responses to DNA damage include sensing damaged 
DNA, transducing DNA damage signals, relocating repair machinery to damage sites, 
completing a repair process and coordinating cell cycle progression with the DNA 
repair process. Accumulating evidence suggests that BRCA1 functions not only in 
association with the DNA repair machinery, but also in DNA damage induced cell 
cycle checkpoint control. BRCA1 may additionally regulate the expression of genes 
involved in DNA damage repair and also directly participates in the repair process 
itself. Finally phosphorylation of BRCA1 upon DNA damage implies a role for 
BRCA1 in DNA damage-induced signal delay.  
 
BRCA1 interacts with the RAD50/MRE11/NBS1 protein complex containing 
the mammalian homologs of yeast molecules known to participate in double strand 
break repair, comigrants to sites marked by phospho-H2AX (Zhong et al., 1999). The 
equivalent of this complex in yeast, the Rad50/Mre11/Xrs2 complex functions in both 
nonhomologous end joining (Ivanov et al., 1992) and homologous recombinational 
repair of DNA double strand breaks (Bressan et al., 1999). Rad50/Mre11/Xrs2 
complex has been shown to be involved in other cellular processes including 
chromatin configuration and telomere maintenance (Chamankhah et al., 2000; 
Gerecke and Zolan, 2000; Ohta et al., 1998). It has been proposed that 
Rad50/Mre11/Xrs2 is responsible for end processing of double strand breaks 
(Tsubouchi and Ogawa, 1998). In support with this idea, recombinant MRE11 
proteins and purified human RAD50/MRE11/NBS1complexes exhibit exonuclease 
and endonuclease activities (Paull and Gellert, 1998). MRE11 encodes a nuclease 
activity, which resects flush DSB ends to generate ssDNA tracts. Under certain in 
vitro conditions, BRCA1 can inhibit this activity of MRE11 (Paull et al., 2001), 
regulating the length and presumably the persistence of ssDNA generation at sites of 
DNA breakage. It has been proposed that RAD50 may be a chromatin-associated 
protein and participate in chromatin structural reconfiguration (Alani et al., 1989). 
NBS1 is the product of the gene mutated in Nijmegen Break Syndrome (Carney et al., 
1998). 
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BRCA1 appears to interact with the RAD50/MRE11/NBS1 complex directly 
through RAD50 (Zhong et al., 1999). Similar to the formation of the 
RAD50/MRE11/NBS1 complex, the association of BRCA1 with this complex does 
not change in response to DNA damage. Rather, the nuclear partitioning of this 
BRCA1-containing complex changes and BRCA1 forms ionising radiation-induced 
foci (IRIF), which is also a characteristic of RAD50, MRE11 and NBS1 (Maser et al., 
1997). 
Besides RAD50/MRE11/NBS1, other components involved in DNA damage 
repair, such as MSH2, MSH6, MLH1, ATM and BLM have been found to reside in a 
large BRCA1-containing DNA repair complex (Wang et al., 2000b). In addition, 
DNA replication factor C and PCNA (proliferating cell nuclear antigen) were also 
found in this complex. This complex has been proposed to present a BRCA1-
associated genome surveillance complex (BASC) since many of its constituent 
proteins individually recognize distinctly abnormal DNA structures such as double 
strand breaks, base pair mismatches and stalled replication forks. Therefore the 
association of BRCA1 with these proteins suggests that BRCA1 may also participate 
in the resolution of aberrant DNA structures that occur during DNA replication or 
when DNA replication is stalled (Wang et al., 2000b). Consistent with this notion, a 
previous observation that BRCA1 foci at S phase disperse in response to DNA 
damage or replication blocks, and relocalize to PCNA-containing structures (Scully et 
al., 1997a), suggestive of a role for BRCA1 in replicational DNA repair.  
 
BRCA1 has also been shown to interact and colocalize with RAD51 (Chen et 
al., 1998b; Scully et al., 1997b). Eukaryotic RAD51 proteins are homologs of 
bacterial RecA and are required for recombination during mitosis and meiosis and for 
recombinational repair of DNA double strand breaks. In response to DNA damage, 
BRCA1 undergoes distinctive phosphorylation that differs from the phosphorylation 
during G1-S transition (Scully et al., 1997a). The association of RAD51 and BRCA1 
is supported by the observation that BRCA1 foci disperse during the S phase, and 
relocalize to PCNA-containing structures in response to UV-treatment or replication 
block by hydroxyurea (Scully et al., 1997b). BRCA1 has also been observed in IR-
induced RAD51 foci; however such foci are distinct from those comprising BRCA1 
and the RAD50/MRE11/NBS1 complex (Zhong et al., 1999). While the 
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RAD50/MRE11/NBS1 complex has been proposed to function in end processing, an 
early step in both homologous recombination and non-homologous end joining based 
repair of DNA double strand breaks, Rad51 is involved in strand exchange, a later 
step in homologous recombination. Homologous recombination is defective in 
BRCA1-deficient cells, but non-homologous end joining is unaffected (Wang et al., 
2001). The biological implications underlying the dual participation of BRCA1 in two 
distinct steps of homology based recombinational DSB remain to be resolved.   
 
On the other hand, besides DSB repair BRCA1 specifically enhances the 
global genomic repair pathway, independent of p53, and can induce p53 independent 
expression of the nucleotide excision repair genes XPC (a gene defective in 
xeroderma pigmentosum group C), DDB2 (a gene defective in xeroderma 
pigmentosum group E cells and the p48 protein) and GADD45 (gene involved in 
growth arrest and DNA damage). (Hartman and Ford, 2002). This work has suggested 
a mechanism for the effect of BRCA1 on global genome repair involving 
transcriptional regulation of nucleotide excision repair genes. BRCA1 can activate 
GADD45 promoter independent of p53, supporting the notion that BRCA1 activates 
GADD45 and maintains global genome repair in p53 deficient cells. This finding 
pointed to an important role for BRCA1 in DNA repair and the maintenance of 
genomic stability suggesting a specific mode of action for BRCA1 in DNA damage 
response pathways.  
 
Transcription coupled repair: Brca1-deficient mouse embryonic stem cells have 
been shown to be defective in the ability to carry out transcription-coupled repair 
(TCR), a process in which DNA damage is repaired more rapidly in transcriptionally 
active DNA than in the genome as a whole (Gowen et al., 1998). DNA damage 
induced by UV as well as oxidative damage caused by IR or H2O2 can be repaired by 
TCR. It has been demonstrated that Brca1-deficient cells are defective in TCR of 
oxidative DNA damage, but not in TCR of UV-induced DNA damage. Consistent 
with this observation, these Brca1-deficient cells are hypersensitive to oxidative DNA 
damage. Presently, it is not clear whether BRCA1 itself participates directly in TCR 
or, alternatively, whether, it functions as a transcription factor essential for the 
expression of genes whose products are required for TCR of oxidative damage 
(Gowen et al., 1998). 
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1.5.4 BRCA1 as a modulator of gene transcription 
 
A role for BRCA1 in transcriptional regulation was initially indicated by the 
identification of an acidic domain near the carboxyl-terminus of BRCA1 with an 
inherent transactivation function that is sensitive to cancer predisposing mutations 
(Chapman and Verma, 1996; Chen et al., 1996a; Monteiro et al., 1996). This segment 
of BRCA1 polypeptide is rich in acidic amino acid residues, a character found in the 
activation domain of many transcription factors. When fused to a heterologous DNA-
binding domain, the carboxyl terminal of BRCA1 was observed to exhibit strong 
transcriptional activity in mammalian cells and this activity was completely abolished 
by familial breast cancer derived BRCA1 mutations (Chapman and Verma, 1996; 
Chen et al., 1996a; Monteiro et al., 1996). The presence of an autonomous 
transactivation function within BRCA1, coupled with the absence of demonstrable 
sequence-specific DNA-binding activity, has led to the hypothesis that BRCA1 
functions as a co-regulator of transcription.  
 
BRCA1 interacts with several transcription factors such as p53, CtIP, c-myc, 
ZBRK1, ATF, E2F and signal transducer STAT1 (Zheng et al., 2000) and modulates 
their activity. In these studies, it appears that BRCA1 can activate transcription in 
some cases and repress transcription in others. For example, BRCA1 can bind to p53 
and enhance its transcription activity at the promoter of p21WAF/CIP or BAX (Ouchi et 
al., 1998; Somasundaram et al., 1997; Zhang et al., 1998). Furthermore BRCA1-
induced cell cycle arrest is dependent on functional p21. A recent study identified the 
transactivation of cyclin dependent kinase inhibitor p27Kip1 by BRCA1 (Williamson et 
al., 2002).  
 
BRCA1-mediated transcriptional activation 
The initiation of RNA polymerase II transcription represents a critical step for 
gene expression regulation within the cell. Gene-specific activators function to 
stimulate the rate of transcription initiation largely through the recruitment of either 
chromatin remodelling activities and/or the general transcription machinery in order 
to override nucleosome-mediated promoter repression and assemble transcription-
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competent pre-initiation complexes, respectively. BRCA1 may mediate gene-specific 
transcriptional activation via both of these recruitment steps. 
 
BRCA1 could play a role in the recruitment of chromatin remodelling 
activities. BRCA1 has been shown to interact directly or indirectly with chromatin 
modifying activities including p300 (Pao et al., 2000), hBRG1 (Bochar et al., 2000) 
and BRCA2 (Chen et al., 1998b), which itself is associated with histone 
deacetyltransferase activity. BRG1 is a component of SWI/SNF chromatin 
remodelling complex. It has recently been shown that BRCA1 carboxyl terminal 
transactivation domain, when targeted to chromatin via a heterologous DNA-binding 
domain, can alter chromatin structure (Hu et al., 1999). Significantly, the cancer-
predisposing mutations that abolish its transcriptional activation function also 
abrogate the ability of this domain to effect chromatin remodelling. 
 
BRCA1 is likely to function in transcriptional activation involving RNA 
polymerase II holoenzyme recruitment. BRCA1 was found to be associated and co-
purified with the RNA polymerase complex and interactions have been demonstrated 
with constituent holoenzyme components, including RNA helicase A (RHA) 
(Anderson et al., 1998; Schlegel et al., 2000; Scully and Livingston, 2000). CBP/p300 
(Pao et al., 2000) and RNA polymerase II itself from its subunits hRBP2 and 
hRBP10a (Schlegel et al., 2000). The ability of BRCA1 to bind to RNA helicase A 
has been shown to be essential for the transactivation activity of BRCA1. CBP/p300 
has been found to interact with BRCA1 and stimulates BRCA1-directed transcription 
activation (Pao et al., 2000). These observations implicate a model to account for 
transcriptional activation by BRCA1: gene-specific activators, by interacting with 
BRCA1, recruit the RNA polymerase II holoenzyme complex onto target promoters 
in order to effect an increase in the transcription rate of genes under their control. 
 
BRCA1-mediated transcriptional repression 
The carboxyl terminus of BRCA1 not only binds transcriptional coactivators 
but also transcriptional corepressors such as CtIP/CtBP complex and histone 
deacetylases (HDACs) (Li et al., 1999; Yarden and Brody, 1999). Interestingly 
familial breast cancer derived mutations that compromise its transactivation activity 
also abolish the binding of BRCA1 to CtIP and HDACs.   
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BRCA1 has been shown to repress c-Myc-mediated transcriptional activation 
from synthetic promoters carrying c-Myc response elements as well as natural c-myc 
responsive CDC25A promoter (Wang et al., 1998). The negative effect of BRCA1 on 
c-myc mediated transactivation could derive from trans-repression involving 
inhibition of either Myc-Max heterodimer formation or DNA binding by Myc-Max 
heterodimers. This BRCA1-mediated transcriptional repression can be correlated with 
its inhibition of c-myc mediated cellular transformation, thus providing one potential 
mechanism for BRCA1-mediated tumour suppression (Wang et al., 1998). 
 
BRCA1 inhibits the transactivation activity of estrogen receptor (Fan et al., 
1999). This BRCA1-mediated inhibition of estrogen receptor transactivation takes 
place by the interaction of p300 and ER-α. Cofactors p300 and CBP modulate the 
ability of BRCA1 protein to inhibit ER-
 α signaling. It has also been suggested that, 
BRCA1 inhibition of ER-
 α activity may be, in part, attributable to the down 
regulation of p300 (Fan et al., 2002). The estrogen signaling pathway controls 
multiple aspects of breast and ovarian cell growth, differentiation and homeostasis. 
Furthermore, estrogen itself is a distinct etiological factor in breast and ovarian 
cancer. By affecting hormone response pathways, BRCA1 may regulate growth or 
differentiation in a cell-type specific manner.  
 
BRCA1 mediated transcriptional repression has also been implicated in 
silencing the DNA-damage inducible p21 and GADD45 genes in their uninduced 
states. BRCA1 can mediate sequence specific transcriptional repression through its 
selective recruitment by a novel DNA-binding transcription factor ZBRK1 (zinc 
finger and BRCA1-interacting protein with a KRAB domain). BRCA1 has been 
shown to mediate ZBRK1-directed repression through a ZBRK1 binding site 
identified in intron 3 of the GADD45 gene, thus providing a potential mechanistic link 
between the activities of BRCA1 in gene-specific transcription control, the cellular 
DNA damage response and the maintenance of genome integrity (Zheng et al., 2000). 
ZBRK1 binds to the specific sequence GGGxxxCAGxxxTTT. This motif has been 
identified in the previously identified BRCA1 downstream targets (Harkin et al., 
1999; MacLachlan et al., 2000) such as GADD153, Ki-67, Bax, p21 EGR1, 
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amphiregulin prothymosin, TIMP-1, TIMP-2, and Topo IIa. BRCA1 mediated control 
of p21 and GADD45 gene transcription may contribute to its role in cell cycle 
checkpoint, since p21 and GADD45 have been implicated in DNA-damage induced 
G1/S and G2/M checkpoint control, respectively (Brugarolas et al., 1995; Deng et al., 
1995; el-Deiry et al., 1993; Wang et al., 1999). 
 
The association of BRCA1 with CtIP/CtBP or HDACs suggests a more direct 
role for BRCA1 in active repression and thus provides an alternative explanation for 
the negative effect of BRCA1 on transcription. 
 
Human CtBP was initially identified as an adenovirus E1A C-terminal 
interacting protein capable of attenuating E1A-mediated transcriptional activation and 
tumorigenesis (Schaeper et al., 1995). CtBP serves as corepressor for a variety of 
DNA binding transcriptional repressors. Each of these CtBP-interacting 
transcriptional repressors harbor a conserved amino acid sequence motif, PLDLS, that 
was originally identified in E1A and that specifies the association of each with CtBP. 
The same sequence motif present in CtBP-interacting transcriptional repressors also 
specifies the interaction of CtBP with CtIP, a protein initially identified by virtue of 
this interaction (Schaeper et al., 1995). Meanwhile, several groups have identified the 
interaction between CtIP and BRCA1 (Li et al., 1999; Wong et al., 1998; Yu et al., 
1998). CtIP was found to link the corepressor CtBP to BRCA1 (Li et al., 1999). 
Interestingly, a second tumour suppressor, the retinoblastoma (Rb) protein and one of 
its associated family members, p130, also interact with CtIP (Meloni et al., 1999). Its 
specific interaction with two distinct tumour suppressor proteins implies a 
fundamental role for CtIP in tumour suppression. 
 
Another distinct corepressor complex which BRCA1 interacts, is the histone 
deacetylase complex (Yarden and Brody, 1999). BRCA1 has been shown to associate 
at least four components of the histone deacetylase complex, HDAC1, HDAC2, 
RbAp46 and RbAp48. This observation suggests that BRCA1-mediated 
transcriptional repression may derive, at least in part, from active recruitment of 
HDACs. 
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Current experimental observations are consistent with several alternate 
possibilities by which BRCA1 mediates transcriptional repression. First, BRCA1 
corepression could involve targeted chromatin remodelling; BRCA1 could, by virtue 
of its direct recruitment of HDAC complexes, alter the chromatin structure of its 
target genes into a repression-favored status. Alternatively, BRCA1 could affect 
remodelling via its interaction with the CtIP-CtBP corepressor complex. Or, the 
association of BRCA1 with the RNA polymerase II holoenzyme may support a 
distinct mechanism for corepression by which BRCA1 directly targets either the 
general transcription machinery or interacting coactivators. 
 
 
1.5.5 Other potential functions of BRCA1 
 
BRCA1 associates with BAP1, which is a de-ubiquitinating enzyme, 
suggesting a role for BRCA1 in ubiquitin-dependent protein degradation. The 
potential role of BRCA1 in post-transcriptional RNA processing may coordinate with 
its role in transcriptional regulation. Like other RING proteins BRCA1/BARD1 
complex functions as an E3 ubiquitin ligase of undetermined specifity (Hashizume et 
al., 2001; Ruffner et al., 2001).  Cancer predisposing mutations within the BRCA1 
RING domain abolishes its ubiquitin ligase activity (Ruffner et al., 2001). The 
ubiquitin ligation function of BRCA1 is poorly understood. The protein encoded by 
FANCD2 mutated in Fanconi’s anemia, a disease characterized by chromosomal 
instability and cancer predisposition, localizes with BRCA1 to focal sites after DNA 
damage (Garcia-Higuera et al., 2001). Redistribution is dependent upon 
monoubiquitination of FNACD2, although it is not known whether the 
BRCA1/BARD1 complex can perform this modification. 
 
The BRCA1 binding protein, BARD1, can associate with polyadenylation 
factor CstF50 and inhibit polyadenylation (Kleiman and Manley, 1999). BARD1 was 
found colocalized with BRCA1 during S-phase but not in G1 (Jin et al., 1997). 
Therefore BRCA1-BARD1 complex may also play a role in gene transcription at the 
level of polyadenylation of mRNA. 
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1.6 Identified BRCA1 regulated targets 
 
Recent studies utilizing gene expression profiling methodologies have 
revealed that ectopic overexpression of BRCA1 can induce a diverse array of genes 
implicated in cell growth control, cell cycle regulation, DNA replication and repair. 
As BRCA1 protein levels increase between mid-S and G2 phases of the cell cycle 
(Chen et al., 1996b), it is possible that BRCA1 overexpression strategies may 
stimulate the status of BRCA1 during these physiological periods and thereby provide 
at least a limited window onto the spectrum of target genes under its transcriptional 
control. 
 
In general, several gene expression-profiling methodologies are used to assess 
the transcriptional activity in the cells. A cell responds to its changing environment in 
many ways, including regulated shifts in gene transcription. Experiments are often 
designed to monitor altered gene expression of the gene of interest in response to a 
stimulus. In addition, enforced expression or inhibition of a gene may induce a 
biological response that illuminates the activity of the gene product. Several 
overexpression studies have been extensively used in order to identify the shifts in 
patterns of gene expression such as tight regulation of the expression of the gene of 
interest (tetracycline or ecdysone inducible system) or expression of the gene of 
interest under modified strong viral promoter (CMV promoters). Once the 
components of the inducible system are stably introduced into the cell, tightly 
regulated expression systems are preferred because the expression of the gene of 
interest is controlled in terms of induction of the gene with a small molecule that is 
not toxic to mammalian cells. Because overexpression of many genes may result in 
apoptosis in cells, the use of inducible systems also overcome this problem. Reporter 
genes (ß-galactosidase or luciferase) with these expression systems are also used to 
elucidate promoter functioning. 
 
As gene expression studies alone will not elucidate the function of the encoded 
protein, expression-profiling methodologies are used to analyse the transcriptional 
response of the cells to the changing environment.  
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Expression profiling describes a group of technologies that simultaneously 
assess the transcriptional activity of a large number of genes. Recent technological 
developments have made it possible to rapidly evaluate hundreds or even thousands of 
genes for their transcriptional responses in biological and pathological situations. 
These methods assess alterations in steady-state levels of mRNA. The strengths and 
the weaknesses of some the techniques are summarized in Table 5: 
 
 
   Gene  Gene               Set-up 
Method   discovery coverage Sensitivity Labor  cost 
EST sequencing  Yes  Low  Low  Medium            Lowa 
SAGE   Yes  Medium  Low  Medium            Lowa 
Real-time Q-PCR  No  Low  High  Low         Medium 
Differential display Yes  Low  High  Medium            Low 
Subtractive hybridization Yes  Low  High  Medium            Low 
cDNA microarrays Yesb  High  Medium  Highc            High 
Oligo microarrays No  High  Medium  Lowd            Highd 
 
Table 5: Summary of methods for gene expression profiling. Seven methods for 
gene expression analysis are compared. Gene discovery refers to the capability of the 
method to identify new genes. Gene coverage indicates the number of genes that are 
reasonably handled by the technique. Sensitivity is an assessment of the technique to 
detect rare mRNAs. Also summarized are the labor and the initial set-up costs 
required to complete a typical experiment. 
a  Assumes adequate DNA sequencing capacity is available. 
b  Considers arraying anonymous genes from cDNA libraries. 
c  Considers labor to fabricate and utilize arrays. 
d  Assumes the purchase of prefabricated arrays. 
(Modified from Stanton, 2001) 
 
 
In this thesis study, subtractive hybridization was used to identify the 
transcriptionally regulated targets of BRCA1 since it is sensitive, allows detection of 
low abundance transcripts, allows discovery of new genes and is cheaper when 
compared to other techniques. Several other studies have aimed to identify the 
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BRCA1 regulated genes by other methodologies. This is the first study to investigate 
the downstream targets of BRCA1 by the SSH technique. 
 
In order to identify a series of downstream targets of BRCA1, Harkin et al 
initially established an osteosarcoma cell line with tightly regulated BRCA1 
expression with the tetracycline inducible system (Harkin et al., 1999). High-density 
oligonucleotide arrays were used to analyze gene expression profiles at various times 
following BRCA1 induction. Among many genes, they have identified GADD45 as 
one of the major targets of BRCA1  (Table 6) and showed the p53 independent 
activation by BRCA1, which suggested the JNK/SAPK pathway for BRCA1-induced 
apoptosis. With the same tetracycline inducible system, but this time with a breast 
carcinoma cell line, Mullan et al have again identified GADD45 as the major target of 
BRCA1 by using oligonucleotide arrays (Mullan et al., 2001). 
 
 
Table 6: List of BRCA1 upregulated genes (Harkin et al., 1999) 
 
Description         Fold induction by northern 
BRCA1      60 
GADD45     35 
EGR1      10 
Tristetraproline (TTP)    5 
Gem GTPase     5 
Br140      4 
Unidentified cDNA (R12810)   4 
PM-scl 75     3 
ATF3      3 
ARD1      3 
Hepatic leukemia factor    3 
Amphiregulin     3 
TR3 Orphan receptor (NAK1)   3 
TNFα-inducible gene A20    2 
Fibroblast activating protein α   2 
IL4 receptor α     2 
EST (R41997)     2 
EST (H81220)     2 
KIAA0055     2 
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Later on MacLachlan et al, have overexpressed BRCA1 by using an 
adenovirus vector and high density cDNA array screening of colon, lung and breast 
cancer cells and have identified several genes affected by BRCA1 expression in a 
p53-independent manner including DNA damage response genes and genes involved 
in cell cycle control (MacLachlan et al., 2000). Notable changes were observed as the 
induction of GADD45 and GADD 153 genes and reduction of cyclin B1 expression. 
 
Table 7: List of BRCA1 downstream genes (MacLachlan et al., 2000) 
Induced genes  
 
Repressed genes  
 
Gene Fold induction Gene Fold reduction  
 
CDC34a 2.14 GRB2 adaptor 2.05  
PCTAIRE1a 1.59 grb10 5.50  
cdk4 2.18 PIN1a 5.30  
p21WAF1/Cip1a 1.68 Cyclin B1a 1.50  
PCNAa 3.40 Cytokeratin 4 1.23  
Cytokeratin 2E 1.23 Cytokeratin 5 1.30  
RhoAa 3.42 BAXa 3.80  
METa 2.70 BAKa 3.70  
Superoxide dismutasea 1.10 Frizzled-relateda 4.30  
IGFBP2 2.08 Frizzled homolog 8.30  
IGFBP4 3.30 Dishevelled homolog 2.00  
Ku70a 2.01 RAR rxr-  3.30  
Ku60a 3.40 Collagen type VIII -1 4.30  
Yeast rad6 homologa 2.62 Zyxin 1.29  
Gadd 153a 1.76 CD59 2.80  
Gadd 45a 2.65 Collagen type XVI -1 1.20  
DNA Topo II  isozyme 2.56 Semaphorin V 1.31  
DNA Topo I 1.32 CD9a 1.17  
Lunatic fringe 1.73  -actin 1.04  
TIMP-1a 2.03    
TIMP-2 1.34    
 Catenina 3.20    
p21RAC1 1.83    
Nucleoside kinase Aa 1.64    
Nucleoside kinase B 1.63    
EB1 (APC binding protein) 1.21    
rho GDP dissociation inhibitor 1 1.76    
Glyceraldehyde-3-phosphate dehydrogenase 1.01    
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Aprelikova et al have analyzed Brca1-deficient mouse embryonic stem cells, 
using oligonucleotide arrays to characterize the BRCA1 regulated genes (Table 8) 
(Aprelikova et al., 2001). They have found that loss of BRCA1 results in decreased 
expression of stress response genes and 14-3-3σ, a major G2/M checkpoint control 
gene. BRCA1 induced transcription of the endogenous 14-3-3σ was in a p53 
dependent manner. 
 
 
Table 8:  Genes downregulated in Brca1 -/- cells (Aprelikova et al., 2001) 
 
Function    Gene name     
G2/M control    14-3-3 σ 
Stress response    DNAJ protein homolog 2  
Heat shock protein 86  
Transription    Id3 
AP-2.2 
EST (S-II TF related) (D00925) 
ATP-dependent RNA helicase 
HMGi-C  
DNA replication 30 kD subunit RPA  
ADP ribosylation factor 1  
Cytoskeleton/ contractyle  Cardiac muscle alpha actin  
Skeletal muscle alpha actin  
Extra-embryonic endodermal cytokeratin 
Tropomyosin isoform 2  
Alpha tubulin isotype M  
Vimentin 
SM22 alpha  
Vascular smooth muscle alpha actin  
Spectrin alpha chain  
NF68 neurofilament 68 kD protein  
ROCK-2 (Rho-associated protein kinase 
Signal transduction   FGFR1  
FGF binding protein  
FGF inducible gene 14  
PLC-alpha  
Pw1 zink finger protein 
Signal transducing adaptor STAM  
Rit (Ras related protein 
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Wnt-3*  
Creatin kinase B   
 
Protein synthesis and degradation  Translation initiation factor 2alpha   
Eukaryotic initiation factor 4A-like, CIF5.10   
Eukaryotic initiation factor 4A-like, NUK-34   
QK1 (Quaking type 1)  
Translation initiation eif-3, p110  
Seryl-tRNA synthetase  
Multifunctional aminoacyl-tRNA synthetase  
Tryptophan-tRNA ligase  
Aspartate aminotransferase  
Protease nexin II  
26S protease regulatory subunit 7 (MSS1)   
ATPase 26S proteasome subunit 4  
ATPase (lysosomal)   
Membrane protein   Annexin V   
Annexin III  
ECM component    Latexin  
Differentiation    Lethal(1) discs large-1 tumor suppressor   
Anhydrase isozyme II  
Unknown    EST U70674 
EST U58494 
EST M29325 
 
 
 
 
Welcsh et al have developed an embryonal kidney epithelial cell line with 
stable ecdysone inducible expression of BRCA1 in modest levels, and then used 
microarray technology to identify the BRCA1 regulated genes: estrogen responsive 
genes MYC and cyclin D1, which are overexpressed in many breast tumours; STAT1 
and JAK1, key components of the cytokine signal transduction pathway; the 
extracellular matrix protein laminin 3A; Id4, an inhibitor of DNA-binding 
transcriptional activators, which in turn negatively regulates BRCA1 expression; and 
the prohormone stanniocalcin, expression of which is lost in breast tumours (Table 9) 
(Welcsh et al., 2002). 
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Table 9: Genes with altered expression following induction of BRCA1 (Welcsh et 
al, 2002). Fold change in expression following BRCA1 induction has been indicated. 
    
Genes up-regulated at least 2-fold  
  PBP Progesterone-binding protein 2.1 
  XIST X inactivation-specific transcript 2.0 
  JAK1 Janus kinase 1 2.4 
  H1F0 H1 histone family member 0 4.6 
  SEPP1 Selenoprotein plasma protein 1 3.2 
  TSNAX Translin-associated factor X 2.2 
  MGAT2 UDP-N-acetylglucosamine 2.3 
  STC1 Stanniocalcin 1 * 
  CALD1 Caldesmon 1 2.6 
  ID4 Inhibitor of DNA binding 4 2.1 
  SEC23A Yeast coat protein complex homolog 4.6 
  HSEC10L1 Saccharomyces cerevisiae Sec10 homolog 2.0 
  STAT1 Signal transducer/activator of transcription 1 2.5 
  VAMP3 Vesicle-associated membrane protein 3 2.3 
  FSTL1 Follistatin-like 1 2.6 
  EXTL2 ER-localized transmembrane glycoprotein 3.6 
  CCNG2 Cyclin G2 2.8 
  CITED2 CBP/p300 transactivator 2 2.1 
  ZNF138 Zinc-finger protein 138 2.2 
  IDH1 Isocitrate dehydrogenase 1 2.7 
  RDX Radixin 3.1 
  LIPA Lipase A 2.0 
  TFPI2 Placental tissue factor pathway inhibitor 2 2.6 
  GALNT3 N-acetylgalactosaminyltransferase 3 4.2 
  ZNF148 Zinc-finger protein 148 2.0 
  IL16 Interleukin 16 3.5 
  Clone 23654  2.7 
  ADD1 Adducin 1 2.3 
  COP9 COP9 subunit 3 2.0 
  NFYC Nuclear transcription factor Y,  2.1 
  RRM2 Ribonucleotide reductase subunit 2 3.0 
  WRB Tryptophan-rich basic protein 2.0 
  PPP1R1A Protein phosphatase 1, regulatory subunit 1A 3.2 
  CLTB Clathrin, light polypeptide B 2.1 
  KCNK1 Inward rectifier potassium channel 4.6 
  MAP2K1 Mitogen-activated protein kinase kinase 1 2.0 
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  KIF2 Kinesin heavy chain 2 2.4 
  LIMS1 LIM and senescent cell antigen-like domain 1 2.5 
  ENPP2 Ectonucleotide phosphodiesterase 2 2.2 
  P2RX1 Ligand-gated ion channel receptor P2X * 
  LAMA3 Laminin, -3 2.5 
  TITF1 Thyroid transcription factor 1 2.2 
  ELANH2 Protease inhibitor 2 2.0 
  HTATIP HIV tat-interacting protein 2.0 
  MICA1 MHC complex, class I-related gene A 2.3 
  APP Amyloid -A4 precursor protein 2.3 
  TCRA T-cell antigen receptor, -subunit 2.3 
 
 Genes down-regulated at least 2-fold 
 HRC1 
 
HRAS-related cluster 1 
 
2.7 
  NDRG1 NMYC downstream-regulated gene 1 2.1 
  CCND1 Cyclin D1 3.2 
  RCD8 Autoantigen RCD8 2.7 
  BOP1 Block of proliferation 1 2.0 
  SLC19A1 Folate transporter 3.1 
  NUP214 Nucleoporin 214 KD 2.1 
  HSF1 Heat-shock transcription factor 1 3.5 
  MYC MYC oncogene 4.2 
  RXRA Retinoid X receptor-  2.0 
  SLC6A10 Solute carrier family 6, member 10 2.4 
  CHD4 Chromatin helicase DNA-binding protein 4 2.3 
  GCN5L2 Control of amino acid synthesis homolog 2 2.0 
  SKIV2L Superkiller viralicidic activity 2 3.0 
  EIF4G1 Eukaryotic translation initiation factor 4  2.4 
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1.7 Strategy 
 
Several lines of evidence suggest that BRCA1 has a role in transcriptional 
regulation. The aim of this study was to identify the genes that are upregulated by 
BRCA1 and therefore contribute to a better understanding of its cellular functions.  
 
The expression profile of control MCF7 cells was compared with MCF7 cells 
ectopically expressing BRCA1 by performing Suppression Subtractive Hybridization 
(SSH). A subtracted cDNA library was generated in order to identify novel BRCA1-
induced genes as candidate mediators of tumour suppression by BRCA1.  
 
The strategies used in this study were as follows: 
 
Generation inducible BRCA1 expression in breast carcinoma cells 
The MCF-7 breast carcinoma cell line was selected to overexpress the BRCA1 
gene in this study since it has a very low endogenous BRCA1 expression level and 
maintains wild-type p53. One allele of BRCA1 is intact but the second allele has been 
lost within the 2 Mb genomic region of chromosome 17q21 containing BRCA1 gene 
(Kachhap et al., 2001).  
 
• First we aimed to generate a stable cell line in which the BRCA1 expression 
could be controlled by an inducible system. To this aim, the full-length 
BRCA1 cDNA was subcloned into the eukaryotic expression vector pIND, 
which is a component of the ecdysone inducible system. Three different 
sources of full-length BRCA1 cDNA were used to generate pIND.BRCA1 
construct, since the first two BRCA1 cDNA sources obtained in the early 
studies were later reported to have some discrepancies. 
• Second, the MCF7 cells were transfected with pVgRXR regulatory plasmid 
which is another component of ecdysone inducible system to generate cells 
stably keeping the pVgRXR plasmid. PVgRXR plasmid works together with 
pIND response plasmid to induce the BRCA1 gene, which was cloned into 
pIND plasmid. 
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• Third, pVgRXR plasmid containing MCF7 cells were transiently transfected 
with pIND.lacZ reporter construct or with pIND.BRCA1 construct and treated 
with ecdysone analog ponasterone A or muristerone A to induce the 
expression of reporter or BRCA1 gene. The cells were then tested for the 
induced reporter gene or BRCA1 expression level with various methods. 
• We also used U2OS osteosarcoma cells which were stably transfected with 
pVgRXR plasmid to introduce pIND.BRCA1 constructs and induce the cells 
as described above. 
 
This strategy did not produce desirable inducible BRCA1 expression system. 
The results of this strategy are explained in the results section (3.1 and 3.2). 
 
 
Ectopic expression of BRCA1 in MCF7 breast carcinoma cells 
• The second strategy to obtain high level expression of BRCA1 was to 
transiently transfect the MCF7 cells with pCMVmycBRCA1 plasmid, which 
has a strong CMV promoter to express BRCA1 gene in mammalian cells. 
• The control MCF7 cells were transfected with the pCMVmyc control plasmid 
lacking BRCA1 insert. 
•  BRCA1 or control plasmid transfected cells were examined for BRCA1 
protein and RNA level by Western and Northern blot analysis respectively. 
 
 
RNA isolation for cDNA subtraction 
DNA-free mRNA samples were prepared from BRCA1 or control plasmid 
transfected cells. 
 
 
Generating forward subtracted cDNA library  
• Suppression Subtractive Hybridization (SSH) technology was used to identify 
genes that are differentially expressed in BRCA1 transfected MCF7 cells. 
• SSH was performed with double strand tester (MCF7/pCMVmycBRCA1) and 
driver (MCF7/pCMVmyc) cDNAs (forward subtraction). 
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• Reverse subtraction was also performed where tester cDNA derived from 
pCMVmyc transfected MCF7 cells and driver cDNA derived from 
pCMVmycBRCA1 transfected MCF7 cells. 
• The resulting differentially expressed cDNAs from forward subtraction were 
ligated into pGEM-T Easy vector to generate a cDNA library enriched for the 
BRCA1 upregulated genes. 
 
 
Screening and analysis of the differentially expressed clones 
• The forward subtracted cDNA library clones were analyzed by dot blot 
hybridization and differential screening. 
• The cDNA clones which showed more than five-fold increase were selected 
for sequencing analysis. 
• The partially sequenced cDNA inserts were subjected to homology search 
with current databanks. 
• Further confirmations of upregulation of the candidate genes were performed 
by Western blot, Northern blot and semi-quantitative RT-PCR analyses. 
 
The results of this strategy are explained in the results section (3.2.4, 3.3 and 
3.4). 
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CHAPTER 2.  MATERIALS AND METHODS   
       
 
 
2.1 Materials 
 
2.1.1 General reagents 
 
The general laboratory chemicals were supplied from Sigma Chemical Co. (St. 
Louis, U.S.A), Merck (Darmstadt, Germany), Stratagene (Heidelberg, Germany), 
Carlo Erba (Rodano, France), Delta Kim. San. (Istanbul, Turkey) and MBI Fermentas 
(Germany). 
 
 
2.1.2 Nucleic Acids and Proteins 
 
1 kb DNA ladder, 100 bp DNA Ladder Plus, and 100 bp DNA Ladder and 
HaeIII-digested φX174 were used as DNA molecular weight size markers in this study 
and supplied from MBI Fermentas, Gibco-BRL and Sigma. Ultrapure 
deoxyribonucleotides were from Pharmacia (Vienna, Austria) and MBI Fermentas. 
Protein size markers were from Bio-Rad (U.S.A) and New England Biolabs (U.K.).  
 
 
2.1.3 Oligonucleotides 
 
The oligonucleotides used in polymerase chain reactions were synthesized in 
the Beckmann Oligo 1000M DNA Synthesizer (Beckmann Instruments Inc. CA, 
U.S.A) at Bilkent University, Department of Molecular Biology and Genetics 
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(Ankara, Turkey) or supplied from Iontek Inc. (Bursa, Turkey) or Oswell DNA 
services (Southampton, U.K.). 
 
 
2.1.4 Enzymes 
 
Restriction endonucleases and Taq DNA polymerases were supplied by MBI 
Fermentas, New England Biolabs, Stratagene or Promega. Sequenase was from USB 
(United States Biochemicals, Cleveland, U.S.A). Ribonuclease A was from Sigma. 
 
 
2.1.5 Bacterial strains 
 
The characteristics of the bacterial strains used in this study were as follows: 
DH5α: F-, (f80dÊ(lacZ) M15), recA1, endA1, gyrA96, thi1, hsdR17, (r-km-k), 
supE44, relA1, deoR, Ê(lacZYA-ar gF) U169 
JM109: recA1, endA1, gyrA96, thi, hsdR17 (rK-, mK+), relA1, supE44, ∆(lac-
proAB), (F´, traD36, proAB, lacIqZ∆M15)(8) 
 
Bacterial strains were stored at –70°C in LB medium containing 50% (v/v) 
glycerol for long-term storage. Recombinant clones were stored under the same 
conditions in media supplemented with appropriate antibiotics. Strains were 
maintained as isolated colonies on LB agar plates at 4°C for short-term storage. 
 
 
2.1.6 Plasmids 
 
pcDNA3.myc.BRCA1 was a gift from Dr. F.J. Calzone (Amgen Center, CA, 
U.S.A.). pRc.CMV.BRCA1 construct was a gift from Dr. Daniel Haber (Harvard 
Medical School, Boston, U.S.A). pCR3.BRCA1 plasmid was a gift from Dr. Barbara 
Weber (University of Pennsylvania Cancer Center, Pennsylvania, U.S.A.). pIND and 
pIND.p53 vectors were gifts from Dr. Kannan Karuppiah and Dr. David Givol 
(Weizmann Institute of Science, Rehovot, Israel). pCMV.myc, pCMV.myc.BRCA1, 
 44
pIND, pIND.lacZ, pVgRXR vectors were gifts from Dr. Tim Crook (Ludwig Institute 
for Cancer Research, London, U.K.). 
 
 
2.1.7 Nucleic acid and protein transfer materials 
 
Hybond N, Hybond N+ nylon membranes and Immobilen P transfer (PVDF) 
membrane were from Amersham (U.K.). 3MM filter paper was from Whatman 
International Ltd. (Madison, U.S.A). 
 
 
2.1.8 Radioisotopes 
 
(α-32P)dCTP (800 Ci/mmol and 3000 Ci/mmol) and (α-35S)dATP (1000 
Ci/mmol) were from Amersham and Perkin Elmer/NEN (Belgium). 
 
 
2.1.9 Sequencing reagents 
 
Sequenase version 2.0 DNA sequencing kit was obtained from USB. 
Sequencing reactions were run on denaturing acrylamide gels made from the 
components of Ultrapure sequagel (concentrate and diluent) from National 
Diagnostics (Atlanta, U.S.A). 
 
 
2.1.10 Tissue culture reagents and cell lines 
 
Dulbbecco’s Modified Eagle’s Medium (DMEM), fetal calf serum, L-
glutamine, penicillin/streptomycin, calcium and magnesium-free phosphate buffered 
saline (PBS) were obtained from Sigma and Gibco-BRL. Electroporation cuvettes 
were supplied from Bio-Rad Inc..  The Ecdysone-Inducible Mammalian Expression 
System, ponasterone A and muristerone A were from Invitrogen Corporation (CA, 
U.S.A). 
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Antibiotics used for selection in medium: Zeocin was from Invitrogen 
Corporation (CA, U.S.A) and Cayla (France), geneticine was from Promega (CA, 
U.S.A), hygromycin was from Boehringer Mannheim, and puromycin and tetracycline 
were from Sigma. 
 
MCF-7 is a human breast carcinoma cell line, HBL-100 is a human breast 
epithelial cell line, U2OS is a human osteosarcoma cell line (see Appendix B for the 
characteristics of these cell lines). U2OS/RXR cell line was a gift from Dr. Tim Cook 
(Ludwig Institute for Cancer Research, London, U.K.) and stably transfected with 
pVgRXR plasmid. UBR60-bcl2 cell line was a gift from Dr. Paul Harkin (Queen’s 
University of Belfast, Ireland), which expresses BRCA1 under the control of 
tetracycline-regulated promoter, has been previously described (Harkin et al., 1999). 
 
 
2.1.11 Kits 
 
Trireagent was from Sigma (U.S.A). PolyA spin mRNA isolation kit was from 
New England Biolabs Inc. (MA, U.S.A).  MessageClean kit was from GenHunter 
Corporation (MA, U.S.A). RevertAid first strand cDNA synthesis kit was from MBI 
Fermentas and cDNA synthesis kit was from Boehringer Mannheim. PCR-Select 
cDNA Subtraction kit, PCR-Select Differential Screening kit, Advantage cDNA PCR 
kit were from Clontech laboratories (CA, U.S.A). Midiprep kit, PCR purification kit 
and QiaexII gel purification kit were from Qiagen (Germany). Quick spin columns 
were from Roche and Hexa-Label plus kit was from MBI Fermentas. pGEM-T Easy 
vector system and TNT Coupled Reticulocyte Lysate System were from Promega 
(WI, U.S.A). ECL western blotting detection reagent was from Amersham (U.K.). Big 
Dye terminator cycle sequencing kit was from Perkin Elmer (CA, U.S.A). Sequenase 
Version 2.0 DNA sequencing kit was from Amersham. 
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2.1.12 Antibodies 
 
BRCA1 (C-20), BRCA1 (D-20) antibodies and anti-mouse HRP conjugated 
secondary antibody were obtained from Santa Cruz Biotechnology (CA, U.S.A). 
BRCA1 (Ab1, MS110) and MSH2 (Ab1) antibodies were from Oncogene Research 
Products (U.K.). BRCA1 (5HU) and cytokeratin 18 (JAR13 clone) antibodies were 
gifts from Dr D. Bellet (IGR, France). Myc (9E10) antibody was a gift from Dr. Tim 
Crook (Ludwig Institute for Cancer Research, London, U.K.). p53 (9E4B1) antibody 
was obtained from Bilkent University, Department of Molecular Biology and 
Genetics. Annexin V was from B.D. Pharmingen (U.S.A). 
 
 
2.2 Solutions and Media 
 
2.2.1 General solutions 
 
1XTAE:    40 mM Tris-acetate, 2 mM EDTA, pH 8.0  
 
1XTBE:    89 mM Tris base, 89 mM boric acid, 2 mM EDTA, pH 8.3  
 
TE:     10 mM Tris, 1 mM EDTA, pH 8.0 
 
10 mM dNTP: 100 µl of four different kinds of dNTP (from 100 mM stock) 
were mixed in 1 ml double distilled water. Working 
concentration was 100 µM in a typical PCR reaction. 
 
Ethidium bromide: 10 mg/ml in water (stock solution), 30 ng/ml (working 
solution)  
 
5x agarose gel loading buffer: 0.25% bromophenol blue, 0.25% xylene cyanol, 50% 
glycerol, 1 mM EDTA 
 
Denaturing solution: 6 N NaOH (stock solution), 0.6 N NaOH (working solution) 
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Neutralization solution: 0.5 M Tris-HCl, pH 7.5 
   
Solutions for plasmid DNA isolation: 
Solution I:    50 mM glucose, 25 mM Tris pH: 8.0, 10 mM EDTA 
Solution II:   0.2 N NaOH, 1% SDS 
Solution III:   3 M potassium acetate, pH 4.8 
 
Solutions for DNA isolation from tissue culture cells: 
Lysis buffer:  10 mM Tris pH 8.0, 100 mM NaCl, 1 mM EDTA, 1% SDS 
with 0.5 mg/ml proteinase K 
 
Lysis mix:   0.05 M EDTA pH 8.0, 1 % sarcosyl, 200 µg/ml proteinase K 
  
 
2.2.2 Microbiological media and antibiotics 
 
LB broth:   1% tryptone, 0.5% yeast extract, 1% NaCl 
 
LB agar plates:  LB+2% agar 
 
SOB:   2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl 
 
SOC:    SOB+ 10 mM MgSO4, 10 mM MgCl2, 20 mM glucose 
 
Transformation buffer: 10 mM K.PIPES, 55 mM MnCl2, 15 mM CaCl2, 250 mM 
KCl, pH 6.7 
 
IPTG:  0.5 M solution in water, filter sterilized and stored at –20°C in 
the dark (working solution 2.5 mM) 
 
X-Gal:  250 mg/ml solution in DMF (stock solution) 
  6.5 mg/ml (working solution) 
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Ampicillin:  100 mg/ml solution in water sterilized by filtration and stored at 
–20°C.(working solution 100 µg/ml) 
 
Kanamycin: 100 mg/ml solution in water, sterilized by filtration and stored 
at –20°C (working solution 30 µg/ml) 
 
 
2.2.3 Tissue culture solutions 
 
Growth medium: DMEM supplemented with 10% fetal calf serum, 1 mM 
glutamine 50 mg/ml penicillin/streptomycin  
 
PBS: 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4.H2O, 1.4 mM 
KH2PO4, pH 7-7.4 
 
Freezing solution: 10% DMSO, 20% FCS, 70% DMEM 
 
2xBBS:   50 mM BES pH: 6.95, 280 mM NaCl, 1.5 mM Na2HPO4 
 
1xHBS: 280 mM NaCl, 10 mM KCl, 1.5 mM Na2HPO4, 12 mM 
dextrose, 50 mM HEPES, pH 6.95 
 
Zeocin: 50 mg/ml in water, sterilized by filtration and stored at  –20°C 
 
Geneticin (G418): 50 mg/ml in PBS, sterilized by filtration and stored at –20°C 
 
Puromycin: 1 mg/ml in DMEM, sterilized by filtration and stored at  –20°C 
 
Tetracyclin:  0.01 gr tetracycline was dissolved in 10 ml of 70% ethanol.  
 
 
 
 49
2.2.4 RNA solutions 
 
DEPC ddH2O: 1 ml DEPC was mixed with one liter of double distilled water, 
stirred at 37°C overnight and autoclaved. 
 
Premix solution:  50% formamide, 6% formaldehyde and 1xMOPS  
 
10XMOPS:   200 mM MOPS, 50 mM NaOAc, 10 mM EDTA, pH 7.0 
 
RNA loading buffer: 50% glycerol in 1xMOPS, 0.12% bromophenol blue 
 
20XSSC:   3M NaCl, 0.3 M Na3.citrate.2H2O, pH 7.0 
 
Hybridization buffer: 0.5 M phosphate buffer pH 7.2, 7% SDS, 1 mM EDTA, 1% 
BSA, 10 µg/ml salmon sperm DNA and yeast total RNA  
 
 
2.2.5 Protein extraction and western blotting solutions 
 
RIPA buffer: 10 mM Tris.Cl pH: 8.0, 1 mM EDTA, 150 mM NaCl, 1% NP-
40, 1% NaDOC, protease inhibitor mix  
 
Bradford stock solution: 17.5 mg Coomassie brilliant blue in 4.75 ml ethanol and 10 
ml phosphoric acid, final volume up to 25 ml with ddH2O 
 
Bradford working solution: 0.75 ml 95% Ethanol, 1.5 ml phosphoric acid, 1.5 ml 
Bradford stock solution, final volume up to 25 ml with ddH2O 
 
Acrylamide-Bisacrylamide solution: 29 gr acrylamide, 1 gr bisacrylamide final 
volume up to 100 ml with ddH2O and stored in dark bottle. 
 
10% APS:  0.1 gr APS dissolved in 1 ml ddH2O. 
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5x loading buffer: 62.5 mM Tris-HCl pH 6.8, 5% β-mercaptoethanol, 2% SDS, 
15% glycerol, and 0.001% bromophenol blue 
 
5x running buffer:  125 mM Tris, 1.25 M glycine, 0.5% SDS; pH 8.3 
 
Wet transfer buffer:  6 g Tris, 28.8 g glycine, 1 ml 10% SDS and 20% methanol, 
final volume up to 1 lt with dH2O 
 
Semi-dry transfer buffer: 2.91 g Tris, 1.465 g glycine, 1.875 ml 10% SDS, 100 ml 
methanol, final volume up to 500 ml with dH2O 
 
TBS-T:   0.1 M Tris, 0.5 M NaCl, 0.5% Tween-20 
 
Blocking solution:  TBS-T and 3% milk powder 
 
10xZ buffer: 0.6 M Na2HPO4.7H2O, 0.4 M NaH2PO4, 0.1 M KCl, 0.01 M 
MgSO4.7H2O, 0.5 M β-mercaptoethanol; pH 7.2  
  
ONPG:   4 mg/ml O-nitrophenyl β-D-galactopyranoside 
 
 
2.2.6 Immunostaining solutions 
 
Annexin V binding buffer:  0.01 M Hepes pH: 7.4, 0.14 M NaCl, 0.25 mM CaCl2 
 
Hoechst stain: 100 mg/ml stock solution in water (300 µg/ml working 
solution) 
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2.3 General methods 
 
2.3.1 Transformation of E.coli 
 
Two different calcium chloride mediated methods were used to prepare 
competent E.coli strains for transformation. 
 
Method I  (Ausubel et al., 1991): 500 µl of DH5α glycerol stock was inoculated into 
5 ml of LB medium and cells were grown at 37oC, shaking at 200 rpm to an optical 
density (OD) of 0.4-0.6 at 590 nm. 1.5 ml of culture was centrifuged at 13000 rpm for 
1 min at 4oC and suspended in 500 µl of ice cold 50 mM CaCl2. After 30 min 
incubation on ice, the cells were centrifuged and the pellet was suspended in 100 µl of 
ice cold 50 mM CaCl2. 1 µl of plasmid DNA (1 ng/µl) was added to the cells and 
incubated on ice for 30 min. The cells were heat shocked at 42oC for 90 seconds and 
then incubated on ice for 2 min. 1 ml of LB medium was added onto the cells and 
incubated at 37oC for 1 h to allow the expression of antibiotic resistance gene before 
plating the cells. After incubation, the transformation mixture was plated on LB agar 
plates containing 100 µg/ml ampicillin. Plates were incubated overnight at 37oC to 
select the recombinant clones carrying the plasmid of interest.  
 
Method II  (Inoue et al., 1990): JM109 cells were grown in SOB at 18°C, shaking at 
200-250 rpm until OD590=0.5-0.6.  They were then centrifuged for 10 min at 3000 
rpm at 4°C. Cells were resuspended in 1/3 of the initial volume of ice-cold 
transformation buffer and incubated on ice for 10 min. After 10 min centrifugation, 
cells were again resuspended in 1/12.5 initial volume of ice-cold transformation 
buffer. DMSO was added to a final concentration of 7%. After incubating 10 min on 
ice, supercompetent cells were distributed to tubes, rapidly freezed by immersing in 
liquid nitrogen and stored at –80°C. For transformation, cells were rapidly thawed on 
ice and plasmid DNA was added onto 200 µl of supercompetent cells. After 30 min 
incubation on ice, cells were heat-shocked for 30 seconds at 42°C and were put back 
on ice.  800 µl SOC was added and the cells were incubated at 37°C with vigorous 
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shaking for 1 h. The transformation mixture was then plated on LB-agar plates 
containing the appropriate antibiotic and the plates were incubated at 37oC overnight. 
 
 
 
2.3.2 Plasmid DNA preparation   
 
Small-scale isolation of plasmid DNA (mini-prep) 
This protocol is based on the alkaline lysis method (Birnboim and Doly, 1989) 
with minor modifications. 
 
The recombinant bacterial clone containing the plasmid of interest was grown 
in 5 ml LB medium containing appropriate the antibiotic at 37oC overnight while 
shaking at 200 rpm. 1.5 ml of grown culture was centrifuged at 13000 rpm for 2 min. 
After removing supernatant, the pellet was resuspended in 100 µl of ice-cold solution 
I and kept at room temperature for 5 min. Freshly prepared 200 µl of solution II was 
added and the contents were mixed by inverting the tube very gently and then placed 
on ice for 5 min. Bacterial chromosomal DNA and cell debris were precipitated by 
adding 150 µl of solution III. The mixture was kept on ice for 5 min and centrifuged 
for 5 min at 13000 rpm at 4oC to remove the cellular debris. Supernatant was 
transferred into a new tube and mixed with 800 µl of ice-cold absolute ethanol and the 
mixture was incubated at -20oC for 20 min. Plasmid DNA was recovered by 
centrifugation at 13000 rpm for 10 min at room temperature. The pellet was washed 
with 300 µl 70% ethanol and centrifuged at 10500 rpm for 10 min at room 
temperature. Ethanol was aspirated and the pellet was air-dried for 10 min at room 
temperature. The pellet was resuspended in 20-30 µl sterile ddH2O containing 10 
µg/ml RNaseA. The sample was stored at 4oC for short-term or -20oC for long-term 
U.S.Age. This method yields approximately 1-1.5 µg of plasmid DNA.  
 
Large-scale isolation of plasmid DNA (midi-prep) 
For large-scale preparation of pure plasmid DNA, the Qiagen 100 plasmid 
isolation kit was used by following the manufacturer’s instructions. This procedure 
yields approximately 60-150 µg of plasmid DNA for 100 ml initial LB culture. 
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2.3.3 Restriction enzyme digestion of plasmid DNA   
 
Restriction enzyme digestions were routinely performed in 15 µl -50 µl 
reaction volumes containing 1 µg -10 µg plasmid DNA. Typically 1 unit enzyme was 
used per µg of plasmid DNA. Reactions were carried out with the appropriate reaction 
buffer, according to the manufacturer’s recommendations. 
 
Digestion of plasmid DNA with two or three different restriction enzymes was 
performed in the same reaction buffer to provide the optimal condition for all the 
restriction enzymes.   
 
 
2.3.4 Agarose gel electrophoresis of DNA  
 
DNA fragments were fractionated by horizontal gel electrophoresis by using 
1xTAE or 1xTBE buffers, and 5xgel loading buffer.  
 
DNA fragments less than 1 kb were generally separated on 1-2% agarose/EtBr 
gels, while those greater than 1 kb (up to 11.5 kb) were separated on 0.8% 
agarose/EtBr gels. 
 
Agarose was completely dissolved in 1xTAE (or 1xTBE) electrophoresis 
buffer to the required percentage and ethidium bromide was added to a final 
concentration of 30 ng/ml. The samples were loaded onto agarose gel with 1/5 volume 
of loading buffer. The gel was run in the appropriate buffer (1xTAE or 1xTBE) at 
different voltage and time settings depending on the size and the fragment separation 
required at room temperature. 
 
Nucleic acids were visualized under ultraviolet light (long wave, 340 nm) and 
different DNA size markers were used in order to estimate the fragment sizes. The 
DNA size markers used in this study were as follows: 
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Gibco-BRL 1 kb ladder:  
12.2, 11.2, 10.2, 9.2, 8.1, 7.1, 6.1, 5.1, 4.1, 3.1, 2.0, 1.6,1.0, 0.5, 0.4, 0.3 and 0.2 kb. 
 
MBI 1 kb ladder:  
10, 8, 7, 6, 5, 4, 3.5, 3, 2.5, 2, 1.5, 1, 0.75, 0.5, 0.25 kb 
 
MBI DNA Ladder Mix:: 
10, 8, 7, 6, 5, 4, 3.5, 2, 1, 1.2, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1 kb 
 
MBI 100 bp DNA Ladder Plus: 
3, 2, 1, 1.2, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1 kb 
 
MBI 100 bp DNA Ladder: 
1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1 kb 
 
HaeIII digested φX174 (Sigma):  
1.3, 1.1, 0.9, 0.6, 0.3 kb 
 
 
2.3.5  Extraction of DNA fragments from agarose gel 
 
DNA fragments were extracted from TAE agarose gels by using the QIAEX II 
gel extraction kit according to the manufacturer’s instructions.   
 
Gel purification with the QIAEX II kit yields 60-70% recovery of DNA 
fragments between 1.0 kb to 6.0 kb in 10-20 µl volumes. 
 
The DNA fragments used as probes were prepared by using the same kit. The 
PCR products or the restriction enzyme digested DNAs were digested subjected to 
agarose gel electrophoresis. The location of the DNA fragment of interest was 
determined under the UV light and the fragment was excised using a scalpel blade. 
The gel slice was transferred into an eppendorf tube and the fragment was purified by 
using the gel extraction kit. 
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2.3.6 Radioactive labelling of DNA 
 
Purified cDNA inserts were labelled with the HexaLabel Plus Kit according to 
the manufacturer’s recommendations. Briefly, 100 ng DNA template was mixed with 
10 µl 5x reaction buffer and the volume was adjusted to 40 µl with ddH2O. This 
mixture was incubated in a boiling water bath for 5-10 min. Following cooling down 
on ice 3 µl Mix C, 6 µl [α-32P]-dCTP and 1 µl (5U) Klenow fragment exo- were 
added to the tube and incubated for 10 min at 37°C. Following the addition of 4 µl 
dNTP, the mixture was incubated for 5 min at 37°C. The reaction was stopped by the 
addition of 1 µl 0.5 M EDTA. Unincorporated dNTPs were removed from the labelled 
DNA with G-50 sephadex chromatography by using Quick Spin columns. Briefly the 
column was centrifuged at 1100xg for 2 min and the eluted buffer was discarded. 
Labelled DNA sample was applied to the center of the column bed and the column 
was centrifuged at 1100xg for 4 min. The eluent contained the purified probe. The 
purity of the probe was checked by capillary paper electrophoresis (in 1 M Na2HPO4) 
and the activity of the probe was detected by counting on the scintillation counter. 
 
 
2.3.7 DNA isolation from tissue culture cells 
 
Method I: 200 µl of trypsinized cells were pelleted and lysed in 500 µl of lysis 
buffer. This mixture was incubated at 37oC overnight. The next day 1 ml isopropanol 
was added to each tube and mixed. After centrifuging for 5-10 min, the pellet was 
washed with 70% ethanol. The pellet was dissolved in 30-50 µl TE or ddH2O. 
 
Method II: Trypsinized cells were pelleted and resuspended in 1 ml of lysis mix. 
After incubation at 55oC overnight, DNA was extracted with an equal volume of 
phenol and then phenol:chloroform (1:1), precipitated with ethanol and washed with 
70% ethanol, air-dried and dissolved in 30-50 µl TE or ddH2O. 
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2.3.8 Amplification of DNA by Polymerase Chain Reaction (PCR) 
 
Polymerase chain reaction was performed to amplify the desired DNA 
fragments from genomic or plasmid DNAs or from cDNAs using the thermal cyclers 
GeneAmp PCR system 9600 or 2400 (Perkin Elmer). Unless otherwise stated, all 
reactions were performed with either 100 ng genomic or 10 ng plasmid DNAs by 
using 1 unit Taq DNA Polymerase supplied with its 10x reaction buffer with the final 
concentrations of the following components: 1 pmol/µl forward and reverse specific 
primers, 100 µM dNTP and 1.5 mM MgCl2. Table 10 shows the primers used in this 
study and PCR conditions are given in the appropriate places in the following 
sections. 
 
The cDNA clones that became available from differential screening 
experiments were amplified by using T7-Sp6 universal primers. These amplifications 
were performed to analyze the presence or absence of cDNA inserts and the length of 
the cDNAs in the positive clones. 
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Table 10: List of primers pairs used in the study with Genbank accession numbers 
and expected PCR product sizes 
 
Gene/vector/ Acc # Primer pair       Product  size         
 
RXR/ Invitrogen  TC222-F:  5’- AGT TGA CCA GTG CCG TTC CG  -3’      361bp 
TC223-R:  5’- CTG CTC CTC GGC CAC GAA GTG -3’ 
 
 
pIND-BRCA1  EcF:    5’- CTC TGA ATA CTT TCA ACA AGT TAC -3’     1103 bp 
TC31-R:  5’- ACC CTG ATA CTT TTC TGG -3’   
 
 
pIND/ Invitrogen  EcF: 5’- CTC TGA ATA CTT TCA ACA AGT TAC -3’     variable due  
EcR: 5’- TAG AAG GCA CAG TCG AGG -3’               to insert size 
 
 
pGEMT-Easy/ Promega T7:   5’- TAA TAC GAC TCA CTA TAG GG-3’    variable due  
  Sp6: 5’- GAT TTA GGT GAC ACT ATA G-3’    to insert size 
  
 
GAPDH/M33197 GAPDH F: 5’-GGC TGA GAA CGG GAA GCT TGT CAT-3’     250 bp 
GAPDH R: 5’-CAG CCT TCT CCA TGG TGG TGA AGA-3’ 
 
BRCA1/U14680               BRCA1 F4  5'– AAC TTA GAA CAG CCT ATG GG –3'              1217 bp    
BRCA1 R4  5'– TTG CTC CTC CAC ATC AAC AA  –3' 
 
GADD45/L24498             GADD45 F  5'– ATG ACT TTG GAG GAA TTC TCG GCT –3'      497 bp         
GADD45 R  5'– TCA CCG TTC AGG GAG ATT AA–3' 
 
pCMV-BRCA1                 PCMV F      5'– GCG TGT ACG GTG GGA GGT CTA–3'              1200 bp 
TC 31 (R)    5’- ACC CTG ATA CTT TTC TGG -3’ 
 
Actin/X00351                   ACTIN F     5’- GTG GGG CGC CCC AGG CAC CA -3’                 550 bp  
                                          ACTIN R    5’- CTC CTT AAT GTC ACG CAC GAT TTC -3’  
 
 
RAD21/NM_006265 RAD21 F: 5’-TCC TCA GCA GGT AGA GCA GAT-3’          406 bp 
RAD21 R: 5’-TCC AGG TGT TGC GAT GAT GTC-3’ 
 
 
MSH2/XM_034901 MSH2 F: 5’-TGA TCT TCG TTC TGA CTT CT-3’                          641 bp 
MSH2 R: 5’-CGT CAT TAG GAA TAA ATG CAA-3’  
 
 
GNAS/ BC002722 GNAS F: 5’-AGC AAC AGC GAT GGT GAG AAG-3’           727 bp 
GNAS R: 5’-CAT CCT CAG GAG TAG TGT AGC-3’  
 
 
MAC30/XM_031536 MAC30 F:  5’-TCT ACT TCC TCA GGC ACA TCC-3’             376 bp 
MAC30 R: 5’-AAC CGT TCA TGC AAA GTC TCA-3’ 
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Amplification of zeocin resistance gene sequence from RXRIII clones 
361 bp of zeocin resistance gene of pVgRXR was amplified with TC222 
(RXR forward) and TC223 (RXR reverse) primers. Isolated genomic DNAs from the 
RXRIII clones were used as template for this reaction. The aim of this experiment was 
to detect the presence of the pVgRXR plasmid in the pVgRXR transfected MCF-7 
cells. The sequences of the primers are shown in Table 10 and the PCR conditions 
were as follows; 
 
Initial denaturing 94oC 5 min 
Denaturing  94oC 30 sec 
Annealing  60oC 30 sec     30 cycles 
Extension  72oC 1 min 
Final extension 72oC 10 min 
  
 
5 µl of 25 µl PCR products were run on 1.5% agarose gel to observe the 361 
bp expected product size. 
 
 
Amplification of pIND.myc.BRCA1 sequence from U2OS cells 
Genomic DNA was isolated from U2OS cells that stably express 
pIND.myc.BRCA1. PCR was carried out with EcF and TC31 primers (Table 10) to 
detect the presence of the plasmid DNA in these clones. EcF primer was for pIND 
plasmid, which was localized at the 5’ end of the multiple cloning site, and TC31 
primer was for exon 11A of BRCA1.  
PCR conditions were as follows; 
 
Initial denaturing 94oC 5 min 
Denaturing  94oC 30 sec 
Annealing  55oC 30 sec     30 cycles 
Extension  72oC 1 min 
Final extension 72oC 10 min 
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5 µl of 25 µl PCR products were run on 1% agarose gel for detection of the 
1103 bp length expected product size. 
 
 
First strand cDNA synthesis and Reverse Transcriptase-PCR (RT-PCR) 
The cDNAs were prepared from total RNA using RevertAid First Strand 
cDNA Synthesis kit according to the manufacturer's instructions. Briefly, 4 µg of total 
RNA was mixed with 1 µl of oligo (dT) primer and incubated at 70°C for 5 min. Then 
4 µl 5x reaction buffer, 1 µl ribonuclease inhibitor and 2 µl 10 mM dNTP were added 
and incubated at 37°C for 5 min. Following addition of 1 µl (200U/µl) RevertAid M-
MuLV reverse transcriptase, the mixture was incubated at 42°C for 60 min. The 
reaction was stopped by heating at 70°C for 10 min. 
 
The quality of first strand cDNA was initially tested by using gene specific 
primers by RT-PCR amplification. 1/40 volume of cDNA preparation was used for 
amplification. GAPDH primer pair was designed in such a way as to amplify 250 bp 
product from genomic DNA and 150 bp from cDNA, which enables detection of 
genomic DNA contamination in the RNA preparation. 
 
PCR was also carried out with the following sequence specific primers in 
order to ensure the removal of plasmid DNA contamination from the cDNA 
preparations of DnaseI treated mRNAs before cDNA subtraction procedure. BRCA1 
specific primers (F4-R4) amplify 1217 bp, actin F and R primers amplify 550 bp, 
GADD45 F and R primers amplify 497 bp and the pCMVmyc F and TC31 primer 
pair amplifies 1200 bp fragment. PCR conditions for GAPDH, F4-R4, GADD45, 
actin and pCMVmyc-TC31 amplification were as follows: 
 
Initial denaturing 94oC 5 min 
Denaturing  94oC 30 sec 
Annealing  55oC 30 sec          30 cycles 
Extension  72oC 30 sec-1 min 
Final extension 72oC 10 min 
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Semi-quantitative Reverse Transcriptase-PCR 
The first strand cDNA product was amplified using the oligonucleotides that 
were designed according to the sequencing data and the gene structure that became 
available from this study. 
 
Further PCR studies were performed with cDNA preparations yielding equal 
amounts of GAPDH amplification products. Briefly, the appropriate cycles for each 
set gene specific primers was detected by performing a 14-33 cycles PCR and taking 
an aliquot at the end of each cycle, which enables the determination of the optimum 
cycle not saturated for the amplified DNA fragment and the difference in expression 
between the two samples under comparison. After cDNA equalization with GAPDH 
amplification, all PCR reactions were carried out under the following conditions 
(Except for MSH2 for which the annealing temperature 60°C): 
 
Initial denaturing 94oC 3 min 
Denaturing  94oC 30 sec 
Annealing  55oC 30 sec     23 cycles for RAD21, 25 for MSH2, 19 for  
Extension  72oC 1 min  GNAS and 23 for MAC30 
Final extension 72oC 5 min 
 
 
All RT-PCR results were repeated at least 3 times. 
 
Signal intensities were monitored by densitometric analysis using Multi-
Analyst Image Software (Bio-Rad). Each product was normalised against GAPDH. 
 
 
2.3.9 DNA sequencing  
 
Manual DNA sequencing 
The sequencing reactions were carried out using the dideoxy chain termination 
method (Sanger et al., 1997). T7 Sequenase version 2.0 DNA sequencing kit was used 
to sequence pIND.BRCA1 and pIND.HA.BRCA1 vectors by using the GenomyxLR 
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Programmable DNA Sequencer according to the manufacturer’s instructions. EcF and 
EcR primers were used for pIND vector sequencing. 
  
Automated DNA sequencing 
Sequencing reactions were performed on double-stranded plasmid templates 
(pGEMT-Easy) with T7 and SP6 universal primers. Sequencing reactions were 
carried out with the Big Dye terminator cycle sequencing kit and analyzed with ABI 
377 DNA Sequencer machine.  
 
 
2.3.10 Computer analysis of DNA sequences and homology search  
 
Restriction endonuclease maps of the plasmid DNAs were analyzed with the 
Webcutter program (designed by Max Heiman, 1995) freely available for public use 
at http://www.firstmarket.com/firstmarket/cutter. 
 
Oligonucleotides for PCR and sequencing were designed with the primer 
programs “Primer Designer-Version 2.0” (Scientific and Educational Software) and 
“Amplify” (Bill Engels, 1992, University of Wisconsin, Genetics, Madison, U.S.A). 
 
Nucleotide sequences were analyzed with the Genbank/EMBL and Expressed 
Sequence Tag (EST) databases. Homology search of the sequenced clones that came 
out from this study was mainly performed by BLAST search, available for public use 
at http://www.ncbi.nlm.nih.gov/Blast. 
 
 
2.3.11 Extraction of total RNA from tissue culture cells 
 
Total RNA was isolated with TRI Reagent from tissue culture cells. Cells were 
lysed in 1 ml Trireagent and the lysates were passed through a 21-gauge needle 
several times. After 5 min incubation at room temperature 0.2 ml chloroform was 
added per ml of Trireagent used. Tubes were shaked vigorously by hand for 15 
seconds and incubated at room temperature for 2-3 min. Following centrifugation at 
12000xg for 15 min at 4°C, the aqueous phase was transferred to a new tube and 0.5 
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ml isopropanol was added per ml of Trireagent. After incubation for 10 min at room 
temperature, total RNA was recovered by centrifugation at 12000xg for 10 min at 
4°C. The pellet was washed with 75% ethanol, mixed and centrifuged at 7500xg for 5 
min. Air-dried pellet was dissolved in ddH2O and stored at –80°C. 
 
 
2.3.12 Extraction of poly(A)+ RNA and removal of DNA contamination 
 
Polyadenylated RNA  (poly (A)+ RNA) was isolated from total RNA with the 
PolyA Spin mRNA isolation kit according to the manufacturer’s instructions. 1 mg of 
total RNA from tissue culture cells yielded approximately 20 µg poly (A)+ RNA.  
 
The isolation of clean and intact mRNA is essential in order to obtain full-
length cDNAs. The preparation should be free of DNA contamination before starting 
to the SSH protocol.  
 
The Message Clean Kit was used to remove DNA contamination from the 
RNA samples according to the manufacturer’s recommendations. 20 µg poly (A)+ 
RNA was mixed with 5.7 ml 10x reaction buffer and 10 U DnaseI and the final 
volume was adjusted to 56.7 µl with ddH2O. This mixture was incubated for 30 min at 
37°C. Phenol:chloroform extraction was performed to ensure the removal of protein 
contamination and DnaseI from the RNA samples. Following ethanol precipitation the 
RNA samples were dissolved in DEPC ddH2O. The integrity of the mRNA 
preparation was checked by running on denaturing formaldehyde agarose gel. Purified 
mRNA appeared as a smear from 0.5-12 kb with weak ribosomal RNA bands at 
approximately 1.9 and 4.5 kb as expected. 
 
 
2.3.13 Northern Blotting 
 
Sample running and transfer 
20-30 µg of total RNA samples were denatured in premix solution at 55-60°C 
water bath for 15 min. Samples were loaded on 1% formaldehyde gel with loading 
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buffer containing ethidium bromide. The gel was run overnight at 50 V in 1xMOPS 
buffer. Before transfer, the gel was washed in ddH2O 5 times each for 5 min, and gel 
and nylon membrane (Hybond N+) were equilibrated in 10xSSC. After overnight 
transfer, the membrane was auto-crosslinked by using Stratalinker under 120 mJ and 
baked at 80°C for 2 h to reverse the formaldehyde reaction and fix the RNA. 
 
Hybridization 
The membrane containing the RNA samples was prehybridized in 
hybridization buffer for 1 h at 65°C. The membrane was then hybridized overnight at 
65°C in hybridization buffer containing at least 107 cpm [α-32P] dCTP-labelled DNA 
probes per membrane. Membranes were sequentially washed in 2x SSC and 0.5% 
SDS, 1x SSC and 0.5% SDS, 0.2x SSC and 0.5% SDS at 68°C and the filters were 
exposed to X-ray film with an intensifying screen at -70°C. 
 
 
2.3.14 Protein extraction from tissue culture cells 
 
Medium was aspirated from the tissue culture plates and the cells were rinsed 
twice with ice cold PBS.  1 ml ice cold PBS was added to the cells and the cells were 
collected by scraping from the plates. The cells were pelleted by centrifugation at 
5000 rpm for 5 min. The cell pellets were lysed with RIPA buffer and incubated on 
ice for 30 min. After centrifugation at 13000 rpm for 30 minutes at 4°C, the 
supernatant was either stored at  -80oC for future use or immediately loaded onto 
SDS-PAGE gel. 
 
After the cell lysates were prepared, their concentrations were detected by 
Bradford assay. 5 µl of the samples were diluted with 95 µl deionised water and then 
1 ml of Bradford working solution was added to the samples and mixed well. After 5 
minutes, OD was measured at 595 nm versus blank reagent. Known concentrations of 
BSA were prepared as a standard and the same procedure was performed. After 
reading at OD595, samples and standard values were plotted; unknown concentrations 
were read from the standard curve. 
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2.3.15 Immunoprecipitation 
  
Immunoprecipitation of BRCA1 was performed from cellular lysates and in 
vitro transcribed-translated radioactive labelled BRCA1 protein. 
 
Immunoprecipitation of BRCA1 from cellular lysates 
Cells were lysed in RIPA buffer and the amount of protein was detected by 
Bradford assay. 500 µg prewashed protein A was added to 1000 µg cellular lysate in a 
final volume was 500 µl. Pre-immune rabbit serum was added at a final dilution of 
1:1000. Tubes were left overnight on shaker at cold room.  Next day, after 10 min 
centrifuge at 2500 rpm, the supernatant was transferred into a clean tube, and 500 µg 
prewashed protein A was again added into the lysate. After leaving 2 h on shaker at 
the cold room, the samples were centrifuged and the supernatant was transferred to a 
new tube. 2 µg of the antibodies were added to the lysates and incubated for 6 h at the 
cold room on shaker. 250 µg of protein A+G mix (1:1, v/v) was added to the tubes 
and left 1 h at cold room on shaker. After centrifugation, the beads were washed 3 
times in 1 ml RIPA buffer, and a final 10 min centrifuge was carried out. The beads 
were resuspended in 50 µl loading buffer and denatured for 10 min at 100°C. Then 
samples were loaded on 5% SDS-PAGE. The remaining protocol was the same as 
western blotting. 
 
Immunoprecipitation of BRCA1 from IVTT product 
pcDNA3.myc.BRCA1 and pCR3.BRCA1 plasmids, which have T7 promoter,  
were used for in vitro transcription/translation assay. Promega’s TNT Coupled 
Reticulocyte Lysate Systems kit was used according to the manufacturer’s 
instructions with minor modifications. The protocol for TNT lysate coupled 
transcription/translation reaction was as follows: 
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TNT rabbit reticulocyte lysate     25 µl 
TNT reaction buffer      2 µl 
T7 polymerase      1 µl 
Amino acid mixture minus methionine   1 µl 
35α-S methionine (1000Ci/mmol) at 10 mCi/ml  4 µl 
Rnasin (ribonuclease inhibitor, 40 u/µl)   1 µl 
DNA template (pcDNA3.myc.BRCA1/ pCR3.BRCA1) 1 µg 
Nuclease free H2O            to final volume 50 µl  
 
 
The tubes were incubated at 25oC for 2.5 h. Afterwards the samples were 
either immunoprecipitated with BRCA1 antibodies or directly loaded on gel. The gel 
was then dried and left for autoradiography. 
 
The final volume of the IVTT product was completed to 100 µl with RIPA and 
1.5 µg of antibodies was added onto the lysate. Samples were left overnight on ice. 
500 µg of prewashed protein A was added to the samples and left 1 h at the cold room 
on shaker. After washing the beads 3 times in 1 ml RIPA, the beads were denatured 
for 10 min at 100°C with loading buffer. The samples were run on 5% gel, the gel was 
dried and left for autoradiography. 
 
 
2.3.16 Western Blotting 
 
Performing SDS-PAGE 
 
Preparation of 5% acrylamide gel (40 ml) was as follows; 
H2O   23.4 ml 
30% Acrylamide mix 6.8 ml 
1.5 M Tris, pH: 8.8 10 ml 
10% SDS  0.4 ml 
1.5 ml APS  0.4 ml 
TEMED  32 µl 
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Preparation of 5% stacking gel (10 ml) was as follows; 
H2O   6.8 ml 
30% Acrylamide mix 1.7 ml 
1.0 M Tris, pH: 6.8 1.25 ml 
10% SDS  0.1 ml 
1.5 ml APS  0.1 ml 
TEMED  10 µl 
 
Equal amounts of proteins were denatured in 5x loading buffer at 95oC for five 
minutes prior to loading on gel. Gels were run at 80-100 V during stacking gel and 
120-150 V during resolving gel in running buffer. The run was stopped as 
bromphenol blue came to the end of the gel, and the gel was prepared for western 
blotting. 
 
10% resolving gels were used for p53, MSH2 and cytokeratin 18 western 
blots. For BRCA1 western blots 5% resolving gel was used. 
 
 
Transfer 
BRCA1 immunoblotting was performed with wet transfer, while p53, MSH2 
and cytokeratin 18 immunoblots were performed with semi-dry transfer procedures. 
 
Wet transfer: Immobilen P transfer (PVDF) membrane was washed with methanol 
for 1-2 min, then rinsed several times with water and kept in wet transfer buffer. Gel 
and immunoblot papers were also kept in transfer buffer for equilibration for 5-10 
min. Two immunoblot papers (prewet by transfer buffer), membrane, gel and two wet 
immunoblot papers were placed on transblotter. Transfer was performed overnight at 
0.75 A at –5°C. After transfer, the membrane was air-dried. The size of the prestained 
molecular weight marker was 205, 121, 74, 47 kDa (Bio-Rad). 
 
Semi-dry transfer: All the transfer protocol was the same as the wet transfer except 
for the use of semi-dry transfer buffer and transfer conditions. Semi-dry transfer was 
performed at 12V for 30 min at room temperature. 
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The membrane was kept in blocking solution for 2 h at room temperature or 
overnight at 4oC. The membrane was washed (3 times, 5 min each) with TBS-T 
washing solution. Primary antibody (final concentration; 1 µg/ml) was added to the 
blocking solution and the membrane was left in primary antibody for 2 h to overnight 
at 4oC on shaker. After washing three times with washing buffer, the membrane was 
left in secondary antibody for 1 h. After washing three times again, the membrane was 
exposed to ECL kit reagents according to the manufacturer’s instructions and 
autoradiography was carried out. 
 
 
2.3.17 Annexin V and Hoechst staining 
 
Method I: Growing culture cells were washed two times with ice cold PBS and then 
resuspended in annexin V binding buffer. Cells were incubated for 20 min in the dark 
with annexin V by diluting 5 µl of annexin V in 100 µl binding buffer per coverslide.  
 
Method II:  Without changing the medium, annexin V was added to the growth 
medium in 10xbinding buffer, and cells were kept in the incubator for 30 minutes. The 
supernatants were collected with a gentle washing with PBS, cells were counted, 
centrifuged and the pellets were fixed on cover slides by cytospin by centrifuging for 
5 minutes at 500 rpm. Later on, the cells grown on coverslides and the fixed cells in 
two methods were subjected to Hoechst staining, which stains the nucleus, as 
described in the following. The procedure was performed under dim light and the 
samples were kept away from direct light exposure. The coverslides were washed 
with binding buffer and fixed in 1 ml 90% cold ethanol for 30 min. After washing 
with PBS, Hoechst staining was performed for 5 min in the dark. The coverslides 
were extensively washed with H2O and mounted onto 80% glycerol droplet. 
 
 
2.3.18 PhosphorImager quantification 
 
The dot blot and northern blot hybridization signals were analyzed by using a 
PhosphorImager (Bio-Rad). Northern blots and dot blots were exposed to phosphor 
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screen and the screen was scanned using Multi-Analyst software which is designed 
for analysing digitised images. After the scanned image was displayed, a rectangular 
area was drawn on the image of the region that needed to be analyzed and each 
signal’s intensity was quantified. Multi-analyst software was also used for the 
quantification of semi-quantitative RT-PCR product intensities and analysing the 
changes in gene expression.  
 
 
2.4 Construction of BRCA1 expressing eukaryotic expression vectors 
 
During this study three different vectors containing full-length BRCA1 cDNA 
were used for subcloning into pIND eukaryotic expression vector: 
 
Vector      Subcloned into Cloning sites 
pcDNA3.myc.BRCA1 (Calzone F.J)  pIND.myc.BRCA1 BamHI-XbaI 
pCR3.BRCA1 (B.Weber)   pIND.BRCA1  HindIII-NotI 
pRC.CMV.BRCA1 (D.Haber)  pIND.HA.BRCA1 HindIII-NotI 
 
 
Principle of Ecdysone-Inducible System 
The Ecdysone-Inducible Mammalian Expression System was used in order to 
generate a stable breast carcinoma cell line where the BRCA1 gene expression can be 
controlled.  
 
This system is based on the molting induction system of Drosophila, but has 
been modified for inducible expression in mammalian cells. The system uses the 
steroid hormone ecdysone analog, muristerone A or ponasterone A, to activate 
expression of the gene of interest via a heterodimeric nuclear receptor.  
 
The Ecdysone-Inducible Mammalian Expression System includes:  
-An inducible expression plasmid, pIND, for expression of the gene of interest that 
contains 5 modified ecdysone response elements (E/GREs) upstream of a minimal 
heat shock promoter and the multiple cloning site. 
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-A second plasmid, pVgRXR, which encodes the receptor subunits.  
-Ponasterone A/muristerone A for inducing expression.  
-A control expression plasmid containing the lacZ gene, that when cotransfected with  
pVgRXR expresses β-galactosidase upon induction with ponasterone A (Figure 7).   
 
 
 
 
Figure 7: Principle of ecdysone inducible system pVGRXR plasmid constitutively 
synthesizes a heterodimer of the ecdysone receptor (VgEcR) and the retinoid X 
receptor (RXR) which binds a hybrid ecdysone response element (E/GRE) in pIND 
vector upstream of the gene of interest, in the presence of the synthetic analogs of  
ecdysone, ponasterone A or muristerone A.  
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2.4.1 Construction of pIND.myc.BRCA1 
 
pcDNA3.myc.BRCA1 vector was used as the source of full-length BRCA1 
cDNA. This vector contains two myc epitopes at the N-terminus of BRCA1, and its 
start codon is at the 5’ end of myc epitopes.  myc.BRCA1 in the pcDNA3 (Figure 8A) 
was subcloned into pIND (Figure 8B).  
 
 
 
 
 
Figure 8: Multiple cloning sites and properties of vectors  (A) pcDNA3 
(Invitrogen) and (B) pIND (Clontech). 
 
 
 
First pcDNA3.myc.BRCA1 was digested with BamHI-XbaI. Recognition sites 
of BamHI were at 907th and 4996th nucleotides on pcDNA3.myc.BRCA1 (11118 bp), 
A 
B 
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while XbaI recognises at 6655th position. After double digestion with BamHI-XbaI, 
the following fragments were expected; 
BamHI- XbaI  5370 bp 
BamHI-BamHI 4089 bp 
BamHI-XbaI  1659 bp 
 
4089 bp and 1659 bp fragments were extracted from the gel. 3 µg pIND vector 
was also digested with 5 U of each enzyme for 5 h in MBI yellow buffer at 37oC and 
then extracted from the gel. 
 
1659 bp fragment of myc.BRCA1 was ligated into BamHI-XbaI digested 
pIND, transformed into E.coli and plasmid DNA was prepared. Resulting construct  -
pIND+1.6 kb myc fragment- was digested with BamHI and extracted from the gel. 
Following treatment with CIAP the fragment was extracted from gel again. The last 
step was ligation of this BamHI digested/CIAP treated pIND+1.6 kb construct and 
4089 bp fragment of BRCA1. The final construct was pIND.myc.BRCA1, which is 
10.71 kb. 
 
In order to check the orientation of the ligation products, a double digestion 
with XhoI-XbaI was performed in Stratagene assay buffer 3. So if the fragment was 
correctly ligated into vector the expected fragments after digestion were 5.6 kb and 
5.1 kb, but if the orientation was wrong, 9.1 kb and 1.6 kb fragments were expected. 
 
 
2.4.2 Construction of pIND.BRCA1  
 
pCR3.BRCA1 vector was the second source of full-length BRCA1 cDNA. 
Multiple cloning site and properties of this vector is shown in Figure 9. Subcloning of 
full-length BRCA1 from pCR3 into pIND was performed by plasmid killing strategy. 
5.6 kb full length BRCA1 cDNA was in 5 kb pCR3 vector between HindIII-NotI sites 
in the pCR3.BRCA1 construct. It was very difficult to gel extract the 5.6 kb BRCA1 
fragment after HindIII-NotI double digest since vector and insert sizes were very 
close. MspI cuts pCR3 vector 21 times and cuts its ampicillin resistance gene 5 times, 
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but this enzyme does not cut BRCA1 sequence. In order to get the intact HindIII-NotI 
digested 5.7 kb BRCA1 fragment without gel extraction, pCR3.BRCA1 was digested 
with HindIII-NotI-MspI with 2xMBI Tango buffer. Meanwhile, pIND vector was 
digested with HindIII-NotI. This strategy eliminated gel extraction steps of the desired 
fragments before ligation reaction. After digestion the products were checked on 
agarose gel and double digested pIND vector was treated with alkaline phosphatase in 
order to prevent self-ligation. Last step was to ligate both HindIII-NotI digested 
BRCA1 and pIND and to transform the final construct into the DH5α strain. 
 
 
Figure 9: Multiple cloning sites and properties of pCR3 vector (Invitrogen). 
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2.4.3 Construction of pIND.HA.BRCA1 
 
pRc/CMV.BRCA1 was the third source of full-length BRCA1 cDNA. 5.7 kb 
full length BRCA1 cDNA was in pRc/CMV vector between HindIII-NotI sites with a 
HA tag at the 5’ end. It was very difficult to distinguish the 5.7 kb BRCA1 fragment 
after HindIII-NotI double digest, because pRc/CMV vector was 5.5 kb in size (Figure 
10). So pRc/CMV.BRCA1 was digested with HindIII-NotI-PvuI (all New England 
Biolabs with Assay buffer 3). PvuI cuts pRc/CMV vector once but does not cut 
BRCA1 sequence. Therefore the 5.7 kb BRCA1 fragment was gel extracted and 
ligated into 5 kb HindIII-NotI digested and purified pIND expression vector. The 
ligation reaction was performed overnight on ice and this mixture was transformed 
into the JM109 strain. The final construct was named as pIND.HA.BRCA1 since there 
is a HA tag at the 5’ end of the BRCA1 sequence. 
 
 
 
 
 
Figure 10: Multiple cloning sites and properties of pRc/CMV vector (Invitrogen). 
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2.5 Tissue Culture Techniques 
 
2.5.1 Growth conditions of cell lines 
 
All cell lines used in this study were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% fetal calf serum, 1 mM glutamine and 
penicillin/streptomycin (50 mg/ml) and appropriate selective antibiotic. 
 
U2OS/RXR cell line was stably transfected with pVgRXR plasmid and always 
grown in selective growth medium containing 100 µg/ml zeocin. UBR60-bcl2 cell 
line, which expresses BRCA1 under the control of tetracycline-regulated promoter, 
has been previously described (Harkin et al., 1999). Briefly, UBR60-bcl2 cells were 
maintained in growth medium, which contained 500 µg/ml geneticine (G418), 1 
µg/ml puromycin, 200 µg/ml hygromycin and 1 µg/ml tetracycline. Upon tetracycline 
withdrawal the cells express the BRCA1 gene (Tet-off system, Clontech Laboratories 
Inc.). 
 
The cells were incubated at a 37oC incubator with an atmosphere of 5 % CO2 
in air.  The cells were passaged before reaching confluence. The growth medium was 
aspirated and the cells were washed once with PBS. Trypsin solution was added to the 
petri dish to remove the monolayer cells from the surface. Fresh medium was added 
and the cell suspension was pipetted gently to disperse the cells. The cells were 
transferred to new petri dishes using different dilutions (from 1:2 to 1:10) depending 
on requirements. 
 
All media and solutions used for tissue culture were kept at 4oC and warmed 
to 37oC before use.  
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2.5.2 Determination of cell sensitivity to selective system 
 
Before generating stable pVgRXR expressing MCF7 breast carcinoma cell line, 
zeocin sensitivity of MCF7 has been determined by performing a kill curve. 1x106 cells 
were plated in 100 mm plates and these cells were grown in DMEM supplemented with 
800, 700, 600, 500, 400, 300 µg zeocin/ml for 3 weeks. Selection medium was changed 
every 2 days. Within the first week, cells stopped growing in zeocin containing medium. 
After 3 weeks cells were left with medium without zeocin for colony formation for one 
week. At the end of these 4 weeks, plates were stained with 2% trypan blue. First the 
medium was aspirated and replaced with 95% ethanol, then stained with 2% trypan blue 
solution for 10 min to stain the colonies. The plates carefully washed with water in order 
to get rid of excess stain. Colonies, which retained blue dye, were counted and as a 
conclusion, 400 µg/ml zeocin seemed to be enough for selection after transfection. 
 
 
2.5.3 Cryopreservation of cell lines       
 
Exponentially growing cells were harvested by trypsinisation and neutralised 
by adding growth medium. The cells were counted and precipitated at 1500 rpm for 5 
min. The pellet was suspended in freezing solution at a concentration of 4x106 
cells/ml/vial. The tubes were left at -70oC overnight. The next day, the tubes were 
transferred into the liquid nitrogen storage tank. 
 
When frozen stocks were recovered from liquid nitrogen, the tubes were 
thawed rapidly at a 37oC waterbath for 1 min. As the solution thawed, the cells were 
transferred into a 15 ml falcon tube and 10 ml DMEM was added gradually. The 
sample was centrifuged at 1500 rpm for 5 min. The supernatant was aspirated and the 
cell pellet was resuspended with 5 ml DMEM and transferred into a 100-mm petri 
dish. 
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2.5.4 Transfection of mammalian cells  
 
2.5.4.1 Electroporation of mammalian cells    
 
The cells were plated a day before the electroporation to obtain 60-90% 
confluency on the day of transfection. Before electroporation the cells were harvested 
by trypsinisation and washed twice with ice-cold calcium-magnesium free PBS. 
Harvested cells were counted with a haemocytometer and centrifuged at 1500 rpm for 
5 min. The pellet was resuspended in ice cold PBS at a density of 4-15x106 cells/800 
µl PBS /cuvette according to the experiment. 20-40 µg of the supercoiled plasmid 
DNA was added to the cell suspension, mixed well and transferred into a 0.4 cm 
electroporation cuvette. The cuvettes were incubated on ice for 10 min and then 
placed into the BioRad Gene Pulser chamber. The cells were electroporated at 950 
µF, 0.22 kV/cm (t=19-22 ms). The cuvettes were then incubated on ice for 10 min and 
the cells were transferred into a tube containing growth medium. The cells were 
plated into one or two 100-mm plates according to the aim of the experiment 
 
 
2.5.4.2 Calcium phosphate mediated transfection of mammalian cells 
 
CaPO4 transfection for generating a stable cell line 
Exponentially growing MCF-7 cells were trypsinized and plated at a 
concentration of  5x105 cells/100 mm plate a day before transfection. The cells were 
incubated overnight in 10 ml growth medium. Next day, the medium was changed 
with 9 ml of fresh medium before transfection. 30 µg of pVgRXR plasmid DNA was 
mixed with 1.25 ml of 1xHBS and then with 62 µl of 2.5 M CaCl2.  This mixture was 
incubated for 20 min at room temperature. The precipitate was mixed gently and 
added onto the cells drop by drop. The cells were incubated at 37oC under 5% CO2 for 
6 h. After the incubation, the medium was aspirated, 3 ml of 15% glycerol in 1xHBS 
was added to cells and distributed gently on the cells for 90 sec to shock the cells. The 
solution was removed and the cells were then  washed twice with calcium-magnesium 
free PBS. 10 ml of growth medium was added to the cells and they were left for 
overnight incubation.  
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24 h after transfection the pEGFP transfected cells were observed to determine 
the efficiency of transfection and the MCF-7 / pVgRXR cells were expanded. 
 
The cells were then passaged into four 150 mm plates 48 h after the 
transfection and the selection medium containing 500 µg/ml zeocin was applied to 
produce stable clones. Zeocin selection was applied for six weeks. Some independent 
colonies were picked and expanded in tissue culture selective medium. The clones 
were transfected with the reporter plasmid, pIND.lacZ to observe pVgRXR 
expression by using β-galactosidase assay. 
 
 
CaPO4 transfection for transient expression (Chen and Okayama, 1987) 
Exponentially growing MCF-7 or U2OS cells or RXRIII clones were 
trypsinized and plated at 5x105-1x106 cells/100 mm plate a day before transfection. 
The cells were incubated overnight in 10 ml growth medium. Next day, the medium 
was replaced with 9 ml of fresh medium. 20-30 µg of plasmid DNA was mixed with 
0.5 ml of 0.25 M CaCl2 and 0.5 ml 2xBBS. This mixture was incubated 10-20 min at 
room temperature. CaPO4.DNA precipitate was added drop by drop onto the cells and 
the plate was mixed gently. Plates were incubated either at 35oC under 3% CO2 or at 
37oC under 5% CO2 for 15-24 h. Afterwards, this medium was removed and the cells 
were rinsed twice with growth medium and incubated at 37oC under 5% CO2. U2OS 
cells and RXRIII clones were expanded into two plates and induced with muristerone 
A or ponasterone A. 
 
 
2.5.4.3 β-galactosidase assay 
 
In order to find the best pVgRXR expressing MCF7 RXRIII clone, pIND.lacZ 
was transiently transfected into these clones and also into U2OS cells as control, 
which already stably expresses pVgRXR plasmid. RXRIII clones and U2OS control 
cells were transfected with pIND.lacZ vector. 24 h after the transfection the cells were 
splitted into two plates. One plate was induced with 10 µM muristerone A or 
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ponasterone A, while the other plate was left uninduced. 48 h after transfection -72 h 
for RXRIII clones- the cells were harvested for β-galactosidase assay, which detects 
the amount of RXR gene induction and the expression of lacZ gene from the reporter 
plasmid pIND.lacZ.  Figure 11 shows the properties of the vectors pVgRXR and 
pIND.lacZ, which are the main components of the ecdysone inducible expression 
system.
 
β-galactosidase assay was performed as follows: Medium was aspirated from 
the plates and cells were rinsed with ice cold PBS. 750 µl ice cold PBS was added to 
the cells and the cells were scraped. The cells were pelleted by centifugating. The cell 
pellets were lysed in 200 µl of 5x reporter lysis buffer (Promega) or in RIPA buffer 
for 30 min. 24 µl of 10xZ buffer, 25 µl lysed cell extract, 40 µl ONPG and 151 µl 
H2O were mixed and incubated at 37oC for 1 h. The reaction was stopped with 760 µl 
1 M Na2CO3 (pH 12). Blank was the same mixture without cell lysate. Optic densities 
of the samples were read at 420 nm. 
 
 
          Figure 11: Properties of the vectors pVgRXR and pIND.lacZ (Clontech) 
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2.6 Subtractive Hybridization 
 
            Subtractive hybridization is a powerful technique to compare two populations 
of mRNA and obtain genes that are expressed in one population but not in the other. 
Both mRNA populations are converted to cDNA. The cDNA population, which 
contains the specific (differentially expressed) transcripts is named as “tester” and the 
reference cDNA population is named as “driver”. Tester and driver cDNAs are 
hybridized and the hybrid sequences are then removed. Consequently, the remaining 
unhybridized cDNAs represent genes that are expressed in the tester, but are absent 
from the driver mRNA. Clontech PCR-Select cDNA Subtraction method is based on 
selective amplification of differentially expressed sequences. Figure 9 summarizes the 
principle of suppression subtractive hybridization technique. First, cDNA is 
synthesized from poly A+ RNA from the two types of population under comparison. 
The tester and driver cDNAs are digested with RsaI, a four base cutting restriction 
enzyme that yields blunt ends. The tester cDNA is then subdivided into two portions 
and each is ligated with a different cDNA adaptor. The ends of the adaptor do not 
have a phosphate group so only one strand of each adaptor attaches to the 5’ ends of 
the cDNA. The two adaptors have stretches of identical sequence to allow annealing 
of the PCR primer once the recessed ends have been filled in.  
 
            During first hybridization, an excess driver is added to each sample of tester. 
The samples are then heat denatured and allowed to anneal, generating the type a, b, 
c, and d molecules in each sample. The concentration of high- and low-abundance 
sequences is equalized among the type a molecules because reannealing is faster for 
the more abundant molecules. At the same time, the ss type a molecules are 
significantly enriched for differentially expressed sequences, as cDNAs that are not 
differentially expressed form type c molecules with the driver.  
 
            During the second hybridization, the two primary hybridization samples are 
mixed together without denaturing. Only the remaining equalized and subtracted 
cDNAs can reassociate and form new type e hybrids. These new hybrids are ds tester 
molecules with different ends, which correspond to the sequences of adaptors 1 and 
2R. Fresh denatured driver cDNA is added to further enrich fraction e for 
differentially expressed sequences.  
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Figure 12: Principle of suppression subtractive hybridization  
 
 
           After filling in the ends by DNA polymerase, the type e molecules -the 
differentially expressed tester sequences- have different annealing sites for the nested 
primers on their 5’ and 3’ ends.  
 
           The entire population of molecules are then subjected to PCR to amplify the 
desired differentially expressed sequences. During PCR, type a and d molecules are 
Add primers, amplify by PCR 
e 
a, d     no  amplification 
b       no  amplification 
c      linear   amplification 
and 
3
’ 
5’ 
5
’ 
3’ 
e   exponential   amplification 
a 
d 
c 
b 
Tester  cDNA with adaptor 1 Driver cDNA (in excess) Tester cDNA with adaptor II 
First hybridization 
a 
b 
c 
d 
a, b, c, d  +  e 
Second hybridization; mix samples, add fresh 
denatured driver and anneal 
Fill in the ends 
 81
missing primer-annealing sites, thus cannot be amplified. Due to the suppression PCR 
effect, most type b molecules form a pan-like structure that prevents their exponential 
amplification. Type c molecules have only one primer-annealing site and can only be 
amplified linearly. Only type e molecules, which have two different adaptors, can be 
amplified exponentially. These are the equalized, differentially expressed sequences. 
Next a secondary PCR amplification is performed using nested primers to further 
reduce any background PCR products and to enrich for differentially expressed 
sequences. The cDNAs can then be directly inserted into a T/A cloning vector for 
identifying the differentially expressed sequences by sequencing and hybridization 
analysis. The PCR mixture can also be used as a hybridization probe to screen cDNA 
libraries. 
 
 
2.6.1 Double strand cDNA synthesis 
 
First and second strand cDNA synthesis were performed with Boehringer 
Mannheim cDNA synthesis kit. During first strand synthesis, the oligo (dT) primer 
included in the PCR-Select TM cDNA subtraction kit, was used. 
 
cDNA synthesis primer       5'–TTTTGTACAAGCTT30N1N–3'  
 
Each of 3.5 µg MCF-7 transfected pCMVmyc (cDNA2) and 
pCMVmycBRCA1 (cDNA1) poly (A)+ RNA and control mRNA (cDNA3) from the 
subtraction kit was used to synthesize ds-cDNA. Briefly, each RNA was mixed with 
1.7 µl oligo(dT) and incubated at 70°C for 2 min. 4 µl first strand buffer, 1 µl Rnase 
inhibitor, 2 µl dNTP mix, 2 µl [α-32P]-dCTP (20 µCi final) and 2 µl AMV-reverse 
transcriptase were added and the final volume was adjusted to 20 µl with deionised 
water. The mixture was incubated at 42°C for 1 h and 40 µl second strand synthesis 
buffer II, 1 µl RnaseH, 34 µl H2O and 5 µl DNA polymerase I were added to tubes. 
The tubes were always kept on ice and mixed thoroughly. The tubes were incubated at 
12°C for 1 h, 22°C for 1 h and 65°C 10 min. Following addition of 4 µl T4 DNA 
polymerase the samples were incubated at 37°C for 10 min. Reactions were stopped 
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by the addition of 5 µl 20xEDTA/Glycogen mixture supplied within the subtraction 
kit. 
 
After this step, all the protocol for cDNA subtraction was performed as 
recommended in Clontech PCR-Select cDNA subtraction kit with minor 
modifications. 
 
Phenol:chloroform extraction was carried out with ds-cDNAs. During this 
protocol, the pellet was checked with a Geiger counter to ensure the presence of the 
pellet. The precipitate was dissolved in 50 µl of H2O. 
 
 
2.6.2 RsaI digestion 
 
44 µl each of cDNA1, cDNA2 and cDNA3 were digested with 15 U of RsaI at 
37°C for 2 h. In order to analyze the efficiency of RsaI digestion, 2.5 µl undigested 
and 5 µl RsaI digested cDNAs were run on a 1% ethidium bromide containing 
agarose gel in 1XTAE buffer. RsaI digested cDNAs were subjected to 
phenol:chloroform extraction. During this protocol, the pellet was checked with a 
Geiger counter. The precipitate was dissolved in 5.5 µl of ddH2O. 
 
 
 
2.6.3 Adaptor ligation 
 
Preparation of experimental cDNAs: 1 µl from 5.5 µl RsaI digested experimental 
cDNAs (cDNA1 and cDNA2) were diluted in 5 µl of ddH2O.  
 
2 µl (3 ng/µl) of HaeIII digest of φX174 DNA was diluted with 38 µl of sterile 
ddH2O. 
 
1 µl from 5.5 µl RsaI digested control skeletal muscle cDNA was mixed with 5 µl of 
the diluted φX174 DNA/ HaeIII DNA. 
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Adaptor ligation:  2 µl of diluted tester cDNAs were mixed with either adaptor 1(10 
µM) or adaptor 2R (10 µM) and 2 µl of 5xligation buffer and 1 µl T4 DNA ligase 
(400 U/µl).  
 
Tester 1.1: cDNA1 ligated to adaptor 1, Tester 1.2: cDNA1 ligated to adaptor 2, 
Tester 2.1: cDNA2 ligated to adaptor 1, Tester 2.2: cDNA2 ligated to adaptor 2, 
Tester 3.1: cDNA3 ligated to adaptor 1, Tester 3.2: cDNA3 ligated to adaptor 2 
 
 
In a fresh tube 2 µl of tester 1.1 and 2 µl of tester 2.2 were mixed. 1 µl from 
this mixture was diluted in 1 ml of H2O and this mixture was named unsubtracted 
tester control (1-c). The same setup was repeated for the other samples and controls 
2-c and 3-c were prepared. After aliquoting the samples for preparation of 
unsubtracted tester controls the tubes were incubated at 16°C overnight for adaptor 
ligation. The ligation reaction was stopped by the addition of 1 µl 
20xEDTA/Glycogen mix. Adaptor ligated tester cDNAs and unsubtracted tester 
controls were ready for ligation efficiency analysis. 
 
 
Ligation efficiency analysis: 1 µl of each ligated tester cDNA was diluted into 200 µl 
ddH2O. PCR setup was as follows: 
 
 
Component      Tube# 1 2 3 4 
Tester 1.1 or 2.1 or 3.1   2 2 - - 
Tester 1.2 or 2.2 or 3.2   -  - 2 2 
G3PDH 3’ primer (25 pmole/µl)  1 1 1 1 
G3PDH 5’ primer (25 pmole/µl)  - 1 - 1 
PCR Primer 1 (25 pmole/µl)  1 - 1 - 
Total volume    4 4 4 4  
G3PDH 5' Primer    5'–ACCACAGTCCATGCCATCAC–3' 
G3PDH 3' Primer   5'–TCCACCACCCTGTTGCTGTA–3' 
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2.5 µl of 10x buffer (MBI), 1.5 µl 25 mM MgCl2, 0.5 µl 10 mM dNTP were 
added to each tube bringing the final volume to 20 µl. After hot start, 5 U Taq 
polymerase (MBI) was added to each tube in 5 µl H2O. PCR condition was as 
follows: 
 
 
Hot start  75°C  1 min (Taq polymerase was added) 
Initial denaturing 75°C  5 min 
Denaturing  94°C  30 sec 
Annealing  60°C  30 sec     30 cycles 
Extension  72°C  2 min 
Final extension 72°C  5 min 
 
5 µl from each reaction was analyzed on a 2% agarose gel run in 1xTAE buffer. 
 
 
2.6.4 First Hybridization 
 
First hybridization setup was as follows for tester 1.1 and 1.2. The same setup 
was repeated for testers 2.1, 2.2, 3.1, 3.3. 
 
Component      Hyb. sample 1             Hyb. Sample 2 
RsaI digested driver cDNA  1.5   1.5 
Adaptor 1 ligated tester 1.1  1.5     - 
Adaptor 2R-ligated tester 1.2   -   1.5 
4X hybridization buffer    1     1                         
Total volume    4 µl   4 µl  
 
 
After overlaying the samples with mineral oil, the tubes were incubated in a 
thermal cycler at 98°C for 1.5 min. After hybridization at 68°C for 8 h the samples 
were subjected to second hybridization immediately. 
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2.6.5 Second Hybridization 
 
1 µl driver cDNA, 1 µl 4xhybridization buffer and 2 µl H2O were mixed; 1 µl 
of this mixture was put in a tube and one drop of mineral oil was added. This diluted 
driver sample was denatured at 98°C for 1.5 min. Hybridization samples 1 and 2 were 
simultaneously mixed with this freshly denatured driver. After incubation at 68°C 
overnight, 200 µl of dilution buffer was added to the tube and mixed. The tubes were 
incubated at 68°C for 7 min. The samples were stored at –20°C. 
 
 
2.6.6 PCR amplification 
 
1, 2 and 5 µl from each 1:200 diluted subtracted experimental cDNAs and 
1:1000 diluted unsubtracted tester control cDNAs were used for first round PCR 
amplification in order to enrich the differentially expressed sequences after second 
hybridization. 
 
Templates were amplified with PCR primer 1 with 5 U Taq polymerase (MBI) 
in 25 µl PCR reaction with the following conditions: 
 
PCR primer 1          5'–CTAATACGACTCACTATAGGGC-3' 
 
Initial denaturing 75°C  1 min (Taq polymerase added) 
Denaturing  94°C   30 sec 
Annealing  66°C  30 sec       30 cycles 
Extension  72°C  1.5 min 
Final extension 72°C  5 min 
 
8 µl of primary PCR products were analyzed on 2% agarose gel. 
 
3 µl of each primary PCR product was diluted in 27 µl of H2O. 1 µl of this 
diluted primary PCR product mixture was used for secondary PCR. These primary 
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PCR products were amplified with nested PCR primer 1 and nested primer 2R with 5 
U Taq polymerase (MBI) in 25 µl PCR reaction with the following conditions: 
 
Nested PCR primer 1      5'–TCGAGCGGCCGCCCGGGCAGGT–3' 
Nested PCR primer 2R   5'–AGCGTGGTCGCGGCCGAGGT–3' 
 
Initial denaturing 75°C  1 min 
Denaturing  94°C  30 sec 
Annealing  68°C  30 sec        15 cycles 
Extension  72°C  1.5 min 
Final extension 72°C  5 min 
 
8 µl each of secondary PCR products were analyzed on 2% agarose gel. 
 
 
2.6.7 Subtraction Efficiency test 
 
Secondary PCR products of subtracted tester cDNAs and unsubtracted tester 
controls were diluted in 10-fold ddH2O. 1 µl of each template was amplified with 
G3PDH 3’ and G3PDH 5’ primers with 5 U taq polymerase (MBI) in 30 µl PCR 
reaction with the following conditions: 
 
Denaturing 94°C  30 sec 
Annealing 60°C  30 sec  18-23-28-33 cycles 
Extension 68°C  2 min     5 µl removed from tubes after each 5 cycles 
 
Samples were run on 2% agarose gel. 
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2.6.8 Cloning and pre-screening of forward subtracted library 
 
pGEM-T Easy Vector system was used for cloning of the forward subtracted 
library into TA vector. Secondary PCR products of forward subtracted library were 
ligated into pGEM-T Easy vector (Figure13), which allows blue/white selection. 
Briefly 3 µl of secondary PCR product was mixed with 1 µl pGEM-T vector, 5 µl 2x 
ligation buffer and 1 µl T4 DNA ligase. The ligation reaction was performed at 4°C 
overnight. Ligation products were transformed into supercompetent JM109 according 
to the manufacturer’s recommendations and each transformation was plated onto two 
150 mm LB agar plates containing ampicillin, IPTG and X-Gal.  
 
The white colonies were picked up and grown in LB medium containing 100 
µg/ml ampicillin and the glycerol stocks were prepared. The bacterial culture was 
directly used as template for PCR amplification of cDNA inserts with T7-SP6 
primers. Amplified PCR products were run on 2% agarose gel and analyzed. 
 
 
 
 
Figure 13: Map of pGEM-T Easy vector (Promega) 
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2.7 Differential Screening  
 
PCR-Select Differential Screening Kit was used according to the 
manufacturer's recommendations with minor modifications. 
 
 
2.7.1 Preparation of cDNA dot blots of forward subtracted library  
 
Equal volumes of PCR products of forward subtracted library (amplified with 
T7/Sp6 primers) and freshly diluted 0.6 N NaOH were mixed in a 96 well plate for 
denaturing the DNA. 1.5 µl of each mixture was blotted onto a nylon membrane 
(Hybond N+) in duplicate. The blots were neutralized for 2-4 min in 0.5 M Tris-HCl 
and washed in ddH2O. The DNA was crosslinked to the membrane with Stratalinker 
under 120 mJ. 
 
 
2.7.2 Probe preparation for dot blots 
 
40 µl each of forward and reverse subtracted secondary PCR products were 
purified (PCR purification kit, Qiagen) and ethanol precipitated with NH4OAc. The 
pellets were dissolved in 28 µl H2O. 3 µl restriction buffer 1 and 1.5 µl RsaI were 
added to each tube. 3 µl of this restriction digest sample was mixed with 25 ng of 
control plasmid (pIND has 5 RsaI digestion sites). The tubes were incubated for 1 h at 
37°C. Without stopping the reactions, 3 µl each of undigested cDNA, 3 µl each of 
digested cDNA and 3 µl each of digested cDNA, digested plasmid and also uncut 
plasmid were run on 2% agarose gel. After analysing the results, 1 µl of SmaI was 
added to the tubes and incubated for 1 h at room temperature. 61 µl H2O, 10 µl 
restriction buffer 2 and 1 µl EagI were added to the tubes. Following incubation for 1 
h at 37°C the digested adaptors were separated from the cDNA by using the Qiagen 
PCR purification kit. The volume of each sample was adjusted to 50 µl.  
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2.7.3 Random primer labelling of cDNA probes 
 
50 ng (in 9 µl H2O) of each adaptor-free digested forward and reverse 
subtracted probes were denatured by heating for 8 min at 95°C and cooled on ice. 3 µl 
reaction buffer (α-dCTP), 2 µl random primer mix, 5 µl (α-32P)-dCTP (3000 
Ci/mmol), and 1 µl Klenow enzyme (exo-) were added and incubated at 37°C for 30 
min. After the reactions were terminated by the addition of 5 µl stop solution, 
unincorporated dNTPs were purified from the labelled probes by using Quick spin 
columns as described. 
 
 
2.7.4 Hybridization of the arrays with the subtracted cDNAs 
 
For each membrane 50 µl of 20xSSC and 50 µl blocking solution were mixed 
and boiled for 5 min. After cooling down on ice, the mixture was combined with 5 ml 
of hybridization solution and the membranes were prehybridized for 2-4 h with 
continuous agitation at 65°C. Hybridization probe was prepared by mixing 50 µl of 
20xSSC, 50 µl blocking solution and 107 cpm [α-32P] dCTP-labelled purified probe. 
After boiling this mixture for 5 min, it was mixed with 5 ml hybridization solution 
and the membranes were prehybridized overnight with continuous agitation at 65°C. 
Membranes were sequentially washed in 2x SSC and 0.5% SDS, 1x SSC and 0.5% 
SDS, 0.2x SSC and 0.5% SDS at 68°C and the filters were exposed to X-ray film with 
an intensifying screen at -70°C. 
 
 
2.7.5 Analysis of differential screening results 
 
Initial screening of cDNA dots on arrays was analyzed by exposing the 
membranes to phosphorimager to measure the intensity of the signals. After first 
screening the clones showing more than five fold increase in signal intensity were 
selected and the differential screening procedure was repeated two more times. The 
signal intensities were normalized to actin signal intensities on each array; the ratio of 
actin values on each forward and reverse subtracted probe labelled arrays were used to 
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normalize the values. The average of three values for every dot was calculated.  The 
clones that showed a dramatic increase in expression were selected for sequencing. 
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CHAPTER 3. RESULTS 
 
 
 
  
3.1  Generating stable pVgRXR expressing MCF7 breast carcinoma cell line 
 
The MCF7 breast carcinoma cells contain one copy of BRCA1 gene and 
display low expression of this gene when compared to other cell lines. These cells 
also represent the cellular environment of breast tissue. Studying the genes that are 
regulated by the BRCA1 gene in this cell line can be expected to give a better 
understanding of their biological mechanism. We therefore wanted to generate a 
MCF7 breast cancer cell line where the BRCA1 gene expression level can be 
controlled. In order to achieve this aim the ecdysone inducible mammalian expression 
system was used. 
The first step in this system was to obtain MCF7 cells stably transfected with 
pVgRXR plasmid. 
 
Determination of effective zeocin concentration 
pVgRXR vector which expresses the heterodimeric ecdysone receptor 
contains the zeocin resistance gene. Mammalian cells lacking this gene are sensitive 
to zeocin which is a toxic agent.  
 
Prior to the transfection experiment, control experiments were set up to 
determine the minimal concentration of zeocin required to prevent growth of the 
MCF7 breast carcinoma cell line. Various zeocin concentrations (800, 700, 600, 500, 
400, 300 µg/ml) were used and a concentration of 500 µg/ml was found to be 
effective in eliminating all MCF7 cells by 7 days.  
 
 
Transfection for generating stable pVgRXR expressing MCF7 breast 
carcinoma cell line was performed as described in the methods section 2.5.4. 48 hr 
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after transfection, the selection medium containing 500µg/ml zeocin was applied to 
the cells. 
 
Two weeks after applying selection medium to the zeocin resistant cell clones, 
96 clones were picked up into 96 microwell plates. 10 days later the growing colonies 
were splitted into 12 well plates and one week later to 100 mm plates. 52 
MCF7/RXRIII clones were viable and grown. 
 
Genomic DNA from these 52 clones were isolated. The presence of zeocin 
resistance gene encoded by plasmid pVgRXR in these clones were detected by using 
RXR-F and RXR-R primers for PCR reaction. 33 out of 52 clones were zeocin 
sequence positive after PCR reaction. Figure 14 shows the results of PCR reaction of 
some MCF7/RXRIII clones. 
 
As expected pVgRXR plasmid DNA and U2OS cell line which carry the 
pVgRXR plasmid stably gave the 361 bp band and control MCF7 cells did not show 
any bands. The positive clones were RXRIII 1,2,5,6, 8, 9, 13, 20, 21,22,23, 24, 25, 26, 
27, 28, 32, 33, 34, 35, 36, 38, 39, 40, 44, 45, 46, 47, 48, 49, 50, 51 and 52. All 33 
positive clones were used for transfection with the pIND.lacZ reporter plasmid in 
order to determine the induction level of LacZ reporter gene. 
 
 
β-galactosidase assay results 
The selected MCF/RXRIII clones were transfected with pIND.lacZ reporter 
plasmid to test whether the zeocin-selected clones were really stably transfected with 
the pVgRXR plasmid. After the reporter plasmid transfection, the cells were induced 
with 10 mM muristrone A and the expression of lacZ gene was determined by the β-
galactosidase assay, as described in the methods section. 23 out of 33 MCF7/RXRIII 
clones were tested and Table 12 shows the results of these assays. 
 
MCF7 and U2OS cells were also transfected with pEGFP plasmid to 
determine the transfection efficiency at each experiment. 
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Figure 14: Analysis of pVgRXR transfected MCF7 cells. The genomic DNA was 
used from RXRIII clones for PCR reaction to determine the presence of the zeocin 
gene. The amplification product was 361bp. Lanes 1: pVgRXR plasmid as a positive 
control, 2: MCF7 cells, 23: negative control, 24: U2OS cells as a positive control, 
Lanes 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 25, 26, 27, 
28, 29, 30 are RXRIII clones 1- 2- 5- 6- 8- 9- 13- 15- 16- 17- 18- 19- 20- 21- 22- 23- 
24- 25- 26- 27-28- 32- 33-34- 35-36 respectively.  
 
 
 
U2OS cells were also transfected with pIND.lacZ in each experiment because 
it stably expresses pVgRXR plasmid and were used as positive control during 
transfection experiments. Table 11 shows the results of β-galactosidase assay of 
pIND.LacZ transfected U2OS cells used as a positive control. Different transfection 
protocols and cell lysis buffers were tried to analyze the induction level. The best 
induction was obtained with protocol 4, but this method requires the usage of a large 
number of cells. Protocol 5 was therefore selected to analyze the RXR/MCF7 clones 
for ß-galactosidase assay. 
 
Table 12 shows the results of ß-gal assay of MCF7/RXR clones after 
transfection with the reporter plasmid pIND.lacZ with protocol 5 in Table 1. Although 
there was induction in U2OS/RXR cells, no induction was observed in the 
MCF7/RXR clones.  
 
  M    23     24     25      26    27     28     29    30 
361bp 
361bp 
 These results indicate that although all the clones were selected with effective 
killing concentration of zeocin antibiotic and were positive for pVgRXR plasmid 
transfection, they were not stably transfected with the plasmid. The positive result of 
the PCR analysis might be due to the detection of the free plasmid present in the cells 
rather than the plasmid integrated into the genome of the cells or the cells may have 
become resistant to zeocin with an unknown mechanism. These MCF7/RXR clones 
were not used for further experiments. We decided to continue to the experiments 
with the U2OS/RXR cells. 
 
 
Table 11: Results of the β-gal assay of U2OS cells after transfection with 
pIND.lacZ reporter plasmid. 
  
 
 
 
 
 
 
 
 
 
 
 
 
1) CaP
2) Ele
3) Ele
4) Ele
5) CaP
hou
6) CaP
 
 
 OD at 420 nm 
        -mA  + mA      Induction fold Protocol
 
     0.1462  1.7548         12             1 
 
     0.0375  0.8531         22  2 
 
     0.1574  0.9355           6  2 
 
     0.0385  1.6889          44  3 
 
     0.0114  1.1189         98  4 
 
     0.0162  1.4341          88  5 
     0.0515  0.1780          19  6 94
O4 transfection with HeBS, reporter lysis buffer 
ctroporation, reporter lysis buffer 
ctroporation, RIPA buffer 
ctroporation, reporter lysis buffer, lysis time was increased 
O4 transfection with BBS, RIPA buffer, lysis time was increased to two 
rs 
O4 transfection with BBS, reporter lysis buffer 
 95
 
Table 12: Results of the β-gal assay of MCF7/RXR clones after transfection with 
pIND.lacZ.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       OD at 420 nm  
    RXR Clone #   -mA  + mA         
1  0.0420  0.0299 
2  0.0554  0.0621 
5  0.0603  0.0660  
 6  0.1980  0.1590  
8  0.0451  0.0304 
9  0.0500  0.0632 
13  0.0687  0.0441 
20  0.0682  0.0708   
 21  0.0377  0.0676   
 22  0.0471  0.0743  
23  0.0708  0.0589   
 24  0.0875  0.0883   
 25  0.0462  0.0615   
 26  0.1056  0.0795   
27  0.0320  0.0349 
28  0.0260  0.0343  
32  0.0311  0.0384 
33  0.0212  0.0226 
34  0.1381  0.1235 
35  0.0958    0.0899 
36  0.0380  0.0309 
38  0.0382  0.0418  
39  0.0242  0.0342 
40  0.0651  0.0632 
44  0.1002  0.0869 
45  0.0491  0.0527 
46  0.0276  0.0499 
 47  0.1421  0.1405  
 48  0.0622  0.0512 
49  0.0289  0.0729 
50  0.0621  0.0872 
51  0.1595  0.1733 
52  0.0203    0.0525 
     U2OS/RXR  0.0550  0.9321 
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3.2 Construction and analysis of eukaryotic expression vectors 
 
Three different full-length BRCA1 cDNA sources were used for construction 
of pIND.BRCA1 as mentioned in the methods section 2.4, because at the beginning of 
this study the full length BRCA1 cDNA was not available to whole community and 
the discrepancies in some of the cDNA constructs were reported later. BRCA1 cDNA 
sources and resulting constructs used during this study were as follows: 
  
 
Vector (Source)    Subcloned into                Cloning sites 
pcDNA3.myc.BRCA1 (F.J. Calzone)  pIND.myc.BRCA1  BamHI-XbaI 
pCR3.BRCA1 (B.Weber)    pIND.BRCA1   HindIII-NotI 
pRC.CMV.BRCA1 (D.Haber)   pIND.HA.BRCA1  HindIII-NotI 
 
 
All full-length BRCA1 cDNAs were subcloned into pIND vector in order to 
express high amount of BRCA1 transcript in a controllable manner. The resulting 
constructs were analyzed after cloning into pIND vector with various methods for the 
appropriate expression of full-length BRCA1 protein. 
 
 
 
3.2.1 Construction and analysis of eukaryotic expression vector 
pIND.myc.BRCA1 
 
3.2.1.1 In vitro transcription-translation and immunoprecipitation assay results 
of  pcDNA3.myc.BRCA1 
 
The first source for the full-length BRCA1 cDNA, pcDNA3.myc.BRCA1, was 
provided from Dr. Calzone. It was partially sequenced from 3’ end 5’- ends and in 
vitro transcription-translation assay was performed as described in the methods 
section 2.3.15. It was important to show that this full-length BRCA1 cDNA was 
translated into expected protein product. Figure 15 shows the result of IVTT and 
immunoprecipitation assays performed with pcDNA3.myc.BRCA1 construct. 
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Following the IVTT assay, radiolabeled IVTT product was immunoprecipitated with 
the antibodies 5HU (for BRCA1) and 9E10 (for myc epitope) in order to check the 
specifity of BRCA1 and myc antibodies that were going to be used for future western 
blot experiments. 
 
 
 
 
Figure 15: In vitro transcription-translation and immunoprecipitation assays of 
pcDNA3.myc.BRCA1 construct. Lane 1: IVTT product of pcDNA3.myc.BRCA1, 
Lane 2: IVTT-IP product of pcDNA3.myc.BRCA1 immunoprecipitated with 9E10, 
Lane 3: IVTT-IP product of pcDNA3.myc.BRCA1 immunoprecipitated with 5HU, 
Lane 4: Beads only of lane 2, Lane 5: Beads only of lane 3, Lane 6: Primary 
supernatant of lane 2 after binding to protein A, Lane 7: Primary supernatant of lane 3 
after binding to protein A sepharose. 
 
 
The band in the first lane corresponds to 220 kDa protein according to the 
molecular weight marker which means that pcDNA3.myc.BRCA1 in vitro 
transcribed-translated into expected BRCA1 protein product. When this IVTT protein 
product immunoprecipitated with myc and BRCA1 antibodies, although 5HU and 
9E10 antibodies specifically recognized IVTT product of BRCA1, the bands were not 
very strong. This indicated that either the antibodies may be too weak or there may be 
a problem with protein A sepharose beads since a high percentage of the radioactive 
protein product was found unbound in the primary supernatant (lanes 6 and 7).  
 
The results of this experiment show that the expected size of the BRCA1 
protein product can be obtained from this construct. Therefore pCDNA3.myc.BRCA1 
construct was used as a source of BRCA1 cDNA and cloned into pIND vector. 
 
 
 
 
    1      2     3    4   5    6     7 
   220 kDa 
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3.2.1.2 Construction of eukaryotic expression vector pIND.myc.BRCA1  
 
Full length BRCA1 cDNA with 2 myc epitopes at the 5’ end, was subcloned 
from pcDNA3 vector into pIND vector. To achieve this, the first step was to perform 
BamHI-XbaI double digestion with both pIND vector and pcDNA3.myc.BRCA1 
construct (Figure 16).  
 
 
 
                                         
 
Figure 16: BamHI-XbaI double digestion profiles of pIND and pcDNA3.myc. 
BRCA1. Lanes M: 1 kb ladder, Gibco-BRL, 1: undigested pIND, 2: BamHI-XbaI 
digested pIND, 3: undigested pcDNA3.myc.BRCA1, 4: BamHI-XbaI digested 
pcDNA3.myc.BRCA1. 
 
BamHI-XbaI double digested 5 kb pIND fragment from lane 2 and 4095 bp 
BamHI-BamHI and 1659 bp BamHI-XbaI fragments from lanes 4 were extracted. As 
a first step BamHI-XbaI digested pIND and 1.65 kb bands were extracted from the 
gel, ligated with vector, transformed into E.coli strain and miniprep DNAs of five 
colonies were purified. The resulting ligation colonies were named pIND+1.6kb myc.  
pIND+1.6 kb myc miniprep DNAs were digested with BamHI-XbaI in order to 
confirm that 1.6 kb insert had been ligated. Figure 17 shows the control BamHI-XbaI 
digestion profile of four of these colonies. 
 
As observed on the gel photo in Figure 17, all pIND+1.6 kb myc colonies 
were positive for the 1.6 kb fragment, so BamHI digested pIND+1.6 kb myc colony 
number 1 from lane 5 was used to isolate the 6.6 kb band and the band was cut and 
purified by gel extraction procedure.  
4095 bp 
1659 bp 
        M      1          2          3          4        4 
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This 6.6 kb BamHI digested vector was used for ligation with the 4 kb BamHI 
fragment of BRCA1 from pcDNA3.myc.BRCA1. 
 
Before ligation BamHI digested pIND+1.6 kb myc vector was treated with 
CIAP in order to minimize the self ligation of the vector without insert. 
 
Figure 18 shows the vector and insert concentrations before the ligation reaction. 
 
 
            
 
Figure 17: BamHI-XbaI double digestion profile of pIND+1.6 kb myc colonies. 
M: Marker1 kb ladder, Gibco-BRL, Lanes 1: undigested pIND, 2: BamHI digested 
pIND, 3: BamHI-XbaI digested pIND; 4, 7, 10, 13: undigested pIND+1.6 kb myc 
colonies 1,2,3,4 respectively; 5, 8, 11, 14: BamHI digested pIND+1.6 kb myc 
colonies 1,2,3,4 respectively; 6, 9, 12, 15: BamHI- XbaI double digested pIND+1.6 
kb myc colonies 1,2,3,4 respectively. 
 
     
                                                         
 
Figure 18: Determination of DNA concentrations by using the ethidium bromide 
containing agarose gels. The BamHI digested pIND+1.6 kb myc (vector) fragment 
and 4 kb BamHI DNA fragment (insert) were dotted on the agarose and the relative 
DNA intensities were determined under ultraviolet light. (Vector, V: 1 µl of BamHI 
digested CIAP treated pIND+1.6 kb myc, Insert, I: 1 µl of BamHI digested 4 kb 
BRCA1 fragment). 
    6.6kb 
    5 kb 
 1.6kb 
   M     1      2      3      4  5      6       7       8       9      10     11     12     13     14     15 
   V          I 
 * 
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The 4kb BamHI BRCA1 fragment and the pIND+1.6kb vector containing 1.6 
kb BRCA1 fragment were ligated and transformed into E.coli strain as described in 
the methods section. The next day 23 colonies were picked up from the plate and 
miniprep DNAs were prepared. There was no colony formation on the control plate. 
 
Ligation products were double digested with XbaI-XhoI to control the 
orientation of the inserted fragment during the ligation and the expected 5.75 kb and 5 
kb fragments after this digestion were observed in 11 out of 33 clones. These clones 
were named pIND.myc.BRCA1/1-2-5-6-9-10-11-13-15-16-23. Figure 19 shows the 
double digest profiles of two of the insert positive clones (lanes 6,8) and one wrong 
oriented clone (clone 4, lane10). Expected fragments after XbaI-XhoI double digestion 
of pcDNA3. myc.BRCA1 are 5.6 and 5.5 kb which was used as control for digestion 
(lane 4). 
 
 
 
 
 
Figure 19: XbaI-XhoI double digestion profiles of pIND.myc.BRCA1 colonies.  
M: 1 kb ladder, Gibco-BRL; Lanes 1: undigested pcDNA3 myc.BRCA1; 2: XbaI 
digested pcDNA3 myc.BRCA1; 3: XhoI digested pcDNA3 myc.BRCA1; 4: XbaI-
XhoI double digested pcDNA3 myc.BRCA1;  5, 7, 9: undigested  pIND.myc.BRCA1/ 
1-2-4;  6, 8,10: XbaI-XhoI double digested pIND.myc.BRCA1/ 1-2-4. 
 
  M     1       2     3    4     5      6      7      8     9      10 
9.1 kb 
5.75kb 
5 kb 
1.65kb 
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3.2.1.3 Generating a U2OS cell line that stably expresses pIND.myc.BRCA1  
 
The pIND.myc.BRCA1 construct carries an antibiotic selection marker 
neomycin gene, which enables the selection of the mammalian cells carrying this 
construct with neomycin analog G418. Before generating U2OS cell line that stably 
expresses the pIND.myc.BRCA1, G418 antibiotic sensitivity of U2OS was 
determined. 5x105 cells were plated on 60 mm plates, and were grown in DMEM 
supplemented with 800, 700, 600, 500, 400, 300 µg/ml G418 for 3 weeks. The 
minimum effective concentration of G418 killing all the cells was found to be 500 
µg/ml. This concentration was used to select the U2OS cells after transfection with 
pIND.myc.BRCA1 construct. 
 
A day before transfection U2OS cells were seeded on 60-mm dishes at a cell 
concentration 2.5x105 in each plate. The BBS mediated transfection method was used 
to transfect the cells with the construct as described in the methods section. 
The cells were selected in 500 µg/ml G418 for five weeks and then maintained in 100 
µg/ml zeocin. A total of 96 putative positive cell clones for pIND.myc.BRCA1 were 
selected. 
 
Genomic DNAs were isolated from the 96 pIND.myc.BRCA1 expressing 
clones. PCR was performed with EcF-TC31 primers for confirming the presence of 
pIND.myc.BRCA1 plasmid in the selected cell clones. 56 of the clones were positive 
for the presence of the 1103 bp expected fragment. Figure 17 shows the result of the 
PCR reactions as an example of the positive clones 7,17,18,19 and 20 for 
pIND.myc.BRCA1 plasmid. 
 
 
 
 
 
 
 102 
 
 
Figure 20: EcF-TC31 amplification results of pIND.myc.BRCA1 colonies.  
M: ΦX 174/HinfI marker, MBI, Lanes 1: negative control; 2,3,4,5,6,7 are clones, 
7,16, 17, 18, 19, 20 respectively 
 
 
3.2.1.4 Analysing the induction of BRCA1 expression in pIND.myc.BRCA1 
clones 
 
The next step was to analyse some of these positive U2OS clones for the 
induction of the expression of the BRCA1 gene by inducing the cells with 10 µM 
muristerone A. These cell clones were grown, expanded and induced with 10 µM 
muristerone, A which was added into the culture medium. The cells were collected 24 
hours after the transfection and lysed for Western blot analysis. 
 
14 clones were analyzed with 5HU (BRCA1 ab), 4 with 9E10 (myc ab) and 7 
with MS110 (BRCA1 ab). 
 
Figures 21 and 22 shows the results of western blot analysis. Although there 
seems to be a slight induction in some of the samples, some of them showed a 
decrease, making the result unsatisfactory. 
 
 
 
 
 
 
    M      1          2         3          4        5         6        7    
1103 bp 
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Figure 21: Western blot result of stable U2OS cell clones for pIND.myc.BRCA1 
construct analyzed with 5HU.  400 µg of the cellular lysates were loaded into each 
well and the blot was hybridized with 5HU BRCA1 antibody Lanes 1: HBL-100, 2: 
U2OS, 3: Transient transfection of U2OS cells pA (-), 4: Transient transfection of 
U2OS cells pA(+),  5: clone 43 pA(-)  6: clone 43 pA(+),   7: clone 66 pA(-), 8: clone 
66 pA(+),  9: clone 70 pA(-),  10: clone 70 pA(+),  11: clone 81 pA(-), 12: clone 81 
pA(+).  
 
 
 
 
                     
 
Figure 22: Western blot result of stable U2OS cell clones for pIND.myc.BRCA1 
construct analyzed with MS110.  400 µg of the cellular lysates were loaded into 
each well and the blot was hybridized with MS110 BRCA1 antibody. Lanes 1: HBL-
100, 2: clone 7 pA(-), 3: clone 7 pA(+),  4: clone 22 pA(-),  5: clone 22 pA(+),  6: 
clone 26 pA(-),  7: clone 26 pA(+),   8: clone 28 pA(-),  9: clone 28 pA(+), 10: clone 
29 pA(-),  11: clone 29 pA(+). 
 
 
 
The first source of the full length BRCA1 cDNA was pcDNA3.myc.BRCA1 
from Dr. Calzone. Although the first source of BRCA1 cDNA gave the expected 
220kDa BRCA1 protein as a result of IVTT experiment, it was later released that this 
BRCA1 cDNA might contain some discrepancies. The stable transfection experiments 
with this BRCA1 cDNA cloned into pIND vector did not show significant increase for 
BRCA1 gene in the U2OS cells which contain RXR regulatory plasmid. Since the 
    1         2         3       4       5       6       7        8        9       10        11       12 
           1         2         3        4         5        6        7         8        9        10         11   
220 kDa 
220 kDa 
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cloning of BRCA1 cDNA into the pIND vector was successful, one possible 
explanation for not getting enough induction could be the following. The cell clones 
selected with G418 were not stably transfected with the pIND.myc.BRCA1 construct 
and the cells therefore did not actually keep the construct. Although the PCR analysis 
of the clones with EcF-TC31 primers for confirming the presence of 
pIND.myc.BRCA1 plasmid gave a positive result, at the time of the analysis the cells 
might still have contained the plasmid but could have degraded or kicked it out from 
the cells after some further passaging of the cells. This is not an unusual mechanism 
and has been observed by scientists who have done similar experiments. 
 
Since the discrepancies for the full length BRCA1 cDNA was released, these 
clones were not pursued further to analyse if they really stably contained the 
pIND.myc.BRCA1 construct, which could have been analyzed by the Southern blot 
method. 
 
 
 
3.2.2 Construction and analysis of eukaryotic expression vector pIND.BRCA1 
 
3.2.2.1 In vitro transcription and translation-Immunoprecipitation assay result of 
pCR3.BRCA1 
 
Since the experiments performed with the previous cDNA did not result in the 
induction of the BRCA1 protein in the U2OS cells, another source for the full length 
BRCA1 cDNA (pCR3.BRCA1 ) was used to clone the BRCA1 gene to pIND vector. 
The pCR3.BRCA1 construct was a gift from Dr. Barbara Weber.  
 
pCR3.BRCA1 was the second source of BRCA1 cDNA. In vitro transcription 
and translation assay (IVTT) has been performed as described in the methods section 
to determine the integrity of this construct. It is important to show that this full-length 
BRCA1 cDNA is translated into protein product properly.  Figure 20 shows the IVTT 
assay results of pCR3.BRCA1. Radiolabelled IVTT product was immunoprecipitated 
with the BRCA1 antibodies MS110, C-20, and D20 (Figure 23). The 
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immunoprecipitation assay was performed to test the efficient binding of the available 
BRCA1 antibodies to the BRCA1 protein. 
 
 
 
 
 
Figure 23: In vitro transcription and translation-Immunoprecipitation assay with 
the pCR3.BRCA1 construct. Lanes 1: IVTT product of pCR3.BRCA1, 2: IVTT-IP 
product of pCR3.BRCA1 immunoprecipitated with MS110, 3: IVTT-IP product of 
pCR3.BRCA1 immunoprecipitated with C-20, 4: IVTT-IP product of pCR3.BRCA1 
immunoprecipitated with D-20,  5: Primary supernatant of lane 2 after binding  to 
protein A, 6: Primary supernatants of lane 3 after binding  to protein A, 7: Primary 
supernatant of lane 4 after binding  to protein A. 
 
 
 
The band in the first lane corresponds to 220 kDa according to the molecular 
weight marker which means that pCR3.BRCA1 had translated into protein product 
properly. When this in vitro translated protein product immunoprecipitated with 
several BRCA1 antibodies, bands indicated that these antibodies specifically bind the 
radiolabelled protein product and a small percentage remained unbound. 
 
 
 
3.2.2.2 Cloning of BRCA1 from pCR3.BRCA1 into pIND vector  
 
Subcloning of full-length BRCA1 from pCR3.BRCA1 vector into pIND vector 
was performed by plasmid killing strategy as described in the methods section. In 
order to get the intact HindIII-NotI digested 5.7 kb BRCA1 fragment without gel 
extraction, pCR3.BRCA1 was digested with HindIII-NotI-MspI with 2xMBI Tango 
buffer. Meanwhile, pIND vector was digested with HindIII-NotI. After digestion the 
products were checked on agarose gel and double digested pIND vector was treated 
with alkaline phosphatase in order to minimize self-ligation. 
    1      2          3             4              5           6            7 
   220 kDa 
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Figure 24: Digestion profiles of pCR3.BRCA1 and pIND. Lanes M: 1 kb ladder, 
MBI, Lanes 1: undigested pIND, 2: HindIII-NotI digested pIND, 3: undigested 
pCR3.BRCA1, 4: HindIII-NotI-MspI digested pCR3.BRCA1 
 
 
After the control of the digestions on the gel, digested samples from lanes 2 
and 4 were ligated in different vector:insert ratios and transformed into E. coli strain 
as described in the methods section. Next day 50 colonies out of about 1500 were 
picked up from the plates with different vector/insert ratios and DNA was isolated 
from the colonies. There was no colony formation in the control plate. The DNA 
samples were first digested with EcoRI in order to eliminate the colonies smaller than 
10 kb and self-ligated vector (Figure 25).  
 
 
 
Figure 25: EcoRI digestion profiles of pIND.BRCA1 colonies. Lanes M: 1 kb 
ladder from MBI; Lanes 
1,3,5,7,9,11,13,15,17,19,21,23,25,27,29,31,33,35,37,39,41,43,45,47,49,51,53,55: 
undigested pIND.BRCA1 colonies 5.9,6.1-6.9,7.1-7.9,8.1-8.9;   2,4,6,8,10, 
12,14,16,18,20,22,24,26,28,30,32,34,36,38,40,42,44,46,48,50,52,54,56:EcoRI 
digested pIND.BRCA1 colonies 5.9,6.1-6.9,7.1-7.9,8.1-8.9 respectively. 
    M      1      2       3       4     
5 kb 
5.7 kb 
 
    M  1  2  3  4 ………   10 ………………    20  ………………   30…………….. 38   M 39  ………………….  50  ………. 56 
10 kb 
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Out of 50 colonies 18 of them were found to be bigger than 10 kb. 9 of them 
were digested with AvaI (Figure 26) and HindIII-NotI (Figure 27) for further 
characterization. 
Expected sizes were as follows: 
 
Vector     Enzyme   Expected fragments (bp) 
pIND     AvaI    3524,1091,391 
pIND.BRCA1(control)   AvaI    5833,3542,1085,92 
pCR3.BRCA1    AvaI    10564,219 
pIND.BRCA1 colonies   AvaI    5833,3542,1085,219 
pIND     HindIII-NotI   4956,68 
pIND.BRCA1(control)   HindIII-NotI   10552 
pCR3.BRCA1    HindIII-NotI   5726,4986 
pIND.BRCA1 colonies    HindIII-NotI   5726,4956 
 
 
 
 
Figure 26: AvaI digestion profiles of pIND.BRCA1 colonies. Lanes M: 1 kb 
ladder, MBI; AvaI digestion profiles of colonies. Lanes 1: pIND; 2: 
pIND.BRCA1(control); 3: pCR3.BRCA1; 4,5,6,7,8,9,10,11,12: pIND.BRCA1 clones 
4.4, 4.9, 5.9, 6.2, 7.2, 7.3, 7.5, 8.5, 8.9 respectively. 
 
 
 
 
 
 
 
 
 
 
  M   1   2  3   4  5   6   7  8  9  10 11 12 
5726 bp 
4956 bp 
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Figure 27: HindIII-NotI digestion profiles of pIND.BRCA1 colonies. M: 1 kb 
ladder, MBI; HindIII-NotI digestion profiles: Lanes 1: pIND; 2: pIND.BRCA1 
(control); 3: pCR3.BRCA1;  4,5,6,7,8,9,10,11,12: pIND.BRCA1 clones 4.4, 4.9, 5.9, 
6.2, 7.2, 7.3, 7.5, 8.5, 8.9 respectively. 
 
According to the gel photo some digests were uncompleted but all 9 colonies gave the 
expected digestion patterns. Colony 5.9 was used for further studies. 
 
 
 
 
3.2.2.3 Sequencing of eukaryotic expression vector pIND.BRCA1  
 
pIND.BRCA1 construct, originated from colony 5.9, has been sequenced from  
5’ and 3’ ends with the manual sequencing kit as described in the methods section. 
Figure 28 shows the sequencing result. 
 
Sequencing result showed that HindIII-linker sequence, start codon and 
BRCA1 sequence were as expected but some mismatch was observed at the 3’ end 
after the stop codon. BRCA1 sequence and stop codon were as expected but no 
matching was observed with the NotI site and linker sequence. The same results were 
observed after the sequencing reactions were repeated once more. 
 
 
 
 
 
 
 
 
 
 
5833 bp 
3542 bp 
  1    2   3    4   5   6   7   8  9  10 11 12  M *
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  420  Ec F priming site    
PIND.BRCA1 GAAGAGAACT CTGAATACTT TCAACAAGTT ACCGAGAAAG AAGAACTCAC 
EcF  ---------- ---------- ---------- ---------- ---------- 
    
470         HindIII linker  start 
PIND.BRCA1 ACACAGCTAG CGTTTAAACT TAAGCTTGCC ACCATGGATT TATCTGCTCT 
EcF  ---------- CGTTTAAACT TAAGCTTGCC ACCATGGATT TATCTGCTCT 
 
  520 
PIND.BRCA1 TCGCGTTGAA GAAGTACAAA ATGTCATTAA TGCTATGCAG AAAATCTTAG 
EcF  TCGCGTTGAA GAAGTACAAA ATGTCATTAA TGCTATGCAG AAAATCTTAG 
 
  570 
PIND.BRCA1 AGTGTCCCAT CTGTCTGGAG TTGATCAAGG AACCTGTCTC CACAAAGTGT 
EcF  AGTGTCCCAT CTGTCTGGAG TTGATCAAGG AACCTGTCTC CACAAAGTGT 
 
  620 
PIND.BRCA1 GACCACATAT TTTGCAAATT TTGCATGCTG AAACTTCTCA ACCAGAAGAA 
EcF  GACCACATAT TTTGCAAATT TTGCATGCTG AAACTTCTCA ACCAGAAGAA 
 
  670 
PIND.BRCA1 AGGGCCTTCA CAGTGTCCTT TATGTAAGAA TGATATAACC AAAAGGAGCC 
EcF  AGGGCCTTCA CAGTGTCCTT TATGTAAGAA TGATATAACC AAAAGGAGCC 
 
  720 
PIND.BRCA1 TACAAGAAAG TACGAGATTT AGTCAACTTG TTGAAGAGCT ATTGAAAATC 
EcF  TAC------- ---------- ---------- ---------- ----------  
 
 
 
  6050 
PIND.BRCA1 GATGTGTGAG GCACCTGTGG TGACCCGAGA GTGGGTGTTG GACAGTGTAG 
EcR  ---------- ---------- ---------- -----TGTTG GACAGTGTAG 
 
  6100 
PIND.BRCA1 CACTCTACCA GTGCCAGGAG CTGGACACCT ACCTGATACC CCAGATCCCC 
EcR  CACTCTACCA GTGCCAGGAG CTGGACACCT ACCTGATACC CCAGATCCCC 
 
  6150   stop linker NotI site 
PIND.BRCA1 CACAGCCACT ACTGACTACG CGGCCGCTCG AGTCTAGAGG GCCCGTTTAA 
EcR  CACAGCCACT ACTGACAGAT GGCCAGCCAC AGGTACAGAG CACAGCACAG 
         **** * * *  ***   *******  ** * *** * 
  6200   Ec R priming site 
PIND.BRCA1 ACCCGCTGAT CAGCCTCGAC TGTGCCTTCT AGTTGCCAGC CATCTGTTGT 
EcR  GGACCCCAAG AATGAAGCTA ACAAAGTGCC TTTCCAGGCC C--------- 
  *** * ** * * ******** ****** * * ** ****** 
 
 6250 
PIND.BRCA1  TTGCCCCTCC CCCGTGCCTT CCTTGACCCT GGAAGGTGCC ACTCCCACTG 
EcR  ---------- ---------- ---------- ---------- ---------- 
 
 
 
Figure 28: Sequencing result of pIND.BRCA1 Upper lines indicate the expected 
sequence, lower line is sequenced fragment. Blue highlight indicates the matching 
sequences. (* : mismatch,   -: no sequence read) 
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3.2.2.4 Analysing BRCA1 expression by transient transfection into U2OS cells 
 
 
             Expression of BRCA1 was analyzed by transfection of pIND.BRCA1 into the 
U2OS cell line. Although sequencing of the construct showed mismatch after stop 
codon, 4 transient transfections were made with pIND.BRCA1 and analyzed with 
MS110 BRCA1 antibody (data not shown) but no induction was observed. 
 
              Since the 3’ end of the cloning site after the stop codon showed mismatches, 
during the preparation of the construct something must have gone wrong and affected 
the induction of this construct in U2OS cells. 
 
              At the same time, pCR3.BRCA1 and pCMV.myc.BRCA1 constructs 
carrying CMV promoters at the upstream of BRCA1, were also transfected into U2OS 
cell line independently and analyzed with western blot for BRCA1 expression by 
using MS110 BRCA1 monoclonal antibody (See appendix A for pCMV.myc.BRCA1 
sequence and the restriction enzyme map). Seven independent transient transfection 
experiments with pCR3.BRCA1 and 8 transfections with pCMV.myc.BRCA1 were 
performed in order to analyse the BRCA1 expression level in U2OS cells (Figures 29 
and 30).  
 
 
 
 
 
Figure 29: Western blot result of the cells transiently expressing BRCA1 in 
U2OS cells.  The cells were transiently transfected with pCR3.BRCA1 and 200 µg of 
the cellular lysates were loaded into each well and the blot was analyzed with MS110 
BRCA1 monoclonal antibody. Lanes 1: HBL-100; 2: U2OS cells only; 3, 6, 8: mock 
transfection of U2OS cells; 4: Transient transfection of U2OS cells with 
pCMV.myc.BRCA1; 5, 7, 9: Transient transfection of U2OS cells with 
pCR3.BRCA1. 
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Figure 30: Western blot result of U2OS cells which were transiently transfected 
with pCMV.myc.BRCA1.  In each lane equal amount (200 µg) of the cellular lysates 
was used and the blot was analyzed with MS110 BRCA1 antibody. Lanes 1: HBL-
100; 2: U2OS; 3,7: mock transfection of U2OS cells; 5, 8,10: Transient transfection 
of U2OS cells with pCMV.myc vector; 4, 6, 9, 11: Transient transfection of U2OS 
cells with pCMV.myc.BRCA1. 
 
              Western blot analysis showed that the BRCA1 expression was high in each 
of the independent transfections with these CMV promoter-containing BRCA1 
constructs. The highest protein expression was observed with the pCMV.myc.BRCA1 
construct. 
 
              MCF7 cells were also transiently transfected with pCMV.myc.BRCA1 and 
after electroporation the cells were harvested within different time intervals. The 
expression level of BRCA1 protein was analyzed with western blot by using MS110 
BRCA1 monoclonal antibody (Figure 31). 
 
 
 
 
Figure 31: Western blot result of MCF7 cells which were transiently transfected 
with pCMV.myc.BRCA1. In each lane an equal amount (100 µg) of the cellular 
lysates was used and the blot was analyzed with MS110 BRCA1 antibody. Lanes 1: 
HBL-100; 2: MCF7; 3: MCF7 mock transfection; 4, 6, 8, 10, 12:  MCF7 cells 
transfected with pCMV.mvc; 5, 7, 9, 11, 13:  MCF7 cells transfected with 
pCMV.mvc.BRCA1; 4-5: harvested 12 hr after electroporation; 6-7: cells harvested 
15 hr after electroporation; 8-9; harvested 18 hr after electroporation; 10-11: cells 
harvested 21 hr after electroporation; 12-13: cells harvested 24 hr after 
electroporation. 
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3.2.3 Construction and analysis of eukaryotic expression vector 
pIND.HA.BRCA1 
 
3.2.3.1 Subcloning of BRCA1 from pRc/CMV.BRCA1 into pIND 
 
pRc/CMV.BRCA1 was the third source of BRCA1. The full length 5.7 kb 
BRCA1 cDNA was cloned into 5.5kb pRc/CMV vector between HindIII-NotI sites 
with a HA tag at the 5’ end of the start codon. Dr. Daniel Haber provided this 
construct and the whole BRCA1 gene was sequenced before using this construct.  
When the construct was double digested with HindIII-NotI, it was very difficult to 
distinguish the 5.7 kb BRCA1 fragment from the 5.5kb pRc/CMV vector. 
pRc/CMV.BRCA1 was therefore digested with HindIII-NotI-PvuI, which PvuI cuts 
pRc/CMV vector (5.5 kb) once but not BRCA1 sequence. The 5.7 kb BRCA1 
fragment was extracted from the gel and ligated into 5 kb HindIII-NotI digested pIND 
expression vector (Figure 32). 
 
 
                                     
 
 
 
Figure 32: Restriction enzyme digestion profiles of pIND and pRc/CMV.BRCA1 
Lanes M: 1 kb ladder, MBI, Lanes 1: undigested pIND, 2: HindIII-NotI digested 
pIND, 3: HindIII-NotI digested pRc/CMV.BRCA1, 4: HindIII-NotI-PvuI digested 
pRc/CMV.BRCA1, 5: uncut pRc/CMV.BRCA1 . 
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The 5 kb pIND band from lane 2 and 5.7 kb BRCA1 band from lane 4 were 
gel extracted. Ligation reaction and transformation into supercompetent JM109 were 
performed as described in the methods section. The next day 10 colonies were picked 
up from plates and miniprep DNA samples were prepared. There was no colony 
formation in control plate. 
In order to check whether ligation had taken place, the plasmid DNAs from the 
colonies were double digested with HindIII-NotI and HindIII-NotI-PvuI. The expected 
fragment sizes after HindIII-NotI digestion were 5.7 and 5 kb (Figure 33). DNA 
samples were also digested with HindIII-NotI-PvuI in order to observe the intact 5.7 
kb BRCA1 band (Figure 34). 
 
 
 
 
 
Figure 33: HindIII-NotI digestion profiles of pIND.HA.BRCA1 colonies. Lanes 
M: 1 kb ladder, MBI; Lanes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10: HindIII-NotI digestion profiles 
of pIND.HA.BRCA1 colonies 1.1, 1.2, 1.3, 1.4, 1.5, 2.1, 2.2, 2.3, 2.4, 2.5 
respectively. 
 
 
 
Figure 34: HindIII-NotI-PvuI digestion profiles of pIND.HA.BRCA1 colonies. 
Lanes M: 1 kb ladder, MBI, Lanes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10: HindIII-NotI-PvuI 
digestion profiles of pIND.HA.BRCA1 colonies 1.1, 1.2, 1.3, 1.4, 1.5, 2.1, 2.2, 2.3, 
2.4, 2.5 respectively. 
     M    1    2     3    4    5    6    7    8    9   10 
  M    1    2     3    4    5    6    7    8    9   10 
5.7 kb 
5 kb 
5.7 kb 
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Colony 1.4 was used for sequencing and further studies and named 
pIND.HA.BRCA1. 
 
 
 
3.2.3.2 Sequencing of pIND.HA.BRCA1 
 
The 5’ and 3’ ends of pIND.HA.BRCA1 were sequenced by using the manual 
sequencing protocol as mentioned in the methods section. Figures 35 and 36 show 
sequencing data and Figure 37 summarizes the sequencing results.  
 
The sequencing result showed that all pIND and BRCA1 fragments, HindIII, start 
codon, HA tag, stop codon and NotI sites were as expected. 
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   G A T C 
 
Figure 35: Sequencing data of pIND.HA.BRCA1 sequenced by EcF  
 
 
 
 
 
                            HindIII site       start   HA taq 
    5´-  GTT TAA ACT TAA GCT TCC GCC ATG GCC TAT CCC TAT GAC  
 
 Ha taq       BRCA1 sequence 
   GTG CCC GAC TAC GCC AGC CTG GGA ATT CTG GAT TTA TCT …  - 3´ 
 
5´ 
HindIII site 
Start codon 
HA taq 
BRCA1 sequence 
3´ 
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Figure 36: Sequencing data of pIND.HA.BRCA1 sequenced by EcR  
 
 
 
 
                BRCA1 sequence                       Stop codon 
5´- CCC CAG ATC CCC CAC AGC CAC TAC TGA CTG CAG CCA GCC 
  
              NotI site 
      ACA GGT ACA GAC CAC AGC TAC GCG GCC GCT CGA GTC TAG- 3´ 
 
3´ 
NotI site 
Stop codon 
BRCA1 sequence 
5´ 
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    420      Ec F priming site    
PIND.HA.BRCA1 AGAAGAGAAC TCTGAATACT TTCAACAAGT TACCGAGAAA GAAGAACTCA 
EcF    ---------- ---------- ---------- ---------- ---------- 
   
    470    HindIII         start     HA taq 
PIND.HA.BRCA1 CACACAGCTA GCGTTTAAAC TTAAGCTTCC GCCATGGCCT ATCCCTATGA  
EcF    CACACAGCTA GCGTTTAAAC TTAAGCTTCC GCCATGGCCT ATCCCTATGA 
  
    520 HA taq     
PIND.HA.BRCA1 CGTGCCCGAC TACGCCAGCC TGGGAATTCT GGATTTATCT GCTCTTCGCG 
EcF    CGTGCCCGAC TACGCCAGCC TGGGAATTCT GGATTTATCT GCTCTTCGCG 
  
    570     
PIND.HA.BRCA1 TTGAAGAAGT ACAAAATGTC ATTAATGCTA TGCAGAAAAT CTTAGAGTGT 
EcF    TTGAAGAAGT ACAAAATGTC ATTAATGCTA TGCAGAAAAT CTTAGAGTGT 
 
 
    620      
PIND.HA.BRCA1 CCCATCTGTC TGGAGTTGAT CAAGGAACCT GTCTCCACAA AGTGTGACCA 
EcF    CCCATC---- ---------- ---------- ---------- ---------- 
   
 
  
 
    6010 
PIND.HA.BRCA1 CTTCCATGCA ATTGGGCAGA TGTGTGAGGC ACCTGTGGTGA CCCGAGAGTG 
EcR    ---------- ---------- ---------- ----------- --CGAGAGTG 
 
    6060 
PIND.HA.BRCA  GGTGTTGGAC AGTGTAGCAC TCTACCAGTG CCAGGAGCTG GACACCTACC 
EcR    GGTGTTGGAC AGTGTAGCAC TCTACCAGTG CCAGGAGCTG GACACCTACC 
 
    6110          stop  
PIND.HA.BRCA1 TGATACCCCA GATCCCCCAC AGCCACTACT GACTGCAGCC AGCCACAGGT 
EcR    TGATACCCCA GATCCCCCAC AGCCACTACT GACTGCAGCC AGCCACAGGT 
          
    6160    NotI site 
PIND.HA.BRCA1 ACAGACCACA GCTACGCGGC CGCTCGAGTC TAGAGGGCCC GTTTAAACCC 
EcR    ACAGACCACA GCTACGCGGC CGCTCGAGTC TAGAGGG--- ---------- 
   
     6210    Ec R priming site 
PIND.HA.BRCA1 GCTGATCAGC CTCGACTGTG CCTTCTAGTT GCCAGCCATC TGTTGTTTGC  
EcR    ---------- ---------- ---------- ---------- ---------- 
 
 
Figure 37: Sequencing results of pIND.HA.BRCA1: Upper lines indicate the 
expected sequence, lower line is the sequenced fragment. Blue highlight indicates the 
matching sequences. (* : mismatch,   -: no sequence read) 
 
 
 118 
3.2.3.3 Analysing the induction of BRCA1 expression in transiently     
pIND.HA.BRCA1 transfected U2OS cells 
 
             The U2OS cells were transiently transfected with pIND.HA.BRCA1 and 24 
hr after transfection the cells were induced with 10 µM ponasterone A. Six transient 
transfection experiments were carried out and induction of BRCA1 protein was 
analyzed by western blotting by using MS110 BRCA1 monoclonal antibody  (Figures 
38 and 39). 
 
 
 
 
 
 
Figure 38: Western blot result of BRCA1 expressing cells that were transiently 
transfected with pIND.HA.BRCA1.  200 µg of the cellular lysates were loaded and 
analyzed with MS110 BRCA1 antibody. Lanes 1: HBL-100; 2: U2OS cells only; 3: 
mock transfection; 4: U2OS cells transfected with pRc/CMV.BRCA1; 5,7: U2OS 
cells transfected with pIND.HA.BRCA1, ponasterone A (-); 6,8: U2OS cells 
transfected with pIND.HA.BRCA1, ponasterone A (+). 
 
 
 
 
 
Figure 39: Western blot result of BRCA1 expressing cells that were transiently 
transfected with pIND.HA.BRCA1 and pCMVmycBRCA1.  50 µg of the cellular 
lysates were loaded and analyzed with MS110 BRCA1 monoclonal antibody. Lanes 
1: HBL-100; 2: U2OS cells only; 3:  U2OS cells transfected with pCMVmyc; 4: 
U2OS cells transfected with pCMV.myc.BRCA1; 5,7,9,11: U2OS cells transfected 
with pIND.HA.BRCA1, ponasterone A (-); 6,8,10,12:  U2OS cells transfected with 
pIND.HA.BRCA1, ponasterone A (+). 
 
There was no significant BRCA1 protein induction in the U2OS cells 
transfected with the pIND.HA.BRCA1 construct and induced with ponasterone A 
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(Lanes 6, 8, 10, 12) but the cells transfected with the pCMV.myc.BRCA1 construct 
showed a significant increase in the BRCA1 protein amount (Lane 4). One possibility 
was that the protein was induced but the induction level was too low to observe with 
the western blot technique. Therefore, immunoprecipitation was performed to increase 
the sensitivity of the protein level detection as described in the methods section. The 
U2OS cells were electroporated with pCMV.myc.BRCA1 as control or 
pIND.HA.BRCA1. The cells electroporated with pIND.HA.BRCA1 were either 
induced with ponasterone A or left uninduced. All cells were then harvested and 
lysed. The lysates were treated with 9E4B1 p53, C-20 BRCA1 and 9E10 myc 
antibodies and loaded on 5% polyacrylamide gel. The level of BRCA1 expression was 
detected by using MS110 BRCA1 monoclonal antibody (Figure 40). 
 
 
 
 
Figure 40: Immunoprecipitation results of the U2OS cells transiently transfected 
with pIND.HA.BRCA1 and pCMV.myc.BRCA1. The cells were 
immunoprecipitated with the indicated antibodies and the protein precipitates 
were blotted. The blot was treated with MS110 BRCA1 antibody.  
1: HBL-100 cellular lysate (150 µg lysate) 
2: HBL-100 cellular lysate immunoprecipitated with 9E4B1 (negative control) 
3: HBL-100 cellular lysate immunoprecipitated with C-20 (positive control) 
4: pCMV.myc transfected cells immunoprecipitated with C-20 
5: pCMV.myc.BRCA1 transfected cells immunoprecipitated with C-20 
6: pIND.HA.BRCA1 transfected cells immunoprecipitated with C-20, pA (-) 
7: pIND.HA.BRCA1 transfected cells immunoprecipitated with C-20, pA (+) 
8: pCMV.myc transfected cells immunoprecipitated with 9E10 (control) 
9: pCMV.myc.BRCA1 transfected cells immunoprecipitated with 9E10 (control) 
10: pCMV.myc transfected cells (150 µg lysate) 
11: pCMV.myc.BRCA1 transfected cells  (150 µg lysate) 
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The results from Figure 40 (lanes 6 and 7) showed that the pIND.HA.BRCA1 
construct could not be induced by ponasterone A. The level of BRCA1 did not show a 
significant increase when compared to uninduced cells (lane 6). 
 
This result was surprising since the construct was cloned correctly according 
to the sequencing results.  
 
We then wanted to analyse the U2OS cell line integrity whether these cells really 
carried the regulatory plasmid RXR stably as indicated when we received the cells 
from another laboratory source. In order to analyse the integrity of the cells, we used a 
different gene, p53, cloned into pIND vector and transfected into U2OS cells. 
 
 
3.2.3.4 Analysing the induction of p53 expression level in transiently transfected 
U2OS cells by using the pIND.p53 construct 
 
       The U2OS cells were transiently transfected with pIND.p53 and 24 hr after 
transfection the cells were induced with 10 µM ponasterone A. Two transient 
transfections experiments were carried out and induction of p53 protein was analyzed 
by western blot with 9E4B1 p53 antibody (Figure 41). 
  
 
 
 
 
 
 
Figure 41: Western blot result of the cells transiently transfected with pIND.p53.  
75 µg of cellular lysates were loaded on the gel and the blot was analyzed with 9E4B1 
p53 antibody. Lanes 1: 3 ug of pure p53 protein; 2: HepG2; 3: mock transfection; 4, 
6: U2OS cells transfected with pIND.p53, ponasterone A (-); 5, 7:  U2OS cells 
transfected with pIND.p53, ponasterone A (+) 
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The pure p53 protein showed a bigger protein size because of six extra 
histidine tags present at its N terminus. 9E4B1 p53 antibody gives two bands at all 
times with western blots. The lower band corresponds to the p53 protein size. Figure 
41, lanes 5 and 7 showed that p53 protein could be induced with the ecdysone 
inducible system in U2OS cells, which contains the RXR plasmid. 
 
The last control experiment showed that there was nothing wrong with the 
U2OS cell line integrity.  It is very difficult to explain why three different constructs 
we made with three different BRCA1 cDNA sources did not result in any induction 
with the ecdysone inducible system in U2OS cells.  
 
We did not want to pursue this inducible system any further and decided to use 
pCMVmycBRCA1 construct to express BRCA1 protein at a high level in the MCF7 
breast carcinoma cell line.  
 
             It was previously shown that pCMVmycBRCA1 could be used to express 
high levels of BRCA1 protein in both U2OS osteosarcoma and MCF7 breast 
carcinoma cell lines (Figures 30 and 31 respectively).  The MCF7 cell line was used 
to express BRCA1 gene because this cell contains only one BRCA1 allele and 
displays a low level of BRCA1 expression.  
 
 
 
3.2.4 Ectopic expression of BRCA1 in MCF7 cells by using pCMVmycBRCA1  
 
            It was previously reported that a high level of BRCA1 expression in the cells 
results in cell cycle arrest. It is therefore not possible to select an expression vector 
carrying the BRCA1 gene stably in the cells unless it is an inducible expression 
system. The MCF7 cells were transiently transfected with pCMVmycBRCA1 
expression vector by using electroporation as a transfection method. 
 
           The MCF7 cells were transfected with the pCMVmycBRCA1 or pCMVmyc 
empty vector and the cells were collected 24 h after the transfection. The level of 
 ectopically expressed BRCA1 was determined by Northern and western blot analyses 
(Figure 42). 
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with the cells transfected with control plasmid, pCMVmycBRCA1 transfected cells 
showed about 20-fold increase in the full-length BRCA1 mRNA (Figure 42a) and 
about 6-fold increase in the BRCA1 protein (Figure 42b). The results of three 
representative experiments are shown in Figure 42b. Both control MCF7 cells (lane 1) 
and the cells transfected with control plasmid without BRCA1 insert (lane 2) 
demonstrated endogenous BRCA1 protein.  As shown in experiment 2 ectopically 
expressed BRCA1 protein level was similar to endogenous BRCA1 level, suggesting 
that transient transfection resulted in a significant increase in total BRCA1 levels in 
pCMVmycBRCA1-transfected MCF7 cells (lane 3). Taken together, these results 
indicated that it was possible to increase BRCA1 levels in MCF7 by transient 
transfection, without compromising cellular integrity. 
 
 
 
Determining the transfection efficiency  
The transfection efficiency of the MCF7 cells was determined by transfecting 
the MCF7 cells with the pEGFP plasmid under the same experimental conditions. 
pEGFP plasmid is an eukaryotic expression plasmid which carries a green fluorescent 
protein gene. This gene is expressed upon transfection of this plasmid to the 
mammalian cells and the protein product gives green fluorescence that can be 
observed under 525 nm wavelength fluorescence light. 
 
Figure 43 shows a typical example of the transfected MCF7 cells with pEGFP 
plasmid. pEGFP plasmid was used in every transfection experiment to control the  
transfection efficiency in parallel to the other transfection experiments. 
 
24 h after the pEGFP transfection the cells were trypsinized and counted under 
the fluorescent microscope.  The transfection efficiency was approximately 40%. 
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Figure 43: pEGFP transfected MCF7 breast carcinoma cells. The photograph was 
taken 24 h after transfection. Panels (a) and (b) show the cells in the same area under 
the microscope. a) The cells expressing GFP protein could be observed under 525 nm 
wavelength fluorescence light. b) pEGFP transfected and untransfected cells could be 
observed together under fluorescent and normal light. 
 
 
 
AnnexinV staining 
It was suggested that the BRCA1 expression also causes apoptosis. In order to 
understand whether the MCF7 cells expressing the BRCA1 gene could undergo 
apotosis, annexin V staining was performed. The pCMVmycBRCA1 and pCMVmyc 
vector transfected MCF7 cells were stained with annexin V 24 h after the transfection 
(Figure 44). Annexin V is an early marker for apoptosis. The MCF7 cells treated with 
ultraviolet light were used as positive control since UV induction causes cells to 
undergo apoptosis. BRCA1 overexpression in MCF7 cells did not result in apoptosis, 
compared to mock and vector only transfected samples. Thus at a transfection 
efficiency of 40%, no more than 5% of BRCA1 expressing cells were apoptotic. 
 
               Another annexinV staining assay was also performed in order to understand 
whether the apoptotic cells present in the tissue culture media of the transfected cells 
were due to apoptosis or electroporation procedure. Briefly, 24 h after transfection, 
annexin V was added to the growth medium without washing the cells, and cells were 
kept in the incubator for 30 minutes. The supernatants were collected, counted and the 
pellets were fixed on cover slides by cytospin. Hoechst staining was also performed 
a b 
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for both methods as described in the methods section in order to observe all the cells 
present on the slide (Figure 45).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44: Annexin V staining with method I. Lanes 1: 50 J/m2 UV treated MCF7 
cells, positive control; 2: MCF7 cells, negative control, 3: Mock-transfected MCF7 
cells, 4: pCMVmyc-transfected MCF7 cells; 5: pCMVmycBRCA1-transfected MCF7 
cells; h: Hoechst staining, a: Annexin V staining, m: Annexin V and Hoechst staining 
images were superimposed to create the merged image. 
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Figure 45: Annexin V staining with method II. Lanes 1: 50 J/m2 UV treated MCF7 
cells, positive control; 2: Supernatant of sample 1; 3: MCF7 cells, negative control; 4: 
Supernatant of sample 3; 5: Mock-transfected MCF7 cells; 6: Supernatant of sample 
5; 7: pCMVmyc transfected MCF7 cells; 8: Supernatant of sample 7; 9: 
pCMVmycBRCA1 transfected MCF7 cells; 10: Supernatant of sample 9.  h: Hoechst 
staining, a: Annexin V staining, m: AnnexinV and Hoechst staining images were 
superimposed to create the merged image. 
 
 
           Figure 45 shows the results of annexinV staining with method II. Samples 1, 3, 
5, 7 and 9 are the cells that were grown on coverslides. Samples 2, 4, 6, 8 and 10 are 
the cells collected from the supernatants. Not more than 10 % of the cells were dead 
in the mock, empty vector and BRCA1 carrying vector transfected samples as 
calculated by counting the supernatants prior to collection. Furthermore there was no 
difference observed in the number of the dead cells between mock (6a) or empty 
vector (8a) and BRCA1 carrying vector (10a) transfected samples, suggesting that the 
dead cells were the result of electroporation. BRCA1 overexpression did not result in 
apoptosis (9a) in our system, which was also shown by the previous experiment 
(Figure 44). 
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3.3 Subtractive hybridization 
 
          Suppression subtractive hybridization (SSH) technology was used to generate a 
library of partial-length cDNAs representing differentially expressed mRNAs in 
BRCA1-overexpressing MCF7 cells. SSH combines subtractive hybridization with 
PCR to generate a population of PCR fragments enriched for sequences from genes 
expressed differentially. SSH-mediated cDNA enrichment allows the equalization of 
wide differences in the abundance of different transcript species. Consequently, 
differentially expressed transcripts of low abundance can be cloned (Diatchenko et al., 
1996). 
 
 SSH was used to identify genes that are differentially expressed in BRCA1 
transfected MCF7 cells. SSH was performed with the double strand as tester (MCF7/ 
pCMVmycBRCA1) and driver (MCF7/pCMVmyc) cDNAs (forward subtraction) by 
using PCR-Select cDNA Subtraction kit as described by the manufacturer with some 
modifications (Clontech).  
 
Reverse subtraction was also performed where tester cDNA was derived from 
pCMVmyc transfected MCF7 cells and driver cDNA derived from 
pCMVmycBRCA1 transfected cells.  
 
 
3.3.1 Preparation of DNA-free mRNA for subtractive hybridization 
 
SSH requires high quality pure mRNA. mRNA was isolated from total RNA and 
treated with DNaseI in order to remove the DNA contamination as described in the 
methods section. Integrity of mRNA was checked by running on a formaldehyde gel. RT-
PCR was also performed with these mRNA samples to control whether DNA 
contamination was still present. After the first strand cDNA synthesis, RT-PCR was 
performed with sequence and vector specific primers in order to control the presence or 
absence of plasmid and genomic DNA contamination. Figure 46 shows the results of 
these amplifications. BRCA1 primers (F4-R4) which are specific to BRCA1 gene, 
amplified 1217 bp, actin primers amplified 550 bp and GADD45 primers amplified 497 
 bp PCR products from cDNA preparations as expected in tubes containing the reverse 
transcriptase enzyme and also in the positive control tube which contained only 
pCMVmycBRCA plasmid as template. pCMVmyc F and TC31 primer pair amplifies 
1200 bp fragment from the pCMVmycBRCA1 plasmid; amplification of this PCR 
product in the tube containing the plasmid, but not in the other tubes showed that plasmid 
DNA contamination was eliminated successfully. 
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cDNA1: pCMVmycBRCA1 transfected MCF7 mRNA 
cDNA2: pCMVmyc transfected MCF7 mRNA 
cDNA3: Control mRNA from human skeletal muscle 
 
Forward subtraction: 
Tester: pCMVmycBRCA1 (cDNA1), Driver: pCMVmyc (cDNA2) 
 
Reverse subtraction:    
Tester: pCMVmyc (cDNA2), Driver: pCMVmycBRCA1 (cDNA1) 
 
Control subtraction:    
Tester: HaeIII digested φX174 cDNA + control cDNA from human skeletal muscle, 
Driver: control cDNA from human skeletal muscle 
 
 
 
3.3.3 RsaI digestion 
 
Tester and driver ds cDNAs were separately digested to obtain shorter, blunt-
ended molecules. Figure 47 shows the profiles of three cDNAs before and after RsaI 
digestions. The ds cDNA preparations appear as a smear from 0.5-10 kb. After RsaI 
digestion, the average cDNA size is smaller.    
 
 
 
3.3.4 Adaptor ligation 
 
Tester cDNAs of each forward, reverse and control subtractions were 
aliquoted into two and each aliquot ligated to adaptors 1 and 2R. These two adaptors 
provide different PCR primer annealing sites. This way, two tester populations from 
the same cDNA were created with different adaptors but driver cDNA had no 
adaptors. 
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Resulting tester cDNAs were named 1-1, 1-2, 2-1, 2-2, 3-1, 3-2. Ligation efficiency 
was analyzed by using internal control primers (G3PDH) and PCR primer 1 which is 
complementary to both adaptor sequences (Figure 48). Internal control G3PDH  
primer pair amplification resulted in amplification of 0.4 kb, while G3PDH 3´primer-
PCR primer 1 pair amplified 0,75 kb fragment. This result showed that the adaptors 
were successfully ligated with cDNAs. 
 
 
 
 
 
 
 
 
 
 
Figure 47: RsaI digestion of ds cDNAs 
L :1 kb ladder (Gibco-BRL), Lanes 1,3,5: ds cDNAs of  cDNA1, cDNA2 & cDNA3, 
2,4,6: RsaI digested cDNA1, cDNA2 & cDNA3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48: Analysis of ligation efficiency  
L: HaeIII digested φX174 (Sigma), (1.3, 1.1, 0.9, 0.6, 0.3 kb);   +: total RNA; 
Lanes 1,3,5,7,9,11: PCR with G3PDH 3´primer-PCR primer 1 (0,75 kb); 
2,4,6,8,10,12: PCR with G3PDH 3´-5´ primers (0,4 kb). 
 
    L            1       2       3      4     5       6 
Template:            1.1          1.2           2.1           2.2         3.1          3.2 
 L     -       +      1      2       3     4      5     6      7       8       9    10    11   12 
10 kb 
0.4 kb 
0.75 kb 
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3.3.5 First and second hybridizations for subtraction 
 
During first hybridization, hybridization kinetics leads to equalization and 
enrichment of differentially expressed sequences. In the first hybridization, each tester 
(1-1, 1-2...) cDNA was hybridized with excess driver cDNA. Single strand cDNAs 
were enriched for differentially expressed sequences, as non-target cDNAs present in 
the tester and driver cDNA form hybrids. In the second hybridization, two samples 
from first hybridization were mixed together and excess driver cDNA was added. 
New hybrid molecules were formed which consists of differentially expressed cDNAs 
with different adaptors on each end that were ready for PCR. 
 
 
3.3.6 Primary and secondary PCRs 
 
Primary PCR led to exponential amplification of only differentially expressed 
sequences by using suppression PCR technology. Secondary PCR reduced the 
background and differentially expressed sequences were further enriched. Figure 49 
shows results of the optimization of primary and secondary PCRs. Lanes 1-5 are 
primary PCR products, amplified by PCR primer 1. Lanes 6-10 are secondary PCR 
amplifications of these products in the same order. Amplifications were carried out 
with nested primers 1 and 2R.  
 
After optimization of the PCR conditions, secondary PCR was performed with 
optimal PCR conditions. Primary and secondary PCRs were also performed with the 
reverse subtraction cDNAs (Figure 50). These secondary PCR products were used for 
subtraction efficiency test and generation of subtracted library construction.  
 
 
 
 
 
 
 
 
 
 
 132 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49: Optimization of primary and secondary PCR conditions 
L : HaeIII digested φX174 (Sigma), ( 1.3, 1.1, 0.9, 0.6, 0.3 kb), Lanes 1,6: PCR 
control subtracted cDNA, 2,7: Subtracted control skeletal muscle cDNA, 3,8: 
Unsubtracted control skeletal muscle cDNA, 4,9: Forward subtracted experimental 
cDNA, 5,10: Unsubtracted tester control 
 
 
 
 
 
 
 
 
 
 
Figure 50: Secondary PCR results 
L : HaeIII digested φX174 (Sigma), ( 1.3, 1.1, 0.9, 0.6, 0.3 kb), Lanes 1: Subtracted 
control skeletal muscle cDNA, 2: Unsubtracted control skeletal muscle cDNA, 3: 
Forward subtracted experimental cDNA, 4: Unsubtracted tester control, 5: Reverse 
subtracted experimental cDNA, 6: Unsubtracted tester control.  
 
 
 
 
  -    1     2    3   4    4    5   L   6   6    6    7   7   7    7   8   8    8   8    9   9   9   9   9   10 10  10  10  L 
     -     L    1     2     3     4     1     2     3    3    4     5     5      6   
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3.3.7 Subtraction efficiency test 
 
In order to compare the abundance of known cDNAs before and after 
subtraction and to analyze the efficiency of subtraction, a quick PCR based assay was 
performed. PCR was performed for a non-differentially expressed gene (G3PDH) 
between the two RNA sources under comparison. Figure 51 shows the results of the 
subtraction efficiency test for the forward and reverse subtracted libraries. In the 
subtracted samples the G3PDH PCR product was observed 5-15 cycles later than the 
unsubtracted samples. 
 
 
 
 
 
 
 
Figure 51: Analysis of subtraction efficiency test 
L : HaeIII digested φX174 (Sigma), ( 1.3, 1.1, 0.9, 0.6, 0.3 kb), Lanes 
1: Forward subtracted experimental cDNA, 2: Unsubtracted tester control for FS,  
3: Reverse subtracted experimental cDNA, 4: Unsubtracted tester control for RS 
 
 
 
 
3.3.8 Cloning and pre-screening of forward subtracted library 
 
Secondary PCR products of the forward subtracted library were cloned into 
the PGEM-T Easy vector system, which allows blue/white selection. More than 500 
white colonies were picked up and used directly as template for PCR amplification of 
inserts with T7-SP6 primers. Figure 52 shows the amplified cDNA inserts of the 
white colonies picked up from the forward subtracted plate. The PCR products, which 
gave a single band, were used for further experiments. 
            # of cycles     18  23  28  33   18  23  28  33        18  23  28  33  18  23  28  33          18  23  28  33  18  23  28  33 
1     1    1    1     2    2    2   2    L    1    1    1    1    2    2    2    2    L     3    3    3    3     4     4    4    4
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Figure 52: T7-Sp6 amplified cDNA inserts from white colonies of the forward 
subtracted library. Lanes L1: DNA Ladder mix, MBI; L2: 1 kb ladder, New 
England Biolabs; -,+: negative and positive controls for PCR; Other lanes: Colony 
numbers from 24 to 1088. 
 
 
 
 
3.4 Differential screening of clones 
 
           Following SSH, the PCR-Select Differential Screening protocol was performed 
in order to identify differentially expressed sequences, minimise the false positives 
and reduce the background.  
 
 
3.4.1 Arraying forward subtracted clones  
 
           Five hundred colonies were chosen and their PCR amplified cDNA inserts 
(Figure 52) were transferred into 96-well plates and denatured in equal amounts of 
  L1   -  999.........................................................................................................................................................................1035 
   L1   1036..........................................................................................................................................................................1073
   1074...........................................................1088   L1 
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NaOH and 1.5 µl of each sample was dot-blotted onto 2 nylon membranes in an 
identical order as described in section 2.7.1. There were total of 6 pairs of 
hybridization membranes. G3PDH, Actin, BRCA1, GADD45, negative hybridization 
controls cDNA1 and cDNA2 were used as control cDNAs on arrays. PCR products of 
some of the control cDNAs are shown in Figure 53. 
 
 
 
 
Figure 53: PCR products of control cDNAs 
L: MBI, DNA ladder 100 bp plus, Lanes 1: G3PDH, 2: Actin, 3:BRCA1, 4: cDNA1, 
5: cDNA2 
 
 
3.4.2 Dot blot hybridization with subtracted cDNA probes 
 
Preparation of probe sources            
 Each identical cDNA array pair was hybridized with [α-32P]-dCTP labelled 
probes. One pair was hybridized with forward subtracted cDNA pool, and the other 
pair was hybridized with reverse subtracted cDNA pool. Figure 54 shows the 
secondary PCR products of forward and reverse subtracted library. 
 
           These secondary amplification products were then digested with RsaI in order 
to get rid of the adaptor sequences on each end of cDNAs. This procedure was 
necessary for inhibiting the background, which might arise during hybridization of the 
adaptor sequences on each end of the PCR products on arrays and radiolabelled 
probes. Figure 55 shows the RsaI digested forward and reverse-subtracted probes with 
the digestion control plasmid pIND. Samples from lanes 2 and 5 were used as forward 
     3    3      L    4    4     4    4      5    5     5    5  
  L     1     1     1     1    2    2     2     2           3    3  
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and reverse probe sources respectively and [α-32P]-dCTP labelled by using random 
primer labelling method. 
 
 
 
 
 
Figure 54: PCR products of forward and reverse subtracted library 
L: DNA ladder mix, MBI, F: Forward subtracted library secondary PCR product, R: 
Reverse subtracted library secondary PCR product, (-) negative control for PCR. 
 
 
 
 
Figure 55: RsaI digestion of forward and reverse subtracted library PCR 
products      L: MBI, DNA ladder 100 bp plus, Lanes 1: Undigested forward 
subtracted library secondary PCR product, 2: RsaI digested forward subtracted library 
secondary PCR product, 3: RsaI digested forward subtracted library secondary PCR 
product and pIND, 4: Undigested reverse subtracted library secondary PCR product, 
5: RsaI digested reverse subtracted library secondary PCR product, 6: RsaI digested 
reverse subtracted library secondary PCR product and pIND, 7: Undigested pIND 
plasmid. 
   L      -        F     F     F     F       R    R    R    R 
      1       2        3        4         5         6       7       L
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Two identical cDNA blots were hybridized with either forward or reverse 
subtracted library probes with the same number of cpm for each pair (at least 2x107 
cpm/membrane). Dot blot hybridization was performed as described in the methods 
section. Figure 56 shows one pair of the six duplicate dot blots hybridized with 
forward and reverse subtracted cDNA probes. 
 
 
                     
 
Figure 56: Differential screening of SSH-selected cDNA clones with forward (left 
panel) and reverse (right panel) subtracted probes. Array number 1: Rows A-G; 
test cDNA samples, Row H; control cDNA samples (H1-H2: GADD45, H3: negative 
PCR control, H4: GAPDH, H5-H6: cDNA1, H7-H8: BRCA1, H9-H10: cDNA2, 
H11: actin, H12: NaOH+water). 
 
 
 
3.4.3 Analysis of differential screening results 
 
         After hybridizing 500 clones on 6 pairs of arrays, all the blots were exposed to 
X-ray films. The signal intensity of each dot was measured by phosphorimaging. 
Appendix C shows the phosphoimager values of each dot present in all 6 arrays. 
Figure 56 shows the array number 1. The dots corresponding to B10, E1, E11, G1, 
G9, G11 are examples of some of the cDNAs, which showed significant increase in 
signal intensity with forward (left panel) probe hybridization when compared to 
reverse (right panel) hybridization. On the other hand, control cDNAs, especially the 
negative hybridization controls (H5-6-9-10) did not give any signals as expected. 
Housekeeping genes like actin (H11) did not show any significant increase in 
expression as expected. Meanwhile, a very significant BRCA1 expression was 
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observed in samples H7-8 due to the enrichment of elevated expression of BRCA1 
cDNA during SSH. 
 
           After first screening, 210 of the clones, which showed a significant increase 
were selected for further screening tests. They were again dotted on 3 sets of nylon 
membranes in pairs and this screening procedure was repeated two further times. 
These arrays have been named as arrays 7, 8 and 9. Figure 57 shows the dot blot 
hybridization of these 3 sets of arrays containing 210 cDNA inserts. Appendix D 
summarizes average of three values for the 210 selected clones after actin 
normalization. 
 
                  
 
 
 
 
 
 
 
       
 
 
           
 
Figure 57: Differential screening of 210 se
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3.4.3.1 Sequencing, homology search and classification of BRCA1 upregulated 
genes 
  
              After actin normalization and analysing the average of three values for each 
dot (summarized in appendix D), clones which showed a robust increase in expression 
were subjected to DNA sequencing. Figure 58 shows the purified PCR products, 
which were selected for sequencing. 
 
 
 
   
 
 
 
 
 
 
Figure 58: Purified PCR products selected for sequencing 
L: MBI 100 bp DNA ladder plus, Lanes 1-18: Clones 321, 324, 326, 352, 358, 359, 
360, 361, 362, 370, 371, 381, 384, 390, 404, 406, 408, 410; 19-33: Clones 59, 67, 
131, 162, 234, 277, 293, 282, 326, 339, 406, 415, 424, 432, 446; 34-53: Clones 67, 
82, 107, 114, 133, 153, 190, 192, 259, 305, 311, 332, 415, 424, 438, 474, 1045, 1060, 
1067, 1070; 54-74: Clones 33, 48, 93, 163, 190, 218, 1060, 41, 55, 66, 89, 113, 114, 
118, 153, 158, 174, 177, 268, 452, 1026; 75-106: Clones 33, 48, 93, 121, 133, 259, 
295, 314, 420, 421, 423, 426, 431, 434, 447, 458, 460, 470, 475, 1029, 1034, 1040, 
1049, 1064, 1065, 1071, 1072, 1073, 1075, 1078, 1083, 1085. 
      L    1………………………………………………………………… 18 
     L   19……………………………………………………33     L 34...................................................................................…… 53 
      L   54……………………………………………………..................................................74 
 X   X  X   
       L  75.. ……………………………………………………....................................................................................106
   X       X 
 X  
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              Appendix E shows the sequencing results of selected clones. 
 
              Homology search was done with known gene sequences available at 
Genbank/EMBL and Expressed Sequence Tag (EST) databases, mainly by BLAST 
search.  (http://www.ncbi.nlm.nih.gov/blast) 
 
             Appendix F shows a list of BRCA1 upregulated genes in this study as defined 
by differential screening and identified by homology search. 
  
The analyzed clones in this study may be summarized as follows: 
 
            
 
        Number 
          
Analyzed putative positive clones after SSH     500 
Confirmed by differential screening a      210 
Number of clones sequenced b         83 
 >90% homology         60   
  known function        44    
  unknown function        16    
            
  
a  The cDNA clones which showed more than five-fold induction were selected for sequencing. 
b  Eight clones yielded poor sequence data. Twelve genes were represented more than once in the 
library.    
 
  Table 13 summarizes the classification of BRCA1 upregulated genes 
according to their functions. BRCA1-induced genes in breast cancer cells form 
several distinct functional classes. Of 60 BRCA1-upregulated genes shown in this 
table, 44 were associated to a known function or putative function. At least 6 of these 
genes were involved in transcriptional regulation, 4 in intermediate metabolism, 3 in 
ubiquitin-mediated proteolysis, 2 in chromatin organization, 2 in DNA repair, 2 in 
receptor mediated signalling and 2 in cytoskeletal organization. Others were involved 
in intermediate metabolism, RNA metabolism and surveillance, amino acid or ion 
transport, cell-cell and cell-ECM interaction, endosome or vesicle trafficking and N-
glycan biosynthesis. The Cdc7 protein kinase, which is involved in the initiation of 
DNA synthesis, was also induced by BRCA1.  
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Table 13: Classification of BRCA1 upregulated genes 
Fold induction values are according to differential screening results. Redundancy indicates the number of representation of a gene in the library. 
* indicates  the  previously reported frequent LOH sites in breast cancers (Hirano et al.,2001). 
Putative Function Gene Name Fold Induction Redundancy Accession# Locus 
Amino Acid Transport Solute carrier family 38, member 2 (SLC38A2) (ATA2) 9 1 XM_028311 12q 
Cell-Cell Interaction CD24 antigen (small cell lung carcinoma cluster 4 antigen) (CD24) 29 1 XM_087865 6q21 
Cell-ECM Interaction Integrin, beta 1 (fibronectin receptor, beta  polypeptide) (ITGB1),transcript variant 1E 6 1 NM_133376 10p11.2 
Chaperon Dystonia 1, torsion (autosomal dominant; torsin A)(DYT1) 11 1 NM_000113 9q34 
Chromatin assembly/DNA repair and response Anti-silencing function 1A (ASF1A) 13 2 AF279306 6q22.31 
Chromatin structure High-mobility group (nonhistone chromosomal) protein 1  (HMG1)    9 1 BC003378   13q12* 
Cytoskeleton organization Vinculin (VCL), transcript variant meta-VCL 7 1 NM_014000 10q22.1-q23 
Cytoskeleton organization Capping protein (actin filament) muscle Z-line, beta 14 1 BC008095 1p36.1* 
DNA Repair MutS homolog 2, colon cancer, nonpolyposis type 1 (E.coli) (MSH2) 9 1 XM_034901 2p22-p21 
DNA Repair RAD21 homolog (S. pombe) (RAD21) 11 1 NM_006265 8q24 
Vesicle Trafficking SEC22, vesicle trafficking protein (S. cerevisiae)-like 1 11 2 BC001364. 1q21.2-q21.3 
Endosome-trafficking Suppressor of K+ transport defect 1 (SKD1) 9 1 NM_004869 18q21.32-q21.33* 
Intermediate Metabolism Fructose-1,6-bisphosphatase 1 (FBP1) 9 1 NM_000507 9q22.3 
Intermediate Metabolism Galactose-4-epimerase, UDP- (GALE) 9 1 XM_032314 1p36-p35* 
Intermediate Metabolism NADH dehydrogenase (ubiquinone) 1 beta subcomplex 9 9 1 BC007672 8q13.3 
Intermediate Metabolism Similar to cytochrome c oxidase subunit IV (LOC146478) 9 1 XM_085483 16q24.1 
Ion Transport ATPase, Na+/K+ transporting, beta 3 polypeptide (ATP1B3) 10 1 NM_001679. 3q22-q23 
N-Glycan Biosynthesis Dolichyl-phosphate N-acetylglucosaminephosphotransferase 1 (GlcNAc-1-P transferase) 6 1 BC008817 11q23.3* 
Nuclear Envelope Protein Thymopoietin (TMPO) 11 1 U18271 12q22 
Cell cycle G1 to S phase transition protein 1 (GSTP1) 7 1 XM_007816 16p13.1 
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Cell cycle Retinoblastoma binding protein 2 (RBBP2) 9 1 XM_006998 12p11 
Protein Kinase/DNA synthesis/Meiosis Cdc7 (CDC7) 11 1 AF015592    1p22* 
Receptor-mediated signalling Erbb2 interacting protein (ERBB2IP) (ERBIN) 6 1 NM_018695 5q31 
Receptor-mediated signalling G protein alpha stimulating activity polypeptide 1 (GNAS) 13 1 BC002722 20q13.2-q13.3 
Transcription Regulation C3HC4-type zinc finger protein (LZK1)(Dif3 homolog) 8 1 NM_024835 17q12 
Transcription Regulation Activity-dependent neuroprotector (ADNP) 9 1 NM_015339 20q13.13-13.2 
Transcription Regulation Hypoxia-inducible factor 1, alpha subunit inhibitor HIF1AN (FIH-1) 7 1 XM_030426 10q24 
Transcription Regulation Sex comb on midleg-like 1 (Drosophila) (SCML1) 9 1 NM_006746 Xp22.2-22.1 
Transcription Regulation Kelch-like protein C3IP1 (C3IP1) 7 2 XM_086284 1q32.1 
Mitochondrial stress response D-prohibitin (Bap37) 8 1 AF178980   12p13 
Ubiquitin-mediated proteolysis  Suppressor of G2 allele of SKP1, S. cerevisiae,homolog of (SGT1)    8 1 NM_006704 13q14.2* 
Ubiquitin-mediated proteolysis  Ubiquitin protein ligase E3A, transcript variant 2 (UbE3A) 9 1 NM_000462 15q11-q13 
Ubiquitin-mediated proteolysis  Proteasome subunit, beta type, 4  (PSMB4) 9 1 XM_047881 1q21 
RNA surveillance Regulator of nonsense transcripts 2 (RENT2), transcript variant 1 7 1 NM_080599.1 10p14-p13 
RNA surveillance 5'-3' exoribonuclease 2 (XRN2) 8 1 XM_009601.3 20p11.2-p11.1 
RNA surveillance PI-3-kinase-related kinase SMG-1 11 1 AY014957.1  16p13.2 
RNA synthesis/translation Poly(A)-binding protein, cytoplasmic 1 (PABPC1) 8 3 XM_018280.1 8q22 
RNA synthesis/translation Sjogren syndrome antigen A2 (SSA2) 9 1 XM_001901.1 1q31 
RNA translation Ribosomal protein S6 (RPS6) 17 3 XM_015349.1 9p21* 
RNA translation Ribosomal protein L5 (RPL5) 6 1 XM_018498.1 1p 
RNA translation Ribosomal protein L3  11 1 BC008492  22q 
RNA translation Ribonuclease P, 40kD subunit (RPP40) 8 2 XM_004104.2 6 
RNA translation Elongation factor G1 (EFG1) 7 1 AF367998 3q25.1-26.2 
RNA translation Ribosomal protein, large, P0 10 1 BC005863  12q24.2 
Unknown KIAA0725 protein (KIAA0725) 12 1 XM_049445 8p11.21 
Unknown Acidic (leucine-rich) nuclear phosphoprotein 32 family, member B (ANP32B) 9 1 NM_006401 9q22.32 
Unknown Candidate tumor suppressor OVCA1 (OVCA1) 12 2 NM_080822 17p13.3* 
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Unknown Hypothetical protein (MAC30), mRNA 17 2 XM_031536 17p11.1 
Unknown Similar to tumor metastasis-suppressor; longevity assurance (LAG1, S. cerevisiae) homolog 2 12 2 XM_065847 2q31.1 
Unknown DNA sequence from clone RP11-165J3 on chromosome 9 16 1 AL583839.1 9q22.1-22.33 
Unknown Hypothetical protein FLJ23375 (FLJ23375) 16 2 NM_024956 15q14 
Unknown Hypothetical protein MGC2714 (MGC2714) 8 1 NM_032299 11q22.1 
Unknown Hypothetical protein BC008322 (LOC92106) 8 3 NM_138381.1 3p24.3 
Unknown Hypothetical protein FLJ20060 12 1 XM_005467.4 16q13 
Unknown CG2277 gene product (LOC221294) 7 1 XM_166297.1 6q22.31 
Unknown Hypothetical protein MGC4767 (MGC4767) 10 1 XM_045844 12q24.31 
Unknown KIAA1007 6 2 XM_168026.1 7p11.2 
Unknown Clone FLB9213 PRO2474 11 1 AF130088 7 
Unknown CGI-48 protein (LOC51096) 13 1 NM_016001 17q21.33 
Unknown Homo sapiens cDNA FLJ31534 8 1 AK056096   9 
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3.4.3.2 Confirmation of BRCA1 induction of some of the candidate genes 
 
It is important to confirm that the genes identified with differential screening 
will also show induction in MCF7 cells overexpressing BRCA1 with Northern and 
western blot analyses. Northern blot will not only confirm that the gene is upregulated 
by BRCA1 overexpression, but also show the true transcript size of the gene. 
 
Several BRCA1-induced genes reported here are known to be involved in 
DNA repair (RAD21, MSH2); (Sonoda et al., 2001; Wang et al, 2000), and 
chromosomal structure maintenance (RAD21, CDC7, SGT1, HMG1); (Nasmyth et 
al., 2000; Lei et al., 2001; Kitagawa et al., 1999; Yamanaka et al., 2002). This 
observation strongly suggests that some of these BRCA1 target genes may mediate 
some of the effects attributed to BRCA1 for chromosomal stability. To further analyse 
their BRCA1-regulated expression, RAD21 and MSH2 expression in two different 
cell lines have been analyzed.  
 
As shown in Figure 59, both RAD21 and MSH2 were upregulated following 
overexpression of BRCA1 in MCF7 cells. Furthermore, the same genes were also 
upregulated in the UBR60-bcl2 cell line following BRCA1 induction (Figure 59d). 
UBR60-bcl2 cells were modified to stably express BRCA1 with tetracycline inducible 
system (Harkin et al., 1999). In Figure 59a semi-quantitative RT-PCR amplification 
of RAD21 and MSH2 transcripts showed that pCMVmycBRCA1-transfected MCF7 
cells (lane B) display higher levels of RAD21 and MSH2, when compared to 
pCMVmyc-transfected cells (lane V). Northern blot analysis confirms BRCA1-
mediated induction of RAD21 expression in BRCA1 overexpressed MCF7 cells 
(Figure 59b). Western blot analysis of MSH2 protein levels confirms induced 
expression of MSH2 gene following BRCA1 overexpression in MCF7 cells (Figure 
59c). Furthermore, following inducible BRCA1 (5,7 kb transcript size) expression in 
the UBR60-bcl2 cells, RAD21 (3,6 kb) and MSH2 (3,1 kb) transcripts also showed 
increased expression (Figure 59d). These observations confirm that, both RAD21 and 
MSH2 are indeed upregulated as a result of BRCA1 overexpression.  
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Another BRCA1-target gene was ERBIN, which encodes ERBB2/HER2-
interacting protein (Borg et al., 2000). As shown in Figure 60, northern blot assays, 
using both MCF7 and UBR60-bcl2 cells, demonstrate that BRCA1 induces 2.5 and 
3.5 fold induction of ERBIN (6,4 kb transcript size) expression respectively. GNAS 
encoding a G protein alpha stimulating activity polypeptide was also interesting for 
further consideration. Figure 60c shows that GNAS expression is also induced by 
BRCA1 (2.1 fold). OVCA1, which has been identified as a candidate tumour 
suppressor gene, was also studied. OVCA1 mRNA transcripts (1.1 kb and 2.3 kb 
species) levels were low in MCF7 cells and BRCA1 overexpression caused 2.4 fold 
induction of 1.1 kb and 1.7 fold induction of 2.3 kb transcripts (Figure 60a). MAC30, 
whose expression was reported to be decreased in meningiomas, schwannomas and 
neurofibromas, has two transcripts (Murphy et al., 1993). The 2.3 and 2.8 kb 
transcripts displayed 2.0 and 4.4 fold induction in MCF7 cells and 2.2 and 3.8 fold 
induction in UBR60-bcl2 by BRCA1, respectively (Figure 60).  
 
These studies performed with UBR60-bcl2 cells that stably express BRCA1 at 
modest levels in an inducible manner confirm and validate our results obtained with a 
transient expression approach to identify potential BRCA1 target genes. 
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Figure 59: BRCA1-mediated upregulation of RAD21 and MSH2 DNA repair 
genes. 
(a) Semi-quantitative RT-PCR amplification of RAD21 and MSH2. GAPDH was 
used as a control for equal template loading in PCR. (b) Northern blot analysis of total 
cellular RNA from MCF7 cells. Ethidium bromide staining shows equal RNA loading 
in each lane. (c) Western blot analysis of MSH2 and BRCA1 proteins in BRCA1 
overexpressed MCF7 cells. Cytokeratin 18 was used for equal protein loading control.  
(d) Northern blot analysis from UBR60-bcl2 cells showing inducible BRCA1, 
RAD21 and MSH2 expressions following tetracycline withdrawal (lane –T) at 24 h. 
Ethidium bromide staining shows equal RNA loading and “FI” indicates fold 
induction in BRCA1-overexpressing cells. 
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Figure 60: BRCA1-mediated upregulation of genes involved in cell signalling or 
tumour suppression.  
(a) Northern blot analysis of total cellular RNA from MCF7 cells shows that the 
expression of ERBIN, OVCA1 and MAC30 genes are induced by BRCA1. (b) 
Northern blot analysis of total cellular RNA from UBR60-bcl2 cells with inducible 
BRCA1 expression shows that these cells overexpress ERBIN and MAC30 genes as a 
result of induction of BRCA1 gene expression upon tetracycline withdrawal (lane -T). 
(c) Semi-quantitative RT-PCR amplification of GNAS and MAC30 transcripts shows 
BRCA1-mediated induction of these genes in MCF7 cells. Ethidium bromide staining 
shows equal RNA loading and “FI” indicates fold induction in BRCA1-
overexpressing cells. 
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CHAPTER 4. DISCUSSION 
 
 
 
 Generating ecdysone inducible BRCA1 expression in the cell lines 
Germ-line mutations in the BRCA1 tumour suppressor gene predispose carriers 
to cancer of the breast and ovaries and account for approximately 50% of inherited 
breast cancers (Miki et al., 1994). BRCA1 gene encodes a multifunctional protein 
involved in different cellular pathways including cellular response to DNA damage, 
cell cycle, growth suppression, apoptosis induction, ubiquitin ligation and 
transcription regulation (Venkitaraman, 2002). Therefore, the identification of genes 
whose expression is affected by BRCA1 as aimed in this thesis work, may contribute 
to a better understanding of breast cancer suppression by this gene. 
 
In this study, initial attempts were to generate an inducible and stable BRCA1 
expressing breast carcinoma cell line. Ecdysone inducible system and its components 
were used to generate a tightly regulated BRCA1 expression. Three full-length 
BRCA1 cDNAs from different sources were used for subcloning into pIND expression 
vector. The first step was to transfect MCF7 breast carcinoma cell line with the 
pVgRXR regulatory plasmid to generate a stable cell line; the next step was to 
introduce the expression plasmid pIND carrying BRCA1 cDNA and to induce 
BRCA1 expression with ecdysone analog ponasterone A or muristerone A. On the 
other hand regulatory plasmid pVgRXR harboring U2OS osteosarcoma cell line, 
pIND.p53 and pIND.lacZ plasmids were used as control during the experiments. After 
generation of stable pVgRXR expressing MCF-7 breast carcinoma cell line, selected 
clones were transiently transfected with pIND.lacZ and induced with mA, but 
induction of the reporter gene was not significant when compared to the pIND.lacZ 
transfected U2OS control cells. Therefore, U2OS cell line harboring pVgRXR 
plasmid was transfected with pIND.myc.BRCA1 plasmid to generate BRCA1 
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expressing clones and these clones were analyzed by western blot for induction of 
BRCA1 protein levels. Later on, U2OS cells were transiently transfected with 
pIND.BRCA1 and pIND.HA.BRCA1 plasmids and western blot analysis was 
performed with different BRCA1 specific antibodies. There were no significant 
increases in BRCA1 expression of the selected clones, compared to control, 
transiently pIND.p53 transfected U2OS cells. The inducible system has worked very 
well with U2OS cells with control plasmids pIND.lacZ and pIND.p53 but, in the case 
of BRCA1, a significant increase was not observed with pIND.BRCA1 constructs.  
 
The first two BRCA1 cDNA sources, pcDNA3.myc.BRCA1 and pCR3. 
BRCA1 were in vitro transcribed-translated to control the translated BRCA1 protein 
product. The expected BRCA1 protein products were observed for both constructs. 
Then they were used for subcloning of BRCA1 into pIND vector. pIND.BRCA1 was 
partially sequenced from both 5’ and 3’ ends to make sure that the cloning sites were 
correct. The 3’ end sequencing showed that there were some mismatched sequences in 
the vector site when compared to the expected vector sequence of the pIND.BRCA1 
construct. Since the mismatch sequences were after the BRCA1 stop codon, not in the 
coding sequence of BRCA1 in pIND.BRCA1 construct, the pIND vector alone was 
also partially sequenced. The pIND vector sequence was correct and there was 
nothing wrong with the vector used for cloning, at least in the multiple cloning site. 
 
Later on, pIND.HA.BRCA1 was prepared with different pIND vector and 
BRCA1 cDNA sources and with partial sequencing no mismatches was observed. 
pIND.HA.BRCA1 was transiently transfected into U2OS, but no significant increase 
was observed again. There might be two explanations for this result: When the cells 
were transfected with endogenous DNA, in some cases, they tend to hypermethylate 
the inducible promoters especially in the case of introducing a growth inhibitor gene. 
Harkin et al, have used tetracycline inducible system to overexpress BRCA1 (Harkin 
et al., 1999) and have solved the hypermethylation problem with 5-azacytidine 
treatments of UBR60-bcl2 cells. Another explanation might be the minor induction of 
BRCA1 protein in our system. In some of the stable pIND.myc.BRCA1 expressing 
U2OS clones (Figure 21, clone 43; Figure 22, clones 22-26) a very slight increase was 
observed in BRCA1 expression, consistent with a recent report, showing the mild 
induction of BRCA1 by the use of ecdysone inducible system (Welcsh et al., 2002). 
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With this system, they aimed to identify BRCA1 downstream targets, with modest 
BRCA expression levels, that would not induce apoptosis. 
 
 
             Ectopic expression of BRCA1 in MCF7 cells 
            Since the desired expression level of BRCA1 protein was not observed with 
the ecdysone inducible system, MCF7 cells were transiently transfected with 
pCMVmycBRCA1 plasmid that constitutively expresses BRCA1. Significant 
increases in BRCA1 mRNA transcript and protein levels were confirmed by northern 
and western blot analyses respectively. The transfection efficiency of the MCF7 cells 
was 40% as determined by the pEGFP reporter plasmid transfection in control MCF7 
cells. In order to determine whether constitutive BRCA1 expression leads to 
apoptosis, the transfected cells were stained with an early apoptosis marker, annexin 
V. Under the experimental conditions used in this study, not more than 1-2% of the 
cells were apoptotic. Thus at a transfection efficiency of 40%, less than 5% of the 
BRCA1 expressing cells were apoptotic. This indicated that ectopically expressed 
BRCA1 was not significantly cytotoxic to MCF7 cells under test conditions. The lack 
of BRCA1 induced apoptosis in our experimental system is in agreement with recent 
findings indicating that BRCA1 directs a selective p53-dependent transcriptional 
response towards growth arrest and DNA repair targets (MacLachlan et al., 2002) 
 
 
 Identification and analysis of BRCA1 induced genes 
Suppression Subtractive Hybridization (SSH) technology was used to generate 
a library of partial-length cDNAs representing differentially expressed mRNAs in 
BRCA1-overexpressing MCF7 cells. SSH combines subtractive hybridization with 
PCR to generate a population of PCR fragments enriched for sequences from genes 
expressed differentially. SSH-mediated cDNA enrichment allows the equalization of 
wide differences in abundance of different transcript species. Consequently, 
differentially expressed transcripts of low abundance can be cloned (Diatchenko et al., 
1996).  SSH has some advantages over microarray analysis; it can theoretically detect 
differences in less abundant mRNAs. 
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By using this approach, 60 genes have been identified that are upregulated as a 
result of BRCA1 overexpression in breast cancer cells (Table 13). None of the genes 
identified in this study have been identified in previous reports (Aprelikova et al., 
2001; Harkin et al., 1999; MacLachlan et al., 2000; Mullan et al., 2001; Welcsh et al., 
2002). This could be due to the fact that a breast cancer cell line was used to identify 
potential BRCA1 target genes by the SSH technique in our study. 
 
In previous studies, Harkin et al. (Harkin et al., 1999) have identified 20 
BRCA1 target genes using microarray technology for screening of transcripts 
upregulated by ectopically expressed BRCA1 in the U2OS osteosarcoma cell line. 
Similarly, MacLachlan et al. (MacLachlan et al., 2000) were able to identify 45 major 
targets in the SW480 colorectal cancer cell line. Aprelikova et al. (Aprelikova et al., 
2001) have identified 51 genes that are down-regulated in BRCA-/- mouse embryonic 
stem cells.  Recently, Welcsh et al identified 62 genes that are targets of BRCA1 by 
using human embryonal kidney epithelial cells (Welcsh et al., 2002). These studies 
have shown that DNA damage-responsive genes such as GADD45 (Aprelikova et al., 
2001; Harkin et al., 1999; MacLachlan et al., 2000; Mullan et al., 2001; Welcsh et al., 
2002), GADD153, Ku70, Ku60  (MacLachlan et al., 2000), and cell cycle control 
genes such as 14-3-3σ (Aprelikova et al., 2001) are upregulated by BRCA1.  
 
In the present work, it has been shown that several DNA damage response 
(RAD21, MSH2, ASF1A, CDC7) and chromosomal structure maintenance (RAD21, 
ASF1A, CDC7, SGT1, HMG1) genes are upregulated targets of BRCA1. As BRCA1-
deficient cells suffer from both DSB repair deficiency and chromosomal instability 
(Wang et al., 2001), at least some of these defects may be attributed to inefficient 
expression of these target genes in the absence of functional BRCA1. The relevance 
of these genes in BRCA1 mediated tumour suppression may be related to their 
functions. RAD21 is a nuclear phosphoprotein that repairs double strand breaks and is 
a component of the cohesin complex that holds sister chromatids during mitosis (Chen 
et al., 2002).  MSH2 encodes a mismatch repair protein and has been shown to be a 
component of BASC (BRCA1-associated genome surveillance complex) (Wang et al., 
2000b).  The histone chaperone anti-silencing function 1 (ASF1) has been implicated 
in efficient assembly of newly replicated and repaired DNA into chromatin (Mello et 
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al., 2002). It has also been proposed that in response to DNA replication blocks and 
DNA damage, Rad53 directs Asf1 to regulated nucleosome deposition and thereby 
links Rad53 to chromatin assembly (Hu et al., 2001). Cdc7 kinase is one of the key 
regulators in the initiation of DNA replication in mammals. Genetic studies in yeast 
indicate additional roles of Cdc7 in meiosis, checkpoint responses, maintenance of 
chromosome structures and repair (Masai and Arai, 2002). SGT1 is required for 
assembly of kinetochore complex and also for both the G1/S and G2/M transitions in 
the cell cycle. It is also a subunit of the SCF ubiquitin ligase complex (Kitagawa et 
al., 1999). HMGB1 (High Mobility Group Box protein) is a non-histone chromosomal 
protein and has role in V(D)J recombination as well as DSB repair. It stimulates DNA 
ligase IV/XRCC4 during non-homologous end joining of DSB repair (Yamanaka et 
al., 2002). HMGB1 is one of the proteins that have been shown to interact with 
steroid hormone receptors, thus dramatically enhancing their binding to estrogen and 
progesterone responsive elements. Intertumoural variation of HMGB1 expression has 
been observed in breast cancers and because of its role in steroid receptor mediated 
gene expression HMGB1 can be considered to be one of the major players involved in 
mechanisms of steroid hormone-dependent growth of breast cancer cells (Flohr et al., 
2001). 
 
Among BRCA1-target genes reported here several (such as SGT1, UbE3A, 
PSMB4) are involved in ubiquitin-mediated protein degradation. This may not be an 
unexpected finding based on the recent demonstration that BRCA1 itself (together 
with BARD1) functions as an E3 ubiquitin ligase (Hashizume et al., 2001; Ruffner et 
al., 2001; Venkitaraman, 2002). It may serve as a signaling event rather than 
proteosomal degradation, such as in DNA repair and or in regulating the BARD1- 
mediated inhibition of mRNA polyadenylation after DNA damage. The UBE3A gene 
encodes the E6-AP ubiquitin-protein ligase, which functions in protein ubiquitination 
and has been shown to be mutated in Angelman syndrome patients (Kishino et al., 
1997). PSMB4 is a subunit of PA28 proteasome activator and proteasome is 
responsible for degradation of short lived and misfolded cytosolic and nuclear 
proteins in cells (McCusker et al., 1997). As suggested by Venkitaraman, the 
involvement of BRCA1 in ubiquitin-mediated protein degradation could help to 
explain the multiplicity of biological roles ascribed to this protein, including 
coordination of DNA repair-related events (Venkitaraman, 2002).  
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Interestingly, a variety of other genes involved in distant cellular processes 
such as intermediate metabolism, cell-cell interaction, receptor-mediated signaling, 
endosome trafficking, cytoskeletal organization and RNA surveillance and 
metabolism also appear to be upregulated by BRCA1 (Table 13). In this context, 
BRCA1 seems to act like another tumour suppressor gene, namely p53 which also 
upregulates a high number of genes involved in many different cellular processes 
(Balint and Vousden, 2001).  
 
Related to its function in transcription regulation, a set of transcription related 
genes have been identified as BRCA1 downstream targets: LZK1 encodes a C3HC4-
type zinc finger protein, which is characteristic for protein-protein and protein-DNA 
interactions. This gene is also a likely ortholog of mouse dioxin inducible factor 3 
(dif3). ADNP gene also has zinc finger and homeobox domains and is implicated in 
modulation of cell survival (Zamostiano et al., 2001). C3IP1 has a kelch domain (beta 
propeller domain) involved in protein-protein interactions and some enzymatic 
activities. Kelch-like proteins have been found to interact with topoisomerase II (Xu 
et al., 2002). HIF1AN has been found to interact and inhibit transcriptional activity of 
HIF1A and it has been suggested that it may interact either directly or indirectly with 
some histone deacetylases (Mahon et al., 2001). Mammalian homologs of the PcG 
(Drosophila Polycomb group) are involved in the transcriptional repression of HOX 
genes. SCML1  (sex comb on midleg like-1) appears to be a new member of this gene 
group and may play role in the control of embryonic development (van de Vosse et 
al., 1998). These genes appear to act as transcriptional activators or repressors 
consistent with the finding that BRCA1 interacts with many transcriptional factors. 
 
Another class of BRCA1 regulated genes were identified which have a role in 
RNA metabolism and surveillance. Some ribosomal genes and RNA metabolism 
genes such as poly(A)-binding protein (PABPC1), which makes a complex with the 3-
prime poly(A) tail of eukaryotic mRNA, that is required for poly(A) shortening, 
translation initiation and mRNA stability (Deo et al., 1999), were identified as 
BRCA1 targets. Interestingly several RNA surveillance genes such as RENT2 
(Mendell et al., 2000), XRN2 (Zhang et al., 1999) and SMG-1 (Yamashita et al., 2001) 
have also been identified as BRCA1 upregulated genes in this study. Gene expression 
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requires the coordination and integration of multiple processes including transcription, 
splicing, polyadenylation, nucleocytoplasmic export, and translation of mRNAs. 
Premature termination codons in such a complex process or nonsense mutations 
introduced during DNA replication result in truncated proteins, which are toxic to 
cells. A mechanism, known as mRNA surveillance or nonsense-mediated mRNA 
decay (NMD) has evolved to recognize mRNAs containing premature termination 
codons and accelerate their degradation. Identification of NMD genes as BRCA1 
target genes may suggest that BRCA1 may upregulate NMD process upon DNA 
damage leading to accelerated degradation of truncated proteins that are toxic to cells.  
 
Of particular interest, several genes that have been identified here are among 
markers of a `poor prognosis` gene expression signature (RAD21, ERBB2IP, UbE3A, 
FBP1, KIAA0725, TMPO, PSMB4, CD24, MSH2, ATP1B3) identified by DNA 
microarray analysis of early primary breast tumours (van't Veer et al., 2002). 
Furthermore, Hirano et al., have reported frequent LOH sites in breast cancers 
(Hirano et al.,2001) that correlates with the chromosomal locations of some of the 
genes (HMG1, SKD1, GALE, Capping protein muscle Z-line beta, GlcNAc-1-P 
transferase, CDC7, SGT1, RPS6, OVCA1) identified in this study. BRCA1-induced 
expression of six of these genes from this library was confirmed by additional 
experiments (semi-quantitative RT- PCR, northern blot or western blot) using MCF7 
and UBR60-bcl2 cell lines. Therefore, a set of BRCA1 target genes that may be 
involved in BRCA1-mediated cellular processes as well as breast carcinogenesis has 
been identified in this study.   
 
In relation to BRCA1-related breast/ovarian carcinogenesis, further analysis of 
the expression of several genes has been carried out. Among these BRCA1-target 
genes ERBIN and GNAS are involved in receptor-mediated signaling.  ERBIN is an 
ERBB2/HER2-binding protein, which locates this receptor to the basolateral 
membrane (Borg et al., 2000). Overexpression of ERBB2/HER2 is frequently 
observed in breast cancers and its overexpression is associated with poor tumour 
prognosis (Borg et al., 1991). Although it is not known whether ERBIN is able to 
inhibit ERBB2/HER2 activity, its deregulation results in the mislocalisation of the 
receptor (Borg et al., 2000). This raises the possibility that ERBIN deficit resulting 
from inactivation of BRCA1 could lead to a loss of epithelial homeostasis, and in 
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consequence pathological disorganisation in breast carcinoma. On the other hand, 
GNAS is a guanine nucleotide-binding protein that stimulates adenylyl cyclase. 
Activated GNAS leads to increase in cAMP and may regulate proliferation at multiple 
sites, which may be advantageous in regulating aggressive proliferative programs in 
metastatic cells. The active form of this protein leads to growth inhibition of breast 
cancer cells both in vitro and in vivo (Chen et al., 1998a; Santore et al., 2002). A third 
gene, namely OVCA1 that we show to be upregulated by BRCA1, was initially 
identified as a candidate ovarian tumour suppressor gene located on chromosome 
17p13.3 (Schultz et al., 1996). This locus displays frequent LOH in both ovarian and 
breast cancers (Hirano et al., 2001; Lynch et al., 1998a; Lynch et al., 1998b; Lynch et 
al., 1998c) and OVCA1 was reported to display reduced expression in ovarian and 
breast cancers. In addition, ectopic expression of OVCA1 causes a dramatic reduction 
in cell proliferation in association with accelerated cyclin D1 degradation (Bruening et 
al., 1999). Even if additional studies are needed, these observations strongly suggest 
that BRCA1 may directly act as a tumour suppressor gene in breast cancer, for 
example through receptor-mediated regulation of cell proliferation. 
 
In conclusion, in this study, 60 genes have been identified whose expression 
levels are upregulated as a result of BRCA1overexpression in breast carcinoma cells. 
The properties of several of these genes are consistent with putative tumour 
suppressor functions in breast neoplasia. It will now be important to construct a 
complete profile of BRCA1-regulated genes in order to achieve an integrated view of 
all the functional events regulated by BRCA1, and to assess how expression of these 
genes is affected by the BRCA1 status of cells. 
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CHAPTER 5. FUTURE PERSPECTIVES 
 
 
 
The genes identified in this study as BRCA1 upregulated targets may help to 
explain the role of BRCA1 in breast cancer suppression. The candidate genes have not 
been previously characterized. Further studies are therefore needed to increase the 
impact of this initial SSH screening.  
 
One approach is to analyze the expression level of these genes in tumours and 
cell lines with known BRCA1 and p53 status, in order to understand whether the 
expression of these genes is regulated by BRCA1. At this point, the analysis of the 
normal-tumour samples for the expression of BRCA1 and the target genes is very 
important in order to confirm that BRCA1 protein deficiency in the tumour samples 
leads to impaired regulation of these genes. It was reported that BRCA1 could 
regulate the expression of many genes through p53-dependent or p53-independent 
pathways such as p21 and GADD45 (Somasundaram et al., 1997, Harkin et al., 1999). 
In order to distinguish this, the regulation of a number of candidate genes can be 
analyzed in breast carcinoma cell lines with known p53 and BRCA1 status, such as 
MCF7 (wt-BRCA1/wtp53), MDA435 (wt-BRCA1/mt-p53 and HCC1937 (mt-
BRCA1/mt-p53) by western and northern blot techniques. 
 
BRCA1 can bind to DNA sequences in a non-specific manner, meaning the 
absence of demonstrable sequence-specific DNA binding activity. But BRCA1 can 
mediate sequence specific transcriptional repression through its selective recruitment 
by a novel DNA-binding transcription factor ZBRK1 (zinc finger and BRCA1-
interacting protein with a KRAB domain). BRCA1 has been shown to bind to many 
transcription regulatory proteins and mediate ZBRK1-directed repression through a 
ZBRK1 binding site identified in intron 3 of the GADD45 gene (Zheng et al., 2000). 
ZBRK1 binds to the specific sequence GGGxxxCAGxxxTTT. This motif has been 
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identified in the regulatory regions of the previously identified BRCA1 downstream 
targets (Harkin et al., 1999; MacLachlan et al., 2000) such as GADD153, Ki-67, Bax, 
p21, EGR1, amphiregulin prothymosin, TIMP-1, TIMP-2, and Topo IIa. Since 
BRCA1 activates GADD45 and p21 via binding to the ZBRK1 transcriptional 
repressor, the regulatory and promoter regions of the candidate genes must be 
examined for BRCA1 responsive sites such as ZBRK1 binding site and whether 
BRCA1 indeed regulates the expression of the target genes. The BRCA1 responsive 
sites in the promoter and regulatory regions of these genes can be identified by using 
deletion-mapping strategies with the construction of reporter gene coding vectors.  
 
Genes identified with an unknown function can be checked for BLAST search 
in the future because their functions may eventually be determined. Studies 
concerning the identification of the functions of these genes with unknown functions 
may bring a better understanding to BRCA1 mediated cancer suppression. 
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Appendix A: Map and sequence of pCMV.myc.BRCA1 
 
 
 
Map and multiple cloning site of pCMV.myc vector (Clontech): 
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Appendix A: Map and sequence of pCMV.myc.BRCA1 
SalI-NotI sites are highlighted (894-6509th nucleotides)
 
                
 pCMV.myc.BRCA1 
9380 base pairs 
 
                                                                            
                 SphI  PstI                                                 
                 BbuI  Sse8387I                                             
gagttcgagcttgcatgcctgcaggtcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgac base pairs 
ctcaagctcgaacgtacggacgtccagcaatgtattgaatgccatttaccgggcggaccgactggcgggttgctg 1 to 75 
                 PaeI  SbfI                                                 
                          BspMI                                             
                                                                            
 
                                                                            
                AatII                                                AatII  
ccccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgg base pairs 
ggggcgggtaactgcagttattactgcatacaagggtatcattgcggttatccctgaaaggtaactgcagttacc 76 to 150 
 
                                                                            
                                                                            
                                                  NdeI                      
gtggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgac base pairs 
cacctcataaatgccatttgacgggtgaaccgtcatgtagttcacatagtatacggttcatgcgggggataactg 151 to 225 
                                                  FauNDI                    
                                                                            
                                                                            
  
  AatII                                                                     
gtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttatgggactttcctacttggcagtac base pairs 
cagttactgccatttaccgggcggaccgtaatacgggtcatgtactggaataccctgaaaggatgaaccgtcatg 226 to 300 
 
  
                                                                            
      BstSNI                                                                
      SnaBI               NcoI                                              
atctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggatagcggttt base pairs 
tagatgcataatcagtagcgataatggtaccactacgccaaaaccgtcatgtagttacccgcacctatcgccaaa 301 to 375 
      BsaAI               Bsp19I                                            
      Eco105I                                                               
 
                                                                            
                                                        AccB1I              
                                      AatII             BshNI               
gactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggac base pairs 
ctgagtgcccctaaaggttcagaggtggggtaactgcagttaccctcaaacaaaaccgtggttttagttgccctg 376 to 450 
                                                        BanI                
                                                        Eco64I              
 
                                                                            
                                                                            
tttccaaaatgtcgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatata base pairs 
aaaggttttacagcattgttgaggcggggtaactgcgtttacccgccatccgcacatgccaccctccagatatat 451 to 525 
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         BanII                                                              
         Eco24I                          Esp3I                              
       EcoICRI Psp124BI               BpmI                                  
agcagagctcgtttagtgaaccgtcagatcgcctggagacgccatccacgctgttttgacctccatagaagacac base pairs 
tcgtctcgagcaaatcacttggcagtctagcggacctctgcggtaggtgcgacaaaactggaggtatcttctgtg 526 to 600 
       Ecl136II                       GsuI                                  
         SacI SstI                       BsmBI                              
         FriOI                                                              
  
 
                 Bsp13I                                                     
                 BspEI  XbaI     BsaWI                                      
                 MroI BsaWI   BamHI                               HpaI      
cgggaccgatccagcctccggactctagaggatccggtactagaggaactgaaaaaccagaaagttaactggtaa base pairs 
gccctggctaggtcggaggcctgagatctcctaggccatgatctccttgactttttggtctttcaattgaccatt 601 to 675 
                 Kpn2I BseAI  BstI                                          
                 BsiMI                                                      
                 AccIII                                                     
 
                                 BstI                                       
                           Psp5II   BsaWI                                   
gtttagtctttttgtcttttatttcaggtcccggatccggtggtggtgcaaatcaaagaactgctcctcagtgga base pairs 
caaatcagaaaaacagaaaataaagtccagggcctaggccaccaccacgtttagtttcttgacgaggagtcacct 676 to 750 
                           PpuMI BamHI                                      
                                                                            
  
                   SseBI                                             SacII  
                   Eco147I                                           KspI Bsp12 
                   StuI                                              SstII  
tgttgcctttacttctaggcctgtacggaagtgttacttctgctctaaaagctgcggaattgtacccgcgggccc base pairs 
acaacggaaatgaagatccggacatgccttcacaatgaagacgagattttcgacgccttaacatgggcgcccggg 751 to 825 
                   AatI                                              Cfr42I 
                   Pme55I                                            Sfr303I 
                                                                      PspOMI 
  
ApaI Bsp19I                                      MscI                       
    0I                                         CfrI                         
Eco24I                              Psp5II BspMI MluNI SfiI   EcoRI  SalI   
accatggcatcaatgcagaagctgatctcagaggaggacctgcttatggccatggaggcccgaattcggtcgaca base pairs 
tggtaccgtagttacgtcttcgactagagtctcctcctggacgaataccggtacctccgggcttaagccagctgt 826 to 900 
 BanII                              PpuMI      EaeI Bsp19I            AccI  
  FriOI                                          BalI                       
  NcoI                                            NcoI                      
 
          Bsp19I                                       VspI                 
HindIII   NcoI                SapI                     PshBI                
agcttgccaccatggatttatctgctcttcgcgttgaagaagtacaaaatgtcattaatgctatgcagaaaatct base pairs 
tcgaacggtggtacctaaatagacgagaagcgcaacttcttcatgttttacagtaattacgatacgtcttttaga 901 to 975 
       BcgI                                            AsnI                 
                                                       AseI                 
 
                         BclI                                               
                         Ksp22I                                             
                 BstXI BpmI                      DraIII                     
tagagtgtcccatctgtctggagttgatcaaggaacctgtctccacaaagtgtgaccacatattttgcaaatttt base pairs 
atctcacagggtagacagacctcaactagttccttggacagaggtgtttcacactggtgtataaaacgtttaaaa 976 to 1050 
                       GsuI                                                 
                         FbaI                                               
 
     SphI                                                                   
     BbuI                                                                   
gcatgctgaaacttctcaaccagaagaaagggccttcacagtgtcctttatgtaagaatgatataaccaaaagga base pairs 
cgtacgactttgaagagttggtcttctttcccggaagtgtcacaggaaatacattcttactatattggttttcct 1051 to 1125 
     PaeI                                                                   
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                                          SapI                              
gcctacaagaaagtacgagatttagtcaacttgttgaagagctattgaaaatcatttgtgcttttcagcttgaca base pairs 
cggatgttctttcatgctctaaatcagttgaacaacttctcgataacttttagtaaacacgaaaagtcgaactgt 1126 to 1200 
                                                                            
                                                                            
 
                                                                            
caggtttggagtatgcaaacagctataattttgcaaaaaaggaaaataactctcctgaacatctaaaagatgaag base pairs 
gtccaaacctcatacgtttgtcgatattaaaacgttttttccttttattgagaggacttgtagattttctacttc 1201 to 1275 
                                                                            
                                                                            
                                                                            
                                                                        
                 Van91I                                                     
                 AccB7I                                                     
tttctatcatccaaagtatgggctacagaaaccgtgccaaaagacttctacagagtgaacccgaaaatccttcct base pairs 
aaagatagtaggtttcatacccgatgtctttggcacggttttctgaagatgtctcacttgggcttttaggaagga 1276 to 1350 
                 Esp1396I                                                   
                 PflMI                                                      
                                                                            
  
 
tgcaggaaaccagtctcagtgtccaactctctaaccttggaactgtgagaactctgaggacaaagcagcggatac base pairs 
acgtcctttggtcagagtcacaggttgagagattggaaccttgacactcttgagactcctgtttcgtcgcctatg 1351 to 1425 
                                                                            
                                                                            
                   AccI                                                     
               PshAI                                                        
aacctcaaaagacgtctgtctacattgaattgggatctgattcttctgaagataccgttaataaggcaacttatt base pairs 
ttggagttttctgcagacagatgtaacttaaccctagactaagaagacttctatggcaattattccgttgaataa 1426 to 1500 
               AatII                                                        
                                                                            
                                                                            
                                                                            
gcagtgtgggagatcaagaattgttacaaatcacccctcaaggaaccagggatgaaatcagtttggattctgcaa base pairs 
cgtcacaccctctagttcttaacaatgtttagtggggagttccttggtccctactttagtcaaacctaagacgtt 1501 to 1575 
                                                                            
 
                                                                            
                             Esp3I                                          
aaaaggctgcttgtgaattttctgagacggatgtaacaaatactgaacatcatcaacccagtaataatgatttga base pairs 
ttttccgacgaacacttaaaagactctgcctacattgtttatgacttgtagtagttgggtcattattactaaact 1576 to 1650 
                             BsmBI                                          
                                                                            
 
                                                                            
                     BsgI                                                   
acaccactgagaagcgtgcagctgagaggcatccagaaaagtatcagggtagttctgtttcaaacttgcatgtgg base pairs 
tgtggtgactcttcgcacgtcgactctccgtaggtcttttcatagtcccatcaagacaaagtttgaacgtacacc 1651 to 1725 
                     PvuII                                                  
                                                                            
                                                                            
                                                                            
agccatgtggcacaaatactcatgccagctcattacagcatgagaacagcagtttattactcactaaagacagaa base pairs 
tcggtacaccgtgtttatgagtacggtcgagtaatgtcgtactcttgtcgtcaaataatgagtgatttctgtctt 1726 to 1800 
                                                                            
                                                                            
                                               BlpI                         
                  EcoRI                        CelII                        
tgaatgtagaaaaggctgaattctgtaataaaagcaaacagcctggcttagcaaggagccaacataacagatggg base pairs 
acttacatcttttccgacttaagacattattttcgtttgtcggaccgaatcgttcctcggttgtattgtctaccc 1801 to 1875 
                                               Bsp1720I                     
                                               Bpu1102I                     
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                                                                   BsaMI    
               BspLU11I                                 BglII      Mva1269I 
ctggaagtaaggaaacatgtaatgataggcggactcccagcacagaaaaaaaggtagatctgaatgctgatcccc base pairs 
gaccttcattcctttgtacattactatccgcctgagggtcgtgtctttttttccatctagacttacgactagggg 1876 to 1950 
               AflIII                                              BsmI     
                                                                            
                                                                            
  
                                                                            
tgtgtgagagaaaagaatggaataagcagaaactgccatgctcagagaatcctagagatactgaagatgttcctt base pairs 
acacactctcttttcttaccttattcgtctttgacggtacgagtctcttaggatctctatgacttctacaaggaa 1951 to 2025 
                                                                            
 
                                                                            
                        BsaMI                                               
                        Mva1269I                                            
ggataacactaaatagcagcattcagaaagttaatgagtggttttccagaagtgatgaactgttaggttctgatg base pairs 
cctattgtgatttatcgtcgtaagtctttcaattactcaccaaaaggtcttcactacttgacaatccaagactac 2026 to 2100 
                        BsmI                                                
 
actcacatgatggggagtctgaatcaaatgccaaagtagctgatgtattggacgttctaaatgaggtagatgaat base pairs 
tgagtgtactacccctcagacttagtttacggtttcatcgactacataacctgcaagatttactccatctactta 2101 to 2175 
                                                                            
  
                                 MscI                                       
                                 MluNI                                      
                               EaeI         RcaI                            
attctggttcttcagagaaaatagacttactggccagtgatcctcatgaggctttaatatgtaaaagtgaaagag base pairs 
taagaccaagaagtctcttttatctgaatgaccggtcactaggagtactccgaaattatacattttcactttctc 2176 to 2250 
                               CfrI         BspHI                           
                                 BalI                                       
                                                                            
  
ttcactccaaatcagtagagagtaatattgaagacaaaatatttgggaaaacctatcggaagaaggcaagcctcc base pairs 
aagtgaggtttagtcatctctcattataacttctgttttataaacccttttggatagccttcttccgttcggagg 2251 to 2325 
 
  
     BfrI                                                                   
     Vha464I                                                                
     MspCI                                                                  
ccaacttaagccatgtaactgaaaatctaattataggagcatttgttactgagccacagataatacaagagcgtc base pairs 
ggttgaattcggtacattgacttttagattaatatcctcgtaaacaatgactcggtgtctattatgttctcgcag 2326 to 2400 
     AflII                                                                  
     BspTI                                                                  
     Bst98I                                                                  
                                           SseBI    CvnI                    
                                     EcoNI Eco147I  AocI                    
                                  BsaI     StuI     Bsu36I                  
ccctcacaaataaattaaagcgtaaaaggagacctacatcaggccttcatcctgaggattttatcaagaaagcag base pairs 
gggagtgtttatttaatttcgcattttcctctggatgtagtccggaagtaggactcctaaaatagttctttcgtc 2401 to 2475 
                                  Eco31I   AatI     Eco81I                  
                                           Pme55I   Bse21I                  
                                                                            
  
 
atttggcagttcaaaagactcctgaaatgataaatcagggaactaaccaaacggagcagaatggtcaagtgatga base pairs 
taaaccgtcaagttttctgaggactttactatttagtcccttgattggtttgcctcgtcttaccagttcactact 2476 to 2550 
                                                                            
 
                                                                            
                 RcaI                                                       
atattactaatagtggtcatgagaataaaacaaaaggtgattctattcagaatgagaaaaatcctaacccaatag base pairs 
tataatgattatcaccagtactcttattttgttttccactaagataagtcttactctttttaggattgggttatc 2551 to 2625 
                 BspHI                                                      
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aatcactcgaaaaagaatctgctttcaaaacgaaagctgaacctataagcagcagtataagcaatatggaactcg base pairs 
ttagtgagctttttcttagacgaaagttttgctttcgacttggatattcgtcgtcatattcgttataccttgagc 2626 to 2700 
 
                                                                            
                                                                            
aattaaatatccacaattcaaaagcacctaaaaagaataggctgaggaggaagtcttctaccaggcatattcatg base pairs 
ttaatttataggtgttaagttttcgtggatttttcttatccgactcctccttcagaagatggtccgtataagtac 2701 to 2775 
                                                                            
 
                                                                            
        SpeI                                                                
cgcttgaactagtagtcagtagaaatctaagcccacctaattgtactgaattgcaaattgatagttgttctagca base pairs 
gcgaacttgatcatcagtcatctttagattcgggtggattaacatgacttaacgtttaactatcaacaagatcgt 2776 to 2850 
        AclNI                                                               
                                                                            
 
                                                                            
gtgaagagataaagaaaaaaaagtacaaccaaatgccagtcaggcacagcagaaacctacaactcatggaaggta base pairs 
cacttctctatttcttttttttcatgttggtttacggtcagtccgtgtcgtctttggatgttgagtaccttccat 2851 to 2925 
                                                                            
                                                                            
                                                                            
                                                                             
                                                                            
          BspMI   BpmI                                                      
aagaacctgcaactggagccaagaagagtaacaagccaaatgaacagacaagtaaaagacatgacagcgatactt base pairs 
ttcttggacgttgacctcggttcttctcattgttcggtttacttgtctgttcattttctgtactgtcgctatgaa 2926 to 3000 
                  GsuI                                                      
                                                                            
                                                                            
                HpaI      SexAI                                             
tcccagagctgaagttaacaaatgcacctggttcttttactaagtgttcaaataccagtgaacttaaagaatttg base pairs 
agggtctcgacttcaattgtttacgtggaccaagaaaatgattcacaagtttatggtcacttgaatttcttaaac 3001 to 3075 
                                                                            
 
                                                                            
                                                                            
tcaatcctagccttccaagagaagaaaaagaagagaaactagaaacagttaaagtgtctaataatgctgaagacc base pairs 
agttaggatcggaaggttctcttctttttcttctctttgatctttgtcaatttcacagattattacgacttctgg 3076 to 3150 
                                                                            
 
                                                                          Asp718I 
                                                                          Acc65I 
     BglII                                   BglII                        BshNI 
ccaaagatctcatgttaagtggagaaagggttttgcaaactgaaagatctgtagagagtagcagtatttcattgg base pairs 
ggtttctagagtacaattcacctctttcccaaaacgtttgactttctagacatctctcatcgtcataaagtaacc 3151 to 3225 
                                                                          BanI 
                                                                          AccB1I 
                                                                          Eco64I 
                                                                            
     KpnI                                                                   
tacctggtactgattatggcactcaggaaagtatctcgttactggaagttagcactctagggaaggcaaaaacag base pairs 
atggaccatgactaataccgtgagtcctttcatagagcaatgaccttcaatcgtgagatcccttccgtttttgtc 3226 to 3300 
    SexAI                                                                   
                                                                            
                                                                            
                              BsgI                                          
aaccaaataaatgtgtgagtcagtgtgcagcatttgaaaaccccaagggactaattcatggttgttccaaagata base pairs 
ttggtttatttacacactcagtcacacgtcgtaaacttttggggttccctgattaagtaccaacaaggtttctat 3301 to 3375 
                                                                            
                                                                            
                                                                            
                                               HpaI                         
atagaaatgacacagaaggctttaagtatccattgggacatgaagttaaccacagtcgggaaacaagcatagaaa base pairs 
tatctttactgtgtcttccgaaattcataggtaaccctgtacttcaattggtgtcagccctttgttcgtatcttt 3376 to 3450 
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                                                           BstH2I           
                                                           Bsp143II         
tggaagaaagtgaacttgatgctcagtatttgcagaatacattcaaggtttcaaagcgccagtcatttgctccgt base pairs 
accttctttcacttgaactacgagtcataaacgtcttatgtaagttccaaagtttcgcggtcagtaaacgaggca 3451 to 3525 
                                                           HaeII            
                                                                            
                                                                            
                                                       Psp5II               
tttcaaatccaggaaatgcagaagaggaatgtgcaacattctctgcccactctgggtccttaaagaaacaaagtc base pairs 
aaagtttaggtcctttacgtcttctccttacacgttgtaagagacgggtgagacccaggaatttctttgtttcag 3526 to 3600 
                                                       PpuMI                
                                                                            
 
                                                                    SspBI   
                                                                    Bsp1407I 
caaaagtcacttttgaatgtgaacaaaaggaagaaaatcaaggaaagaatgagtctaatatcaagcctgtacaga base pairs 
gttttcagtgaaaacttacacttgttttccttcttttagttcctttcttactcagattatagttcggacatgtct 3601 to 3675 
                                                                    BsrGI   
                                                                            
                                                                            
                                                                            
                 PstI                                                       
cagttaatatcactgcaggctttcctgtggttggtcagaaagataagccagttgataatgccaaatgtagtatca base pairs 
gtcaattatagtgacgtccgaaaggacaccaaccagtctttctattcggtcaactattacggtttacatcatagt 3676 to 3750 
                                                                            
                                                                            
                                                                            
                                                                            
aaggaggctctaggttttgtctatcatctcagttcagaggcaacgaaactggactcattactccaaataaacatg base pairs 
ttcctccgagatccaaaacagatagtagagtcaagtctccgttgctttgacctgagtaatgaggtttatttgtac 3751 to 3825 
                                                                            
 
                                                                            
                       AccI                                                 
gacttttacaaaacccatatcgtataccaccactttttcccatcaagtcatttgttaaaactaaatgtaagaaaa base pairs 
ctgaaaatgttttgggtatagcatatggtggtgaaaaagggtagttcagtaaacaattttgatttacattctttt 3826 to 3900 
                        Bst1107I                                            
                                                                            
                                                                            
                                                                            
atctgctagaggaaaactttgaggaacattcaatgtcacctgaaagagaaatgggaaatgagaacattccaagta base pairs 
tagacgatctccttttgaaactccttgtaagttacagtggactttctctttaccctttactcttgtaaggttcat 3901 to 3975 
                                                                            
 
                                                                   VspI     
                                            DraI                   PshBI    
cagtgagcacaattagccgtaataacattagagaaaatgtttttaaagaagccagctcaagcaatattaatgaag base pairs 
gtcactcgtgttaatcggcattattgtaatctcttttacaaaaatttcttcggtcgagttcgttataattacttc 3976 to 4050 
                                                                   AsnI     
                                                                   AseI     
 
                               GsuI                                         
           Acc113I         FriOI  VspI                                      
           Eco255I         Eco24I PshBI                                     
taggttccagtactaatgaagtgggctccagtattaatgaaataggttccagtgatgaaaacattcaagcagaac base pairs 
atccaaggtcatgattacttcacccgaggtcataattactttatccaaggtcactacttttgtaagttcgtcttg 4051 to 4125 
           ScaI            BanII  AsnI                                      
                               BpmI                                         
                                  AseI                                      
                                                          CvnI              
                               BsaMI                      AocI              
                               Mva1269I                   Bsu36I            
taggtagaaacagagggccaaaattgaatgctatgcttagattaggggttttgcaacctgaggtctataaacaaa base pairs 
atccatctttgtctcccggttttaacttacgatacgaatctaatccccaaaacgttggactccagatatttgttt 4126 to 4200 
                               BsmI                       Eco81I            
                                                          Bse21I            
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gtcttcctggaagtaattgtaagcatcctgaaataaaaaagcaagaatatgaagaagtagttcagactgttaata base pairs 
cagaaggaccttcattaacattcgtaggactttattttttcgttcttatacttcttcatcaagtctgacaattat 4201 to 4275 
  
                                                              Mph1103I      
                                                              EcoT22I       
                                                          Ppu10I            
cagatttctctccatatctgatttcagataacttagaacagcctatgggaagtagtcatgcatctcaggtttgtt base pairs 
gtctaaagagaggtatagactaaagtctattgaatcttgtcggatacccttcatcagtacgtagagtccaaacaa 4276 to 4350 
                                                              NsiI          
                                                              Zsp2I         
                                                                            
                                                SpeI                        
ctgagacacctgatgacctgttagatgatggtgaaataaaggaagatactagttttgctgaaaatgacattaagg base pairs 
gactctgtggactactggacaatctactaccactttatttccttctatgatcaaaacgacttttactgtaattcc 4351 to 4425 
                                                AclNI                       
                                                                            
                                          BlpI                              
                                          CelII                             
aaagttctgctgtttttagcaaaagcgtccagaaaggagagcttagcaggagtcctagccctttcacccatacac base pairs 
tttcaagacgacaaaaatcgttttcgcaggtctttcctctcgaatcgtcctcaggatcgggaaagtgggtatgtg 4426 to 4500 
                                          Bsp1720I                          
                                          Bpu1102I                                                               
  
            BstPI                                                           
            EcoO65I                                                         
            PspEI                                                           
atttggctcagggttaccgaagaggggccaagaaattagagtcctcagaagagaacttatctagtgaggatgaag base pairs 
taaaccgagtcccaatggcttctccccggttctttaatctcaggagtcttctcttgaatagatcactcctacttc 4501 to 4575 
            Eco91I                                                          
            BstEII                                                          
   SapI                                                  AccI               
agcttccctgcttccaacacttgttatttggtaaagtaaacaatataccttctcagtctactaggcatagcaccg base pairs 
tcgaagggacgaaggttgtgaacaataaaccatttcatttgttatatggaagagtcagatgatccgtatcgtggc 4576 to 4650 
 
                                                                            
                                                                            
                                                                        PstI 
ttgctaccgagtgtctgtctaagaacacagaggagaatttattatcattgaagaatagcttaaatgactgcagta base pairs 
aacgatggctcacagacagattcttgtgtctcctcttaaataatagtaacttcttatcgaatttactgacgtcat 4651 to 4725 
 
                                                                            
                                                                            
                                          EcoNI                PstNHI       
accaggtaatattggcaaaggcatctcaggaacatcaccttagtgaggaaacaaaatgttctgctagcttgtttt base pairs 
tggtccattataaccgtttccgtagagtccttgtagtggaatcactcctttgttttacaagacgatcgaacaaaa 4726 to 4800 
 SexAI                                                         NheI         
                                                                            
 
             BsgI                                 BamHI                     
cttcacagtgcagtgaattggaagacttgactgcaaatacaaacacccaggatcctttcttgattggttcttcca base pairs 
gaagtgtcacgtcacttaaccttctgaactgacgtttatgtttgtgggtcctaggaaagaactaaccaagaaggt 4801 to 4875 
                                                  BstI                      
 
                                                                            
                                 BstXI                                      
aacaaatgaggcatcagtctgaaagccagggagttggtctgagtgacaaggaattggtttcagatgatgaagaaa base pairs 
ttgtttactccgtagtcagactttcggtccctcaaccagactcactgttccttaaccaaagtctactacttcttt 4876 to 4950 
                                                                            
 
                                                                            
                                    SapI                                    
gaggaacgggcttggaagaaaataatcaagaagagcaaagcatggattcaaacttaggtgaagcagcatctgggt base pairs 
ctccttgcccgaaccttcttttattagttcttctcgtttcgtacctaagtttgaatccacttcgtcgtagaccca 4951 to 5025 
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                      Esp3I                                                 
gtgagagtgaaacaagcgtctctgaagactgctcagggctatcctctcagagtgacattttaaccactcagcaga base pairs 
cactctcactttgttcgcagagacttctgacgagtcccgataggagagtctcactgtaaaattggtgagtcgtct 5026 to 5100 
                      BsmBI                                                 
                                                                            
                                                                            
  
                                   BpmI                                     
gggataccatgcaacataacctgataaagctccagcaggaaatggctgaactagaagctgtgttagaacagcatg base pairs 
ccctatggtacgttgtattggactatttcgaggtcgtcctttaccgacttgatcttcgacacaatcttgtcgtac 5101 to 5175 
                                   GsuI                                     
                                                                            
                                                                            
                                                        Psp5II BspMI        
ggagccagccttctaacagctacccttccatcataagtgactcttctgcccttgaggacctgcgaaatccagaac base pairs 
cctcggtcggaagattgtcgatgggaaggtagtattcactgagaagacgggaactcctggacgctttaggtcttg 5176 to 5250 
                                                        PpuMI               
                                                                            
 
                                                                         SseBI 
                                                                         Eco147I 
                                                                         StuI 
aaagcacatcagaaaaagcagtattaacttcacagaaaagtagtgaataccctataagccagaatccagaaggcc base pairs 
tttcgtgtagtctttttcgtcataattgaagtgtcttttcatcacttatgggatattcggtcttaggtcttccgg 5251 to 5325 
                                                                         AatI 
                                                                         Pme55I 
 
                                                                            
                             PstI                                           
tttctgctgacaagtttgaggtgtctgcagatagttctaccagtaaaaataaagaaccaggagtggaaaggtcat base pairs 
aaagacgactgttcaaactccacagacgtctatcaagatggtcatttttatttcttggtcctcacctttccagta 5326 to 5400 
                                                                            
                                                                            
                                                                            
  
 
ccccttctaaatgcccatcattagatgataggtggtacatgcacagttgctctgggagtcttcagaatagaaact base pairs 
ggggaagatttacgggtagtaatctactatccaccatgtacgtgtcaacgagaccctcagaagtcttatctttga 5401 to 5475 
 
  
                   BanII                                                    
                   Eco24I                                                   
                 EcoICRI Psp124BI                 PvuII                     
acccatctcaagaggagctcattaaggttgttgatgtggaggagcaacagctggaagagtctgggccacacgatt base pairs 
tgggtagagttctcctcgagtaattccaacaactacacctcctcgttgtcgaccttctcagacccggtgtgctaa 5476 to 5550 
                 Ecl136II                                                   
                   SacI SstI                                                
                   FriOI                                                    
  
                             BglII                                          
tgacggaaacatcttacttgccaaggcaagatctagagggaaccccttacctggaatctggaatcagcctcttct base pairs 
actgcctttgtagaatgaacggttccgttctagatctcccttggggaatggaccttagaccttagtcggagaaga 5551 to 5625 
                                XbaI                                        
                                                                            
 
                                      FriOI                                 
                                      Eco24I          BsiI                  
ctgatgaccctgaatctgatccttctgaagacagagccccagagtcagctcgtgttggcaacataccatcttcaa base pairs 
gactactgggacttagactaggaagacttctgtctcggggtctcagtcgagcacaaccgttgtatggtagaagtt 5626 to 5700 
                                      BanII           BssSI                 
                                                                            
 
                                                                            
                     MfeI                             PvuII                 
cctctgcattgaaagttccccaattgaaagttgcagaatctgcccagagtccagctgctgctcatactactgata base pairs 
ggagacgtaactttcaaggggttaactttcaacgtcttagacgggtctcaggtcgacgacgagtatgatgactat 5701 to 5775 
                     MunI                                                   
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                    BsrDI                                                   
ctgctgggtataatgcaatggaagaaagtgtgagcagggagaagccagaattgacagcttcaacagaaagggtca base pairs 
gacgacccatattacgttaccttctttcacactcgtccctcttcggtcttaactgtcgaagttgtctttcccagt 5776 to 5850 
 
  
                                                        BssSI               
                                                       SspBI                
             NcoI                                      Bsp1407I             
acaaaagaatgtccatggtggtgtctggcctgaccccagaagaatttatgctcgtgtacaagtttgccagaaaac base pairs 
tgttttcttacaggtaccaccacagaccggactggggtcttcttaaatacgagcacatgttcaaacggtcttttg 5851 to 5925 
             Bsp19I                                    BsrGI                
                                                        BsiI                
                                                                            
 
accacatcactttaactaatctaattactgaagagactactcatgttgttatgaaaacagatgctgagtttgtgt base pairs 
tggtgtagtgaaattgattagattaatgacttctctgatgagtacaacaatacttttgtctacgactcaaacaca 5926 to 6000 
 
  
                                                                 BstPI Tth111I 
                                                                 EcoO65I    
                                                                 PspEI AtsI 
gtgaacggacactgaaatattttctaggaattgcgggaggaaaatgggtagttagctatttctgggtgacccagt base pairs 
cacttgcctgtgactttataaaagatccttaacgccctccttttacccatcaatcgataaagacccactgggtca 6001 to 6075 
                                                                 Eco91I     
                                                                 BstEII     
                                                                       AspI 
  
 
ctattaaagaaagaaaaatgctgaatgagcatgattttgaagtcagaggagatgtggtcaatggaagaaaccacc base pairs 
gataatttctttctttttacgacttactcgtactaaaacttcagtctcctctacaccagttaccttctttggtgg 6076 to 6150 
                                                                            
                                                                            
               
 
                                                              
  
                                                                         BanII 
                                                                         Eco24I 
                                     BglII                           PspOMI 
aaggtccaaagcgagcaagagaatcccaggacagaaagatcttcagggggctagaaatctgttgctatgggccct base pairs 
ttccaggtttcgctcgttctcttagggtcctgtctttctagaagtcccccgatctttagacaacgatacccggga 6151 to 6225 
                                                                     Bsp120I 
                                                                         ApaI 
                                                                         FriOI 
 
                    XcmI                 PvuII                              
tcaccaacatgcccacagatcaactggaatggatggtacagctgtgtggtgcttctgtggtgaaggagctttcat base pairs 
agtggttgtacgggtgtctagttgaccttacctaccatgtcgacacaccacgaagacaccacttcctcgaaagta 6226 to 6300 
                                                                            
 
                                                                            
                            MfeI            BsgI    BstXI                   
cattcacccttggcacaggtgtccacccaattgtggttgtgcagccagatgcctggacagaggacaatggcttcc base pairs 
gtaagtgggaaccgtgtccacaggtgggttaacaccaacacgtcggtctacggacctgtctcctgttaccgaagg 6301 to 6375 
                            MunI                                            
                                                                            
 
                                BstPI Ama87I                                
      BstXI            AccB1I   EcoO65I                                     
    MfeI               BshNI    PspEI Eco88I                                
atgcaattgggcagatgtgtgaggcacctgtggtgacccgagagtgggtgttggacagtgtagcactctaccagt base pairs 
tacgttaacccgtctacacactccgtggacaccactgggctctcacccacaacctgtcacatcgtgagatggtca 6376 to 6450 
    MunI               BanI     Eco91I BsoBI                                
                       Eco64I   BstEII BcoI                                 
   
 
 188 
                                     AvaI                                   
                                                           NotI  Cfr42I     
        Van91I                                             CfrI EclXI Sfr303I 
        AccB7I                                             EaeI Eco52I BamHI 
gccaggagctggacacctacctgataccccagatcccccacagccactactgactacgcggccgcggggatccag base pairs 
cggtcctcgacctgtggatggactatggggtctagggggtgtcggtgatgactgatgcgccggcgcccctaggtc 6451 to 6525 
        Esp1396I                                           CciNI SstII BstI 
        PflMI                                              EagI XmaIII      
                                                           BstZI KspI SacII 
                                                                     
                                                BsaMI                       
                                                Mva1269I                    
acatgataagatacattgatgagtttggacaaaccacaactagaatgcagtgaaaaaaatgctttatttgtgaaa base pairs 
tgtactattctatgtaactactcaaacctgtttggtgttgatcttacgtcactttttttacgaaataaacacttt 6526 to 6600 
                                                BsmI                        
                                                                            
 
                                                                        BsaMI 
                                                     HpaI     MfeI      Mva1269I 
tttgtgatgctattgctttatttgtaaccattataagctgcaataaacaagttaacaacaacaattgcattcatt base pairs 
aaacactacgataacgaaataaacattggtaatattcgacgttatttgttcaattgttgttgttaacgtaagtaa 6601 to 6675 
                                                              MunI      BsmI 
                                                                            
 
                                                                     NheI   
                                                                     PstNHI 
                                         BamHI XbaI            PstI  BbuI   
ttatgtttcaggttcagggggaggtgtgggaggttttttcggatcctctagagtcgatctgcaggcatgctagct base pairs 
aatacaaagtccaagtccccctccacaccctccaaaaaagcctaggagatctcagctagacgtccgtacgatcga 6676 to 6750 
                                         BstI                        PaeI   
                                                                     SphI   
                                                                            
                                                                            
                                                  AccBSI                    
                                                  BsrBI                     
tggcgtaatcatggtcatagctgtttcctgtgtgaaattgttatccgctcacaattccacacaacatacgagccg base pairs 
accgcattagtaccagtatcgacaaaggacacactttaacaataggcgagtgttaaggtgtgttgtatgctcggc 6751 to 6825 
                                                  BstD102I                  
                                                                            
 
 
 
                                                                            
                        AccB1I                     VspI                     
                        BshNI                      PshBI                    
gaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaattgcgttgcgctcactgcccg base pairs 
cttcgtatttcacatttcggaccccacggattactcactcgattgagtgtaattaacgcaacgcgagtgacgggc 6826 to 6900 
                        BanI                       AsnI                     
                        Eco64I                     AseI                     
                                                                            
 
                                   VspI                                     
                             PvuII PshBI    EaeI                            
ctttccagtcgggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtttgcgta base pairs 
gaaaggtcagccctttggacagcacggtcgacgtaattacttagccggttgcgcgcccctctccgccaaacgcat 6901 to 6975 
                                   AsnI     CfrI                            
                                   AseI                                     
 
                                                                            
        BstH2I                                                    AccBSI    
        Bsp143II                                                  BsrBI     
ttgggcgctcttccgcttcctcgctcactgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctc base pairs 
aacccgcgagaaggcgaaggagcgagtgactgagcgacgcgagccagcaagccgacgccgctcgccatagtcgag 6976 to 7050 
        HaeII                                                     BstD102I  
             SapI                                                           
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                                                       BspLU11I             
actcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaagaacatgtgagcaaaaggccagc base pairs 
tgagtttccgccattatgccaataggtgtcttagtcccctattgcgtcctttcttgtacactcgttttccggtcg 7051 to 7125 
                                                       AflIII               
                                                                            
                                                                            
  
                                                                            
aaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgcccccctgacgagcatcaca base pairs 
ttttccggtccttggcatttttccggcgcaacgaccgcaaaaaggtatccgaggcggggggactgctcgtagtgt 7126 to 7200 
 
                                                                            
             DrdI                                                           
aaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctggaagct base pairs 
ttttagctgcgagttcagtctccaccgctttgggctgtcctgatatttctatggtccgcaaagggggaccttcga 7201 to 7275 
                                                                            
                                                                            
                                                                            
        BsiI                        BsaWI                                   
ccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtgg base pairs 
gggagcacgcgagaggacaaggctgggacggcgaatggcctatggacaggcggaaagagggaagcccttcgcacc 7276 to 7350 
        BssSI                                                               
                                                                            
                                                                            
   BstH2I                                                            Alw44I 
   Bsp143II                                                          VneI   
cgctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacg base pairs 
gcgaaagagtatcgagtgcgacatccatagagtcaagccacatccagcaagcgaggttcgacccgacacacgtgc 7351 to 7425 
   HaeII                                                             ApaLI  
                                                                            
 
                                                                            
                                 BsaWI                                      
aaccccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgact base pairs 
ttggggggcaagtcgggctggcgacgcggaataggccattgatagcagaactcaggttgggccattctgtgctga 7426 to 7500 
                                                                            
 
                                                                            
                                                                            
tatcgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttga base pairs 
atagcggtgaccgtcgtcggtgaccattgtcctaatcgtctcgctccatacatccgccacgatgtctcaagaact 7501 to 7575 
                                                                            
                                                                            
 
                                                                            
                                                                          
agtggtggcctaactacggctacactagaaggacagtatttggtatctgcgctctgctgaagccagttaccttcg base pairs 
tcaccaccggattgatgccgatgtgatcttcctgtcataaaccatagacgcgagacgacttcggtcaatggaagc 7576 to 7650 
                                                                            
 
                                                                            
                                                                            
gaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagc base pairs 
ctttttctcaaccatcgagaactaggccgtttgtttggtggcgaccatcgccaccaaaaaaacaaacgttcgtcg 7651 to 7725 
                                                                            
 
                                                                                                                 
agattacgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacg base pairs 
tctaatgcgcgtctttttttcctagagttcttctaggaaactagaaaagatgccccagactgcgagtcaccttgc 7726 to 7800 
                                                                            
                                                                           
                                                                            
                         RcaI                                   DraI        
aaaactcacgttaagggattttggtcatgagattatcaaaaaggatcttcacctagatccttttaaattaaaaat base pairs 
ttttgagtgcaattccctaaaaccagtactctaatagtttttcctagaagtggatctaggaaaatttaattttta 7801 to 7875 
                         BspHI                                              
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                                                                       AccB1I 
        DraI                                                           BshNI 
gaagttttaaatcaatctaaagtatatatgagtaaacttggtctgacagttaccaatgcttaatcagtgaggcac base pairs 
cttcaaaatttagttagatttcatatatactcatttgaaccagactgtcaatggttacgaattagtcactccgtg 7876 to 7950 
                                                                       BanI 
                                                                       Eco64I 
 
                                                Eam1105I                    
                                                AspEI                       
ctatctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacgatacggg base pairs 
gatagagtcgctagacagataaagcaagtaggtatcaacggactgaggggcagcacatctattgatgctatgccc 7951 to 8025 
                                                EclHKI                      
                                                AhdI                        
 
                                                     Cfr10I                 
                                BsrDI        BsaI    BssAI     BpmI         
agggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagcaa base pairs 
tcccgaatggtagaccggggtcacgacgttactatggcgctctgggtgcgagtggccgaggtctaaatagtcgtt 8026 to 8100 
                                             Eco31I  BsrFI     GsuI         
                                                     Bse118I                
 
                                                                      VspI  
                                                                      PshBI 
taaaccagccagccggaagggccgagcgcagaagtggtcctgcaactttatccgcctccatccagtctattaatt base pairs 
atttggtcggtcggccttcccggctcgcgtcttcaccaggacgttgaaataggcggaggtaggtcagataattaa 8101 to 8175 
                                                                      AsnI  
                                                                      AseI  
 
                                             AviII                          
                                             FspI               BsrDI       
gttgccgggaagctagagtaagtagttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcatcg base pairs 
caacggcccttcgatctcattcatcaagcggtcaattatcaaacgcgttgcaacaacggtaacgatgtccgtagc 8176 to 8250 
                                             Acc16I                         
                                                 Psp1406I                   
 
                                                                            
                                       BsaWI                                
tggtgtcacgctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcgagttacatgatccc base pairs 
accacagtgcgagcagcaaaccataccgaagtaagtcgaggccaagggttgctagttccgctcaatgtactaggg 8251 to 8325 
                                                                            
 
                                           Ple19I                           
                                           BspCI             EaeI           
ccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttggccgcagtgttat base pairs 
ggtacaacacgttttttcgccaatcgaggaagccaggaggctagcaacagtcttcattcaaccggcgtcacaata 8326 to 8400 
                                           PvuI              CfrI           
                                                                            
cactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtg base pairs 
gtgagtaccaataccgtcgtgacgtattaagagaatgacagtacggtaggcattctacgaaaagacactgaccac 8401 to 8475 
                                                                            
                                                                            
   Acc113I                                                                  
   Eco255I                                        BcgI                      
agtactcaaccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggata base pairs 
tcatgagttggttcagtaagactcttatcacatacgccgctggctcaacgagaacgggccgcagttatgccctat 8476 to 8550 
   ScaI                                                                     
                                                                            
 
                                                                            
                         DraI                  Psp1406I                     
ataccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaagga base pairs 
tatggcgcggtgtatcgtcttgaaattttcacgagtagtaaccttttgcaagaagccccgcttttgagagttcct 8551 to 8625 
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                                          BssSI                             
                                        Alw44I                              
                                        VneI                                
tcttaccgctgttgagatccagttcgatgtaacccactcgtgcacccaactgatcttcagcatcttttactttca base pairs 
agaatggcgacaactctaggtcaagctacattgggtgagcacgtgggttgactagaagtcgtagaaaatgaaagt 8626 to 8700 
                                        ApaLI                               
                                          BsiI                              
                                                                            
  
ccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataagggcgacacggaaatgtt base pairs 
ggtcgcaaagacccactcgtttttgtccttccgttttacggcgttttttcccttattcccgctgtgcctttacaa 8701 to 8775 
 
 
                                                                   AccBSI   
                                                          RcaI     BsrBI    
gaatactcatactcttcctttttcaatattattgaagcatttatcagggttattgtctcatgagcggatacatat base pairs 
cttatgagtatgagaaggaaaaagttataataacttcgtaaatagtcccaataacagagtactcgcctatgtata 8776 to 8850 
                                                          BspHI    BstD102I 
                                                                            
 
                                                                            
                                                                      AatII 
ttgaatgtatttagaaaaataaacaaataggggttccgcgcacatttccccgaaaagtgccacctgacgtctaag base pairs 
aacttacataaatctttttatttgtttatccccaaggcgcgtgtaaaggggcttttcacggtggactgcagattc 8851 to 8925 
                                                                            
 
                                                                            
             RcaI                                BsiI         Esp3I         
aaaccattattatcatgacattaacctataaaaataggcgtatcacgaggccctttcgtctcgcgcgtttcggtg base pairs 
tttggtaataatagtactgtaattggatatttttatccgcatagtgctccgggaaagcagagcgcgcaaagccac 8926 to 9000 
             BspHI                               BssSI        BsmBI         
                                                                            
 
 
                                         Esp3I                              
atgacggtgaaaacctctgacacatgcagctcccggagacggtcacagcttgtctgtaagcggatgccgggagca base pairs 
tactgccacttttggagactgtgtacgtcgagggcctctgccagtgtcgaacagacattcgcctacggccctcgt 9001 to 9075 
                                         BsmBI                              
                                                                            
 
                                                                            
       DrdI                                                                 
gacaagcccgtcagggcgcgtcagcgggtgttggcgggtgtcggggctggcttaactatgcggcatcagagcaga base pairs 
ctgttcgggcagtcccgcgcagtcgcccacaaccgcccacagccccgaccgaattgatacgccgtagtctcgtct 9076 to 9150 
 
                                                                      Eco64I 
            Alw44I                                                    BanI  
            VneI   NdeI                                               KasI  
ttgtactgagagtgcaccatatgcggtgtgaaataccgcacagatgcgtaaggagaaaataccgcatcaggcgcc base pairs 
aacatgactctcacgtggtatacgccacactttatggcgtgtctacgcattcctcttttatggcgtagtccgcgg 9151 to 9225 
            ApaLI  FauNDI                                             BshNI 
                                                                      AccB1I 
                                                                       Nar 
                                                                            
BbeI              AviII                Ple19I                               
EheI              FspI                 BspCI                        PvuII   
attcgccattcaggctgcgcaactgttgggaagggcgatcggtgcgggcctcttcgctattacgccagctggcga base pairs 
taagcggtaagtccgacgcgttgacaacccttcccgctagccacgcccggagaagcgataatgcggtcgaccgct 9226 to 9300 
 Bsp143II         Acc16I               PvuI                                 
  BstH2I                                                                    
 HaeII                                                                                                           
                                                                            
                                                                         EaeI 
aagggggatgtgctgcaaggcgattaagttgggtaacgccagggttttcccagtcacgacgttgtaaaacgacgg base pairs 
ttccccctacacgacgttccgctaattcaacccattgcggtcccaaaagggtcagtgctgcaacattttgctgcc 9301 to 9375                         
CfrI 
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ccagt  base pairs 
ggtca  9376 to 9380 
  
 
Table by Enzyme Name 
 
 
Enzyme       No.  Positions                        Recognition 
name         cuts of sites                         sequence 
AatI          3   769 2443 5323                    agg/cct             
AatII         6   91 144 227 413 1440 8920         gacgt/c             
Acc113I       2   4061 8478                        agt/act             
Acc16I        2   8220 9243                        tgc/gca             
Acc65I        1   3224                             g/gtacc             
AccB1I        6   431 3224 6398 6849 7946 9220     g/gyrcc             
AccB7I        2   1292 6458                        ccannnn/ntgg        
AccBSI        3   6800 7041 8842                   gagcgg              
AccI          4   895 1444 3848 4632               gt/mkac             
AccIII        1   617                              t/ccgga             
AclNI         2   2783 4398                        a/ctagt             
AflII         1   2330                             c/ttaag             
AflIII        2   1890 7105                        a/crygt             
AhdI          1   7998                             gacnnn/nngtc        
Alw44I        3   7419 8665 9162                   g/tgcac             
Ama87I        1   6412                             c/ycgrg             
AocI          2   2452 4183                        cc/tnagg            
ApaI          2   824 6223                         gggcc/c             
ApaLI         3   7419 8665 9162                   g/tgcac             
AseI          6   955 4042 4084 6876 6935 8170     at/taat             
AsnI          6   955 4042 4084 6876 6935 8170     at/taat             
Asp718I       1   3224                             g/gtacc             
AspEI         1   7998                             gacnnn/nngtc        
AspI          1   6071                             gacn/nngtc          
AtsI          1   6071                             gacn/nngtc          
AvaI          1   6412                             c/ycgrg             
AviII         2   8220 9243                        tgc/gca             
BalI          2   874 2208                         tgg/cca             
BamHI         5   630 708 4850 6518 6716           g/gatcc             
BanI          6   431 3224 6398 6849 7946 9220     g/gyrcc             
BanII         6   534 824 4077 5494 5663 6223      grgcy/c             
BbeI          1   9224                             ggcgc/c             
BbuI          3   17 1055 6744                     gcatg/c             
BcgI          2   907 8525                         cgannnnnntgc        
BclI          1   1000                             t/gatca             
BcoI          1   6412                             c/ycgrg             
BfrI          1   2330                             c/ttaag             
BglII         5   1931 3155 3195 5579 6187         a/gatct             
BlpI          2   1847 4467                        gc/tnagc            
BpmI          6   563 998 2943 4081 5135 8088      ctggag              
Bpu1102I      2   1847 4467                        gc/tnagc            
BsaAI         1   306                              yac/gtr             
BsaI          2   2434 8070                        ggtctc              
BsaMI         5   1942 2049 4156 6573 6672         gaatgc              
BsaWI         6   617 633 711 7311 7458 8289       w/ccggw             
Bse118I       1   8078                             r/ccggy             
Bse21I        2   2452 4183                        cc/tnagg            
BseAI         1   617                              t/ccgga             
BsgI          4   1671 3330 4813 6344              gtgcag              
BshNI         6   431 3224 6398 6849 7946 9220     g/gyrcc             
BsiI          5   5679 5906 7283 8667 8974         ctcgtg              
BsiMI         1   617                              t/ccgga             
BsmBI         5   566 1604 5047 8987 9041          cgtctc              
BsmI          5   1942 2049 4156 6573 6672         gaatgc              
BsoBI         1   6412                             c/ycgrg             
Bsp120I       2   820 6219                         g/ggccc             
Bsp13I        1   617                              t/ccgga             
Bsp1407I      2   3668 5905                        t/gtaca             
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Bsp143II      4   3509 6983 7353 9224              rgcgc/y             
Bsp1720I      2   1847 4467                        gc/tnagc            
Bsp19I        5   326 827 875 910 5863             c/catgg             
BspCI         2   8368 9264                        cgat/cg             
BspEI         1   617                              t/ccgga             
BspHI         5   2219 2567 7825 8833 8938         t/catga             
BspLU11I      2   1890 7105                        a/catgt             
BspMI         4   26 868 2935 5238                 acctgc              
BspTI         1   2330                             c/ttaag             
BsrBI         3   6800 7041 8842                   gagcgg              
BsrDI         3   5795 8057 8239                   gcaatg              
BsrFI         1   8078                             r/ccggy             
BsrGI         2   3668 5905                        t/gtaca             
BssAI         1   8078                             r/ccggy             
BssSI         5   5679 5906 7283 8667 8974         ctcgtg              
Bst1107I      1   3849                             gta/tac             
Bst98I        1   2330                             c/ttaag             
BstD102I      3   6800 7041 8842                   gagcgg              
BstEII        3   4512 6065 6407                   g/gtnacc            
BstH2I        4   3509 6983 7353 9224              rgcgc/y             
BstI          5   630 708 4850 6518 6716           g/gatcc             
BstPI         3   4512 6065 6407                   g/gtnacc            
BstSNI        1   306                              tac/gta             
BstXI         4   992 4908 6352 6381               ccannnnn/ntgg       
BstZI         1   6509                             c/ggccg             
Bsu36I        2   2452 4183                        cc/tnagg            
CciNI         1   6509                             gc/ggccgc           
CelII         2   1847 4467                        gc/tnagc            
Cfr10I        1   8078                             r/ccggy             
Cfr42I        2   819 6515                         ccgc/gg             
CfrI          6   872 2206 6509 6944 8386 9373     y/ggccr             
CvnI          2   2452 4183                        cc/tnagg            
DraI          4   4019 7864 7883 8575              ttt/aaa             
DraIII        1   1024                             cacnnn/gtg          
DrdI          2   7213 9082                        gacnnnn/nngtc       
EaeI          6   872 2206 6509 6944 8386 9373     y/ggccr             
EagI          1   6509                             c/ggccg             
Eam1105I      1   7998                             gacnnn/nngtc        
Ecl136II      2   532 5492                         gag/ctc             
EclHKI        1   7998                             gacnnn/nngtc        
EclXI         1   6509                             c/ggccg             
Eco105I       1   306                              tac/gta             
Eco147I       3   769 2443 5323                    agg/cct             
Eco24I        6   534 824 4077 5494 5663 6223      grgcy/c             
Eco255I       2   4061 8478                        agt/act             
Eco31I        2   2434 8070                        ggtctc              
Eco52I        1   6509                             c/ggccg             
Eco64I        6   431 3224 6398 6849 7946 9220     g/gyrcc             
Eco81I        2   2452 4183                        cc/tnagg            
Eco88I        1   6412                             c/ycgrg             
Eco91I        3   4512 6065 6407                   g/gtnacc            
EcoICRI       2   532 5492                         gag/ctc             
EcoNI         2   2437 4767                        cctnn/nnnagg        
EcoO65I       3   4512 6065 6407                   g/gtnacc            
EcoRI         2   887 1818                         g/aattc             
EcoT22I       1   4337                             atgca/t             
EheI          1   9222                             ggc/gcc             
Esp1396I      2   1292 6458                        ccannnn/ntgg        
Esp3I         5   566 1604 5047 8987 9041          cgtctc              
FauNDI        2   200 9169                         ca/tatg             
FbaI          1   1000                             t/gatca             
FriOI         6   534 824 4077 5494 5663 6223      grgcy/c             
FspI          2   8220 9243                        tgc/gca             
GsuI          6   563 998 2943 4081 5135 8088      ctggag              
HaeII         4   3509 6983 7353 9224              rgcgc/y             
HindIII       1   900                              a/agctt             
HpaI          4   666 3016 3422 6653               gtt/aac             
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KasI          1   9220                             g/gcgcc             
Kpn2I         1   617                              t/ccgga             
KpnI          1   3228                             ggtac/c             
Ksp22I        1   1000                             t/gatca             
KspI          2   819 6515                         ccgc/gg             
MfeI          4   5721 6328 6379 6662              c/aattg             
MluNI         2   874 2208                         tgg/cca             
Mph1103I      1   4337                             atgca/t             
MroI          1   617                              t/ccgga             
MscI          2   874 2208                         tgg/cca             
MspCI         1   2330                             c/ttaag             
MunI          4   5721 6328 6379 6662              c/aattg             
Mva1269I      5   1942 2049 4156 6573 6672         gaatgc              
NarI          1   9221                             gg/cgcc             
NcoI          5   326 827 875 910 5863             c/catgg             
NdeI          2   200 9169                         ca/tatg             
NheI          2   4788 6744                        g/ctagc             
NotI          1   6509                             gc/ggccgc           
NsiI          1   4337                             atgca/t             
PaeI          3   17 1055 6744                     gcatg/c             
PflMI         2   1292 6458                        ccannnn/ntgg        
Ple19I        2   8368 9264                        cgat/cg             
Pme55I        3   769 2443 5323                    agg/cct             
Ppu10I        1   4333                             a/tgcat             
PpuMI         4   702 861 3580 5231                rg/gwccy            
PshAI         1   1440                             gacnn/nngtc         
PshBI         6   955 4042 4084 6876 6935 8170     at/taat             
Psp124BI      2   534 5494                         gagct/c             
Psp1406I      2   8224 8597                        aa/cgtt             
Psp5II        4   702 861 3580 5231                rg/gwccy            
PspEI         3   4512 6065 6407                   g/gtnacc            
PspOMI        2   820 6219                         g/ggccc             
PstI          5   23 3692 4722 5354 6738           ctgca/g             
PstNHI        2   4788 6744                        g/ctagc             
PvuI          2   8368 9264                        cgat/cg             
PvuII         6   1671 5525 5754 6266 6929 9293    cag/ctg             
RcaI          5   2219 2567 7825 8833 8938         t/catga             
SacI          2   534 5494                         gagct/c             
SacII         2   819 6515                         ccgc/gg             
SalI          1   894                              g/tcgac             
SapI          5   930 1167 4578 4986 6988          gctcttc             
SbfI          1   23                               cctgca/gg           
ScaI          2   4061 8478                        agt/act             
SexAI         3   3026 3227 4726                   a/ccwggt            
SfiI          1   880                              ggccnnnn/nggcc      
Sfr303I       2   819 6515                         ccgc/gg             
SnaBI         1   306                              tac/gta             
SpeI          2   2783 4398                        a/ctagt             
SphI          3   17 1055 6744                     gcatg/c             
Sse8387I      1   23                               cctgca/gg           
SseBI         3   769 2443 5323                    agg/cct             
SspBI         2   3668 5905                        t/gtaca             
SstI          2   534 5494                         gagct/c             
SstII         2   819 6515                         ccgc/gg             
StuI          3   769 2443 5323                    agg/cct             
Tth111I       1   6071                             gacn/nngtc          
Van91I        2   1292 6458                        ccannnn/ntgg        
Vha464I       1   2330                             c/ttaag             
VneI          3   7419 8665 9162                   g/tgcac             
VspI          6   955 4042 4084 6876 6935 8170     at/taat             
XbaI          3   624 5582 6722                    t/ctaga             
XcmI          1   6245                             ccannnnn/nnnntgg    
XmaIII        1   6509                             c/ggccg             
Zsp2I         1   4337                             atgca/t             
 
 
  195 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX B: Characteristics of cell lines 
(MCF7, U2OS, HBL-100) 
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APPENDIX B: Characteristics of cell lines 
(MCF7, U2OS, HBL-100) 
 
 
 
 
 
ATCC Number:  HTB-22 
Organism:  Homo sapiens (human) 
Designations:  MCF7 
Tissue:  adenocarcinoma; mammary gland; pleural effusion 
Age/Stage:  69 years 
Gender:  female 
Ethnicity:  Caucasian 
Morphology:  epithelial 
Oncogene:  wnt7h + 
Karyotype:  The stemline chromosome numbers ranged from hypertriploidy to hypotetraploidy, with 
the 2S component occurring at 1%. There were 29 to 34 marker chromosomes per S metaphase; 24 to 
28 markers occurred in at least 30% of cells, and generally one large submetacentric (M1) and 3 large 
subtelocentric (M2, M3, and M4) markers were recognizable in over 80% of metaphases. 
No DM were detected. Chromosome 20 was nullisomic and X was disomic. 
FreezeMedium:  Culture medium, 95%; DMSO, 5% 
FluidRenewal:  2 to 3 times weekly 
SubCulturing:  Remove medium, add fresh 0.25% trypsin - 0.03% EDTA solution for 1 minute, 
remove and let the culture sit at room temperature for 5 to 10 minutes. Add fresh medium, aspirate and 
dispense into new flasks. Subculture every 6 to 8 days. 
SplitRatio:  A ratio of 1:3 to 1:6 is recommended 
Receptors expressed:  estrogen 
Growth Properties:  monolayer 
Comments:  The MCF7 line retains several characteristics of differentiated mammary epithelium 
including ability to process estradiol via cytoplasmic estrogen receptors and the capability of forming 
domes. Contains the Tx-4 oncogene. Growth of MCF7 cells is inhibited by tumor necrosis factor alpha 
(TNF alpha). Secretion of IGFBP's can be modulated by treatment with anti-estrogens. 
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ATCC Number:  HTB-96 
Organism:  Homo sapiens (human) 
Designations:  U2OS 
Age/Stage:  15 years 
Gender:  female 
Ethnicity:  Caucasian 
Morphology:  epithelial 
Karyotype:  (P11-46) hypodiploid to near tetraploid; (P111-118) modal numbers 34 to 37 and 64 to 67 
with abnormalities including dicentrics, breaks, rings, and pulverizations plus acrocentric 
subtelocentric and minute markers 
FreezeMedium:  Culture medium, 95%; DMSO, 5% 
FluidRenewal:  2 to 3 times weekly 
SubCulturing:  Remove medium, rinse with fresh 0.25% trypsin solution, remove trypsin and let the 
culture sit at room temperature (or at 37C) until the cells detach (about 10 minutes). Add fresh medium, 
aspirate and dispense into new flasks. Subculture every 6 to 8 days. 
SplitRatio:  A ratio of 1:3 to 1:6 is recommended 
Receptors expressed:  insulin-like growth factor I (IGF-I); insulin-like growth factor II (IGF-II) 
Growth Properties:  monolayer 
Comments:  J. Ponten and E. Saksela derived this line (originally 2T) in 1964 from a moderately 
differentiated sarcoma of the tibia of a 15 year old girl.  
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ATCC Number:  HTB-124 
Organism:  Homo sapiens (human) 
Designations:  HBL-100 
Tissue:  mammary gland 
Age/Stage:  27 years 
Gender:  female 
Ethnicity:  Caucasian 
Morphology:  epithelial 
Tumorigenic:  no (at passages below 25); yes, in nude mice at passage 35 and greater (tumorigenicity 
increases with increasing number of passages) 
Karyotype:  The stemline chromosome number is near triploid with the modal number of 67 
chromosomes, and the 2S component occurring at 0.6%. Most chromosome complements consist of 
about 39 normal and 28 marker chromosomes. Markers such as 2q, 11q+, 11q, t(2q;12), t(2q;5q?), 
t(6p?;16), 16pt and many others are common to most metaphases. Normal chromosomes 11, 14, 15 and 
16 are absent; 2, 12, 17 and 19 are monosomic, and the X is disomic. Double minutes (DM) were not 
detected. 
FreezeMedium:  Culture medium, 90%; glycerol, 10% 
FluidRenewal:  2 to 3 times weekly 
SubCulturing:  Remove medium, rinse with fresh 0.25% trypsin, 0.02% EDTA solution, remove 
trypsin and let the culture sit at room temperature (or at 37C) until the cells detach (about 10 minutes). 
Add fresh medium, aspirate and dispense into new flasks. Subculture every 6 to 8 days. 
SplitRatio:  A ratio of 1:2 is recommended 
Receptors expressed:  estrogen; prolactin 
Growth Properties:  monolayer 
Comments:  HBL-100 is an epithelial cell line derived by E.V. Gaffney and associates from the milk of 
a nursing mother and obtained 3 days after delivery. Although there was no evidence of a breast lesion 
in the milk donor and she had no family history of breast cancer, the karyotype of the recovered cells 
was abnormal as early as passage 7. Tumorigenicity has been reported to increase with passage above 
passage 35. The cells contain a tamdemly integrated SV40 genome. 
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Appendix C: Phosphoimager values of 6 arrays 
(500 clones)  
 
Array numbers (1-6), position of the clones on arrays, and clone numbers are 
indicated.  
F: Phosphoimager values of forward subtracted probe hybridized array 
R: Phosphoimager values of reverse subtracted probe hybridized array 
F long, R long, F/R long: Values of the same arrays exposed longer. 
Average: Average values of short and long exposures
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Appendix C: Phosphoimager values of 6 arrays  
(500 clones) 
 
 
Array # Position Clone # F R F/R F long R long F/R long 
    
Average 
1 A1 24 1548,66 953,27 1,62 3252,71 2451,77 1,33 1,48 
 A2 25 1009,25 777,04 1,30 2489,47 1706,65 1,46 1,38 
 A3 26 3052,55 1217,11 2,51 6368,23 2635,04 2,42 2,46 
 A4 27 2458,93 1138,24 2,16 4845,04 3281,44 1,48 1,82 
 A5 28 11488,49 11464,24 1,00 21482,51 21653,73 0,99 1,00 
 A6 31 3970,83 1187,75 3,34 8482,75 2946,56 2,88 3,11 
 A7 33 3888,88 865,7 4,49 9127,14 3168,98 2,88 3,69 
 A8 34 1727,59 870,51 1,98 4202,48 2556,39 1,64 1,81 
 A9 35 18816,54 6441,36 2,92 34208,55 12099,38 2,83 2,87 
 A10 36 4758,83 1374,67 3,46 10488,32 3195,05 3,28 3,37 
 A11 37 2110,01 1639,85 1,29 4423,61 3712,62 1,19 1,24 
 A12 38 2021,29 1604 1,26 4368,23 3816,01 1,14 1,20 
 B1 39 2109,61 1125,44 1,87 4375,88 1694,1 2,58 2,23 
 B2 40 1976,89 1025,57 1,93 4317,11 1410,65 3,06 2,49 
 B3 41 6335,44 1044,88 6,06 12057,34 1642,93 7,34 6,70 
 B4 42 1332,91 752,64 1,77 3024,82 1980,65 1,53 1,65 
 B5 43 1419,52 933,24 1,52 3302,9 2311,16 1,43 1,48 
 B6 44 3511,34 807,41 4,35 7202,19 1846,98 3,90 4,12 
 B7 45 21230,76 8680,85 2,45 38797,67 15980,63 2,43 2,44 
 B8 46 1531,89 2629,23 0,58 3226,75 5316,24 0,61 0,59 
 B9 47 3319,04 838,19 3,96 6661,1 2245,07 2,97 3,46 
 B10 48 14323,05 590,61 24,25 24933,52 1582,08 15,76 20,01 
 B11 50 1249,62 770,23 1,62 2745,4 2091,57 1,31 1,47 
 B12 51 3008,45 875,08 3,44 6624,29 2928,83 2,26 2,85 
 C1  52 3740,87 1654,67 2,26 7476,66 2499,89 2,99 2,63 
 C2   53 3277,08 999,98 3,28 6746,94 1273,43 5,30 4,29 
 C3 55 5018,27 861,68 5,82 9853,51 1502,52 6,56 6,19 
 C4 56 2641,56 1234,26 2,14 6249,89 3173,72 1,97 2,05 
 C5 57 6834,85 1599,08 4,27 14259,1 2458,47 5,80 5,04 
 C6 58 1576,07 855,42 1,84 3448,24 1987,98 1,73 1,79 
 C7 59 3407,52 754,23 4,52 6908,55 2776,95 2,49 3,50 
 C8 60 1465,13 723,42 2,03 3165,95 1660,01 1,91 1,97 
 C9 61 2273,4 711,09 3,20 4838,75 1511,78 3,20 3,20 
 C10 62 3144,95 715,06 4,40 6267,07 1524,04 4,11 4,26 
 C11 63 3499,75 1187,26 2,95 7464,52 2326,93 3,21 3,08 
 C12 64 10773,2 2770,74 3,89 20906,2 5139,38 4,07 3,98 
 D1 65 1510,63 1444,39 1,05 3577,17 2129,36 1,68 1,36 
 D2 66 3577,22 1120,87 3,19 7508,07 1445,48 5,19 4,19 
 D3 67 4592,32 829,75 5,53 9389,58 1677,8 5,60 5,57 
 D4 68 4446,49 2024,46 2,20 9472,67 4321,81 2,19 2,19 
 D5 70 35403,01 35125,26 1,01 64663,77 61704,97 1,05 1,03 
 D6 71 3355,81 1058,05 3,17 7039,21 2411,55 2,92 3,05 
 D7 74 1733,92 955,78 1,81 4049,18 3783,63 1,07 1,44 
 D8 76 2189,75 1272,89 1,72 5897,07 3318,81 1,78 1,75 
 D9 77 5114,85 1800,48 2,84 10414,51 3050,65 3,41 3,13 
 D10 78 1488,52 741,46 2,01 2990,47 1561,41 1,92 1,96 
 D11 80 7437,93 1890,24 3,93 14246,7 3480,74 4,09 4,01 
 D12 81 12929,53 7405,33 1,75 24233,83 13655,26 1,77 1,76 
 E1 82 6026,38 1656,64 3,64 12349,18 3313,79 3,73 3,68 
 E2 83 27234,54 15692,98 1,74 50217,52 28039,48 1,79 1,76 
 E3 84 11185,21 2277,01 4,91 20723,94 4186,31 4,95 4,93 
 E4 85 5398,15 1865,33 2,89 10439,44 3762,11 2,77 2,83 
 E5 86 3794,69 1566,95 2,42 7217,83 4263,52 1,69 2,06 
 E6 87 7626,15 1830,39 4,17 15407,55 4552,06 3,38 3,78 
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 E7 89 4597,16 1656,25 2,78 10800,08 2847,65 3,79 3,28 
 E8 90 40438,86 14809,05 2,73 75754,38 23045,77 3,29 3,01 
 E9 91 3117,39 996,8 3,13 6212,94 2158,6 2,88 3,00 
 E10 92 1043,46 2171,32 0,48 2332,54 4153,53 0,56 0,52 
 E11 93 4819,66 715,51 6,74 9428,83 1398,12 6,74 6,74 
 E12 94 2191,89 806,46 2,72 3957,29 1480,6 2,67 2,70 
 F1 95 10125,92 9700,65 1,04 19335,2 17630,78 1,10 1,07 
 F2 96 2691,28 1401,92 1,92 5373,01 3943,23 1,36 1,64 
 F3 97 2251,08 1233,76 1,82 4518,32 3805,25 1,19 1,51 
 F4 98 5814,33 1330,75 4,37 11145,43 4673,49 2,38 3,38 
 F5 99 2983,9 1360,96 2,19 6047,41 6374,26 0,95 1,57 
 F6 100 2329,77 1814,11 1,28 5554,26 7837,03 0,71 1,00 
 F7 101 66303 61225,94 1,08 125967,3 111106,9 1,13 1,11 
 F8 102 4882,9 3535,5 1,38 9178,86 6048,07 1,52 1,45 
 F9 103 6270,97 6804 0,92 12407,86 12251,67 1,01 0,97 
 F10 104 1786,29 1431,37 1,25 3999,45 3022,98 1,32 1,29 
 F11 105 1467,47 837,36 1,75 3165,7 1655,36 1,91 1,83 
 F12 106 1065,49 746,63 1,43 2248,08 1496,85 1,50 1,46 
 G1 107 4768,29 1629,82 2,93 9967,32 6259,73 1,59 2,26 
 G2 108 28019,74 18034,24 1,55 52161,42 34741,07 1,50 1,53 
 G3 109 3313,89 890,84 3,72 6676,84 3852,25 1,73 2,73 
 G4 110 1470,48 878,05 1,67 2981,27 3090,74 0,96 1,32 
 G5 111 2218,38 761,78 2,91 4512,64 2247,16 2,01 2,46 
 G6 112 1429,75 1124,8 1,27 3131,72 2117,49 1,48 1,38 
 G7 113 4837,25 1159,62 4,17 9245,16 1931,95 4,79 4,48 
 G8 114 3819,02 790,38 4,83 7781,45 1459,36 5,33 5,08 
 G9 115 5672,75 775,69 7,31 11408,14 1536,93 7,42 7,37 
 G10 116 6616,37 4294,64 1,54 12539,59 7786,66 1,61 1,58 
 G11 118 4455,38 641,56 6,94 8553,3 1361,78 6,28 6,61 
 G12 119 1614,76 894,17 1,81 3501,78 1835,86 1,91 1,86 
 H1 GADD45 1634,34 949,09 1,72 3143,84 1682,91 1,87 1,80 
 H2 GADD45 1771,49 1010,25 1,75 3165,96 2079,91 1,52 1,64 
 H3  neg PCR 856,3 822,75 1,04 1888,6 1670,88 1,13 1,09 
 H4 GADPH 2632,19 4898,89 0,54 5237,3 9214,35 0,57 0,55 
 H5 cDNA1 804,73 668,62 1,20 1771,64 1406,5 1,26 1,23 
 H6 cDNA1 962,99 657,03 1,47 2308,54 1348,62 1,71 1,59 
 H7 BRCA1 8962,31 606,93 14,77 17553,83 1337,15 13,13 13,95 
 H8 BRCA1 13280,44 568,85 23,35 25351,56 1555,45 16,30 19,82 
 H9 cDNA2 1033,68 594,18 1,74 2119,33 2081,33 1,02 1,38 
 H10 cDNA2 939,14 647,71 1,45 1823,95 1857,97 0,98 1,22 
 H11 actin 1642,91 976,47 1,68 3263,96 2079,39 1,57 1,63 
 H12 H2O 659,81 497,42 1,33 2057,27 1248,01 1,65 1,49 
          
2 A1 120 480,95 237,97 2,02 1397,12 627,1 2,23 2,12 
 A2 121 5479,54 271,76 20,16 10852,34 682,27 15,91 18,03 
 A3 122 1069,97 309,23 3,46 2331,06 767,68 3,04 3,25 
 A4 123 1758 370,38 4,75 3821,2 975,56 3,92 4,33 
 A5 124 1588,4 304,77 5,21 3286,5 894,02 3,68 4,44 
 A6 125 1007,53 223,19 4,51 2578,91 610,7 4,22 4,37 
 A7 126 1348,8 210,36 6,41 3447,04 531,47 6,49 6,45 
 A8 127 1199,41 403,83 2,97 3005,32 831,91 3,61 3,29 
 A9 128 1557,34 322,78 4,82 8425,74 635,45 13,26 9,04 
 A10 129 1844,64 465,3 3,96 5062,52 1075,19 4,71 4,34 
 A11 130 747,08 376,83 1,98 2204,74 1455,75 1,51 1,75 
 A12 131 2111,46 408,69 5,17 5373,77 1056,28 5,09 5,13 
 B1 132 827,9 186,92 4,43 2260,16 528,31 4,28 4,35 
 B2 133 3790 234,85 16,14 7016,96 550,42 12,75 14,44 
 B3 134 9450,9 3462,84 2,73 16158,32 6736,5 2,40 2,56 
 B4 135 4906,27 4222,59 1,16 8741,52 8263,21 1,06 1,11 
 B5 136 1798,71 441,61 4,07 3377,22 1197,14 2,82 3,45 
 B6 137 1405,76 232,24 6,05 3062,99 608,56 5,03 5,54 
 B7 138 1359,63 189,38 7,18 2968,34 480,24 6,18 6,68 
 B8 139 986,53 259,71 3,80 2459,24 549,04 4,48 4,14 
 B9 140 49974,8 17835,4 2,80 87909,53 32370,4 2,72 2,76 
 B10 141 5726,61 1352,48 4,23 7168,27 2012,69 3,56 3,90 
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 B11 142 6748,53 4165,73 1,62 11494,01 8128,83 1,41 1,52 
 B12 143 5626,08 1807,06 3,11 8481,63 3204,31 2,65 2,88 
 C1  144 680,47 269,84 2,52 1892 763,02 2,48 2,50 
 C2   145 1301,8 393,55 3,31 2650,6 858,07 3,09 3,20 
 C3 146 1095,46 331,94 3,30 2236,16 726,3 3,08 3,19 
 C4 147 2575,2 422,65 6,09 5145,31 886,66 5,80 5,95 
 C5 148 664,07 223,52 2,97 1517,7 552,17 2,75 2,86 
 C6 149 795,46 240,29 3,31 1966,57 570,05 3,45 3,38 
 C7 150 2049,98 326,89 6,27 4126,03 694,7 5,94 6,11 
 C8 151 611,91 213,93 2,86 1870,35 499,14 3,75 3,30 
 C9 152 1238,2 690,07 1,79 3156,25 902,64 3,50 2,65 
 C10 153 5358,37 638,29 8,39 10058,57 1186,43 8,48 8,44 
 C11 156 1793,22 512,62 3,50 3227,99 1063,78 3,03 3,27 
 C12 157 3884,78 1694,07 2,29 6141,31 3156,41 1,95 2,12 
 D1 158 5261,87 348,65 15,09 9481,25 946,89 10,01 12,55 
 D2 159 942,46 223,03 4,23 1639,66 527,78 3,11 3,67 
 D3 160 532,73 194,53 2,74 1252,99 512,42 2,45 2,59 
 D4 161 889,48 225,76 3,94 2065,73 550,06 3,76 3,85 
 D5 162 1909,7 310,65 6,15 3725,93 727,73 5,12 5,63 
 D6 163 5224,43 387,56 13,48 9775,73 860,63 11,36 12,42 
 D7 164 2656,1 254,75 10,43 5039,11 648,32 7,77 9,10 
 D8 165 4165,34 218,5 19,06 7861,17 594 13,23 16,15 
 D9 166 948,14 275,35 3,44 3877,54 642,33 6,04 4,74 
 D10 167 1291,04 935,02 1,38 3237,66 1644,72 1,97 1,67 
 D11 168 868,75 372,97 2,33 2089,23 727,33 2,87 2,60 
 D12 169 1721,1 464,94 3,70 3452,88 997,87 3,46 3,58 
 E1 170 3334,34 313,71 10,63 6536,69 889,96 7,34 8,99 
 E2 171 4286,37 436,95 9,81 7787,14 868,3 8,97 9,39 
 E3 172 1214,2 339,09 3,58 2322,13 783,84 2,96 3,27 
 E4 173 3525,36 689,71 5,11 6605,91 1705,53 3,87 4,49 
 E5 174 2887,38 385,53 7,49 5388,31 945,59 5,70 6,59 
 E6 175 2558,26 1584,07 1,61 4776,79 3073,44 1,55 1,58 
 E7 176 4932,14 1216,08 4,06 9173,18 2527,65 3,63 3,84 
 E8 177 1848,33 236,42 7,82 4697,94 828,69 5,67 6,74 
 E9 179 4587,43 470,86 9,74 10115,02 1083,29 9,34 9,54 
 E10 180 1820,2 365,34 4,98 3544,16 844,25 4,20 4,59 
 E11 181 762,02 286,1 2,66 1946,83 648,27 3,00 2,83 
 E12 182 1212,64 294,38 4,12 2029,11 929,34 2,18 3,15 
 F1 183 1356,12 187,29 7,24 2634,62 863,28 3,05 5,15 
 F2 184 469,31 304,81 1,54 1183,66 454,1 2,61 2,07 
 F3 185 934,04 734,37 1,27 1942,83 757,26 2,57 1,92 
 F4 186 390,17 374,29 1,04 917,33 1422,18 0,65 0,84 
 F5 187 594,63 824,42 0,72 1294,88 1896,24 0,68 0,70 
 F6 188 879,97 1090,25 0,81 1922,13 1925,13 1,00 0,90 
 F7 189 1457,12 2312,76 0,63 3086,15 4705,69 0,66 0,64 
 F8 190 5101,88 345,35 14,77 10607,91 1369,6 7,75 11,26 
 F9 191 21079,12 3352,63 6,29 35759,68 6663,67 5,37 5,83 
 F10 192 2500,53 321,47 7,78 3661,74 1059,49 3,46 5,62 
 F11 193 955,23 327,1 2,92 1844,73 794,88 2,32 2,62 
 F12 194 18073,74 4782,65 3,78 30562,91 9695,1 3,15 3,47 
 G1 195 320,48 183,59 1,75 926,01 1276,95 0,73 1,24 
 G2 197 592,51 237,84 2,49 1394,07 602,75 2,31 2,40 
 G3 198 1965,66 608,3 3,23 3778,18 605,14 6,24 4,74 
 G4 199 576,75 461,17 1,25 1248,26 1002,78 1,24 1,25 
 G5 200 718,45 396,56 1,81 1469,85 1046,78 1,40 1,61 
 G6 211 822,7 985,62 0,83 1782,41 974,4 1,83 1,33 
 G7 212 1490,81 803,24 1,86 3423,98 1878,59 1,82 1,84 
 G8 213 3105,26 301,59 10,30 5955,64 1479,66 4,03 7,16 
 G9 214 2854,34 407,78 7,00 3207,62 725,99 4,42 5,71 
 G10 215 2085,93 332,6 6,27 3195,81 727,28 4,39 5,33 
 G11 216 6671,44 5336,26 1,25 11555,52 10657,92 1,08 1,17 
 G12 217 3107,5 773,79 4,02 5881,44 1356,11 4,34 4,18 
 H1 GADD45 564,17 464,72 1,21 1331,31 1590,2 0,84 1,03 
 H2 GADD45 558,12 486,01 1,15 1304,47 1232,98 1,06 1,10 
 H3  neg PCR 231,26 438,99 0,53 753,6 677,53 1,11 0,82 
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 H4 GADPH 1036,56 4045,89 0,26 2107,35 7748,05 0,27 0,26 
 H5 cDNA1 354,54 535,3 0,66 849,74 1499,63 0,57 0,61 
 H6 cDNA1 347,89 1121,24 0,31 994,37 1294,07 0,77 0,54 
 H7 BRCA1 2175,22 753,96 2,89 4756,15 2097,57 2,27 2,58 
 H8 BRCA1 7796,33 298,25 26,14 14587,27 1408,4 10,36 18,25 
 H9 cDNA2 1176,36 246,01 4,78 960,83 653 1,47 3,13 
 H10 cDNA2 572,26 316,89 1,81 1007,94 642,7 1,57 1,69 
 H11 actin 1680,57 3136,65 0,54 3387,46 6158,32 0,55 0,54 
 H12 H2O 490,52 235,11 2,09 1181,82 717,26 1,65 1,87 
          
3 A1 218 1523,71 367,18 4,15 3154,58 863,84 3,65 3,90 
 A2 219 2023,97 1103,14 1,83 4148,98 2189,65 1,89 1,86 
 A3 232 705,1 605,69 1,16 1629,56 1221,24 1,33 1,25 
 A4 233 642,92 473,32 1,36 1502,28 987,28 1,52 1,44 
 A5 234 1016,69 361,06 2,82 2171,15 785,72 2,76 2,79 
 A6 235 472,63 307,69 1,54 1070,5 702,11 1,52 1,53 
 A7 236 481,1 338,57 1,42 1123,31 760,87 1,48 1,45 
 A8 237 1699,82 633,8 2,68 3381,94 1415,22 2,39 2,54 
 A9 238 717,46 513,82 1,40 1739,22 1420,4 1,22 1,31 
 A10 239 2906,75 1345,01 2,16 5872,16 2720,32 2,16 2,16 
 A11 240 758,02 450,74 1,68 1619,52 1027,66 1,58 1,63 
 A12 241 890,06 636,1 1,40 1781,5 1385,01 1,29 1,34 
 B1 242 1292,06 877,54 1,47 2740,29 1928,32 1,42 1,45 
 B2 243 1705,07 1185,93 1,44 3458,6 2374,43 1,46 1,45 
 B3 244 1075,4 477,98 2,25 2373,15 1157,5 2,05 2,15 
 B4 245 1559,33 849,59 1,84 3407,01 1832,45 1,86 1,85 
 B5 246 2734,91 468,32 5,84 5615,55 1021,58 5,50 5,67 
 B6 247 1261,78 749,74 1,68 2630,42 1670,4 1,57 1,63 
 B7 248 1986,88 809,42 2,45 4004,41 1747,97 2,29 2,37 
 B8 249 970,01 641,67 1,51 2268,85 1558,85 1,46 1,48 
 B9 250 15046,64 6296,65 2,39 28597,18 12831,41 2,23 2,31 
 B10 251 4085,51 1011,54 4,04 8358,32 1974,74 4,23 4,14 
 B11 252 2130,82 1059,46 2,01 4357,8 2394,71 1,82 1,92 
 B12 253 3973,64 1473,95 2,70 8116,1 3168,28 2,56 2,63 
 C1  254 967,75 646,48 1,50 2132,25 1395,5 1,53 1,51 
 C2   255 1462,01 1561,39 0,94 3147,74 3132,58 1,00 0,97 
 C3 256 2617,19 857,24 3,05 6145,96 1924,51 3,19 3,12 
 C4 257 10933,33 3163,21 3,46 20502,84 6241,67 3,28 3,37 
 C5 258 1049,63 679,71 1,54 2165,94 1355,44 1,60 1,57 
 C6 259 3236,43 634,48 5,10 6700,91 1446 4,63 4,87 
 C7 260 883,44 493,27 1,79 1907,49 1167,98 1,63 1,71 
 C8 261 3178,4 1917,71 1,66 6537,17 3928,85 1,66 1,66 
 C9 262 3210,52 2409,65 1,33 6590,11 4788,36 1,38 1,35 
 C10 264 21157,04 6298,73 3,36 39769,84 12478,15 3,19 3,27 
 C11 265 15939,46 8237,41 1,94 30202,11 16349,97 1,85 1,89 
 C12 266 13432,28 14357,1 0,94 25534,16 27813,9 0,92 0,93 
 D1 267 627,68 397,6 1,58 1529,03 870,52 1,76 1,67 
 D2 268 2524,51 394,91 6,39 5276,39 928,58 5,68 6,04 
 D3 269 2399,18 720,2 3,33 5479,07 1797,06 3,05 3,19 
 D4 270 18836,63 6199,39 3,04 35911,26 12163,6 2,95 3,00 
 D5 271 1999,62 872,52 2,29 3927,45 1816,99 2,16 2,23 
 D6 272 4252,35 4213,74 1,01 8726,1 8531,55 1,02 1,02 
 D7 273 1382,08 770,07 1,79 2825,49 1654,6 1,71 1,75 
 D8 274 1044,08 840,25 1,24 2167,88 1850,79 1,17 1,21 
 D9 275 988,43 704,44 1,40 1950,5 1565,63 1,25 1,32 
 D10 276 1345,51 662,07 2,03 2648,85 1409,11 1,88 1,96 
 D11 277 2749,62 934,68 2,94 5452 1858,06 2,93 2,94 
 D12 278 2351,86 1271,82 1,85 4747,88 2002,14 2,37 2,11 
 E1 279 757,87 932,41 0,81 1717,05 1989,72 0,86 0,84 
 E2 280 764 538,18 1,42 1782,91 1223,07 1,46 1,44 
 E3 281 4459,39 1018,33 4,38 9239,7 2188,35 4,22 4,30 
 E4 282 2141,25 626,08 3,42 4198,42 1534,64 2,74 3,08 
 E5 283 10206,1 4913,54 2,08 19327,47 9838,19 1,96 2,02 
 E6 284 1720,68 1087,96 1,58 3426,58 2302,95 1,49 1,53 
 E7 285 4877,85 2430,38 2,01 9802,98 4913,47 2,00 2,00 
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 E8 286 2707,78 1270,78 2,13 5436,77 2689,84 2,02 2,08 
 E9 287 999,28 753,06 1,33 2097,46 1818,16 1,15 1,24 
 E10 288 1931,64 1120,92 1,72 3896,34 2448,85 1,59 1,66 
 E11 289 1414,57 776,52 1,82 2816,28 1733,03 1,63 1,72 
 E12 290 1977,51 1122,15 1,76 3895,52 2231,68 1,75 1,75 
 F1 291 579,65 6037,73 0,10 1310,48 11512,76 0,11 0,10 
 F2 292 571,75 629,49 0,91 1297,75 1274,93 1,02 0,96 
 F3 293 1727,02 551,17 3,13 3524,73 1755,74 2,01 2,57 
 F4 294 5385,59 1746,8 3,08 11016,33 3072,5 3,59 3,33 
 F5 295 3185,27 662,65 4,81 6223,85 1584,27 3,93 4,37 
 F6 297 948,61 574,91 1,65 2052,22 1341,64 1,53 1,59 
 F7 299 1559,74 1487,12 1,05 3283,05 3216,22 1,02 1,03 
 F8 300 11860,48 4375,25 2,71 22701,47 9084,47 2,50 2,60 
 F9 303 1280,91 1382,83 0,93 2558,23 2923,2 0,88 0,90 
 F10 304 1208,49 582,15 2,08 2449,37 1345,85 1,82 1,95 
 F11 305 1075,84 532,05 2,02 2220,96 1162,3 1,91 1,97 
 F12 306 1527,47 742,04 2,06 3087,52 1543,38 2,00 2,03 
 G1 307 504,9 427,73 1,18 1042,69 1143,87 0,91 1,05 
 G2 308 2196,31 2079,48 1,06 4386,68 4160,78 1,05 1,06 
 G3 309 1218,46 466,21 2,61 2513,77 1232,71 2,04 2,33 
 G4 310 1869,22 1003,88 1,86 3615,69 2227,46 1,62 1,74 
 G5 311 828,36 521,5 1,59 1765,73 1216,55 1,45 1,52 
 G6 312 1398,17 528,57 2,65 2839,06 1224,94 2,32 2,48 
 G7 313 1730,57 464,34 3,73 3550,02 1141,16 3,11 3,42 
 G8 314 3279,41 529,03 6,20 6431,47 1231,97 5,22 5,71 
 G9 315 1397,42 691,62 2,02 2751,82 1507,34 1,83 1,92 
 G10 316 1845,31 1311,42 1,41 3668,54 2705,14 1,36 1,38 
 G11 319 1385,4 799,11 1,73 2758,95 1602,04 1,72 1,73 
 G12 320 1107,15 598,14 1,85 2252,82 1258,47 1,79 1,82 
 H1 GADD45 337 317,92 1,06 740,66 815,84 0,91 0,98 
 H2 GADD45 455,98 342,03 1,33 962,02 873,52 1,10 1,22 
 H3  neg PCR 363,98 280,41 1,30 785,29 927,15 0,85 1,07 
 H4 GADPH 474,43 2893,85 0,16 962 5759,84 0,17 0,17 
 H5 cDNA1 390,96 341,86 1,14 880,01 797,67 1,10 1,12 
 H6 cDNA1 444,61 296,48 1,50 958,43 759,45 1,26 1,38 
 H7 BRCA1 807,3 302,42 2,67 1688,11 718,62 2,35 2,51 
 H8 BRCA1 764,42 305,1 2,51 1542,38 743,6 2,07 2,29 
 H9 cDNA2 424,97 295,26 1,44 905,9 720,39 1,26 1,35 
 H10 cDNA2 439,46 350,45 1,25 869,25 851,41 1,02 1,14 
 H11 actin 910,13 1995,74 0,46 1845,26 3905,94 0,47 0,46 
 H12 H2O 384,14 316,33 1,21 768,58 745,66 1,03 1,12 
          
4 A1 321 6001,38 957,61 6,27     
 A2 322 1069,6 858,47 1,25     
 A3 323 3965,85 3431,85 1,16     
 A4 324 1157,52 490,46 2,36     
 A5 325 841,41 823,46 1,02     
 A6 326 3345,14 1397,66 2,39     
 A7 327 985,1 2217,21 0,44     
 A8 328 19445,38 25876,97 0,75     
 A9 329 25333,42 39019,93 0,65     
 A10 331 4162,46 1281,56 3,25     
 A11 332 4490,38 1934,85 2,32     
 A12 333 3054,28 6095,83 0,50     
 B1 334 3235,46 3158,95 1,02     
 B2 335 314,63 428,22 0,73     
 B3 336 1603,92 4778,12 0,34     
 B4 337 1734,44 3266,33 0,53     
 B5 338 2693,29 4487,75 0,60     
 B6 339 1877,24 761,72 2,46     
 B7 340 518,38 1135,04 0,46     
 B8 341 1118,62 1856,67 0,60     
 B9 342 1411,95 1543,59 0,91     
 B10 343 15256,37 17045,52 0,90     
 B11 344 1540,6 1798,56 0,86     
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 B12 345 1364,43 2375,03 0,57     
 C1  346 2025,52 319,26 6,34     
 C2   347 243,46 303,29 0,80     
 C3 348 519,45 314,73 1,65     
 C4 349 601,14 425,61 1,41     
 C5 350 695,8 1830,97 0,38     
 C6 352 952,6 307,57 3,10     
 C7 353 1734,5 829,42 2,09     
 C8 354 638,47 456,66 1,40     
 C9 355 790,1 442,52 1,79     
 C10 356 645,9 486,16 1,33     
 C11 357 1259,74 415,43 3,03     
 C12 358 4295,84 395,57 10,86     
 D1 359 1053,2 408,91 2,58     
 D2 360 530,11 304,39 1,74     
 D3 361 508,77 233,21 2,18     
 D4 362 2682,13 615,14 4,36     
 D5 364 460,65 419,54 1,10     
 D6 365 1022,92 367,94 2,78     
 D7 366 2362,38 3160,43 0,75     
 D8 367 443,42 421,84 1,05     
 D9 369 477,9 312,21 1,53     
 D10 370 2758,64 316,17 8,73     
 D11 371 2598,74 477,33 5,44     
 D12 372 2639,41 986,16 2,68     
 E1 373 317,28 516,13 0,61     
 E2 374 304,16 291,76 1,04     
 E3 375 254,54 215,41 1,18     
 E4 377 281,33 217,41 1,29     
 E5 378 439,99 235,62 1,87     
 E6 380 935,85 2833,76 0,33     
 E7 381 918,19 329,07 2,79     
 E8 382 514,27 226,63 2,27     
 E9 383 951,51 433,57 2,19     
 E10 384 962,22 221,71 4,34     
 E11 385 1701,03 285,14 5,97     
 E12 386 659,08 309,96 2,13     
 F1 387 484,1 508,22 0,95     
 F2 388 293,31 337,8 0,87     
 F3 390 553,88 192,8 2,87     
 F4 391 444,87 226,11 1,97     
 F5 392 451,43 214,76 2,10     
 F6 393 782,49 2625,72 0,30     
 F7 394 2350,89 1914,26 1,23     
 F8 395 411,14 364,79 1,13     
 F9 396 455,5 236,35 1,93     
 F10 397 313,29 227,22 1,38     
 F11 398 901,75 341,54 2,64     
 F12 400 1209,13 456,15 2,65     
 G1 401 313,66 263,05 1,19     
 G2 402 712,79 284,86 2,50     
 G3 403 267,37 263,05 1,02     
 G4 404 641,48 283,97 2,26     
 G5 405 279,64 253,9 1,10     
 G6 406 823,86 287,9 2,86     
 G7 407 1307,94 2308,29 0,57     
 G8 408 800,96 341,28 2,35     
 G9 409 517,19 261,31 1,98     
 G10 410 931,91 210,1 4,44     
 G11 411 1548,57 277,01 5,59     
 G12 412 1392,51 600,47 2,32     
 H1 GADD45 322,1 1374,51 0,23     
 H2 GADD45 296,63 2134,65 0,14     
 H3  neg PCR 194,92 741,75 0,26     
 H4 GADPH 297,73 6627,27 0,04     
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 H5 cDNA1 301,99 367,84 0,82     
 H6 cDNA1 297,13 305,15 0,97     
 H7 BRCA1 1488,84 326,23 4,56     
 H8 BRCA1 1440,33 342,23 4,21     
 H9 cDNA2 317,48 348,2 0,91     
 H10 cDNA2 319,14 569,14 0,56     
 H11 actin 701,47 2719,74 0,26     
 H12 H2O 639,71 455,19 1,41     
          
5 A1 413 594,67 342,4 1,74 1837,77 762,1 2,41 2,07 
 A2 415 3465,18 865,76 4,00 9738,55 2039,12 4,78 4,39 
 A3 416 48177,87 25493,52 1,89 88723,84 46532,48 1,91 1,90 
 A4 417 1280,71 525,6 2,44 2023,28 961,18 2,10 2,27 
 A5 418 1941,51 672,22 2,89 3611,47 1325,03 2,73 2,81 
 A6 419 1892,28 1137,69 1,66 3672,13 2169,06 1,69 1,68 
 A7 420 3385,16 310,83 10,89 6680,38 664,07 10,06 10,48 
 A8 421 2047,92 316,36 6,47 4039,48 800,23 5,05 5,76 
 A9 422 1312,87 335,46 3,91 2707,18 1310,13 2,07 2,99 
 A10 423 4856,86 552,41 8,79 9752,36 2237,52 4,36 6,58 
 A11 424 1883,7 463,83 4,06 3751,1 1296,98 2,89 3,48 
 A12 426 3615,76 559,9 6,46 7422,46 1185,06 6,26 6,36 
 B1 427 1361,27 344,82 3,95 2971,32 971,33 3,06 3,50 
 B2 428 1770,21 631,14 2,80 3990,96 1695,36 2,35 2,58 
 B3 429 1414,86 801,14 1,77 3616,17 1026,3 3,52 2,64 
 B4 430 6725,08 1100,91 6,11 13034,82 2152,48 6,06 6,08 
 B5 431 3197,48 379,01 8,44 6321,17 802,46 7,88 8,16 
 B6 432 1127,68 273,46 4,12 2256,87 564,68 4,00 4,06 
 B7 433 735,79 364,91 2,02 1545,87 736,46 2,10 2,06 
 B8 434 1911,2 317,06 6,03 3851,58 666,55 5,78 5,90 
 B9 435 3394,94 2390,47 1,42 7042 4483,42 1,57 1,50 
 B10 436 8772,47 6699,98 1,31 16339,03 11552,17 1,41 1,36 
 B11 437 3379,15 1012,23 3,34 6833,71 1608,68 4,25 3,79 
 B12 438 1042,82 257,13 4,06 2110,41 557,11 3,79 3,92 
 C1  439 984,76 470,44 2,09 2473,09 1126,1 2,20 2,14 
 C2   440 9632,9 10322,44 0,93 17648,67 18932,6 0,93 0,93 
 C3 441 2019,59 357,1 5,66 3995,13 741,59 5,39 5,52 
 C4 442 1409,91 455,89 3,09 2962,95 1022,25 2,90 3,00 
 C5 443 3218,08 500,89 6,42 6335,1 1045,8 6,06 6,24 
 C6 444 1772,94 262,6 6,75 3458,8 511,97 6,76 6,75 
 C7 445 1814,2 357,13 5,08 3597,24 698,21 5,15 5,12 
 C8 446 3492,74 394,66 8,85 6974,21 784,73 8,89 8,87 
 C9 447 5034,06 305,02 16,50 10174,02 629,78 16,15 16,33 
 C10 448 766,19 347,66 2,20 1635,77 683,19 2,39 2,30 
 C11 449 707,94 289,88 2,44 1572,05 667,84 2,35 2,40 
 C12 450 3109,19 407,56 7,63 6208 854,04 7,27 7,45 
 D1 451 490,69 350,25 1,40 1456,74 734,48 1,98 1,69 
 D2 452 3237,01 528,75 6,12 6674,63 898,52 7,43 6,78 
 D3 453 5148,38 312,36 16,48 9917,09 725,85 13,66 15,07 
 D4 455 1775,38 1278,09 1,39 3474,33 2512,81 1,38 1,39 
 D5 456 1082,01 627,7 1,72 2209 1259,41 1,75 1,74 
 D6 457 700,91 244,52 2,87 1531,38 558,12 2,74 2,81 
 D7 458 2197,7 239,87 9,16 4337,04 526,62 8,24 8,70 
 D8 459 581,35 239,18 2,43 1415,61 498,85 2,84 2,63 
 D9 460 4152,05 297,73 13,95 8482,02 686,64 12,35 13,15 
 D10 461 2360,56 500,1 4,72 4646,06 1028,61 4,52 4,62 
 D11 462 1414,92 696,54 2,03 2769,92 1415,74 1,96 1,99 
 D12 463 577,26 267,9 2,15 1286,7 647,95 1,99 2,07 
 E1 464 874,41 304,21 2,87 1991,09 698,46 2,85 2,86 
 E2 465 485,09 298,25 1,63 1335,02 721,64 1,85 1,74 
 E3 466 475,39 315,89 1,50 1216,35 765,08 1,59 1,55 
 E4 468 1089,24 434,7 2,51 2518,35 1067,92 2,36 2,43 
 E5 469 3389,98 753,56 4,50 6189,73 1974,91 3,13 3,82 
 E6 470 2564,36 357,15 7,18 4487,22 921,89 4,87 6,02 
 E7 471 1777,71 286,98 6,19 3309,49 693,21 4,77 5,48 
 E8 472 682,62 250,69 2,72 1897,65 580,01 3,27 3,00 
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 E9 473 9665,28 1086,13 8,90 17985,71 2165,09 8,31 8,60 
 E10 474 1859,38 324,43 5,73 3612,17 667,66 5,41 5,57 
 E11 475 2935,33 404,44 7,26 5801,47 984,08 5,90 6,58 
 E12 476 2377,49 524,38 4,53 4668,3 1445,01 3,23 3,88 
 F1 479 1868,62 386,32 4,84 3442,28 899,47 3,83 4,33 
 F2 480 2559,53 1748,01 1,46 4905,81 3368,81 1,46 1,46 
 F3 482 3866,58 2199,91 1,76 7861,11 4467,34 1,76 1,76 
 F4 484 2491,12 691,23 3,60 6633,24 1708,33 3,88 3,74 
 F5 485 36648,14 31498,04 1,16 65760,16 59234,81 1,11 1,14 
 F6 486 4926,54 1703,67 2,89 6328,93 2878,22 2,20 2,55 
 F7 487 1116,24 837,92 1,33 1896,4 1531,18 1,24 1,29 
 F8 491 1139,42 973,35 1,17 2357,73 1960,83 1,20 1,19 
 F9 493 938,67 311,12 3,02 2009,5 673,98 2,98 3,00 
 F10 494 945,57 363,06 2,60 2215,48 774,58 2,86 2,73 
 F11 495 17546,85 3763,37 4,66 32092,33 7413,8 4,33 4,50 
 F12 496 28411,03 11815,08 2,40 53042,84 21852,14 2,43 2,42 
 G1 500 38391,81 8802,13 4,36 70218,97 16582,31 4,23 4,30 
 G2 501 941,81 332,46 2,83 1959,48 740,75 2,65 2,74 
 G3 502 564,67 304,5 1,85 2207,93 718,75 3,07 2,46 
 G4 503 1558,96 348,45 4,47 5905,94 884,52 6,68 5,58 
 G5 504 3159,15 878,72 3,60 8046,43 2025,62 3,97 3,78 
 G6 506 2269,74 448,52 5,06 3614,74 1038,13 3,48 4,27 
 G7 507 3722,58 723,5 5,15 7218,46 1299,5 5,55 5,35 
 H1 GADD45 1244,91 645,61 1,93 1761,46 1810,54 0,97 1,45 
 H2 GADD45 772,79 439,54 1,76 1230,57 922,83 1,33 1,55 
 H3  neg PCR 372,55 270,26 1,38 1118,93 615,94 1,82 1,60 
 H4 GADPH 1244,51 3334,95 0,37 2980,18 6506,96 0,46 0,42 
 H5 cDNA1 724,67 357,41 2,03 2069,1 749,41 2,76 2,39 
 H6 cDNA1 998,71 304,69 3,28 1842,09 705,85 2,61 2,94 
 H7 BRCA1 4730,51 464,53 10,18 9521,14 966,73 9,85 10,02 
 H8 BRCA1 7844,02 389,18 20,16 14655,55 767,52 19,09 19,62 
 H9 cDNA2 588,53 265,08 2,22 1128,37 611,28 1,85 2,03 
 H10 cDNA2 559,26 285,47 1,96 1077,46 623,29 1,73 1,84 
 H11 actin 1080,13 2092,15 0,52 2168,45 4095,37 0,53 0,52 
 H12 H2O 362,83 287,12 1,26 984,03 660,67 1,49 1,38 
          
6 A1 999 446,31 266,09 1,68 1008,96 604,96 1,67 1,67 
 A2 1000 437,2 278,16 1,57 943,75 620,45 1,52 1,55 
 A3 1001 786 415,89 1,89 1675,78 867,19 1,93 1,91 
 A4 1002 1760,84 1520,55 1,16 3671,14 3699,81 0,99 1,08 
 A5 1003 653,75 463,35 1,41 1585,88 1431,29 1,11 1,26 
 A6 1004 1579,35 704,07 2,24 3258,92 1428,68 2,28 2,26 
 A7 1005 732,32 965,78 0,76 1911,79 2735,53 0,70 0,73 
 A8 1006 1573,82 645,15 2,44 3269,82 2220,89 1,47 1,96 
 A9 1007 1140,25 579,28 1,97 2354,46 1277,97 1,84 1,91 
 A10 1008 756,31 468,62 1,61 1601,69 918,45 1,74 1,68 
 A11 1009 1707,47 3763,24 0,45 3214,77 5763,78 0,56 0,51 
 A12 1010 16440,83 37122,43 0,44 30576,12 64456,21 0,47 0,46 
 B1 1011 2558,23 603,11 4,24 5078,04 1207,07 4,21 4,22 
 B2 1012 421,81 294,36 1,43 970,37 640,83 1,51 1,47 
 B3 1013 1200,78 649,83 1,85 2455,32 1093,68 2,25 2,05 
 B4 1014 19331,93 22293,22 0,87 36307,74 40892,38 0,89 0,88 
 B5 1015 2842,64 4324,56 0,66 5840,51 8552,05 0,68 0,67 
 B6 1016 2295,22 1108,6 2,07 4298,47 1823,06 2,36 2,21 
 B7 1018 28292,81 27411,94 1,03 52167,17 49944,89 1,04 1,04 
 B8 1019 1115,08 1096,53 1,02 3005,53 2530,05 1,19 1,10 
 B9 1020 2593,73 506,74 5,12 5275,49 1110,67 4,75 4,93 
 B10 1021 1193,86 387,87 3,08 2501,41 796,15 3,14 3,11 
 B11 1022 931,09 836,42 1,11 1935,82 1566,1 1,24 1,17 
 B12 1024 1640,34 878,38 1,87 3212,14 1740,63 1,85 1,86 
 C1  1025 1168,68 392,83 2,98 2357,85 800,41 2,95 2,96 
 C2   1026 1629,9 411,44 3,96 3229,76 852,47 3,79 3,88 
 C3 1027 1471,35 375,14 3,92 2948,1 781,2 3,77 3,85 
 C4 1028 1469,25 639,88 2,30 2940,01 1314,86 2,24 2,27 
 C5 1029 3297,1 465,02 7,09 6669,19 1041,35 6,40 6,75 
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 C6 1031 1756,77 546,46 3,21 3368,09 1080,02 3,12 3,17 
 C7 1033 1988,93 780,82 2,55 4169,92 1615,25 2,58 2,56 
 C8 1034 2382,7 458,74 5,19 5089,23 1035,53 4,91 5,05 
 C9 1035 1474,94 423,26 3,48 3016,16 940,94 3,21 3,35 
 C10 1036 613,24 474,52 1,29 1419,48 986,52 1,44 1,37 
 C11 1037 4449,82 654,98 6,79 8401,09 1343,57 6,25 6,52 
 C12 1038 1473,24 3434,05 0,43 3218,79 6642,13 0,48 0,46 
 D1 1039 2023,47 290,97 6,95 4074,2 615,44 6,62 6,79 
 D2 1040 5852,05 287,14 20,38 11154,27 608,24 18,34 19,36 
 D3 1041 558,08 308,23 1,81 1218,98 682,75 1,79 1,80 
 D4 1042 2082,41 338,1 6,16 4180,25 739,24 5,65 5,91 
 D5 1044 689,14 474,32 1,45 1506,4 944,28 1,60 1,52 
 D6 1045 2014,49 335,2 6,01 3991,26 744,16 5,36 5,69 
 D7 1046 1165,21 348,85 3,34 2380,5 782,29 3,04 3,19 
 D8 1048 989,27 1706,67 0,58 2068,51 3309,68 0,62 0,60 
 D9 1049 10807,35 484,59 22,30 20405,36 1087,14 18,77 20,54 
 D10 1050 3094,15 466,9 6,63 6718,79 1050,84 6,39 6,51 
 D11 1051 1329,75 683,65 1,95 2701,66 1345,57 2,01 1,98 
 D12 1052 1991,62 649,95 3,06 3605,93 1306,2 2,76 2,91 
 E1 1053 2432,08 457,48 5,32 4911,86 947,35 5,18 5,25 
 E2 1055 3058,17 480,37 6,37 6210,32 981,72 6,33 6,35 
 E3 1056 485,53 367,95 1,32 1096,57 762,5 1,44 1,38 
 E4 1057 1234,42 524,98 2,35 2491,84 1085,98 2,29 2,32 
 E5 1058 841,02 420,56 2,00 1759,83 844,76 2,08 2,04 
 E6 1059 1464,01 838,37 1,75 2944,33 1682,78 1,75 1,75 
 E7 1060 1929,47 277,38 6,96 3798,98 670,41 5,67 6,31 
 E8 1061 1118,34 666,06 1,68 2231,81 1331,81 1,68 1,68 
 E9 1062 21631,52 9872,58 2,19 39848,27 18193,55 2,19 2,19 
 E10 1064 4025,9 612,69 6,57 9074,27 1685,03 5,39 5,98 
 E11 1065 4269,26 470,24 9,08 8612,32 1017,52 8,46 8,77 
 E12 1066 1069,87 1168,28 0,92 2356,48 2254,73 1,05 0,98 
 F1 1067 1879,36 270,01 6,96 3776,6 607,66 6,21 6,59 
 F2 1068 513,62 325,3 1,58 1110 735,91 1,51 1,54 
 F3 1069 1287,12 245,6 5,24 2571,68 556,12 4,62 4,93 
 F4 1070 1129,41 323,81 3,49 2294,19 694,06 3,31 3,40 
 F5 1071 8572,25 580,74 14,76 16256,52 1216,9 13,36 14,06 
 F6 1072 3908,11 561,64 6,96 7708,11 1175,4 6,56 6,76 
 F7 1073 2899,74 238,22 12,17 5656,66 628,07 9,01 10,59 
 F8 1074 894,76 509,57 1,76 1946,35 1066,11 1,83 1,79 
 F9 1075 2980,33 389,68 7,65 6136,32 950,47 6,46 7,05 
 F10 1076 2003,62 354,41 5,65 4474,4 812,49 5,51 5,58 
 F11 1077 1234,17 1436,18 0,86 2687,87 2718,2 0,99 0,92 
 F12 1078 3666,89 385,75 9,51 7576,4 919,17 8,24 8,87 
 G1 1079 862,24 257,97 3,34 1780,36 592,75 3,00 3,17 
 G2 1080 1040,68 276,09 3,77 2092,05 607,02 3,45 3,61 
 G3 1081 1370,22 929,59 1,47 2682,78 1758,36 1,53 1,50 
 G4 1082 1759,75 572,91 3,07 3468,01 1182,97 2,93 3,00 
 G5 1083 9026,92 1395,6 6,47 17045,83 2681,78 6,36 6,41 
 G6 1084 3034,25 652,95 4,65 6176,51 1391,42 4,44 4,54 
 G7 1085 3138,61 344,44 9,11 6272,49 790,59 7,93 8,52 
 G8 1087 2085,57 434,66 4,80 4186,39 953,07 4,39 4,60 
 G9 1088 1133,91 282,26 4,02 2381,16 639,2 3,73 3,87 
 H1 GADD45 936,53 409,08 2,29 1888,61 858,98 2,20 2,24 
 H2 GADD45 834,27 523,42 1,59 1713,31 1068,46 1,60 1,60 
 H3  neg PCR 414,89 394,25 1,05 928,9 850,77 1,09 1,07 
 H4 GADPH 1747,41 4176,2 0,42 3404,74 7662,31 0,44 0,43 
 H5 cDNA1 528,86 385,13 1,37 1373,96 915,97 1,50 1,44 
 H6 cDNA1 545,34 335,92 1,62 1296,46 754,74 1,72 1,67 
 H7 BRCA1 4906,62 296,68 16,54 9497,72 657,48 14,45 15,49 
 H8 BRCA1 10319,32 336,14 30,70 19420,54 765,8 25,36 28,03 
 H9 cDNA2 590,97 291,21 2,03 1526,08 617,81 2,47 2,25 
 H10 cDNA2 336,49 364,53 0,92 820,45 717,38 1,14 1,03 
 H11 actin 795,51 3925,06 0,20 1572,64 7621,25 0,21 0,20 
 H12 H2O 244,67 421,84 0,58 608,12 1047,07 0,58 0,58 
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Appendix D: Actin normalized average values of 210 clones 
 
Array numbers (7, 8, 9), position of the clones on arrays, and clone numbers are 
indicated.  
F/R: Phosphoimager value ratio of forward/reverse subtracted probe hybridized 
array for 3 repeats. 
Average: Average values three repeated F/R subtracted probe hybridized array 
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Appendix D: Actin normalized average values of 210 clones 
 
 
Array Position Clone # F/R 1 F/R 2 F/R 3 Average 
7 A1 33 4,49 15,32 5,53 8,18 
 A2 41 6,06 9,39 4,41 6,83 
 A3 44 4,35 10,61 3,86 6,20 
 A4 48 24,25 18,48 7,82 15,44 
 A5 51 3,44 7,92 4,63 5,13 
 A6 53 3,28 11,03 5,87 7,07 
 A7 55 5,82 10,29 7,22 7,90 
 A8 57 4,27 7,30 8,14 6,83 
 A9 59 4,52 14,90 10,66 9,69 
 A10 62 4,4 10,23 6,16 6,88 
 A11 64 3,89 5,73 6,85 5,52 
 A12 66 3,19 10,40 6,95 7,18 
 B1 67 5,53 9,80 6,18 7,18 
 B2 71 3,17 8,24 6,38 5,89 
 B3 82 3,64 12,41 8,22 8,11 
 B4 84 4,91 8,90 7,76 7,20 
 B5 87 4,17 7,88 6,88 6,18 
 B6 89 2,78 12,04 10,29 8,54 
 B7 93 6,74 9,20 10,64 8,86 
 B8 94 2,72 7,76 6,18 5,55 
 B9 98 4,37 7,82 9,42 6,87 
 B10 107 2,93 11,48 8,46 7,40 
 B11 113 4,17 12,71 9,27 8,82 
 B12 114 4,83 13,78 12,21 10,36 
 C1  115 7,31 4,57 8,05 6,66 
 C2   118 6,94 6,17 8,58 7,12 
 C3 121 20,16 5,21 6,78 10,01 
 C4 123 4,75 9,92 7,93 7,39 
 C5 124 5,21 4,93 6,25 5,21 
 C6 125 4,51 6,99 6,04 5,80 
 C7 126 6,41 5,32 6,63 6,13 
 C8 128 4,82 5,07 5,52 6,54 
 C9 129 3,96 6,04 7,12 5,83 
 C10 131 5,17 10,23 7,15 7,51 
 C11 132 4,43 6,24 6,20 5,60 
 C12 133 16,14 14,10 8,63 12,39 
 D1 136 4,07 2,81 5,76 4,00 
 D2 137 6,05 4,04 4,61 4,73 
 D3 138 7,18 3,91 7,16 5,92 
 D4 141 4,23 5,30 8,90 6,03 
 D5 147 6,09 4,94 5,61 5,50 
 D6 150 6,27 4,16 8,40 6,22 
 D7 153 8,39 9,47 9,99 9,30 
 D8 156 3,5 5,47 9,99 6,24 
 D9 158 15,09 7,59 11,73 10,62 
 D10 162 6,15 11,40 11,13 9,39 
 D11 163 13,48 13,71 9,21 11,78 
 D12 164 10,43 8,76 9,19 9,02 
 E1 165 19,06 2,05 4,48 7,56 
 E2 169 3,7 3,24 6,52 4,45 
 E3 170 10,63 4,48 5,67 6,38 
 E4 171 9,81 4,16 5,50 6,35 
 E5 172 3,58 4,19 5,70 4,39 
 E6 173 5,11 5,74 7,05 5,76 
 E7 174 7,49 12,73 7,33 8,89 
 E8 176 4,06 5,36 10,32 6,51 
 E9 177 7,82 11,46 15,67 11,29 
 E10 179 9,74 12,16 12,27 11,32 
 E11 183 7,24 9,79 14,14 9,69 
 E12 190 14,77 13,70 25,17 16,71 
 F1 191 6,29 4,07 0,86 3,59 
 F2 192 7,78 5,71 7,01 6,12 
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 F3 194 3,78 3,48 3,01 3,32 
 F4 198 3,23 6,59 8,37 6,56 
 F5 212 1,86 5,95 10,77 6,19 
 F6 213 10,3 7,78 17,34 10,76 
 F7 214 7 7,20 7,33 6,75 
 F8 215 6,27 8,24 16,22 9,93 
 F9 217 4,02 13,84 15,82 11,28 
 F10 218 4,15 17,40 11,33 10,88 
 F11 234 2,82 13,91 15,69 10,80 
 F12 237 2,68 6,07 15,70 8,10 
 G1 239 2,16 6,62 5,85 4,88 
 G2 244 2,25 4,62 8,40 5,06 
 G3 246 5,84 5,04 10,76 7,16 
 G4 248 2,45 5,34 9,21 5,64 
 G5 251 4,04 3,63 11,47 6,41 
 G6 252 2,01 8,53 16,47 8,97 
 G7 253 2,7 10,91 18,52 10,69 
 G8 256 3,05 7,27 8,90 6,43 
 G9 259 5,1 25,51 9,33 13,24 
 G10 264 3,36 8,83 10,57 7,56 
 G11 268 6,39 31,96 23,66 20,55 
 G12 269 3,33 4,77 6,92 4,96 
 H1 GADD45  2,62 0,68 1,65 
 H2 GADD45  1,97 0,64 1,30 
 H3  neg PCR  1,16 1,24 1,20 
 H4 GADPH  0,60 1,13 0,86 
 H5 cDNA1  1,81 1,36 1,58 
 H6 cDNA1  5,71 1,39 3,55 
 H7 BRCA1  37,99 16,36 27,18 
 H8 BRCA1  29,79 18,26 24,03 
 H9 cDNA2  7,76 1,49 4,62 
 H10 cDNA2  6,08 1,21 3,64 
 H11 actin  1,01 1,00 1,00 
 H12 H2O  5,16 1,24 3,20 
       
8 A1 270 3,04 1,92 5,41 3,44 
 A2 273 1,79 1,60 5,72 3,02 
 A3 276 2,03 2,98 6,15 3,70 
 A4 277 2,94 7,03 12,37 7,45 
 A5 278 1,85 4,40 8,78 5,10 
 A6 281 4,38 2,18 8,17 4,88 
 A7 282 3,42 9,29 13,00 8,46 
 A8 293 3,13 11,19 7,15 6,97 
 A9 294 3,08 4,60 8,55 5,50 
 A10 295 4,81 10,16 3,82 6,12 
 A11 304 2,08 5,73 4,25 3,98 
 A12 305 2,02 9,62 6,79 6,13 
 B1 306 2,06 3,72 7,71 4,49 
 B2 309 2,61 6,58 4,97 4,63 
 B3 312 2,65 5,79 5,91 4,73 
 B4 313 3,73 7,28 10,15 6,95 
 B5 314 6,2 16,21 13,24 11,72 
 B6 320 1,85 4,47 6,20 4,16 
 B7 321 6,27 5,91 8,74 6,97 
 B8 326 2,39 10,40 9,60 7,46 
 B9 331 3,25 11,27 7,84 7,45 
 B10 332 2,32 10,27 4,76 5,78 
 B11 339 2,46 9,61 10,40 7,49 
 B12 342 0,91 7,87 6,78 5,19 
 C1  346 6,34 8,37 14,05 9,59 
 C2   352 3,1 3,79 5,04 3,98 
 C3 355 1,79 3,64 6,36 3,93 
 C4 358 10,86 4,60 6,42 7,30 
 C5 359 2,58 4,59 12,11 6,43 
 C6 360 1,74 4,11 11,81 5,89 
 C7 361 2,18 5,64 11,50 6,44 
 C8 362 4,36 5,67 7,00 5,67 
 C9 370 8,73 5,87 7,03 7,21 
 C10 371 5,44 15,37 6,34 9,05 
 C11 381 2,79 5,11 6,93 4,94 
 212 
 C12 383 2,19 3,17 7,09 4,15 
 D1 384 4,34 3,79 9,81 5,98 
 D2 385 5,97 3,67 9,02 6,22 
 D3 398 2,64 3,47 8,99 5,03 
 D4 400 2,65 3,79 10,84 5,76 
 D5 402 2,5 4,47 13,29 6,75 
 D6 404 2,26 4,75 16,94 7,98 
 D7 406 2,86 6,35 19,52 9,58 
 D8 408 2,35 5,04 11,72 6,37 
 D9 410 4,44 5,39 11,94 7,25 
 D10 411 5,59 6,79 10,80 7,73 
 D11 412 2,32 2,93 6,32 3,86 
 D12 415 4 6,09 14,04 8,17 
 E1 420 10,89 10,23 13,83 11,51 
 E2 421 6,47 4,07 8,54 6,12 
 E3 422 3,91 3,63 7,49 4,70 
 E4 423 8,79 14,34 19,76 13,56 
 E5 424 4,06 7,83 16,30 9,20 
 E6 426 6,46 8,27 11,58 8,73 
 E7 427 3,95 9,02 13,33 8,62 
 E8 430 6,11 5,63 11,43 7,71 
 E9 431 8,44 9,16 14,13 10,48 
 E10 432 4,12 7,71 12,04 7,94 
 E11 434 6,03 9,21 6,93 7,35 
 E12 437 3,34 4,99 10,16 6,31 
 F1 438 4,06 4,75 8,29 5,65 
 F2 441 5,66 3,57 7,88 5,66 
 F3 443 6,42 5,53 11,10 7,62 
 F4 444 6,75 4,89 15,03 8,89 
 F5 445 5,08 5,29 13,80 8,07 
 F6 446 8,85 5,81 9,36 8,01 
 F7 447 16,5 5,64 16,21 12,73 
 F8 450 7,63 7,31 15,66 10,14 
 F9 452 6,12 7,25 14,70 9,58 
 F10 453 16,48 4,46 10,60 10,04 
 F11 457 2,87 5,26 8,30 5,45 
 F12 458 9,16 8,14 16,68 11,17 
 G1 460 13,95 7,91 12,29 11,12 
 G2 461 4,72 6,95 10,06 7,21 
 G3 464 2,87 3,79 8,08 4,91 
 G4 468 2,51 5,02 9,59 5,68 
 G5 469 4,5 6,57 11,65 7,35 
 G6 470 7,18 8,85 11,86 8,91 
 G7 471 6,19 6,69 11,08 7,75 
 G8 473 8,9 6,72 17,13 10,82 
 G9 474 5,73 9,72 12,15 9,15 
 G10 475 7,26 7,35 12,17 8,70 
 G11 476 4,53 5,43 9,81 6,37 
 G12 479 4,84 6,19 15,49 8,67 
 H1 GADD45  1,54 1,12 1,33 
 H2 GADD45  2,10 0,94 1,52 
 H3  neg PCR  2,04 1,46 1,75 
 H4 GADPH  0,68 1,37 1,02 
 H5 cDNA1  2,40 1,78 2,09 
 H6 cDNA1  3,14 1,47 2,31 
 H7 BRCA1  25,91 23,61 24,76 
 H8 BRCA1  27,64 13,24 20,44 
 H9 cDNA2  2,91 2,36 2,64 
 H10 cDNA2  2,06 1,96 2,01 
 H11 actin  1,00 1,01 1,00 
 H12 H2O  1,80 1,83 1,81 
       
9 A1 484 3,6 10,63 5,14 6,50 
 A2 486 2,89 5,39 3,56 3,83 
 A3 501 2,83 7,33 2,84 4,30 
 A4 503 4,47 9,50 4,60 6,56 
 A5 506 5,06 10,57 2,61 5,82 
 A6 507 5,15 16,31 4,90 8,85 
 A7 1004 2,24 15,45 4,14 7,28 
 A8 1006 2,44 20,60 5,49 9,35 
 213 
 A9 1011 4,24 12,05 6,80 7,69 
 A10 1013 1,85 12,99 4,73 6,59 
 A11 1016 2,07 6,48 8,68 5,79 
 A12 1020 5,12 21,42 5,69 10,68 
 B1 1021 3,08 7,29 4,38 4,93 
 B2 1026 3,96 17,59 4,98 8,81 
 B3 1029 7,09 21,59 9,82 12,72 
 B4 1034 5,19 17,27 4,38 8,90 
 B5 1037 6,79 14,08 3,75 8,12 
 B6 1039 6,95 12,24 3,34 7,45 
 B7 1040 20,38 23,94 5,76 16,35 
 B8 1042 6,16 14,14 4,07 8,04 
 B9 1045 6,01 13,11 6,92 8,57 
 B10 1049 22,3 26,93 11,33 19,60 
 B11 1050 6,63 8,91 5,17 6,87 
 B12 1052 3,06 11,69 8,44 7,68 
 C1  1053 5,32 23,69 7,87 12,27 
 C2   1055 6,37 7,97 6,04 6,79 
 C3 1060 6,96 17,88 6,30 10,16 
 C4 1064 6,57 25,54 8,33 13,28 
 C5 1065 9,08 15,20 7,32 10,43 
 C6 1067 6,96 13,36 6,09 8,68 
 C7 1069 5,24 13,32 5,68 7,98 
 C8 1070 3,49 15,11 7,45 8,66 
 C9 1071 14,76 47,96 24,99 29,00 
 C10 1072 6,96 29,41 7,70 14,62 
 C11 1073 12,17 16,00 5,87 10,82 
 C12 1075 7,65 17,99 8,09 11,05 
 D1 1076 5,65 8,12 10,25 7,98 
 D2 1078 9,51 27,03 12,17 16,02 
 D3 1079 3,34 5,76 6,48 5,14 
 D4 1080 3,77 8,07 6,33 6,00 
 D5 1083 6,47 28,70 14,02 16,38 
 D6 1085 9,11 15,06 8,29 10,62 
 D7 1087 4,8 12,73 7,36 8,23 
 D8 1088 4,02 12,52 10,99 9,13 
 E1 GADD45  3,12 0,99 2,41 
 E2 GADD45  3,96 0,86 2,41 
 E3  neg PCR  2,51 1,35 1,93 
 E4 GADPH  0,66 1,09 0,87 
 E5 cDNA1  3,88 1,47 2,68 
 E6 cDNA1  4,95 1,21 3,08 
 E7 BRCA1  49,42 21,33 35,37 
 E8 BRCA1  47,40 19,95 33,68 
 E9 cDNA2  5,51 1,27 3,39 
 E10 cDNA2  3,69 1,29 2,49 
 E11 actin  0,99 1,01 1,00 
 E12 H2O  2,82 1,54 2,18 
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Clone 33 (ad1) 
TCNCTACGCCCTGGGCCCGTACGTCGCATGCTCCCGGCCGCCATGGNCGGCCGCGGGAAT
TCGATTTCGAGCGGCCGCCCGGGCAGGTCTGTAGGGATACTGCTTCATAAGCACCAGCA
GAACACCAAAGGAGACCATATGGGTGAAAGCAACCAGCACTGCCCTGGCGCTTCATAGGT
TCTTAGAGTTTTTATCTTTTACTTTCAGTCTAACACAGCACTGCCTGCTTTTTGTTTTTGTTG
CTTGGTTTGTTTTTTTCTTACCGTGTTCACCAAACTTGTGTCCAAATAGCTTTGGGCTGATG
CAAAAATATCTATGTGGAAGAGAAGAAGTTGTTCTCATGGAGGGCCTTCAGATGAGTGCT
ATAGACTCTCTAGGCAACTCCAAGAGGCTTCTCAAGCAGGGTGGGCAGTGAGAGCTGCTA
TGG 
 
Clone 41 (ad1) 
ATTTTTACGNCCTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGNCGGCCGCGGGAAT
TCGATTTCGAGCGGCCGCCCGGGCAGGTTCAATCTCCAACAACATGCCAGTGATTTTAC
CAGCAAGAGTAGGGTGCATGGCTTGAATAAGAGGAAACAGCCGTTCACCCAACATTTGCT
TTTGCTCTTGAGGAGGGGCAGATGCCAACATGGAAGCAGTCAAAGGTTCCTGGCCTTGTA
CATGAACAGCAGGCTGTTGCATTGTAACTTGTGGCTGTGCATTAAGATGTTGCTGAGGATT
GCGAACTCCTGCAGCATATTTATACTGTGGAACGGTGCGGACAGCAGGAGTAGCTGCGGC
GGCTGCAGCTGAGGACGTGGACCCATTGTCTGTGTGATGTGTTAGCAACACGCTGTGTTGA
CATGACTCGTGGAAC 
 
Clone 48 (ad1) 
NTTNTTACGACCTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGNCGGCCGCGGGAAT
TCGATTTCGAGCGGCCGCCCGGGCAGGTACTTTCTATGAGAAGCGTATGGCCACAGAA
GTTGCTGCTGACGCTCTGGGTGAAGAATGGAAGGGTTATGTGGTCCGAATCAGTGGTGGG
AACGACAAACAAGGTTTCCCCATGAAGCAGGGTGTCTTGACCCATGGCCGTGTCCGCCTG
CTACTGAGTAAGGGGCATTCCTGTTACAGACCAAGGAGAACTGGAGAAAGAAAGAGAAA
ATCAGTTCCGTGGTTGCATTGTGGATGCAAATCTGAGCGTTCTCAACTTGGTTATTGTAAA
AAAAGGAGAGAAGGATATTCCTGGACTGACTGATACTACAGTGCCTCGCCGCCTGGGCCC
CAAAAGAGCTAGCAGAATCCGCAT 
 
Clone 55 (ad2) 
ATTNTTGCGNCCTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGCGGCCGCGGGAATT
CGATTAGCGTGGTCGCGGCCGAGGTACTTCAGATGAGGAAATCTTTATCTCACAAGATG
AAATACAGTCATTTATGGCTAATAACCAGTCTTTCTACAGCAATAGAGAACAATACCGAC
AGCATCTGAAGGAGAAATTTAATAAATACTGCCGGTTAAATGATCACAAGAGGCCCATTT
GTAGTGGCTGGTTGACAACGGCTGGAGCAAATTAAATAAATAAAATAGCTCTGTCTTTCA
ATGAAACACTCACGATGACTACTGCGCCTTCTCTTTCGAAAAACTCTTAATTTAGTGACTT
ATGGCAAAATTTTATCTTAAATCAATGTGATTCTTTCTTGTTTTGGGAGACGGGGAAGGTA
TCCTCATTAGTTCTTTCTT 
 
Clone 59 (ad1) 
GNNCTCGTNATTGCGGTCANCGTNNNCGCGNATGNTTNCCGGCCGCCATNGACGGCCGCG
GGCAATTCGATTTCGAGCGGCCGCCCGGGCAGGTACACCAAGCATGTGGTAAGTTAGA
AATGACAGGAAAGTGCTCCCCAAAGCAGTGGGAGAGGCAATGTGGTCTCTNACATCCATT
CAATGTGCATTCTTTTTCCTGGAATATCTGTTACCCANCCTTCTCAGGAACAAGAACCAGG
ACGACGGGGAGTATGTGTCAAATAAGTNCCTCGGCCGAGACCACNCTAATCTCTAGTGAA
TTCGCGGCCGCTGCAGGTCGACCNTATGGNAAAGNTCCCAACGCGTTGGATGCATAGCTT
GAGTATTCTATANTGTACCTA 
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Clone 66 (ad2) 
ATTNTTTCGNCCTGGGCCCCGACGTCGCATGCTCCCGGCCGCCATGGNCGGCCGCGGGAA
TTCGATTAGCGTGGTCGCGGCCGAGGTGTCAGAATAAAGAGTCCAGCAAAGATGATAC
CAAAGAGGCAAAAGAATCTAAGGAGAATAAGGAGGTATCAAGTCCCGATGATTTGGAAC
TTGAGTTGGAGAATCTAGAAATTAATGATGCCACCTTAGAATTAGAGGGTGGAGATGAAG
CTGAAGATCTTACAAAGAAACTTCTTGATGAACAAGAACAAGAAGATGAGGAAGCCAGC
ACTGGATCTCATCTCAAGCTCATAGTAGATGCTTTCCTACAGCAGTTACCCAACTGTGTCA
ACCGAGATCTGATAGACAAGGCAGCAATGGATTTTTGCATGAACATGAACACAAAAGCAA
ACAGGAAGAAGTTGGTACGGGCN 
 
Clone 67 (ad2) 
TTCTNGACTACGCTTCTTGNNTCCCGACGCNCGCATGCTCCCGGCCGCCATGGACGGCCGC
GGGCAATTCGATTAGCGTGGTCGCGGCCGAGGTACGAAAATGGGACCAGACACATGAA
CAGCCTGGCCTAAATGAACTCCATCAATCTTAACTGTGACAGAAGTAATGGAGGATAAGG
AAAAGGCCAAGACTCTGATGTGTGTTGAGTGAAGAAGTTTTTCTAGTGGNTCATGTTCACC
ACTANTATAANGGANTGATTTTTANNNGTGATAAAAACCTGGCCTTTCCTAANATCAATTN
TTNTGNGCACANNAGANTNGATCGAATNNATNNANCCNCCCTGCNNGGCNNCGNCCANTT
NNTACNTATTCNNGNACCNTGTANNNNGACCNNTGGGANACTTTGACGCC 
 
Clone 82 
TTTATGANANNGAANNGTGNATNTCTAACAGTGGTNNCANTTATNNCCGTATATGGNNCG
ATNGNGANNTATCTATATGAGTAGATGGNNCACNGACCNATAGTANTATGATNAAGTCTT
TNATATGAATGAAAATGCACCCGNTGGATTTTTTTCNCCCTCATNACATTAGCTTGTATAC
ACGTGGGAATTGAAAGGNTTGCATTTTCTTNACATAGTTCTTGCTATGATGACTGANGGAC
TTTTTGCCCTCAACAAATTNATCAAGAAAAACAGGCCAAGCANCATNTTCATATANNNCC
TAANATCNANATGNACTGTTCTGNTGAANTCTAATACNTTGTACCTGCCCGGNNTAANGT
NNNANNTCCTTNNGANTNTNCNNNTCNNTGCANNNNCCAAGCNGACTAGATGNNNNNAN
TTNANCNTTNCCNANTTCNCTATAGGCACTCTAAANNANNTNATNNNNTNTCA 
 
Clone 89 (ad1) 
NTCTGCGCCCTGNGTCCGTATTGCNGATGCTNCCGNCCGCCATGGNCGGCCGCGGGAATT
CGATTTCGAGCGGCCGCCCGGGCAGGTACAGAAAGTGAAAATGCTGTTACAATCTCAG
TGTAACTGGTAGCCACAGACGGTTGACTCACCAATCACAACTATCCACGCTACAGCAAGA
ATCTTACACAAAAACCTAACAACGCTTACAATTTTGTTGGGGTGAAGTCCACAAGCTTGGT
GGTAGATTACCAAGAGGGACTACATGGAAGGAAGGCGGAATGTCACAGGAACTATTCTTT
GGCTCTTTGGGTGGNGGGGTGTCCTCGGGTTTGTATCACAGCTACCTTTTTTTTTTTTTTAA
ACAGNTNCAAAATCCNTGANCAGNCCANCCAATACTGAACAGTTNTGTTTNTGCNGGTNA
TNT 
 
Clone 93 (ad2) 
TTTTTTCGACNTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGNCGGCCGCGGGAATTC
GATTAGCGTGGTCGCGGCCGAGGTACAGGTTTCCTAAAGACAAAAAAAAATGGAGGAA
TCTGTAAACCAAATGCAGCCACTGGATGAGAAGCAGATAGCCAATTCTCAGGATGGATAT
GTATGGCAAGTCACTGACATGAATCGACTACACCGGTTCTTATGTTTCGGTTCTGAAGGTG
GGACTTATTATATCAAAGAACAGAAGTTGGGCCTTGAAAATGCTGAAGCTTTAATTAGAT
TGATTGAAGATGGCAGAGGATGTGAAGTGATACAAGAAATAAAGTCATATAGTCAAGAA
GGCAGAACCACAAAGCAAGAGCCTATGCTCTTTGCACTTGCCATTTGTTCCCAGTGCTCCG
ACATAAGCACAAAACAAC 
 
Clone 107 
NGCAGACNNCTCCNTNCTATCCCGNTGCTNCNNTCCGTACTTGGNCNGATCGCGANANTT
TATATTTCGTGCGGCACGNCCGTACAGGTACATCCAAAAGTCTCAGTGTAATAGCAGGAC
CAAAATATTCTGTCAATCAGCTGACCATATACTTAATGACTCCTAAAATCTCGTGGACTTC
TAAGAAAGCGCCATGGCCTGTGCTGCTGTTATGATTCCTGGGTTGTTGCGGTGCTCTGTTG
GAGCCATCCGTATTGAGGCTGCGTCACTGAGATTGACACTCAGCACTTTGCGCCATCTTAC
TCTAACCAGCATAATGAAATCCAAAAGGAAAACTGATCACATGGAGAGAACTGCAAGTGT
 
 
 
 
 
217 
CCTTCGACGGGAGAGCAACTTATTTCATCAAGGGAGAAAGCACTAACATCTGAGAAAGGA
AAGTGGACGAGCTCTTGTTACCCATCTAATGTACCTCGGCCGCGACACGCA 
 
Clone 113 (ad1) 
ATTTTTACGCCTGGGCCCGTNGTCGCATGCTCCCGGCCGCCATGGCGGCCGCGGGAATTCG
ATTTCGAGCGGCCGCCCGGGCAGGTACAAGAGCTGTTGGCTGTGTTAAGGTGGTGTTTA
TTGTTTCGTTAATTATCAAAGCAGCTTCCACAGGACACGGAACCTGAAATTTCTTGCAAAT
GACCACAATCAGAAAGAACACCATACACAACAAGGAAAGGCCACTGGTATATCCCAAAT
ATCCTAAATTTCTAAGCAGCGACAAAGGAAGAATGACCACCAATGACACCAACAGAACC
AAATAGTTCCCGTTCAGATACCACAATCCAGTTTTATCTTCAATGTTCTTAGNGCCTGGAN
CCCAAGGGNCTCTTATNTTTCTNTNNGAAGNGGGNTCTTGTATATCCCCANTGNTNANTNT
GNAAGNGCCCANA 
 
Clone 114 (ad1) 
TTNTTACGACCCTGGGTCCCGACGTCGCATGCCTCCCGGCCGCCATGGNCGGCCGCGGGA
ATTCGATTTCGAGCGGCCGCCCGGGCAGGTACCATCTTATTTCTTTTGGGGATTATACAC
CTCAGCCGCCTGAGATGGGGGTCAGCTCTTTATATAAAGGGAAACCAGACCAGGCCTAAA
GCCCACCCCTACCCTCACCCCCCCAATCCTCTCCTGAAACTTAAAAACAGTGGGAATATAG
GAAAGGGAACCAAATCTCATTAATTAATTGTTCTCCCCCATTACCCCACTGAATGAATGGC
CATACAGGCTAAGCTGAATAATGACGAAGTTGAAAGGACCAATACAGCCCCTTTTATAAG
GATTTTGAATGTTTTGCAAATGTATTGGCCCTGTGTTGTATTTTGTAGCCTTTTCCTGGGCT
TCAGCTCCCCTACT 
 
Clone 118 (ad1) 
TTTCGCNTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGCGGCCGCGGGAATTCGATTT
CGAGCGGCCGCCCGGGCAGGTACTCCCAAGGGAACGCTGTCCACCTCTATGAACTTCTG
AAGAAAATGACTGGCAAACCCGAACCCAAGGCTGTTTATTTTGGTGACAGCATGCATTCA
GATATTTTCCCAGCTCGTCACTATAGTAATTGGGAGACAGTCCTCATCCTGGAAGAACTCA
GAGGGGATGAAGGCACGAGGAGTCAGAGGCCTGAGGAGTCAGAGCCTCTAGAGAAGAAA
GGAAAATATGAGGGACCAAAAGCAAAACCTTTAAATACTTCATCTAAAAAATGGGGCTCT
TTTTTTATTGTTCAGTTTTGGGACTGGAAAATCAGAAGACTCCTTGGTTTATACATGGTCTT
GTAAGAGAATC 
 
Clone 121 (ad2) 
TTTTNTTNNCGNAAACCCNTTACTATAGGNTTNCNTACCNTCACGTATTGGGTNGATCGCC
GNCTAATCTNTATTAGTCGTGGCCACNGACCGAGGTACCTTAACCACACACCCTACGAC
CAAGNAGAAATTANCAGTTGAGCAAAGATACAGACCAAATGCCTCTGGGAGATGGACTG
AAGCAGCTCCAAAGAAAGCTGTAAAAAAGTGACAAGAATTTGTTCTTCCACTTTGAGACT
GTTCGATTCAAACATGAGTCCAAGGCACGTATCCTTAAGAGGAGATGCTCTGCTGCTGTCT
CATTTGCCAGATTATCCTTCAGTTCCAGGCTTTCAACAGGATATGACTGGTTCATGCTCCA
TGATAGGAAAGGAATTAAAGTTTGAAGTCAGAGTGAATGGCCACAATGCCTGATGTTAGA
CTTTCGTAAGTCACCTTGTGA 
 
Clone 133 
TNGGCAGNNNCTACCTACTATCCCGACGTANNANTCCTATTGGNCCATACGACTCACTAT
ATGGNAANAGCNACTCNNTATAGGGACAGNNCANGGNCNTTATAATTTGGGCCTCAAGA
ATTGATAGTTGTCTCTTAACTGGTTCTGCTGAGGCGCACTCACAGCAGTGAGTGGAGGGTC
CTGGGAGGGCATGGATGACGGAGGCTGCCCCTAGAGGAGCTGGATGTAGGAGCAGAGAC
ATTTCTTGATCTTTCACTCTGCAAACTGGTCCAAGAACTTGAGGTAGGCCTGACGCTGGGG
TGCAGCTGCTGGAATGAAGTGGCCACCAGAGTGGGTGAGGGTGATGGCTCCGGGAAATTG
GCTGACCAGTTGCACACTCTCCTGAGAGGGGATGACTTTGTCAGTGTCCCCAAAAACATG
GAGCGAAGGCAATGACAAGGGCCTTTGCAGGATGGATTCTTGAA  
 
Clone 153 (ad2) 
ATTTNNTTCGACNTGGGCNCCGACGTCGCATGCTCCCGGCCGCCATGGCGGCCGCGGGAA
TTCGATTAGCGTGGTCGCGGCCGAGGTACAGTCAGCTACTCATTTTAAAAAGGTTCGCG
GACCTTCCCGAGCTGATCCTAACCATCTTGTAGATGATCTGCTAACACCTTGCTCTCCAGG
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TGACCCTGGTGCCATTGAAATGACATGGATGGATGTCCCTGGAGATAAACTTTTGGAGCC
AGTTGTTTCCATGTCGGATATGTTGCGGTCACTATCTAACACAAAACCTACAGTCAATGAA
CATGACTTGCTGAAATTAAAGAAGTTTACAGAAGATTTTGGTCAAGAAGGCTAAGCCAAA
GACAAGGAAGATGCCTACCATATGTATTCTTTCTTTCATAGATATTTTTGCTATTTGGATCG
CATTAATTGNTTCCA 
 
Clone 158 (ad1) 
NTNTTTACGNCCTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGCGGCCGCGGGAATT
CGATTTCGAGCGGCCGCCCGGGCAGGTCCACATTGCACTTTCCACATGCTTCAAACATC
ACCTTGTACAAGGATCAGTTACAGTTGTGGATTCGAGGCAACGTGAGTGCCTGTGCGAGG
TCCATCTTCATATTTGATGAAATGGATAAGATGCATGCAGGCCTCATAGATGCCATCAAGC
CTTTCCTCGACTATTATGACCTGGTGGATGGGGTCTCCTACCAGAAAGCCATGTTCATGTT
TCTCAGCAATGCTGGAGCAGAAAGGATCACAGATGTGGCTTTGGATTTCTGGAGGAGTGG
AAAGCGGAGGGAAGACATCAAGCTCAAAGACATTGAACACGCGTTGTCTGGTCGGTTTTC
AATAACAAGAACAGTGA 
 
Clone 162 (ad2) 
CCNGNACCNCNTNTTCACCGTCCCNCGCATGCTCCCGGCCGCCATGGCGGCCGCGGGAAT
TCGATTAGCGTGGTCGCGGCCGAGGTTGAAAACCTATATCCCTCCCAAAGGGGAGACA
AAAAAGAAGTTCAAGGATCCCAATGCACCCAAGAGGCCTCCTTCGGCCTTCTTCCTCTTCT
GCTCTGAGTATCGCCCAAAAATCAAAGGAGAACATCCTGGCCTGTCCATTGGTGATGTTG
CGAAGAAACTGGGAGGGATGTGGAATAACACAGCTGCAGATGACAAGCAGCCTTATGAA
AAGAAGGCTGCGAAGCTGAAGGAAAAATCGAAAAGGATATTGCTGCATATCGAGCTAAA
GGAAAGCCTGATGCAGCAAAAAAGGGAGTTGTCAAGGCTGAAAAAAGCAAGAAAAAGA
AGGAAGAGGAGGAAGATGAGGAAGATGAGAGGATNAGGGG 
 
Clone 174 (ad2) 
TTTTTTCGNCTTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGCGGCCGCGGGAATTCG
ATTAGCGTGGTCGCGGCCGAGGTACTGTAGATATACAGAAGAATGGTGTTAAATTTACC
AACAGCAAATTGACTTCTTTAAATGAAGAGTATACCAAAAATAAAACAGAATATGAAGAA
GCCCAGGATGCCATTGTTAAAGAAATTGTCAATATTTCTTCAGGCTATGTAGAACCAATGC
AGACACTCAATGATGTGTTAGCTCAGCTAGATGCTGTTGTCAGCTTTGCTCACGTGTCAAA
TGGAGCACATGTTCCATATGTACGACCAGCCATTTTGGAGAAAGGACAAGGAAGAATTAT
ATTAAAAGCATCCAGGCGTGCTTGTNTGAAAGTTCAAGATGAAATTGCATTTATTCCTAAT
GACG 
 
Clone 177 (ad2) 
NTTACGNCNTGGGCCCGTACGTCGCATGCTCCCGGCCGCCATGGNCGGCCGCGGGAATTC
GATTAGCGTGGTCGCGGCCGAGGTACGGTTCTTCCTGTGTCAGCTCAATAGCTTGCTGCT
TTTTAAGAACCAAGAAGCTGTAGAACTTTGCGGCAGCTTGTTTTCTGTTCGTATTTCGACA
TAACTCAAGCAAACTGATAGATTCAGCTCCAGTTTAAGCAAGAGCACGCTGAAGACCATG
AAGCATCTGCTGAGTCCTTTTGTTCCATCTTCTTTCTTCCTGATCTTGATCGCCCCCTGATG
CATCTTCATCCTCTTCCTCTTCATCATCTTCTTTTTCCTTCTCTTTCTCCTTCTCTTTTTCTGG
AGAAGTTCTAACTCTGGTATTAGCTGACAGATATTGNAGGTTCTTCTGGGGGAAG 
 
Clone 190 (ad2) 
TTTNTTACGNCTTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGNCGGCCGCGGGAATT
CGATTAGCGTGGTCGCGGCCGAGGTACCACTAATCGGGCCAATATGGCTTGTGAGCAAA
ATGGGTGAAAATAGAGGGAACTGACTGGGACCTGTTGTCTAACATCATTTTAAGGTTGAA
CTTGAGCAAAGACTTAGAGAAAGCTGATGGAATGCCAAGCATCAACGTGAAGAGACCCTC
TATGCACACAGTGGATATGTTATGCCTGGCTGTAGCCACCTTCTCTTCTGAAAACAAGATG
GGAATGACGGAACTGTATTAAAAGATTAAGTTATCCACTAGGGAGCATACTAGCACACTT
CCAGATCAGCCTTGAGATGCTAGACTTCAGATACAGGGACTTGTGTCAGGTGGCCTCTAG
AAATGT 
 
Clone 192 (ad2) 
NNGGGGGACCNCNNANCNTNCGTANCCCGCATGCCTNCCGNCCGCCATGGCCGGCCGCG
GGTAATTCGATTAGCGTGGTCGCGGCCGAGGTCCAGAATGTTGCAGATTACATGCGCTA
 
 
 
 
 
219 
CTTAAAGGAAGAAGATGAAGATGCTTACAAGAAACAGTTCTCTCTATACATAAAGAACAG
CGTAACTCCAGACATGATGGAGGAGATGTATAAGAAAGCTCATGCTGCTATACGAGAGAA
TCCAGTCTATGAAAAGAAGCCCAAGAAAGAAGTTAAAAAGAAGAGGTGGAACCGTCCCG
AAATGTCCCTTGCTCAGAAGAAGGATCGGGTAGCTCAAAAGAAGGCAAGCTTCCTCAGAG
CTCAGGAGCGGGCTGCTGAGAGCTAAACCCAGCAATTTTCTATGATTTTTTCAGATATAGA
TAATAAACTTATGAACAGCAAAAAAAAAACCTGCCCGNNGNNCNNTNNAAATCCTANGA
ATTCC 
 
Clone 218 (ad2) 
ATTTTTACGNCTTGGGCCCGTNGTCGCATGCTCCCGGCCGCCATGGNCGGCCGCGGGAATT
CGATTAGCGTGGTCGCGGCCGAGGTGGCTTGGCACCCAGAGAAAGCCTCTGCCCCCGA
AAGAGACTTTCTACATAGGGTTAAGCTTCATTAAATGAGGTGCAACCTTTCATTTTCAGGG
CATCTCTTTTCTTGCAAGGTCTTTAGAGGCAGAAGTTCCACTTGGATTCTAATACACATCTC
TGTGAGCTCAGTTTCCTGAAAATATACACCTACTGGGTTCTAGGTTCTCCCTTACCAGTGA
CTGTATTCATTATTTCACAGCCACCAGAATCGGACATACNCTATTAACATGATGAAAAATA
CAGCTACTGCTGCAAGTTTGGCATAAGTGGAACGCATGTTCAAGTACTTCNCATCCTGGCG
GA 
 
Clone 234 (ad1) 
NNTTNCCNCAACCNCTTNTTTACCGTACCTCNGCATGNCTNCCGGCCGCCATGGNCGGCCG
CGGGAATTCGATTTCGAGCGGCCGCCCGGGCAGGTGGCGTGATGTCTCACAGAAAGTT
CTCCGCTCCCAGACATGGGTCCCTCGGCTTCCTGCCTCGGAAGCGCAGCAGCAGGCATCGT
GGGAAGGTGAAGAGCTTCCCTAAGGATGACCCGTCCAAGCCGGTCCACCTCACAGCCTTC
CTGGGGTACAAGGCTGGCATGACTCACATCGTACGGGAAGTCGACAGGCCGGGATCCAAG
GTGAACAAGAAGGAGGTGGTGGAGGCTGTGACCATTGTAGAGACACCACCCATGGTGGTT
GTGGGCATTGTGGGCTGCGTGGAAACCCCTCGAGGCCTCCGGACTTCAAGACTGTCTTTGC
TGAGCACATCAGTGATGAATGCAAGAGGCGTTTCTATAAGAATTGGCATAAATCTAAGAA
GAAGCCTTTACAAGTACCTCGGNCGCGACACGCTAATCCTATGAATTCGCGGCCGCTGAG
TCGACATATG 
 
Clone 259 (ad1) 
TTTNTTNCCTTGAACCCNGTTCCTACGTCNCATGCTCCCGGCCGCCATGGNCGGCCGCGGG
AATTCGATTTCGAGCGGCCGCCCGGGCAGGTACCAAATTCAGGAGCATCAGCCAAAAG
TAGCACTGAGCACGTTGAGAGATCTCCAGTGCCCAGTGCTGCAGAGCAGCGAGCTGGAGG
GAACGCCAGAGGTGTCCTGCCGGGCTCTGGAGCTCTTCGACTGGCTCGGCGCCGTCTTCAG
TAATGTCGACCTTAATAATGAGCCTAATAATTTCATATCAACCTATTGCTGTCCTGAGCCA
AGCACAGTGGCGGCAAAAGCTTATTTTGTGTACCTCGGCCGCGACCACGCTAATCACTAG
TGAATTCGCGGCCGCCTGCAGGTCGACCATATGGGAGAGCTCCCAACGCGTTGGATGCAT
ACTTGAGTATTTAT 
 
Clone 268 (ad2) 
NGNCNNCTTCTGATTCCTATCGTGNTGCNTNCNNCCGCCATGGNCGGCCGCGGGAATTCG
ATTAGCGTGGTCGCGGCCGAGGTACATTAAGTAGAAAGTTTCTAACTACCCTAAAGTCA
CAAACCAAGATTCAAAATGAACCTCTAGGCCTTGCCCTAACATTTCCCCAACACCACAAA
ATTGTCCAACTTGCTCTATTGTAAGTAACCTTTAAACTATTAGCGAGTTTAGTAACATCCC
GCGAGGCAGATTTTAAACTACGATACAGTTTCTATCTAGGCCACTGTGTTTAGTGTGTTTA
CAAACAGCTTGGAGTTCTAGGTTTCTTCATCATCAGTGAACACAGAGCGTCCTANAGCGCC
AGCCTGTTCATGAGGGGTGTCCACAAAAGCACGCAAACTATAGCAGAGTGNGNGGGAGT
G 
 
Clone 277 (ad2) 
CTCCNNCACCCNCTTGTNCCCGACCNCGCATGCTCCCGGCCGCCATGGCGGCCGCGGGAA
TTCGATTAGCGTGGTCGCGGCCGAGGTACCTCCACTGGCTCTGTGGAACCTGTCTGGTA
CAGCTCTAAAATGAAGTCATGGAGTGGGTGATGTTTCCCCACAAATAAGACATCACCTCC
AAGGCTGTTTCTTCTGGTCTCTTCTGGAGTGAGGTCTGGGTATACCTCTTCTAGGGCAGCT
CGTAGCCTTCGCTCATCCACGAATGGCAAGAGAGCGACACCTTGCCATGCATATTTCTTCC
CATTCAAATCAATAGCAAAATCTTCAGGATAGAGGTCAACTATACTAGAATCAGGATCAC
TCATGAGCTTCCGCCATGATGGAGGTAGAAAATTCCACTTGCAGCTGGAAATCCCCCATA
 
 
 
 
 
220 
AGTTGTTCTAGTGGTTAAACGGTTCGACCTNCCCGGGGNCGTCAAATCCTANNGAATTCNC
GGNCGCTGCANTCNACTATGGGANACTCCAACNCNTGGANCTACTTGAGATTCTATA 
 
Clone 282 (ad1) 
TNAAGGCGACNTCTTGTTCCCGTCNCNGCNGATGCCTTCCGNCCGCCATGGNCGGCCGCG
GGAATTCGATTTCGAGCGGCCGCCCGGGCAGGTACCTATCGAGGACAAGAATTTATTA
GAGTTGGCTATTATGTAAATAATGAATATACTGAGACAGAATTAAGGGAAAATCCACCAG
TAAAACCAGACTTTTCTAAGATTCAAAGGAATATTTTGGCATCTAATCCCAGGGTCACAAG
ATTCCACATTAATTGGGAAGATAACACAGAAAAACTGGAAGATGCAGAGAGCAGTAATC
CAAATCTACAGTCACTTCTTTCAACAGATGCATTACCTTCAGCATCAAAGGGATGGTCCAC
ATCAGAAAACTCACTAAATGTCATGTTAGAATCCCACATGGACTGCATGTGACCACCTAC
CATCCCTTTAGTACCTCGGCGCGACACGCTAATCCTAGTGAATTCGCGGCGCTGCAGGTCG
ACTATGGGAGAGCTCCACGCGTGGATGCATAGCTTGAGATTCTATAGTGCNCCCNAAA 
 
 
Clone 293 (ad1) 
AGNGTCCNGGGACNNNCTTNNGTCCCGCACNCTTCGCATGCTCCCGGCCGCCATGGACGG
CCGCGGGAATTCGATTTCGAGCGGCCGCCCGGGCAGGTACACCAAGCATGTGGTAAGT
TAGAAATGACAGGAAAGTGCTCCCCAAAGCAGTGGGAGAGGCAATGTGGTCTCTCACATC
CATTCAATGTGCATTCTTTTTCCTGGAATATCTGTTACCCACCCTTCTCAGGAACAAGAAC
CAGGACGACGGGGAGTATGTGTCAAATAAGTACCTCGGCCGCGACCACGCTAATCACTAG
TGAATTCGCGGCCGCCTGCAGGTCGACCATATGGGAGAGCTCCCAACGCGTTGGATGCAT
AGCTTGAGTATTCTATAGTGTACCTAATCA 
 
Clone 295 (ad1) 
TTTNTTNNTNAACCANTCCTATAGCGNTGCNTACCNNCCGTCATGGGCGGCCGCGGGTAA
TTCGATTTCGAGCGGCCGCCCGGGCAGGTACCAAATTCAGGAGCATCAGCCAAAAGTA
GCACTGAGCACGTTGAGAGATCTCCAGTGCCCAGTGCTGCAGAGCAGCGAGCTGGAGGGA
ACGCCAGAGGTGTCCTGCCGGGCTCTGGAGCTCTTCGACTGGCTCGGCGCCGTCTTCAGTA
ATGTCGACCTTAATAATGAGCCTAATAATTTCATATCAACCTATTGCTGTCCTGAGCCAAG
CACAGTGGCGGCAAAAGCTTATTTGTGTACCTCGGCCGCGACCACGCTAATCACTAGTGA
ATTCGCGGCCGCCTGCAGGTCGACCATATGGGAGAGCTCCCAACGCGTTGGATGCATAGC
TTGAGTATTCTATAC 
 
Clone 305 (ad1) 
TGACNNCNCCTACCTCCTATCCCGNNNCCTACNNTCCGCCATGGCNGCCGCGGGAATTCG
ATTTCGAGCGGCCGCCCGGGCAGGTACTACTTTTCTCACTTTTTCTGGTTAGCCAGAATG
TTCCATTAAGAAACAATAAAAGTTGTATAGTTCTCTAAGATGAAAGATTAGTATATTCAAT
GGCTATTATATTAACCATTTAGTGAACACACAACAAAAACTATCCTTATATTAATTGACTG
AAGTTATAACATAAGAAATAAGTTACACTACTACTTTGTCATTCACTTAATGCTTACAAGA
TTACTCAAGAAATCAAAATGGCTTCCCATTGCTTGACGTTTGTTGTCCAAATACTTCACAT
TTCAATCTCATATACCTACAAAGAGGAAAAAATCCAAACATACTTTCCTTACCTAAAAATA
TTAAAGAAGGCTAAAAGGCATTAGGAATTTTTTTAAACCTTGAAAAC 
 
Clone 314 (ad1) 
TTTNTTTTTTGGAAACCGGNCCGTCGTCNCATGCTCCCGGCCGCCATGGCCGGCCGCGGGA
ATTCGATTTCGAGCGGCCGCCCGGGCAGGTACAGTGTGTTAATGATTTTCGCAGTGTTT
CCTTGAACTTGCTACAGACACATTTTAAGAAAGCCCAAGAAAATCAGCAGATTGGGAGGG
TAGAATTTCTTCCAGTCAACTGGCACAGTCCTTTGCATTCTACTGGTGTGGATGTAGATCT
GCAGCGAATAACCCTGCCCAGCATTAACCGCCTCAGGCACTTCACCAATGACACAATTCT
GGATGTCTTCTTCTACAATAGTCCCACCTACTGTCAGACTATTGTGGACACAGTTGCTTCT
GAAATGAACCGAATATACACACTTTTTCTACAGAGGAACCCTGATTTCAAAGGGGGGTGT
ATCCATTGCTGGACAT 
 
Clone 321 (ad2) 
GNNNNTTTTTCGNCTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGCGGCCGCGGGAA
TTCGATTAGCGTGGTCGCGGCCGAGGTACAGTGCCAGACCATGACTGTCAATCGTCAGA
TGAAGCGCTACAACGTTCCGTTTCTAACTTTTATTAACAAATTGGACCGAATGGGCTCCAA
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CCCAGCCAGGGCCCTGCAGCAAATGAGGTCTAAACTAAATCATAATGCAGCGTTTATGCA
GATACCCATGGGTTTGGAGGGTAATTTTAAAGGTATTGTAGATCTTATTGAGGAACGAGC
CATCTATTTTGATGGAGACTTTGGTCAGATTGTTCGATATGGTGAGATTCCAGCTGAATTA
AGGGCGGCGGCCACTGACCACCGGCAGGAGCTAATTGAATGTGTTGCAATTCAGATGAAC
AGCTTGGTGAGATGTTTCTGGAAGAAAAAATCCCCTCGATTTCTGATTAAAGCTAGCAATT
CGAAGAGCTCTCTGAAAAGACATTTACTCCTGATTTTT 
 
Clone 326 (ad1) 
CGNCCNGGACCCCTTGNGCCCGACCNCGCATGCTCCCGGCCGCCATGGCGGCCGCGGGAA
TTCGATTTCGAGCGGCCGCCCGGGCAGGTACAACTACCCCTATCAGTCACTCACAACTG
ACCTTCACTACTATTACATCCTGGAGCTGTCGTTTTATTGGTCTTTGATGTTTTCTCAGTTC
ACTGATATCAAAAGAAAGGACTTTGGCATTATGTTCCTGCACCACCCTGTATCTATTTTCT
TGATTACCTTTTCATATGTCAACAATATGGCCCGAGTAGGAACGCTGGTCCTTTGTCTTCA
TGATTCAGCTGATGCTCTTCTGGAGGCTGCAAAATGGCAAATTATGCCAAGTTTCAGAAA
ATGTGTGATCTCCTGTTTGTATGTTTGCCGTGGTTTTTATCACCACACGACTGGGTATATTC
CCTCTCTGGGTGTTAAATACCACATTATTTGAAAGCTGGGAGACGTTGGACCTTACCCTTC
TGGGGGTTTTAACCTACTGTATTGTAGTCCTCGGCGCGACACCTAATNCTANGAATCGCGG
CT 
 
Clone 332 
GGGAAATTCGTTACCTCACNTAATCNNCTGCTANGANCNTGATATATGCACGTCATANTG
GCGCNCAATCAGNGGNANATACACTTCATAAGTAGTCAGATGNCTGCANNNNGACCTGAT
NGGTGACTAGAATACTCGGGAACAGNTATTTCANAGGNGNCAANACGTGNGNAGNATGT
GNNCAGNACCTGCCTTGGTGACTGTGCTGAGCATAAAGNAATGTGTTCAGTGCAGNAGCC
TTCAATAAAGGNAGNAAAAGNAAAGNACACATGCACACAGGGNATGGNNTCCTAATTTT
AACATTACCAAGGGTAGNAAAGTNGGGNACAANATTACCCCAAGNCGGTCCAACCTGNA
TCCTGGTGGTNCCATTGNAAGGG 
 
Clone 339 (ad2) 
TCCCCNTACCCCTTGTGCCCGACCTCGCATGCTCCCGGCCGCCATGGCGGCCGCGGGAATT
CGATTAGCGTGGTCGCGGCCGAGGTACTTTCAACAAAGATTGAAATTAAACTGAAAAA
GCCAGAGGCTGTGAGATGGGAAAAGCTAGAGGGGCAAGGAGATGTGCCTACGCCAAAAC
AATTCGTAGCAGATGTAAAGAACCTATATCCATCATCATCTCCTTATACAAGAAATTGGGA
TAAATTGGTTGGTGAGATCAAAGAAGAAGAAAAGAATGAAAAGTTGGAGGGAGATGCAG
CTTTAAACAGATTATTTCAGCAGATCTATTCAGATGGTTCTGATGAAGTGAAACGTGCCAT
GAACAAATCCTTATGGAGTCGGGTGGACCTGCCGNNGNNCNNTNNNAATCCTATGAATTC
NNGGCCGCTGCNNNCNCCTATGGGAGACTCCACGCNNGATGCATACTNGATATTCTATAN
GCNCCANT 
 
Clone 358 (ad2) 
GNNNNTTTTTTTCGACCTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGCGGCCGCGG
GAATTCGATTAGCGTGGTCGCGGCCGAGGTACACATTCGATGTTGGGAACTAACACACA
GCGATGGGTGGGAAGGAAGGATGTTCAGGCAAGGTTCTTACTCCTTTACTCATCTGGTTCT
GGCTTTGGGAAAAAATAAGGTTTCATGTGCTGGGAAATACTTAGCAGTAATAAGTACCAA
AAAGGAAACATTGCCCTCTCATTTTGCCTAGTAGGAACTTACTGTGGTGATAAGAAATATG
AAACCCATTACTCTCTTGAACCCCATACTTGGGAGTAGATGCAGAGAGCTTGGTTGTAGTT
GGTTGCAGGGAGGTAGGAATTCAGGAGTAGTATTTCCCATTGATTCATCTTCAGCAGCACT
AGAATTCTAGTCTGCAAATCCACTCTCCCTCAGGCAGGAAGTGTCTTCAGACTGGCTGCTT
GCATTAAACACTCTTAGGGGACAAGCACTCCTCTTTTTT 
 
Clone 362 (ad1) 
TTTTTTACGACNTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGCGGCCGCGGGAATTC
GATTTCGAGCGGCCGCCCGGGCAGGTTCAATCTCCAACAACATGCCAGTGATTTTACCA
GCAAGAGTAGGGTGCATGGCTTGAATAAGAGGAAACAGCCGTTCACCCAACATTTGCTTT
TGCTCTTGAGGAGGGGCAGATGCCAACATGGAAGCAGTCAAAGGTTCCTGACCTTGTACA
TGAACAGCAGGCTGTTGCATTGTAACTTGTGGCTGTGCATTAAGATGTTGCTGAGGATTGC
GAACTCCTGCAGCATATTTATACTGTGGAACGGTGCGGACAGCAGGAGTAGCTGCAGCGG
CTGCAGCTGCAGGACGTGGACCCATTGTCTGTGTTGATGTGTTAGCAACACGCTGTGTTGA
 
 
 
 
 
222 
CATGACTCGTGGACCTGTGAAGAACTGGCTATAGTACCTCGGCGCGACACGCTATCCTAT
GAATTCNGGCGCCTGAGTCGACATATGGA 
 
Clone 370 (ad2) 
NNNNNTTTTTTACGCCTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGNCGGCCGCGG
GAATTCGATTAGCGTGGTCGCGGCCGAGGTGCAGAGAGAGAAGGTGCTGGGGCACAAG
AGGCAAGGGTATGAAGTCCCTCCAAATAGGAGTGGAGTGCCAACTGCCCTGCCTCGCTCC
AAACACCTGACTCCTGGGCCATGGCAAGAGTCCAGTCCATTAAGTGCAGCGTGCAATACT
AGCGCTTGGAGTCTCCTGTCCTCATCAATGAAGCGGTGTGGACGGGATAGCAGTCACCTG
GCAGGAGGCCTTGACCCCTGGCAGGCTAGTTGTATCGGCCCTTGATCATTGTGTTCAACAA
GGGCCCCACCTCTTGTGGGTTCCCCAAGGCCTCTCCAAGCATCTTCTCAATGTTTCTCATTA
TGGCACTTTCTGATGAGCTTTGAGAGGATATTCAATTCTCTTAGGGGTGGGAGCCCCTTAT
ACCNGAAGTTACAGTNTGGAATCCCCCATTAGTAATGACTTN 
 
Clone 371 (ad2) 
NNNNNTTTNTTACGNCNTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGCGGCCGCGG
GAATTCGATTAGCGTGGTCGCGGCCGAGGTACCAAGGCTTTAACGTGTCTGTGCAGGGT
ATTATCATCTACCGAGCCGCCTACTTCGGTATCTATGGCACTGCAAAGGGAACGCTTCCGG
ATCCCAAGAACACTCACATCGTCATCAGCTGGATGATCGCACAGACTGTCACTGCTGTTGC
CGGGTTGACTTCCTATCCATTTGACACTGTTCGCCGCCGCATGATGATGCAGTCAGGGCGC
AAAGGAACTGACATCATGTACACAGGCACGCTTGACTGCTGGCGGTAGATTGCTCGTGAT
GAAGGAGGCAAAGCTTTTTTAAGGGTGCATGGTCCAATGTTCTCAGAGGCATGGGTGGTG
CTTTTGTGTTGCTTGTATGATGAAATCAAGAAGCACCTGGCCCNGGCGCTCGAAATCCTAT
GAATCGCGGCGCTGAGTCGACATATGGAGACTT 
 
Clone 384 (ad2) 
GNNNNTTTTTTGCGNCCTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGCGGCCGCGG
GAATTCGATTAGCGTGGTCGCGGCCGAGGTACAAATTCAAGTGCAGAATTATTACGCCA
TTTTAAGTATTATCTACTTTTTTAAAAAATCACAGTGGTCTTCATCACATGGCGAAAAAAC
AAACTTCACTCTTCTCCAAAGGGATAAGTCATCCTAAATGTAACTACAAACAATTGTATAA
ACCTTTATAGTTTTTCCCCCTAATCTACTAAACCTATTCCAGTGTCATTTAGTAGTTTTACA
TAGAATCTGCACTATACTTGGATACTCAGGGAAAATAAGATGACATATATTGTAGTTTTAG
AACGCAAAAGAGCTTTCATTTTAGACAAATATACAACATAGAAGCCCTAAAAAATATGGG
TCTATTAATCAAGAGCCCATTTCAAAATGATAAGAGCATTTAGATGTAGATCTGGAATGCC
AGTTCTGAGTATTAGAACTAGGGTTACAGTGCCTTATCN 
 
Clone 406 (ad1) 
NGNACGCGGACCCCTTGNGTNCGTCCCGCGGATGCNTTCCGGCCGCCATGGCGGCCGCGG
GAAATTCGATTCGAGCGGCCGCCCGGGCAGGTACCACACACCTTTCTCCAAGGTGGTCT
CATAATTCTAGAATGGAAGGTCCAGCTGTTACAAAATGAAGACAGACAACACAACATTTA
CTCTGTGGAGATATCCTACTCATACTACGCACGTGCTGNGATTTTGAACATAACTCGTCCC
AAAAACTTGTCACGATCATCCTGACTTTTTAGGNTGGCTGATCCNTCAATCTTGCACTCAA
CTGNTACTTNTTTCCCAGNGNTGNTAGGAGCNAAGCTGACCTGAACAGNAACCAATGGCT
GGAGATCCCNACATGCNGGTTTTTCCCATAATATGGGAAAATTTAAGNCTATCATTCCTTT
GAGGAAAACTGNACNTTTGGGATATCTTCATTTTTGAAACACAATCTATNCTTGGNCTCCT
TAGGCTTAATCCANTATTTTGNGATTTTNCANNAAACANGGGTTCTTGAGANACCCAATA
GATATT 
 
Clone 410 (ad1) 
GNNNNNTTTTTNCGACNTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGNCGGCCGCG
GGAATTCGATTTCGAGCGGCCGCCCGGGCAGGTGGACAGACAAGAGAACATGCAATGT
TGGCAAAGACAGCAGGTGTAAAACACCTAATTGTGCTAATTAATAAGATGGATGATCCAA
CAGTAAATTGGAGCAATGAGAGATATGAAGAATGTAAGGAGAAACTAGTGCCATTTTTGA
AAAAAGTTGGCTTCAATCCCAAAAAGGACATTCACTTTATGCCCTGCTCAGGACTTACTGG
AGCAAATCTCAAAGAGCAGTCGGATTTCTGTCCTTGGTACATTGGATTACCGTTTATTCCA
TATCTGGATAATTTGCCGAACTTCAATAGATCAGTTGATGGACCAATCAGATTTCAGCAAC
AACTGGAACAACTCAGTGCAATGGGATTTTTGAACCGTGAAGCAAACTTGCAAGCTCTAA
TAGCAACAGAGGTGATATCAATGCAGCTATTGAAGGTACTGGGCTCCCACA 
 
 
 
 
 
 
223 
 
 
Clone 415 (ad1) 
GANCGGNGACCNCTTNNTCCCGTCCNCGCATGCTNCCGGCCGCCATGGNCGGCCGCGGGA
ATTCGATTTCGTGCGGCCGCCCGGGCAGGTACATCCAAAAGTCTCAGTGTAATAGCAGG
ACCAAAATATTCTGTCAATCAGCTGACCATATACTTAATGACTCCTAAAATCTCGTGGACT
TCTAAGAAAGCGCCATGGCCTGTGCTGCTGTTATGATTCCTGGGTTGTTGCGGTGCTCTGT
TGGAGCCATCCGTATTGAGGCTGCGTCACTGAGATTGACACTCAGCACTTTGCGCCATCTT
ACTCTAACCAGCATAATGAAATCCAAAAGGAAAACTGATCACATGGAGAGAACTGCAAG
TGTCCTTCGACGGGAGAGCAACTTATTTCATCAAGGGAGAAAGCACTAACATCTGAGAAA
GGAAAGTGGACGAGCTCTTGTACCCATCTAATGTACCTCGGCGCGACACGCTAATACTAG
TGAATTCCGGCCGCTGAGGTCGACTATGGGAGAGCTCCCACGCGTGGATGCATAGCTTGA
TATTTATAGTGCACA 
 
Clone 420 (ad1) 
TTTNNTTTNCTNNAAACCCAGTCCGTATAGCCGCATGCNTACCGNCCGCCATGGGCGGCC
GCGGGAATTCGATTTCGAGCGGCCGCCCGGGCAGGTACAACTACCCCTATCAGCCACTC
ACAACTGACCTTCACTACTATTACATCCTGGAGCTGTCGTTTTATTGGTCTTTGATGTTTTC
TCAGTTCACTGATATCAAAAGAAAGGACTTTGGCATTATGTTCCTGCACCACCTTGNATCT
ATTTTTCTTGATTACCTTTTCATATGTCAACAATATGGCCCGAGTAGGAACGCTGGTCCTTT
GTCTTCATGTTTCAGCTGATGCTCTTCTGGAGGCTGCCAAAATGGCAAATTATGCCNAGTT
TCAGAAAATGNGTGANCTCCTGNTTGGTATGTTTGCCGCGGGTTTTATCACCCACNACTGG
GNATATTTCCTCTCTA 
 
Clone 421 (ad2) 
NNNTNNTTTTTTTGAGACCCTGGNTTCCGTACNTCNGCATGCCTCCCGGCCGCCATGGNCG
GCCGCGGGAATTCGATTAGCGTGGTCGCGGCCGAGGTGTAGGATTAATGCATGGTTATA
TGGACCAGAAAAAAGTGCCATAGAAGACCAATAACTGTTTAGTTGAGGCTAGTCTGGAAC
CTTTCATTAGAGCAATATTTGGTTATTGCACTTCATTTTTATTTACTAAGAAATGCAATTTG
GGAATTTTTAATCTGTTATGCTTTGTTTATCAACCTTGATTTTAATTAAGACTTTTATAAGA
CTAGCATAAAACACCAACCAACATTATTTTTGCAAAAGTGAGTTGGTCTCACTTTCCATTC
TTGCTAGTCAGAGTAAGTAGGCAGCACTTTTAAAAATATGTGAACTCAAATATTGCACTTC
TTTCAAGATGTATCAATTGCTATTGACCTGCCGCGGGNCGTCGAAATCCTAGTGAATCGCG
GCGCTGAGGTCGACTATGGGAGACTC 
 
Clone 423 (ad2) 
TTTNTTNCTTNAACCCACTCCTATAGNGNNGCNTACCNNCCGCCATGGGCGGCCGCGGGA
ATTCGATTAGCGTGGTCGCGGCCGAGGTACGCTGAACGAGATCTACTTTGGAAAAACAA
AGGATATCGTCAATGGGCTGAGGTCTGTGCAGACTTTTGCAGACAAATCAAAACAAGAAG
CTCTGAAGAATGACCTGGTGGAGGCTCTGAAGAGAAAGCAGCAATGCTAAACCTCTGTTT
CATGCTAACCAGACACGCCGTGCACTCGTTAGATTCCTCTCTTAGAAAACTCGTTTACTGC
TCCCTTCCCTCGTCCCTTCCCTCCCCGACAGGTCACATAACAGCTGCATCATTGACCGCAC
AGCGCCATCTCTCCCTGAGAATAAAGCCGATAGCCACCCTCCTCCGGCTCCGAGCCTGCTT
CTGCCACACCTCC 
 
Clone 424 (ad2) 
TGATANNNCCNTNNCTNNANTNAACCGCCCGATGNTTTTCGGCANGAACANCCCCGGCCG
CGGGAATTCGATTAGCGTGGTCGCGGCTCGAGGTNNTATGCCAATCAGAGTANACTGN
CCCTCAGTTTNAAAAGAAGATGGATTAAACCAAAACAATTTTGTAGATTCATCGTATGTG
AACATACCAATATCTGGATTGAAGATTTCCTCCACAACCAGATGAAAAAATTNTNTGNAA
ACANCTCNCTNATCAACTCCTTGNTNTCCCACAAATTCCACATACAAGNGCTTCTTNAAGN
CTGCAGGATTTTCCATAGGGATCATCTNTAGCCGGACAAGTGCATCATCTATGATATGGNC
ACGTCTAACTTTGAGNCTCAAATATGGNTTCAACTGCTGNNCTTGAACTAANCTGGNAGA
ACANAGANNNTTNNTTCACTGTACCTGCCCGGGNCGGNCACTCCAANTCGAAATAATCNA
GACNNNCGCCCTNNNTNGGACNCCCCNCCCGACANGNTNCNGNACNCTNCAGCCNCCCG
NCNCNTCCGGCCCCCTANC 
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Clone 426 (ad1) 
TTTNTTCACTAAACCCATTNCTATAGCGCATGCNTACCNNNCGCCATGGGCGGCCGCGGG
AATTCGATTTCGAGCGGNCGNCCGGGCAGGTACCATGCTGGGTGCCTCTGGCGACTACG
CTGATTTCCAGTATTTGAAGCAAGTTCTCGGCCAGATGGTGATTGATGAGGAGCTTCTGGG
AGATGGACACAGCTATAGTCCTAGAGCTATTCATTCATGGCTGACCAGGGCCATGTACAG
CCGGCGCTCGAAGATGAACCCTTTGTGGAACACCATGGTCATCGGAGGCTATGCTGATGG
AGAGAGCCTCCTCGGTTATGTGGACATGCTTGGTGTAGCCTATGAAGCCCCTTCGCTGGCC
ACTGGTTATGGAGCATACTTGGCTCANCCTCTGCTGCGAGAANTTCTGGNAGAANCAACC
AGTGCTNAGCCAGACCGA 
 
Clone 431 (ad2) 
TTNTANANNCTACCTTCTNTTCCCGTCCCCCGCATGCTCCCGGCCGCCATGGNCGGCCGCG
GGAATTCGATTAGCGTGGTCGCGGCCGAGGTACTGGATTTTAAATCTGTATGTATCTGTT
GATTTTTTTTTCTAATATTTCAGTTGAGCTGCTGTTTTCTTCCATGCAATATTGTATACTCAA
TTGTGTATAGAAGAAGCTGGTGAGAGTGCCCTCCTACATAAATAAGCAATTGCAGTGTTTT
GCATGCAAAATATAAAAAATTTAAATTGTCCTGATTCTATTTTGTAAATGGAGAAACAATC
ATATCTTTCTAAGCGGTAATGGAGGAAGACTAGTGCTTTGTGCATTTTGATATATTTGAGT
CCATTTTTTCCCAATGTCATACTTTTNCCGCAGTTGGGTTTCTCATAAGTATCCTAGTCATG
TCCTGCCGGGC 
 
 
Clone 434 (ad1) 
NTNTNNTTTNCCTTAGACCCTGNTTCCGTATNCGCATGCCTNCCGGCCGCCATGGNCGGCC
GCGGGAATTCGATTTCGAGCGGCCGCCCGGGCAGGTACATCCAAAAGTCTCAGTGTAA
TAGCAGGACCAAAATATTCTGTCAATCAGCTGACCATATACTTAATGACTCCTAAAATCTC
GTGGACTTCTAAGAAAGCGCCATGGCCTGTGCTGCTGTTATGATTCCTGGGTTGTTGCGGT
GCTCTGTTGGAGCCATCCGTATTGAGGCTGCGTCACTGAGATTGACACTCAGCACTTTGCG
CCATCTTACTCTAACCAGCATAATGAAATCCAAAAGGAAAACTGATCACATGGAGAGAAC
TGCAAGTGTCCTTCGACGGGAGAGCAACTTATTTCATCAAGGGAGAAAGCACTACATCTG
AGAAAGGAAAGTGGACGAGCTCTTGTACCCATCTAATGTCCTCGGCGCGACACGCTAATA
CTATGAATTCGCGGCCGCTGAGTCGACTAT 
 
Clone 438 
TTTTTNGNGNGAACCCCGTTACCTTCACNTAATCCCCCGGCTATGCCTTCNCNANCACGCN
CATTGGCCCGCGNCNCGCGGGNAATTCGNATTTCGNAGNCGGCNCGCCCGGGNCAGGTAC
NCCATTCACGGGNTGTTTGTGGGNAGNATACCTTCTGTTACNTTTGCTGGCATGNACNCTT
TGCNCGTGGTGGGCATCTTGGGNACACTTCAGCAAGNACCATGCTACNTATTCTTCATGCC
CCAGGNTGTTCAAACNTTCCTCTACTCACNTGCCTCAAGCTCCTGCAATATCATCCCCTGC
CCTCGCCACCGCATACCCAAGNACTCAAATTATTCAAGNACAGGGCAAACTGGGNAGNAT
GGAAGCTTATTCCAAGGTTCAAAGGAACCAAGGAAGCCTCTTCTTTCTTGGGGGCCACCTT
TTATTTTTAAAAAGGGTGGGGCAAGAAGAAAGCCCTNCAAGCTTGGGTGGACAAGGTAAC
CCTTCGGGNNCNGNGGAANCAACGGCTTAAATCAACTTAAGNGGAAATTTCNNGGGNCG
GNCTGGCANGGNNCGGAACCATTAATGGGGAAANAA 
 
Clone 446 (ad2) 
NNTTNCCNNANCCCTTNTGCCCGACCTCGCATGCTCCCGGCCGCCATGGCGGCCGCGGGA
ATTCGATTAGCGTGGTCGCGGCCGAGGTACCCCATTATCTATGACATTCGGGCCAGACC
TCGAAAAATCTCCTCCCCTACAGGCTCCAAAGACCTACAGATGGTGAATATCTCCCTGCGA
GTGTTGTCTCGACCCAATGCTCAGGAGCTTCCTAGCATGTACCAGCGCCTAGGGCTGGACT
ACGAGGAACGAGTGTTGCCGTCCATTGTCAACGAGGTGCTCAAGAGTGTGGTGGCCAAGT
TCAATGCCTCACAGCTGATCACCCAGCGGGCCCAGGTATCCCTGTTGATCCGCGGGAGCT
GACAGGGAGGGCCAAGGACTTCAGCCTCATCCTGGATGATGTGGCATCACAGAGCTGAGC
TTTACCGAGAGACCTGCCCGCGGNCGTCNAAATCCTANNGAATTCCGGNCGCTGCAGTCG
ACCTATGGGAAGCTCCAAGCGTTGGATCTANTTGATATTTATANTGNNNCCT 
 
Clone 447 (ad1) 
GGNNNNNNAGTTTGNNNNCCNNNNNTTTNNNTTTCCTTACGCCCTGNNTCCCGTACGTCG
CATGCCTCCCGGCCGCCATGGCCGGCCGCGGGNAATTCGATTTCGAGCGGCCGCCCGGG
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CAGGTACCTATCGAGGACAAGAATTTATTAGAGTTGGCTATTATGTAAATAATGAATATA
CTGAGACAGAATTAAGGGAAAATCCACCAGTAAAACCAGACTTTTCTAAGATTCAAAGGA
ATATTTTGGCATCTAATCCCAGGGTCACAAGATTCCACATTAATTGGGAAGATAACACAG
AAAAACTGGAAGATGCAGAGAGCAGTAATCCAAATCTACAGTCACTTCTTTCAACAGATG
CATTACCTTCAGCATCAAAGGGATGGTCCACATCAGAAAACTCACTAAATGTCATGTTAG
AATCCCACATGGACTGCATGTGACCACCTACCATCCCTTTAGTACCTCGGCGCGACACGCT
AATCACTAGTGAATTCGCGGCCGCTGCAGTCGACNTATGGGAGAGCTCCC 
 
Clone 452 (ad2) 
ATTTTTACGNCNTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGCGGCCGCGGGAATT
CGATTAGCGTGGTCGCGGCCGAGGTGCGTTGTTCTCTTCAGGTTTAGGCATGTAAGCCA
ATGACATTCAAAAATGTATCAATAAGTTTTGGTATGGAGAGTCTCAAATCACAGGGTGGC
AGGTTTATCCCCAAATCACAGCCAGCCTCAATTTCTTATCAGGCAAAGTAAGTCACACTAT
TCACAACAGCTCTGTGTTGATTCAATTAAACAATACGTAAACATTCACTGAACATTGCTGG
TTGGCCCTTANACCTTTCGTTGTGCCCTTTCTGGCTTCTTCTCATCTCTCCATTCATACATAT
CCATATCTATATCTATATATATATAATCCCTATAAGGCAAATGTTACTTTCTAATCAATAC
ATTTTTCCTTG 
 
Clone 458 (ad1) 
NTATCTNAANACCTCTTNTTCCTATCCTGANNCNTACNTCCGCCATGGCGGCCGCGGGAAT
TCGATTTCGAGCGGCCGCCCGGGCAGGTACCATCTTATTTCTTTTGGGGGATTATACAC
CTTAACCNGCCTGAGATGGGGGTCAGCTCTTTATATAAAGGGAAACCAGACCAGGCCTAA
AGCCCACCCCTACCCTCACCCCCCCAATCCTCTCCTGAAACTTAAAANCAGNGGGAATAT
AGGAANGGGAACCAAATCTCATTAATTAATGGTTCTCCCCCATTACCCCACTGAATGAAN
GGCCATACAGGCTAAGCTGAATAGTGNCGAAGTTGAAAGGACCAATACAGCCCCTTTTAT
AAGGATTTTGAATGTTTTGCAAATGTATTGCCCCTGTGTGTATTTTGTACCCTTTTNTGGGC
TTCANCTCNCTATTTTGNNTGATNTGCATACTGCTCTNACCTTANGTNATGACCAAAAAAA
AAAAAAAT 
 
Clone 460 (ad1) 
GAGGATTNNTTTCCGNNATANTTACNCATGACCNCTNNNTGCANTATCCNTGTATNCCNTA
CCNTCACGCCATGGNCGGCCGCGGGCAATTCGATTTCGAGTCGGCCGCCCGGGCAGGT
ACACTCAGGTATTCAGAGCACCAGAGGTCTTGACAAAGTGCCCCATNAAACTACAGCAAT
TGACATGTGGTTTGCAGGTGTCATATTTCTTTCTTTGCTTAGTGGACGATATCCATTTTATA
AAGCAAGTGATGATTTAACTGCTTTGGCCCAAATTATGACAATTAGGGGATCCAGAGAAA
CTATCCAAGCTGCTAAAACTTTTGGGAAATCAATATTATGTAGCGAAGAAGTTCCAGCAC
AANACTTGNGAAAACTCTGTGAGAGACTCAGGGGTATGGATTTAGCACTCCCAAGNTAAC
AAGTGATATACAANGGCATGCTTCTCTCAACAGCTATTTANAGAANACTGATATNNAGTT
NTGCTNGTTATACCCTNAGGACATACTCAGA 
 
Clone 470 (ad1) 
TNTNTANGNNCNNCATNCNNAGNTNACTATNCTGTNNCTTTAATCACGNCATGNCGGCCG
CGGGTAATTCGATTTCGAGCGGCCGCCCGGGCAGGTACGAATGCAACCCCATGGCCCA
CGTCATGGAGAAGGCTGGGGGAATGGCCACCACTGGGAAGGAGGCCGTGTTAGACGTCA
TTCCCACAGACATTCACCAGAGGGCGCCGGTGATCTTGGGGTCCCCCGACGACGTGCTCG
AGTTCCTGAAGGTGTATGAGAAGCACTCTGCCCAGTGAGCACCTGCCCTGCCTGCATCCG
GAGAATTGCCTCTACCTGGACCTTTTGTCTCACACAGCAGTACCTCGGCCGNGACCCGCTA
ATCACTAGTGAATTCGCGGCGCTGCAGGTNGACATATGGGAGAGCTCCAACGCGTTGGAT
GATAGTTGAGTATTCTTANTGCCCTAAATCANCCATTCTNCCCTCTCCCATCNTTCCTCNNC
TTCC 
 
Clone 474 (ad2) 
TTNTGNCCGATNCNCNNCNTACGTATCCCCGATGNCTNCTTTCCGNACATGGCCNGCTCGC
GGGTAATTCGATTAGCGTGGTCGCGGCCGAGGTACTGGGGGTTCCCGTACACAGTGGCT
GAGCTGCTGAACACCAGGTTCTTCACCCCGTGGGCCTTCATGATCTCCAGAAGCTGGATGG
TCCCGGTCAGGTTAACTCTGTAATAATCCAGAGGCTTCTGCACCGACTCGCCCACGGCCTT
GAGCCCCGCAAAGTGGATGACCGCCATAAAGCTGTACCTGCCCGGGCG 
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Clone 475 (ad1) 
NTNTNNGNNCGNNTTTTNTTCCTATNCTGTNNCNTAAATNCGCCATGGCGGCCGCGGGAA
TTCGATTTCGAGCGGCCGCCCGGGCAGGTACCGTCAGCATCCACAGCCATACATCTTCC
CTGACTCTCCTGGGGGCACCTCCTATGAGAGATACGATTGCTACAAGGTCCCAGAATGGT
GCTTAGATGACTGGCATCCTTCTGAGAAGGCAATGTATCCTGATTACTTTGCCAAGAGAGA
ACAGTGGAGGAAACTGCGGAGGGAAAGCTGGGAACGAGAGGTTAAGCAGCTGCAGGAGG
AAACGCCACCTGGTGGTCCTTTAACTGAAGCTTTGCCCCCTGCCCGAAAGGAAGGTGATTT
GCCCCATGTGGTGGATATTGTGACCAGACCCGGGAGCGGCCATGTAGAAAGAGAGAGAC
CTCATCTTTCTGCTTGCAAGTGAAATATGTCAGACATGCACTTGCCTATAAAAAAAAAAAA
AAAAAAAN 
 
Clone 1026 (ad2) 
NTCCTACGCCCTGNNCCCGTCNNCGGATGCTCCCGGCCGCCATGGNCGGCCGCGGGAATT
CGATTAGCGTGGTCGCGGCCGAGGTACAAGCCTGGCGTGTTGCTGGGGTTTAACATGAA
AGAATTAAATAAAGTCAAGCATGAGATGGATTTTGATGCTGAGTGGCTATTTGAAAATCA
TGATGAGAAGGATTCCAGAGTCAATGCTAGTAAGACTGCTGACAAAAAGCTCAACCTTGG
GAAGGAAGATGACAGTTCCTCAGACAGTTTTGAAAATTTGGAAGAAGAATCCAATGAAAG
TGGTAGCCCTTTTGACCCTGTTTTTGAAGTTGAACCTAAAATCTCTAACGATAACCCAGAG
GAACATGTACCTGCCGGGGCCGGNCGCTCGAAATCCTAGTGAATTCCGGNCGCTGCAGGT
CGAC 
 
Clone 1029 (ad1) 
AGTGTNGGGNNTCTCTTTCNNTTNGAATNTANTGTCANTTATNTGACGTATTCCGGGAGCG
TGNGTNATTCGATTTCGAGCGGNCGCCCGGGCAGGTNCCCACAGCAAGGTTCTTTATGT
CTATGANATGCTGGCTGGAAAGTTAATTCCTGTGCATCANGTGAGAGGTTTGAANGAGAA
GATAGNGAGGAGCTTTGAAGTCTNCCCANATGGGTCCTTCTTGCTCATANATGGCATTGCT
GGATATTTGCATTTGCTAGCAATGAAGACCAAAGAACTGATTGGAAGCATGAAAATTAAT
GGAAGGGTTGCAGCATCCNCACTCTCTTCAGATAGNAAGAAAGTNTACGCCTATTNGGGG
ANGGANAANTANNGTTACANGNTCACTNTTTNNNANNNNANANCANTNNTNAANNNANT
NNCNGTCAATCNTCNNCNTTNNATGNNANTCNTCNCTANNNNTTNCNTNCTNGAA 
 
Clone 1034 (ad2) 
GNATTTANTACNANCCNTGCATTTNNNGTAANTACCCCTGANGCATTNCCGNCACGTACA
TGNCGGCTCGNGGGNAATTCGATTAGACGTGGTCGCGGCCGAGGTACTCCAATCCCTCT
CCAACTATCCCAATGAAGGAGATCCAAGCAATTAGCACCTTCAGTTGGCGCTGCTCCTAA
GTTGTAAGCCTCTAACTACTATCAGCTGGACAAAAGCCACATCCTATATGCCCTGTTAGCA
CACCAATGTATTAATACTAACCAGCCACCCTAGAGCTCAATTAAGCATCTGGCCTTAATGC
AGTAAACCACACTCAAAGGAGACATGAAATATTGGCTGNTGTACCTGCCCGGGCGNCNCC
NTCNANCACTCTCNNNNNNANTCCCTNTCANNNNNNNTATNTNCNATATCNNCCNANNNA
ACGAGCNTNACTNCTTNCNTANTNNATNNNCCCCCCTCACCCTCNCCCCNNTANNNCACC
CANCNNCNTACCCCA 
 
Clone 1040 
GTTNTANGNCTNNTTCTACTCCTACNCGGTANNANGACNCCTATTGGGNAATACGACTCA
CTATAGGGTANTGCGAGTCCGTATAGGGNCTTCTATGNNCTGTGNGNGGNCACNGAAGNT
GCTGCTGACGCTCTGGGTGAAGAATGGAAGGGTTATGTGGTCCGAATCAGTGGTGAGAAC
GACNAACNNGGTTTCCCCATGAAGCAGGGTGTCNTGACCCATGGCCGTGTCCGCCTGCTA
CTGANTAAGGGGCATTGCTGTTACAGACCNAGGAGAACTGGAGAACGAANGAGAAAATC
TNTCCGTGGNGCATNGAGGNNGCCNACNNGCCGTNCTCACNNTGGACTGAGCNTANNCCT
AGCNTANAAGGACNGACCCCNTCTGCCATGCNNCTCCTTCNCTGNTACCCTNGCCTCTGCT
TCATCGNNNCNGCCTNGNNCCNNCCTNTNCNGGNAANNCCCNNCA 
 
Clone 1049 (ad1) 
CTTATNNNNNCNTCCTCNGANTCCTACANTGTNNCTTAAANCCGTACATGGNTGGCCGNG
GGTAATTCGATTTCGAGCGGCCGCCCGGGCAGGTACTTTCTATGAGAAGCGTATGGCCA
CAGAAGTTGCTGCTGACGCTCTGGGTGAAGAATGGAAGGGTTATGTGGTCCGAATCAGTG
GTGGGAACGACAAACAAGGTTTCCCCATGAAGCAGGGTGTCTTGACCCATGGCCGTGTCC
GCCTGCTACTGAGTAAGGGGCATTCCTGTTACAGACCAAGGAGAACTGGAGAAAGAAAG
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AGAAAATCANTTCGTGGTTGCATTGTGGATGCNAATCTGAGCGTTCTCAACTTGGTTTTGN
NNNNAGGAGAGAAGGATATTCTGGACTGACTGATACTACANTGCTCGCCGCTGGCCCCNA
AAGACTANCATAATCGCAACTTTAATCTCTTAAGAAGAGATGTCCCCATATGNCTNNAAA
GCCN 
 
Clone 1060 (ad2)  
ATNTTTGCGCCNTGGGCCCGTNGTGCGGCATGCCTCCCGGCCGCCATGGTCGGCCGCGGG
TAATTCGATTAGCGTGGTCGCGGCCGAGGTGGCTTGGCACCCAGAGAAAGCCTCTGCCC
CCAAAAGAGACTTTCTACATAGGGTTAAGCTTCATTAAATGAGGTGCAACCTTTCATTTTC
AGGGCATCTCTTTTCTTGCAAGGTCTTTAGAGGCAGAAGTTCCACTTGGATTCTAATACAC
ATCTCTGTGAGCTCAGTTTCCTGAAAATATACACCTACTGGGTTCTAGGTTCTCCCTTACCA
GTGACTGTATTCATTATTTCACAGCCACCAGAATCGGACATACACTATTAACATGATGAAA
AATACAGCTACTGCTGCAAGTTTGGCATAAGTGGAACGCATGTTCAAGTACTTCGCATCCT
GGCA 
 
Clone 1064 (ad1) 
TTTATNNNAACNANCNTCTGTTTACCGTATCCCGGCATGTNTCCCGNCCGTACNTGGNGGG
CCGCGNGTAATTTAGATTTCGAGTCGGCACGNCCGNNCAGGTACTTCATTCGAGCATGA
GTTTCTGAGGATCAGCACTGCCAGTGGAGATGGGCGTCACTACTGCTACCCTCACTTCACC
TGCGCTGTGGACACTGAGAACATCCGCCGTGTGTTCAACGACTGCCGTGACATCATTCAGC
GCATGCACCTTCGTCAGTACGAGCTGCTCTAAGAAGGGAACCCCCAAATTTAATTAAAGC
CTTAAGCACAATTAATTAAAAGTGAAACGTAATTGTACAAGCAGTTAATCACCCACCATA
GGGCATGATTAACAAAGCAACCTCCCCCTTCCCCCGAGTGATTTTGCGAAACCCCCTTTTC
CCTTCAGCTTGTTAGATGTCCAAATTTAGAAAGCTTAAGGCGGCTACAGAAAAGGAAAAA
AGCCAAAAGTTCCTCCCN 
 
Clone 1065 (ad2) 
TTTTCTCAAGTACCCGNTTCCTATANNGATGCTTCCGNCCGCCATGGCGGCCGCGGGAATT
CGATTAGCGTGGTCGCGGCCGAGGTACTGATGCAACAGTTGGGTAGCCAATCTGCAGAC
AGACACTGGCAACATTGCGGACACCCTCCAGGAAGCGAGAATGCAGAGTTTCCTCTGTGA
TATCAAGCACTTCAGGGTTGTAGATGCTGCCATTGTCGAACACCTGCTGGATGACCAGCCC
AAAGGAGAAGGGGGAGATGTTGAGCATGTTCAGCAGCGTGGCTTCGCTGGCTCCCACTTT
GTCTCCAGTCTTGATCGGCTGCACATCACTCAGGATTTCAATGGTGCCCCTGGAGATTTTA
GTGGTGATACCTAAAGCCTGGAAAAAGGAGGTCATCTCGGGCCCGAGNCAGTGTTCTGGA
CTGCCGGCGGCGTCGAAATCCTATGAATTCCGGCGCTGCAGTCGACTATGGGAACTCCAC
GCGTGATGCTAN 
 
Clone 1070 
TTTTTNGGGCGGGAANCTTCNTTAACCTCACNTAATCCCCCTGCTATGCCATTTNCTATTCA
CGTACTATGGCCCGGNCTCCGTCGGGATACATTCGTATNTAAGNCGTGGTCGCGGCNCGN
AGGNTACNCGCAAGGNGTGGTTTGGNATGNAAGNTCTGNACTACTTTCTTTCAAACAANA
CTATTATATTAAAACTGTCATATTTTGGCTAAAGTTTGGGNACCTATAACTACACTTTCAT
NTGTTTGGCAATCTCTCTATGNAAGNATACGTCTGTCCAAACTTTTAAAAGGGCAATAAAC
TGGTAATTTTTATGGTGGTTTAATNTCTTTATAATAAGGAATANGTAATNTTTAATAATTTT
AATTTCTTCAACCCGAAAAGTATTTCAACAACAAATCTTTTTTTAAAAAAAAAAATTTGGG
GAAAATGGGGCAATTTTTGGTAATTGGCCCACAAGAAGGGTAANGGAATGGAAGCCATTA
ATAATTTAANTGGAAAATGGTNTNTAATTTTTGGNNAAAAATATAAANNNGGGGAATTAA
TTTNNGNCCATTNNNTTTAANTAACCTGGNCCCGGG 
 
 
Clone 1071 (ad2) 
NNTGTNCCGNCNNACNTCTTNTTTNCTCCCCNGCATGNNTTCCGNCCGTCATGGNGGGCCG
CGGGTAATTCGATTAGCGTGGTCGCGGCCGAGGTATAATCTTGAAATTAAGAAGGCAA
AAATGTAAAGGAGTCAAAACTATAAATCAAGTATTTGGGAAGTGAAGACTGGAAGCTAAT
TTGCATTAAATTCACAAACTTTTATACTCTTTCTGTATATACATTTTTTTTCTTTAAAAAAC
AACTACGGATCAGAATAGCCACATTTAGAACACTTTTTGTTATCAGTCAATATTTTTAGAT
AGTTAGAACCTGGTCCTAAGCCTAAAAGTGGGCTTGATTCTGCAGTAAATCTTTTACAACT
GCCTCGACACACATAAACCTTTTTAAAAATAGACACTCCCCGAAGTCTTTTGTCGCATGGT
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CACACACTGATGCTAGATGTCCAGTAATCTAATATGGCCCAGTAGCTTGATGACCAAAGC
CTTTTTTCTCTTTAGAAACT 
 
 
 
Clone 1072 (ad2) 
NTTNCCGGNGAACCNCTTTTTCCCGTACGCCCGGCATGCCTNCCGGCACGCCATGGNCGG
CCGCGGGAATTCGATTAGCGTGGTCGCGGCCGAGGTACAGCTACAGCTTCATCAACCTT
AGAACGGAGTGACTCTGGAGACTCGAGCATATGAAGAAGTTCTGAATTATCAATCTCCAA
CAACATGCCAGTGATTTTACCAGCAAGAGTAGGGTGCATGGCTTGAATAAGAGGAAACAG
CCGTTCACCCAACATTTACTTTTGCTCTTGAGGAGGGGCAGATGCCAACATGGAAGCAGTC
AAAGGTTCCTGACCTTGTACCGCCGGGGCGGGCGCTCGAAATCCTAGTGAATTCGCGGCC
GCTGCAGGTCGACCATATGGGAGAGCTCCCAACGCGTTGGATGCATAGCTTGAGTATTCT
ATAGTGCACCCTATA 
 
 
Clone 1073 (ad1) 
AGTTTNNGNAGCNCATNCGNACNTCACTACNCGGTACACNTAAATCCGTATTGGGCNGAN
CGTNANNCTTTATATTTGCGAGCCGGAACGTCCGGGCAGGTACAGGGCAGGGCCCTTA
TAATTTGGGCCTCAAGAATTGATAGTTGTCTCTTAACTGGTTCTGCTGAGGCGCACTCACA
GCAGTGAGTGGAGGGTCCTGGGAGGGCATGGATGACGGAGGCTGCCCCTAGAGGAGCTG
GATGTAGGAGCAGAGACATTTCTTGATCTTTCACTCTGCAAACTGGTCCAAGAACTTGAGG
TAGGCCTGACGCTGGGGTGCAGCTGCTGGAATGAAGTGGCCACCAGAGTGGGTGAGGGTG
ATGGCTCCGGGAAATTGCTGACCAGTTGCACACTCTCTGAGAGGGGATGACTTTGTCAGT
GCCCCAAAACATGGAGCGAAGCAATGACAGGCCTTTCAGATGGATTCTTGACCCATGCCC
GGGGACAGAACCAGCCCAGA 
 
Clone 1073 (sequenced with sp6 primer) 
GAGTTTTTTTNNTTCAAANGATGAAACCNCGTTNTTTTANTNNGCTATCCGCNGCNGCGNG
TGNTGTAGACTCTACCCATGATGGGGCTGCGAACTCTGCAGGTCGGCCGCGNAATTCACN
TAGNTGNATNTAGCGTGGTCGCGGCCGNAGGTCGNACGTTTTCTCCGCATTGGNAAGNAG
CCCGCCGTCTGCAGGGGCCTGGNAGGGAATCACTGGGGATGGTGGCACCAAGGCACTGG
AACAGGCTTGGGGCCTTTTGACGGCCTTCTTGGGTTTCAAGCCAAGGGGCTGCGCTAGCA
GCCCTTGTGTGTGCCCTGGGGCCAAGGCAGGCGATCCCCGCTTCTCCTTGCCACGGTTTAT
CCTCTTGGTGGTCTGGGTTTCTGTCCCCGGGGCCATTGGGGTTCAAGGGAATCCATCCTTG
CAAAGGCCCTTGTCATTGCCTTCGCTCCATGTTTTTGGGGGGACACTTGGACAAAAGTCAT
CCCCTCTCAGGGAGAGTGTGCAAACTGGGTCAAGCCAATTTCCCGGGAGCCATCACCCTN
ACCCACTCTGGGTGGGCCACTTCATTCCA 
 
Clone 1075 (ad1) 
TCTNCTTCNCNNNAANCACGANTCCTATNCTGGTCACNTAAATCCGNCATGCCGGCCGCG
GGNAATTCGATTTCGAGCGGCCGCCCGGGCAGGTACGCAAATGTTTTTCAACAGTTATT
GAAAATAGGAGACCAAGTTGAACGTGCCAAAGAGATACCATTCAGTTGGATTTTCTAGGG
TCAACATGAAGAAAATTAGAGAAGGGATTTACTTGGTTGGTTTCCATAGCTTGATAGACC
AAAAACAAAAAAACTGCCACAACAACAAACAGCAAAATTTTTATCCATACGGGAATGGA
GCGTCCCTTTTTTGTCTTTTCTGACTTGACATCTGCCAAGGGAACATACTTAGGAACATATT
TAGATGAAAAAGACTCCTCCGTCCTGAAATCCTGAGTTCTGATGGCGGCTGAGCCTTTGAT
GGCTGCGGCACTAGCCTAATTCTGNGGGTAATGTTATANGGGACATTTCTTAAGATATCCC
TTTTCTCC 
 
Clone 1078 (ad2) 
GNNNNGAGGNNNNNNTTTANTTTCAAACCGCNTCTNNTTCCTATCNNNGNNNCNTANNTC
CGTATTGGGNGGACGTNNNTAATTCGATTAGTCGTGGTCCGCGGCCGAGGTACGAAAA
TGGGACCAGACACATGAACAGCCTGGCCTAAATGAACTCCATCAATCTTAACTGTGACAG
AAGTAATGGAGGATAAGGAAAAGGCCAAGACTCTGATGTGTGTTGAGTGAAGAAGTCTTT
CTAGTGGTTCATGTTCACCACAACTATAAAGGAGTGATTTAGGATTGGTGATAAGAACCA
CAGGCCACTTCCCAAAGATCAAATCTGCAAAGCTAAAGAGGTCGTGATCAAAAGCAAAA
ATCCGGTACCTCCCGGGCG 
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Clone 1083 (ad1) 
NTNTNCNNGNNACCNCGTTTCCTATCCGATGCTTCCGNCCGTACATGGCGGCCGCGGGAA
TTCGATTTCGAGCGGCCGCCCGGGCAGGTCTGTAGGGATACTGCTTCATAAGCACCAGC
AGAACACCAAAGGAGACCATATGGGTGAAAGCAACCAGCACTGCCCTGGCGCTTCATAG
GTTCTTAGAGTTTTTATCTTTTACTTTCAGTCTAACACAGCACTGCCTGCTTTTTGTTTTTGT
TGCTTGGTTTGTTTTTTTCTTACCGTGTTCACCAAACTTGTGTCCAAATAGCTTTGGGCTGA
TGCAAAAATATCTATGTGGAAGAGAAGAAGTTGTTCTCATGGAGGGCCTTCAGATGAGTG
CTATAGACTCTCTAGGCAACTCCAAGAGGCTTTAAGCAGGGTGGGCAGTGAGAGCTGTAT
GGAATCAATGGACAAACTGACAGGGACTGTTTGAAAGACAGACCTCGGCGGACACGCTA
ATCCTATGAATA 
 
Clone 1085 
GTTNTAGNNCCATATACGGANCGTAACTAATCGCGGGTANNACAACNCACTATAGGGNAA
TACGACTCACTATAGGGTNATNCGAGTCACTATAGGGTCTNCCGAATCACNATNGGGNGA
TAGCTGNGAGAANAAAGCNTGNCCTTACANAGAGCCACNGAGCNNGCNNGGNCACATTT
CTCTGCAGCANTNTCATTCATTCTGANAGTTNACNANCANGAACTGCCGANGCCTTNAAC
CTGGATGCGGCGCCANTNGAACTAATCAAGCGACGNCAGCAGANGTGNTCGNNTGCATC
ACAGCTTAACAGCTCANNGTCTGAGTNAGAGCTNCNCTNATTNCAGANAGTGGACACTGN
NCTTGNACATCCTAANGGCACCTCTGNATGGCTCNTGCAGCNCACAAACAGCNGNCCCAG
GANATGNCTACTCANAGGGCGNTAGACAGAGACGAGCANANATCCANCGGCTGCAATAN
TCNGNTCNGCTGNACTNCACN 
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Appendix F: BLAST search results of the sequenced clones 
 
 
 
Clone and accession numbers have been indicated.  
Blast bp: Number of base pairs subjected to BLAST search. 
Identities: Percentage of homology of the sequence identified by BLAST search. 
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 Appendix F: BLAST search results of the sequenced clones   
 
 
 
   
Clone # accession #, gene BLAST bp Identities  
    
33 gi|16551409|dbj|AK056096.1|AK056096  Homo sapiens cDNA FLJ31534 fis, clone NT2RI2000671 338 168/169 (99%) 
    
41 gi|13642967|ref|XM_018280.1| Homo sapiens poly(A)-binding protein, cytoplasmic 1 (PABPC1), mRNA 349 345/349 (98%) 
362 gi|13642967|ref|XM_018280.1| Homo sapiens poly(A)-binding protein, cytoplasmic 1 (PABPC1), mRNA 424 359/360 (99%) 
1072 gi|13642967|ref|XM_018280.1| Homo sapiens poly(A)-binding protein, cytoplasmic 1 (PABPC1), mRNA 339 223/224 (99%) 
    
48 gi|13640156|ref|XM_015349.1| Homo sapiens ribosomal protein S6 (RPS6), mRNA 354 345/353 (97% 
1040 gi|13640156|ref|XM_015349.1| Homo sapiens ribosomal protein S6 (RPS6), mRNA 280 177/189 (93%) 
1049 gi|13640156|ref|XM_015349.1| Homo sapiens ribosomal protein S6 (RPS6), mRNA 388 301/313 (96%) 
    
55 gi|13376244|ref|NM_024835.1| Homo sapiens C3HC4-type zinc finger protein (LZK1), mRNA 355 353/355 (99%) 
    
59 gi|21361889|ref|NM_021633.2|  Homo sapiens kelch-like protein C3IP1 (C3IP1), mRNA 286 170/172 (98%) 
293 gi|21361889|ref|NM_021633.2|  Homo sapiens kelch-like protein C3IP1 (C3IP1), mRNA 291 174/174 (100%) 
    
66 gi|18375675|ref|NM_080599.1|  Homo sapiens regulator of nonsense transcripts 2 (RENT2), transcript variant 1, mRNA 352 350/352 (99%) 
    
67 gi|13650772|ref|XM_016712.1| Homo sapiens hypothetical protein FLJ23375 (FLJ23375), mRNA 352 161/167 (96%) 
1078 gi|13650772|ref|XM_016712.1| Homo sapiens hypothetical protein FLJ23375 (FLJ23375), mRNA 265 259/259 (100%) 
    
82 gi|14150014|ref|NM_032299.1| Homo sapiens hypothetical protein MGC2714 (MGC2714), mRNA 263 203/236 (86%) 
    
89 gi|1552325|emb|Y07969.1|HSAPRIL H.sapiens mRNA for APRIL protein 337 253/258 (98%) 
   51/60 (85%) 
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93 gi|11425596|ref|XM_001901.1| Homo sapiens Sjogren syndrome antigen A2 (60kD, ribonucleoprotein autoantigen  353 324/326 (99%) 
 SS-A/Ro) (SSA2), mRNA   
    
107 gi|19923906|ref|NM_138381.1| Homo sapiens hypothetical protein BC008322 (LOC92106), mRNA 395 289/290 (99%) 
434 gi|19923906|ref|NM_138381.1| Homo sapiens hypothetical protein BC008322 (LOC92106), mRNA 415 287/288 (99%) 
415 gi|19923906|ref|NM_138381.1| Homo sapiens hypothetical protein BC008322 (LOC92106), mRNA 466 287/288 (99%) 
    
113 gi|13751653|gb|XM_028311| Homo sapiens solute carrier family 38,member 2 (SLC38A2), mRNA (ATA2) 348 260/261 (99%) 
    
114 gi|20561660|ref|XM_168026.1| Homo sapiens KIAA1007 protein (KIAA1007), mRNA 349 340/349 (97%)  
458 gi|20561660|ref|XM_168026.1| Homo sapiens KIAA1007 protein (KIAA1007), mRNA 402 318/345 (92%) 
    
118 gi|20551719|ref|XM_166297.1|  Homo sapiens CG2277 gene product (LOC221294), mRNA 351 342/353 (96%) 
    
121 >gi|14150079|ref|NM_032314.1| Homo sapiens hypothetical protein MGC4767 (MGC4767), mRNA 345  339/345 (98%) 
    
133 gi|13160958|gb|AF321876.1|AF321876 Homo sapiens candidate tumor suppressor (DPH2L1) mRNA, complete cds 365 357/360 (99%) 
1073 gi|13160958|gb|AF321876.1|AF321876 Homo sapiens candidate tumor suppressor (DPH2L1) mRNA, complete cds 398 343/352 (97%) 
    
153 gi|13646652|ref|XM_008741.3| Homo sapiens suppressor of K+ transport defect 1 (SKD1), mRNA 351 348/352 (98%) 
    
158 gi|11429541|ref|XM_005622.1| Homo sapiens dystonia 1, torsion (autosomal dominant; torsin A)(DYT1), mRNA 351 348/351 (99%) 
    
162 gi|13097233|gb|BC003378.1|BC003378 Homo sapiens, high-mobility group (nonhistone chromosomal) protein 1, 369 286/289 (98%) 
    
174 gi|13637791|ref|XM_002696.3| Homo sapiens mutS (E. coli) homolog 2 (colon cancer, nonpolyposis type 1) (MSH2) 343 337/343 (98%) 
    
177 gi|13641527|ref|XM_005078.3| Homo sapiens RAD21 (S. pombe) homolog (RAD21), mRNA 338 223/224 (99%) 
    
190 gi|307154|gb|L19183.1|HUMMAC30X Human MAC30 mRNA, 3' end 341 337/341 (98%) 
268 gi|307154|gb|L19183.1|HUMMAC30X Human MAC30 mRNA, 3' end 443 379/392 (96%) 
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192 gi|13636890|ref|XM_018498.1| Homo sapiens ribosomal protein L5 (RPL5) 391 343/346 (99%) 
    
218 gi|12655032|gb|BC001364.1|BC001364 Homo sapiens, SEC22, vesicle trafficking protein (S. cerevisiae)-like 1 341 338/340 (99%) 
1060 gi|12655032|gb|BC001364.1|BC001364 Homo sapiens, SEC22, vesicle trafficking protein (S. cerevisiae)-like1,mRNA 335 333/334 (99%) 
    
234 gi|14250147|gb|BC008492.1|BC008492 Homo sapiens, ribosomal protein L3, clone MGC:14821, mRNA 455 386/390 (98%) 
    
259 gi|12731938|ref|XM_004104.2| Homo sapiens ribonuclease P, 40kD subunit (RPP40), mRNA 343 231/235 (98%) 
295 gi|12731938|ref|XM_004104.2| Homo sapiens ribonuclease P, 40kD subunit (RPP40), mRNA 346 237/241 (98%) 
    
277 gi|13630833|ref|XM_009601.3| Homo sapiens 5'-3' exoribonuclease 2 (XRN2), mRNA 452 355/361 (98%) 
    
282 gi|15076870|gb|AF279306.1|AF279306 Homo sapiens anti-silencing function 1A (ASF1A) mRNA 445 339/340 (99%) 
447 gi|15076870|gb|AF279306.1|AF279306 Homo sapiens anti-silencing function 1A (ASF1A) mRNA, complete cds 406 339/340 (99%) 
    
305 gi|13640144|ref|XM_005467.4| Homo sapiens hypothetical protein FLJ20060 (FLJ20060), mRNA 387 366/367 (99%) 
    
314 gi|3882170|dbj|AB018268.1|AB018268 Homo sapiens mRNA for KIAA0725 protein, partial cds 347 342/343 (99%) 
    
321 gi|14039833|gb|AF367998.1|AF367998 Homo sapiens elongation factor G1 (EFG1) mRNA, complete cds 433 427/431 (99%) 
    
326 gi|217461916|ref|XM_065847| Homo sapiens similar to tumor metastasis suppressor; LAG1 homolog  460 326/331 (98%) 
420 gi|217461916|ref|XM_065847| Homo sapiens similar to tumor metastasis suppressor; LAG1 homolog  346 264/277 (95%)  
    
332 gi|13629831|ref|XM_005799.3| Homo sapiens integrin, beta 1 (fibronectin receptor, beta) (ITGB1) 335 61/64 (95%) 
    
339 gi|12654186|gb|BC000911.1|BC000911 Homo sapiens, suppressor of G2 allele of SKP1, mRNA, complete cds 399 299/300 (99%) 
    
358 gi|13645714|ref|XM_011883.2| Homo sapiens vinculin (VCL), mRNA 433 427/436 (97%) 
    
370 gi|14741441|ref|XM_030426.1| Homo sapiens hypoxia-inducible factor 1, alpha subunit inhibitor (HIF1AN), mRNA 433 401/404 (99%) 
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371 gi|11421392|ref|XM_010362.1| Homo sapiens solute carrier family 25,member 5 (SLC25A5),nuclear gene 426 362/368 (98%) 
    
384 gi|21700561|gb|AC092140.3| Homo sapiens chromosome 16 clone RP11-413H22, complete sequence 433 393/397 (98%) 
    
406 gi|4502280|ref|NM_001679.1| Homo sapiens ATPase, Na+/K+ transporting, beta 3 polypeptide (ATP1B3), mRNA 457 363/393 (92%) 
    
410 gi|13627221|ref|XM_007816.3| Homo sapiens G1 to S phase transition 1 (GSPT1), mRNA 439 317/317 (100%) 
    
421 gi|13643398|ref|XM_003719.3| Homo sapiens erbb2-interacting protein ERBIN (LOC55914), mRNA 415 342/346 (98%) 
    
423 gi|13627242|ref|XM_001436.2| Homo sapiens capping protein (actin filament) muscle Z-line, beta (CAPZB), mRNA 347 343/346 (99%) 
    
424 gi|12803510|gb|BC002582.1|BC002582 Homo sapiens, ubiquitin protein ligase E3A (human papilloma virus 436 334/336 (99%) 
             E6-associated protein)   
    
426 gi|12653128|gb|BC000331.1|BC000331 Homo sapiens, proteasome (prosome, macropain) subunit, beta type, 348 340/348 (97%) 
            4, PSMB4, clone MGC:8522, mRNA, complete cds   
    
431 gi|11493480|gb|AF130088.1|AF130088 Homo sapiens clone FLB9213 PRO2474 mRNA, complete cds 348 321/335 (95%) 
    
438 gi|4557530|ref|NM_001382.1| Homo sapiens dolichyl-phosphate (UDP-N-acetylglucosamine) 525 161/175 (92%) 
            N-acetylglucosaminephosphotransferase 1 (GlcNAc-1-P  transferase) (DPAGT1), mRNA   
    
446 gi|7271466|gb|AF178980.1|AF178980 Homo sapiens D-prohibitin mRNA, complete cds 445 336/339 (99%) 
    
452 gi|11968293|gb|AC010368.4|AC010368 Homo sapiens chromosome 5 clone CTD-2046J7, complete sequence 351 265/268 (98%)  
    
460 gi|11038647|ref|NM_003503.2| Homo sapiens CDC7 (cell division cycle 7, S. cerevisiae,homolog)-like 1 (CDC7L1) 393 311/320 (97%) 
    
470 gi|13641498|ref|XM_005572.3| Homo sapiens fructose-1,6-bisphosphatase 1 (FBP1), mRNA 388 243/245 (99%) 
    
474 gi|9945333|ref|NM_000403.2| Homo sapiens galactose-4-epimerase, UDP- (GALE) 196 185/185 (100%) 
 235 
    
475 gi|14043355|gb|BC007672.1|BC007672 Homo sapiens, NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9 398 358/366 (97%) 
            (22kD, B22), clone MGC:1186, mRNA, complete cds   
    
1026 gi|13653412|ref|XM_016771.1| Homo sapiens activity-dependent neuroprotective protein (ADNP), mRNA 339 285/285 (100%) 
    
1029 gi|13653050|ref|XM_008502.3| Homo sapiens CGI-48 protein (LOC51096), mRNA 258 244/255 (95%) 
    
1034 gi|13652652|ref|XM_006998.3| Homo sapiens retinoblastoma-binding protein 2 (RBBP2), mRNA 269 239/241 (99%) 
    
1064 gi|12803766|gb|BC002722.1|BC002722 Homo sapiens, guanine nucleotide binding protein (G protein), alpha 397 376/384 (97%) 
             stimulating activity polypeptide 1, clone MGC:3330, mRNA   
    
1065 gi|13543411|gb|BC005863.1|BC005863 Homo sapiens, ribosomal protein, large, P0, clone MGC:3679, mRNA 407 332/336 (98%) 
    
1070 gi|11419784|ref|XM_010122.1| Homo sapiens sex comb on midleg (Drosophila)-like 1 (SCML1)  485 123/134 (91%) 
    
1071 gi|14043361|gb|BC007674.1|BC007674 Homo sapiens, CD24 antigen (small cell lung carcinoma cluster 4 antigen) 409 385/400 (96%) 
    
1075 gi|885681|gb|U18271.1|HSTMPO6 Human thymopoietin (TMPO) gene, partial exon 6, complete exon 7, 396 142/142 (100%) 
             partial exon 8, and partial cds for thymopoietin beta   
    
1083 gi|18181683|emb|AL583839.12|AL583839 Human DNA sequence from clone RP11-165J3 on chromosome 9 405 203/209 (97%) 
    
1085 gi|14132743|gb|AY014957.1| Homo sapiens PI-3-kinase-related kinase SMG-1 (SMG1) mRNA 371 256/321 (79%) 
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Abstract
Inherited mutations of the BRCA1 gene predispose to breast, ovarian, and other cancers. The role of the BRCA1 gene in the
maintenance of chromosomal integrity is linked to a number of biological properties of its protein product, including transcriptional
regulation. In the present study, we have used suppression subtractive hybridisation (SSH) to identify genes induced by BRCA1 by
comparing control MCF7 breast carcinoma cells (driver) with MCF7 cells ectopically expressing BRCA1 (tester) and generated a
forward subtracted cDNA library. We screened 500 putative positive clones from this library. Two hundred and ten of these clones
were positive by diﬀerential screening with forward and reverse subtracted probes and the 65 cDNA clones which showed more than
ﬁvefold increase were selected for sequencing analysis. We clustered 46 diﬀerent genes that share high homology with sequences in
the GenBank/EMBL databases. Among these, 30 were genes whose function had been previously identiﬁed while the remaining 16
clones were genes with unknown functions. Of particular interest, BRCA1 gene induces the expression of genes encoding DNA
repair proteins RAD21 and MSH2, ERBB2/HER2 interacting protein ERBIN, meningioma-associated protein MAC30, and a
candidate ovarian tumour-suppressor OVCA1. Northern and Western blot analyses conﬁrmed that the expression of these ﬁve genes
are up-regulated following BRCA1 overexpression in MCF7 and UBR60-bcl2 cells. This is the ﬁrst study reporting a set of BRCA1-
induced genes in breast carcinoma cells by the SSH technique. We suggest that some known genes identiﬁed in this study may
provide new insights into the tumour-suppressor function of BRCA1.
 2002 Elsevier Science (USA). All rights reserved.
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Germ-line mutations in the BRCA1 tumour-sup-
pressor gene predispose carriers to breast and ovarian
cancers and account for approximately 50% of inherited
breast cancers [1]. BRCA1 gene encodes a 220 kDa
multifunctional nuclear phosphoprotein involved in
diﬀerent cellular pathways including cellular response to
DNA damage, cell cycle, growth suppression, apoptosis
induction, ubiquitin ligation, and transcription regula-
tion [2]. Several functional regions have been described
in BRCA1: an N-terminal RING ﬁnger domain, two
nuclear localisation signals, and two BRCA1 carboxyl
terminal (BRCT) motifs at the carboxyl terminus.
BRCA1 is the main component of the BRCA1-associ-
ated genome surveillance complex (BASC) which serves
as a sensor for DNA damage. BASC comprises tumour
suppressors and DNA damage repair proteins MSH2,
MSH6, MLH1, ATM, BLM, the RAD50–MRE11–
NBS1 protein complex, and DNA replication factor C
[3,4]. In addition, the carboxyl terminal of BRCA1 acts
as a strong transcriptional activator when fused to a
heterologous DNA binding domain [5]. BRCA1 co-pu-
riﬁes with RNA polymerase II holoenzyme complex,
suggesting that it is a component of core transcription
machinery [6]. BRCA1 also interacts with several tran-
scription factors such as p53, CtIP, c-myc, ZBRK1,
ATF, E2F, and signal transducer STAT1 [7] and mod-
ulates their activity. These ﬁndings, together with the
interaction of BRCA1 with histone deacetylases
(HDACs) and the SWI/SNF-related chromatin remod-
elling complex, imply that transcriptional regulation is
one of the main functions of BRCA1 [8]. In addition,
nearly all germ-line BRCA1 mutations involve trunca-
tion or loss of the C-terminal BRCT transcriptional
activation domain, suggesting that transcriptional reg-
ulation is a critical function of the BRCA1 gene. Our
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purpose in this study was to identify the genes whose
expression is regulated by BRCA1 and therefore con-
tribute to a better understanding of its cellular func-
tions. We used MCF7 breast carcinoma cell line which
has low endogenous BRCA1 expression level and
maintains wild-type p53 [9]. We compared the expres-
sion proﬁle of control MCF7 cells with MCF7 cells ec-
topically expressing BRCA1 by performing SSH. We
generated a subtracted cDNA library and identiﬁed
novel BRCA1-induced genes as candidate mediators of
tumour suppression by BRCA1.
Materials and methods
Cell lines and cell culture. MCF7 breast carcinoma cells (American
Type Culture Collection) and UBR60-bcl2 cells were maintained in
Dulbeccos modiﬁed Eagles medium (DMEM) supplemented with
10% fetal calf serum, 1mM glutamine, 10U/ml penicillin G, and 10lg/
ml streptomycin, at 37 C in 5% CO2-containing atmosphere. The
UBR60-bcl2 cell line (a gift from Dr. Paul Harkin) which expresses
BRCA1 under the control of tetracycline-regulated promoter has been
previously described [10].
Plasmids and transfections. pCMVmycBRCA1 was constructed by
subcloning the full-length BRCA1 insert from pCR3.BRCA1 (pro-
vided by Dr. Barbara Weber) into pCMVmyc vector (Clontech labo-
ratories, Palo Alto, CA). pCR3.BRCA1 was cut withHindIII, the ends
were ﬁlled with Klenow, and SalI linkers were ligated into the ends.
The plasmid was digested with SalI/NotI and the BRCA1 cDNA was
cloned into pCMVmyc vector (Clontech). MCF7 cells were grown to
80% conﬂuency 24 h prior to electroporation. Brieﬂy, cells were har-
vested with trypsin, washed twice with ice-cold calcium and magne-
sium-free PBS, and re-suspended in ice-cold PBS. Plasmid DNA was
added (30lg=15 106 cells/cuvette) and electroporation was carried
out at 950lF, 0.22 kV/cm (t ¼ 19–22ms) (BioRad Gene Pulser).
pEGFP-N2 (Clontech) was used as a control plasmid to calculate the
transfection eﬃciency using the same experimental conditions. Total
RNA and protein extractions were performed 24 h after transfection.
Annexin V staining. Binding of Annexin V to the cell surface, which
is an early indication of apoptosis, was determined with the Annexin
V-PE stain (PharMingen, BD Biosciences). Cells were washed twice
with cold PBS and then incubated in the dark in 100ll binding buﬀer
(0.01M Hepes, pH 7.4, 0.14M NaCl, and 0.25mM CaCl2) containing
5ll Annexin V-PE stain per coverslide. The coverslides were washed
with binding buﬀer and ﬁxed in 1ml of 90% cold ethanol for 30min
under dim light. After washing with PBS, Hoechst staining (300lg/ml
ﬁnal concentration) was performed for 5min in the dark. The cover-
slides were extensively washed with H2O and mounted onto 80%
glycerol droplet. As a positive control for apoptosis, MCF7 cells were
treated under 50 J/m2 ultraviolet light and the same experimental
conditions were applied.
Western blot analysis. Cells were harvested using RIPA lysis buﬀer
(10mM Tris–Cl, pH 8.0, 1mM EDTA, 150mM NaCl, 1% NP-40, 1%
NaDOC, and protease inhibitors). Equal amounts of protein extracts
were loaded in 10% (for MSH2 and cytokeratin 18) or 5% (for
BRCA1, Ab-1) SDS–polyacrylamide gels and transferred onto
polyvinylidene diﬂuoride (PVDF) membranes. After overnight incu-
bation at 4 C in blocking solution (TBS-T: 20mM Tris–HCl, pH 7.6,
0.137M NaCl, 0.5% Tween 20, and 3% milk) membranes were incu-
bated for 2 h at room temperature with mouse anti-human BRCA1
monoclonal (Ab-1, Oncogene Research Products), mouse anti-human
MSH2 monoclonal (Ab-1, Oncogene Research Products), or cytoker-
atin 18 (JAR13 clone, a gift from Dr. D. Bellet, IGR, France) anti-
bodies. Blots were washed three times for 10min in TBS-T and
incubated with the secondary antibody (Horseradish peroxidase-con-
jugated anti-mouse IgG, 1:2000, Santa Cruz Biotechnology) for 1 h at
room temperature with constant shaking. After extensive washing,
chemiluminescence detection was carried out with the Amersham ECL
detection kit according to manufacturers instructions.
RNA isolation for cDNA subtraction. Total RNA was prepared
with TRI Reagent (Sigma). mRNA was isolated from total RNA with
poly(A) Spin mRNA Isolation Kit (New England Biolabs) according
to manufacturers speciﬁcations. For removal of DNA contamination
from RNA samples, the MessageClean Kit (GenHunter) was used
according to manufacturers instructions.
Suppression subtractive hybridisation (SSH). SSH was performed
with PCR-Select cDNA Subtraction Kit (Clontech) as described by the
manufacturer with minor modiﬁcations. In brief, 3.5lg polyðAÞþ
RNA from MCF7 cells electroporated with pCMVmyc used as the
driver and 3.5 lg from pCMVmycBRCA1-transfected cells was used as
the tester to construct a forward subtracted library. Reverse subtrac-
tion was also performed where tester cDNA was derived from MCF7
electroporated with pCMVmyc and driver cDNA derived from MCF7
electroporated with pCMVmycBRCA1 using the same experimental
conditions. SSH was performed with double-strand tester and driver
cDNAs. Primary PCR condition was 94 C for 30 s, 66 C for 30 s, and
72 C for 90 s for 30 cycles in 25 ll reaction volume. One microliter of
1/10th diluted primary PCR product was added into a new PCR tube
for a second round of PCR. The secondary PCR condition was 94 C
for 30 s, 68 C for 30 s, and 72 C for 90 s for 15 cycles. All PCR and
hybridisation steps were performed on a Perkin–Elmer 9600 thermal
cycler.
Cloning of cDNA mixture. The ﬁnal PCR-generated forward sub-
tracted cDNA mixture, enriched for BRCA1 up-regulated sequences,
was cloned into the cloning vector pGEM-T Easy (Promega) and
transformed into supercompetent Escherichia coli strain JM109. The
transformed bacteria were plated on 150mm ampicillin agar plates
containing 100mM IPTG and 50mg/L X-Gal and bacteria were grown
overnight at 37 C. Plates were then incubated further at 4 C until
blue/white staining could be clearly distinguished.
Diﬀerential screening of clones. The PCR-Select Diﬀerential
Screening Kit (Clontech) was used to screen the subtracted cDNA li-
brary to analyse the diﬀerentially expressed sequences according to
manufacturers recommendations. Five hundred white clones were
picked randomly, inoculated into sterile 96-well plates containing LB
medium with ampicillin, and grown overnight shaking at 37 C. Then
1 ll of each bacteria culture was used to amplify the cDNA inserts with
SP6 and T7 universal primers. The PCR products were then trans-
ferred into 96-well plates and denatured in equal amount of NaOH and
1.5 ll of each sample was blotted onto two nylon membranes (Hybond
Nþ) in an identical order. Negative hybridisation controls cDNA1 and
cDNA2 (provided by the manufacturer), and BRCA1 cDNA were
included as control in the blots. The forward and reverse subtracted
cDNA pools in SSH steps were used as probes which were labelled
with ½a-32PdCTP using Random Primers DNA Labeling System
(Clontech). Two identical blots were hybridised with either forward or
reverse probes with the same number of cpm for each pair and signal
intensity was measured by phosphorimaging (Bio-Rad Molecular
Imaging System). Two hundred and ten clones which showed more
than ﬁvefold increase in signal intensity were again dotted onto
membranes and diﬀerential screening was repeated two further times.
Sequencing and homology search. All sequencing reactions were
performed on double-stranded plasmid templates with T7 and SP6
primers. Sequencing reactions were carried out with the Big Dye ter-
minator cycle sequencing kit and analysed with the ABI 377 DNA
sequencer. Partial cDNA sequences were compared with entries in the
GenBank/EMBL database using the BLAST homology search pro-
gram at http://www.ncbi.nlm.nih.gov/blast/.
Northern blot analysis. Total RNA was isolated with TRI Reagent
(Sigma). Thirtylg of total RNA samples was resolved by formalde-
hyde gel electrophoresis, run overnight at 50V, and then transferred to
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nylon membrane (Hybond Nþ). Puriﬁed cDNA inserts were labelled
with HexaLabel Plus Kit (MBI Fermentas) and separated by Quick
Spin columns (Boehringer–Mannheim). Membrane hybridisation was
carried out overnight at 65 C in hybridisation buﬀer (0.5M phosphate
buﬀer, pH 7.2, 7% SDS, 1mM EDTA, 1% BSA, and 10 lg/ml salmon
sperm DNA, and yeast total RNA) containing at least 107 cpm
½a-32PdCTP-labelled cDNA PCR products as probes per membrane.
Membranes were sequentially washed in 2 SSC and 0.5% SDS, 1
SSC and 0.5% SDS, and 0:2 SSC and 0.5% SDS at 68 C and the
ﬁlters were exposed to X-ray ﬁlm with an intensifying screen at )70 C.
Results
Ectopic expression of BRCA1 in MCF7 breast carcinoma
cells
MCF7 cells were transiently transfected with either
pCMVmycBRCA1 or a control plasmid pCMVmyc
lacking BRCA1 insert. The transfection eﬃciency, veri-
ﬁed by pEGFP-N2 reporter plasmid, was approximately
40%. Under these conditions, less than 1–2% of cells were
apoptotic, as tested by Annexin V staining at 24 h, fol-
lowing transfection with either BRCA1 or control plas-
mid (data not shown). Thus, at a transfection eﬃciency of
40%, no more than 5% of BRCA-1 expressing cells were
apoptotic. This indicated that ectopically expressed
BRCA1 was not signiﬁcantly cytotoxic to MCF7 cells
under test conditions. BRCA1 or control plasmid-trans-
fected cells were examined for the BRCA1protein level by
Western blot analysis. The results of two representative
experiments are shown in Fig. 1. Both controlMCF7 cells
(lane 1) and the cells transfected with control plasmid
without BRCA1 insert (lane 2) demonstrated endogenous
BRCA1 protein. As shown in Fig. 1 (experiment 1) ec-
topically expressed BRCA1 protein level was similar to
endogenous BRCA1 level, suggesting that transient
transfection resulted in a signiﬁcant increase in total
BRCA1 levels in pCMVmycBRCA1-transfected MCF7
cells (lane 3). Taken together, these results indicated that
it was possible to increase BRCA1 levels in MCF7 by
transient transfection, without compromising cellular
integrity.
Generation of a subtracted library and screening of
diﬀerentially expressed clones
We used suppression subtractive hybridisation (SSH)
technology to identify genes that are diﬀerentially ex-
pressed in BRCA1-transfected MCF7 cells. SSH was
performed with the double-strand tester (MCF7/
pCMVmycBRCA1) and driver (MCF7/pCMVmyc)
cDNAs (forward subtraction). Reverse subtraction was
also performed where tester cDNA was derived from
pCMVmyc-transfected MCF7 cells and driver cDNA
derived from pCMVmycBRCA1-transfected cells. Fol-
lowing SSH, diﬀerential screening was performed with
these forward and reverse subtracted probes in order to
identify diﬀerentially expressed genes. Five hundred
clones were selected at random from the forward sub-
tracted library enriched for BRCA1 up-regulated se-
quences and the cDNA inserts were ampliﬁed. The PCR
products were then blotted onto membranes together
with control cDNAs and probed with the forward and
reverse subtracted cDNA pools. Two hundred and ten
of them were screened positive by diﬀerential screening
with forward and reverse subtracted probes and 65
cDNA clones which showed more than ﬁvefold increase
were selected for sequencing analysis (Table 1). Fig. 2
shows an example of duplicate dot blots hybridised with
forward (Fig. 2A) and reverse subtracted cDNA probes
(Fig. 2B), respectively. Control experiments indicated
the subtraction allowed the enrichment of BRCA1
cDNA. As expected, the negative hybridisation controls
cDNA1 and cDNA2 were not hybridised.
BRCA1-induced genes in breast cancer cells form several
distinct functional classes
To characterise the 65 diﬀerentially expressed clones,
the inserts were partially sequenced and the output se-
quences, compared to the GenBank/EMBL database in
order to ﬁnd homologies with already known genes.
Eight clones yielded poor sequence data and eleven
genes were represented more than once in the library
(Table 1). Overall, 57 clones showed more than 90%
Table 1
Summary of the analysed clones
Number
Analysed putative positive clones after SSH 500
Conﬁrmed by diﬀerential screeninga 210
Number of clones sequencedb 65
>90% homology 57
Known function 30
Unknown function 16
a The cDNA clones which showed more than 5-fold induction were
selected for sequencing.
b Eight clones yielded poor sequence data and eleven genes were
represented more than once in the library.
Fig. 1. Ectopic expression of BRCA1 in MCF7 breast carcinoma cells.
MCF7 cells electroporated without any plasmid (lane 1), cells trans-
fected with control plasmid pCMVmyc (lane 2), and pCMVmycBR-
CA1 plasmid (lane 3) are shown. Total protein extracts were prepared
and analysed for BRCA1 by Western blot using Ab-1 antibody speciﬁc
to BRCA1. Blots shown are representative of Western blot analysis
from six separate experiments.
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homology to known genes. As shown in Table 2, we
associated 30 of the genes to a known or putative
function: 5 in transcriptional regulation, 3 in interme-
diate metabolism, 3 in ubiquitin-mediated proteolysis, 2
in chromatin organisation, 3 in DNA repair, 2 in re-
ceptor-mediated signalling, and 2 in cytoskeletal orga-
nisation. The others were involved in amino acid or ion
transport, cell–cell and cell–ECM interaction, endosome
or vesicle-traﬃcking, and N-glycan biosynthesis. The
Cdc7 protein kinase which is involved in the initiation of
DNA synthesis was also induced by BRCA1. The
function of the remaining 16 genes was unknown.
Conﬁrmation of BRCA1-induced genes by Northern and
Western blot analysis
Several BRCA1-induced genes reported here are
known to be involved in DNA repair (RAD21, MSH2);
[11,4] and chromosomal structure maintenance
(RAD21, CDC7, SGT1, and HMG1); [12–15]. This
observation strongly suggests that at least some of the
eﬀects attributed to BRCA1 for chromosomal stability
are mediated by these genes. To further analyse their
BRCA1-regulated expression, we analysed RAD21 and
MSH2 expression in two diﬀerent cell lines. Both
RAD21 and MSH2 were up-regulated following over-
expression of BRCA1 in MCF7 cells (Figs. 3A and B) as
well as in the UBR60-bcl2 cell line following BRCA1
induction (Fig. 3C).
Northern blot assays, using both MCF7 and UBR60-
bcl2 cells, demonstrate that BRCA1 induces ERBIN
expression (Fig. 4). OVCA1 that was identiﬁed as a
candidate tumour-suppressor gene was also studied. The
levels of OVCA1 mRNA transcripts (1.1 and 2.3-kb
species) were low in MCF7 cells and BRCA1 overex-
pression caused induction of both transcript forms (Fig.
4A). Finally, MAC30 transcript, whose expression has
been reported to be decreased in meningiomas, sch-
wannomas, and neuroﬁbromas [16] was also induced in
MCF7 as well as UBR60-bcl2 by BRCA1 (Fig. 4B).
These studies performed with UBR60-bcl2 cells that
stably express BRCA1 at modest levels in an inducible
manner [10] conﬁrm and validate our results obtained
with a transient expression approach to identify poten-
tial BRCA1 target genes.
Discussion
In the present study, we have used SSH technology to
generate a library of partial-length cDNAs representing
diﬀerentially expressed mRNAs in BRCA1-overex-
pressing MCF7 cells. SSH combines subtractive hy-
bridisation with PCR to generate a population of PCR
fragments enriched for sequences from genes expressed
diﬀerentially. SSH-mediated cDNA enrichment allows
the equalisation of wide diﬀerences in abundance of
diﬀerent transcript species. Consequently, diﬀerentially
expressed transcripts of low abundance can be cloned
[17]. Using this approach we were able to identify 46
genes that are up-regulated as a result of BRCA1
overexpression in breast cancer cells.
Several studies have previously reported the identiﬁ-
cation of BRCA1 target genes in osteosarcoma [10],
colorectal cancer [18], mouse BRCA)/) embryonic stem
[19], and human embryonal kidney epithelial [20] cells.
None of the genes that we report here have been iden-
tiﬁed in these previous studies. This could be due to the
fact that we used a breast cancer cell line to identify
potential BRCA1 target genes by the highly sensitive
SSH technique.
We report that several DNA damage response
(RAD21, MSH2, ASF1A, and CDC7) and chromo-
somal structure maintenance (RAD21, ASF1A, CDC7,
SGT1, and HMG1) genes are positively regulated tar-
gets of BRCA1. As BRCA1-deﬁcient cells suﬀer from
both DSB repair deﬁciency and chromosomal instability
[21], at least some of these defects may be attributed to
ineﬃcient expression of these target genes in the absence
of functional BRCA1.
Several other genes (such as SGT1, UbE3A, and
PSMB4) are involved in ubiquitin-mediated protein
degradation. This may be expected since BRCA1 itself
(together with BARD1) functions as an E3 ubiquitin
ligase [2,22,23]. The involvement of BRCA1 in ubiqu-
itin-mediated protein degradation could help explain the
multiplicity of biological roles ascribed to this protein,
including coordination of DNA repair-related events.
Other genes involved in distant cellular processes such as
intermediate metabolism, cell–cell interaction, receptor-
mediated signalling, endosome-traﬃcking, or cytoskel-
etal organisation also appear to be up-regulated by
BRCA1 (Table 2). In this context, BRCA1 seems to act
like another tumour-suppressor gene, namely p53 which
Fig. 2. Diﬀerential screening of SSH-selected cDNA clones with for-
ward (A) and reverse (B) subtracted probes. Selected cDNA inserts
were PCR-ampliﬁed from forward subtracted cDNA library, enriched
for BRCA1 up-regulated sequences, spotted in two identical mem-
branes, and hybridised with ½a-32PdCTP-labelled forward or reverse
subtracted cDNA probes. Rows A–H; test cDNA samples, Rows H3:
negative PCR control, H5–H6: cDNA1, H9–H10: cDNA2 as negative
control cDNAs, H7–H8: BRCA1, and H12: NaOH+water). For ex-
ample E2 cDNA showed no signiﬁcant increase (1.76-fold), but C3
cDNA (zinc ﬁnger protein, LZK1) displayed 7.0-fold increase. The
signal intensities were measured by phosphorimager.
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Table 2
List of BRCA1 up-regulated genes in MCF7 breast carcinoma cells
Putative function Gene name Accession No. Fold
induction
Redundancy cDNA
insert size
Amino acid transport Solute carrier family 38, member 2 (SLC38A2) XM_028311 9 1 800 bp
Cell–cell interaction CD24 antigen (small cell lung carcinoma
cluster 4 antigen) (CD24)
XM_087865 29 1 800 bp
Cell–ECM interaction Integrin, b1 (ﬁbronectin receptor, b polypeptide)
(ITGB1), transcript variant 1E
NM_133376 6 1 800 bp
Chaperon Dystonia 1, torsion (autosomal dominant;
torsin A) (DYT1)
NM_000113 11 1 1.1 kb
Chromatin assembly/DNA
repair and response
Anti-silencing function 1A (ASF1A) AF279306 13 2 500 bp
Chromatin structure High-mobility group (nonhistone chromosomal)
protein 1 (HMG1)
BC003378 9 1 650 bp
Cytoskeleton organisation Vinculin (VCL), transcript variant meta-VCL NM_014000 7 1 800 bp
Cytoskeleton organisation Capping protein (actin ﬁlament) muscle Z-line, b BC008095 14 1 800 bp
DNA repair MutS homolog 2, colon cancer, nonpolyposis
type 1 (E. coli) (MSH2)
XM_034901 9 1 600 bp
DNA repair RAD21 homolog (S. pombe) (RAD21) NM_006265 11 1 500 bp
Vesicle-traﬃcking SEC22, vesicle-traﬃcking protein
(Saccharomyces cerevisiae)-like 1
BC001364 11 2 900 bp
Endosome-traﬃcking Suppressor of Kþ transport defect 1 (SKD1) NM_004869 9 1 700 bp
Intermediate metabolism Fructose-1,6-bisphosphatase 1 (FBP1) NM_000507 9 1 500 bp
Intermediate metabolism Galactose-4-epimerase, UDP- (GALE) XM_032314 9 1 400 bp
Intermediate metabolism NADH dehydrogenase (ubiquinone)
1b subcomplex 9
BC007672 9 1 750 bp
Ion transport ATPase, Naþ/Kþ transporting, b3 polypeptide
(ATP1B3)
NM_001679 10 1 800 bp
N-Glycan biosynthesis Dolichyl-phosphate N-acetylglucosaminephospho-
transferase 1 (GlcNAc-1-P transferase)
BC008817 6 1 550 bp
Nuclear envelope protein Thymopoietin (TMPO) U18271 11 1 900 bp
Protein kinase/DNA
synthesis/Meiosis
Cdc7 (CDC7) AF015592 11 1 800 bp
Receptor-mediated signalling Erbb2 interacting protein (ERBB2IP) (ERBIN) NM_018695 6 1 700 bp
Receptor-mediated signalling G protein a stimulating activity polypeptide 1
(GNAS)
BC002722 13 1 700 bp
Transcription regulation C3HC4-type zinc ﬁnger protein (LZK1)
(Dif3 homolog)
NM_024835 7 1 700 bp
Transcription regulation Activity-dependent neuroprotector (ADNP) NM_015339 9 1 500 bp
Transcription regulation Hypoxia-inducible factor 1, a subunit inhibitor
HIF1AN (FIH-1)
XM_030426 7 1 700 bp
Transcription regulation Sex comb on midleg-like 1 (Drosophila) (SCML1) NM_006746 9 1 600 bp
Transcription regulation Kelch-like protein C3IP1 (C3IP1) XM_086284 7 2 400 bp
Mitochondrial stress response D-Prohibitin (Bap37) AF178980 8 1 500 bp
Ubiquitin-mediated proteolysis Suppressor of G2 allele of SKP1, S. cerevisiae,
homolog of (SGT1)
NM_006704 8 1 450 bp
Ubiquitin-mediated proteolysis Ubiquitin protein ligase E3A, transcript variant
2 (UbE3A)
NM_000462 9 1 600 bp
Ubiquitin-mediated proteolysis Proteasome subunit, b type, 4 (PSMB4) XM_047881 9 1 800 bp
Unknown KIAA0725 protein (KIAA0725) XM_049445 12 1 1.0 kb
Unknown Acidic (leucine-rich) nuclear phosphoprotein
32 family, member B (ANP32B)
NM_006401 9 1 800 bp
Unknown Candidate tumour-suppressor OVCA1 (OVCA1) NM_080822 12 2 1.0 kb
Unknown Hypothetical protein (MAC30), mRNA XM_031536 17 2 900 bp
Unknown Similar to tumour metastasis-suppressor; longevity
assurance (LAG1, S. cerevisiae) homolog 2
XM_065847 12 2 600 bp
Unknown DNA sequence from clone RP11-165J3 on
chromosome 9
AL583839.1 16 1 800 bp
Unknown Hypothetical protein FLJ23375 (FLJ23375) NM_024956 16 2 500 bp
Unknown Hypothetical protein MGC2714 (MGC2714) NM_032299 8 1 500 bp
Unknown Hypothetical protein BC008322 (LOC92106) NM_138381.1 8 3 700 bp
Unknown Hypothetical protein FLJ20060 XM_005467.4 12 2 700 bp
Unknown CG2277 gene product (LOC221294) XM_166297.1 7 1 500 bp
Unknown Hypothetical protein MGC4767 (MGC4767) XM_045844 10 1 700 bp
Unknown KIAA1007 XM_168026.1 11 2 700 bp
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also up-regulates a high number of genes involved in
many diﬀerent cellular processes [24]. Although we have
not investigated these target genes in tumours yet, we
notice that 10 of the 46 genes (22%) that we report here
(RAD21, ERBB2IP, UbE3A, FBP1, KIAA0725,
TMPO, PSMB4, CD24, MSH2, and ATP1B3) are
among markers of a poor prognosis gene expression
signature identiﬁed by DNA microarray analysis of
early primary breast tumours [25]. Therefore, we believe
that we identiﬁed a large set of BRCA1 target genes that
may be involved in BRCA1-mediated cellular processes
as well as breast carcinogenesis.
In relation to BRCA1-related breast/ovarian carci-
nogenesis, we further analysed the expression of ERBIN
Table 2 (continued)
Putative function Gene name Accession No. Fold
induction
Redundancy cDNA
insert size
Unknown Clone FLB9213 PRO2474 AF130088 11 1 700 bp
Unknown Chromosome 5 clone CTD-2085H24 AC025447 10 1 800 bp
Unknown CGI-48 protein (LOC51096) NM_016001 13 1 750 bp
Fig. 4. BRCA1 mediated up-regulation of genes involved in cell signalling or tumour suppression in MCF7 cells and UBR60-bcl2 cells. (A) ERBIN,
MAC30, and OVCA1 transcript induction in MCF7 cells (B) ERBIN and MAC30 induction in UBR60-bcl2 cells. Cells were treated and Northern
blotting was performed as described in Fig. 3.
Fig. 3. BRCA1 induces up-regulation of RAD21 and MSH2 in MCF-7 (A, B) and UBR60-bcl2 (C) cells following BRCA1 induction. (A) Northern
blot with total RNA from MCF7 cells transfected with control plasmid pCMVmyc (lane V) and pCMVmycBRCA1 plasmid (lane B) conﬁrms
BRCA1-mediated induction of RAD21 expression. (B) Western blot analysis of MSH2 protein levels conﬁrms induced expression of MSH2. Cy-
tokeratin 18 was used for equal protein loading control. (C) Northern blot of total RNA from UBR60-bcl2 cells with inducible BRCA1 expression
shows over-expression of ectopic BRCA1, RAD21, and MSH2 following tetracycline withdrawal ()T) at 24 h. Ethidium bromide staining shows
equal RNA loading in each lane. ‘‘FI’’ indicates fold induction.
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and OVCA1. ERBIN, an ERBB2/HER2-binding pro-
tein which locates this receptor to the basolateral
membrane [26], was also up-regulated by BRCA1.
Overexpression of ERBB2/HER2 is frequently observed
in breast cancers and its overexpression is associated
with poor tumour prognosis [27]. Although it is not
known whether ERBIN is able to inhibit ERBB2/HER2
activity, its deregulation results in the mislocalisation of
the receptor [26]. This raises the possibility that ERBIN
deﬁcit resulting from inactivation of BRCA1 could lead
to a loss of epithelial homeostasis, and in consequence,
pathological disorganisation in breast carcinoma. An-
other gene, namely OVCA1 which we show to be
up-regulated by BRCA1, was initially identiﬁed as a
candidate ovarian tumour-suppressor gene located on
chromosome 17p13.3 [28]. This locus displays frequent
LOH in both ovarian and breast cancers [29] and
OVCA1 was reported to display reduced expression in
breast and ovarian cancers [30]. In addition, ectopic
expression of OVCA1 causes a dramatic reduction in
cell proliferation in association with accelerated cyclin
D1 degradation [30]. Even if additional studies are
needed, these observations strongly suggest that BRCA1
mediates its tumour-suppressor functions through a
large set of downstream genes involved in DNA repair,
receptor-mediated signalling, and ovarian cancer sup-
pression.
In conclusion, we have identiﬁed 46 genes whose
expression levels are up-regulated as a result of BRCA1
overexpression in breast cancer cells. The properties of
several of these genes are consistent with putative tu-
mour-suppressor functions in breast neoplasia. To our
knowledge, our study is the ﬁrst to report BRCA1-in-
duced genes in breast carcinoma cells with the SSH
technique. It will now be important to construct a
complete proﬁle of BRCA1-regulated genes in order to
achieve an integrated view of all the functional events
regulated by BRCA1, and to assess how expression of
these genes is aﬀected by the BRCA1 status of cells.
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